[{"polarity": 0, "orig_sen": " PURPOSE: The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. ", "disease": "NSCLC", "drug": "thalidomide"}, {"polarity": 0, "orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "thalidomide"}, {"polarity": 0, "orig_sen": " PURPOSE: The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. ", "disease": "NSCLC", "drug": "thalidomide"}, {"polarity": 0, "orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "thalidomide"}, {"polarity": 1, "orig_sen": "The effects of GDC-0941 (a pan PI3K inhibitor), GDC-0980 (a dual PI3K/mTOR inhibitor) and GDC-0973 (a MEK inhibitor) alone and in combination were assessed in 3 NSCLC cell lines.PIK3CA was mutated in 5.17% of NSCLC patients. ", "disease": "NSCLC", "drug": "GDC-0941"}, {"polarity": 1, "orig_sen": "GDC-0941 and GDC-0980 treatment induced anti-proliferative and pro-apoptotic responses across all NSCLC cell lines, while GDC-0973 treatment induced only anti-proliferative responses. ", "disease": "NSCLC", "drug": "GDC-0941"}, {"polarity": 1, "orig_sen": "We found that a high efficacy of antitumor activity was shown with GDC-0941 treatment in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. ", "disease": "NSCLC", "drug": "GDC-0941"}, {"polarity": 1, "orig_sen": "Additionally, the blockade of PI3K, mTOR and Erk with GDC-0941 and MEK inhibitors shows promise for treating gefitinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "GDC-0941"}, {"polarity": 1, "orig_sen": "Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "The intravenous (IV) pharmacokinetics (PK) of onartuzumab were investigated in a phase I study and a phase II study in recurrent non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "The intravenous (IV) pharmacokinetics (PK) of onartuzumab were investigated in a phase I study and a phase II study in recurrent non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "Given the role of MET in non-small-cell lung cancer (NSCLC), we investigated whether onartuzumab added to first-line chemotherapy efficacy in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "However, with the lack of clinical activity seen in the present study, the development of onartuzumab for squamous cell NSCLC will not be pursued further. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": " The objective of this study was to evaluate circulating hepatocyte growth factor (cHGF) as a pharmacodynamic biomarker of Met inhibition for onartuzumab (MetMAb, OA5D5v2) in a phase I trial in patients with advanced cancers and a phase II trial in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "onartuzumab"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "NSCLC patients with the WEE1 rs3910384 G/G homozygote genotype showed 13.5 months extended OS, 3.2 months extended PFS, and a 274% relative increase in their 3-year survival rate (from 7.4% to 27.7%) compared to the A/A+A/G genotype after treatment with platinum-gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In conclusion, the WEE1 rs3910384 G/G homozygote genotype can be used as a selective biomarker for NSCLC patients to indicate treatment with platinum and gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We investigated whether ERCC1 (19007C>T) and RRM1 (-37C>A) polymorphisms impact response to chemotherapy and survival in 62 patients with NSCLC treated with platinum and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) treated by gemcitabine/platinum chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This trial tested custirsen (OGX-011), an inhibitor of CLU protein production, combined with gemcitabine/platinum in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggested that metuzumab could significantly enhance chemosensitivity of human NSCLC cells to gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Metuzumab/gemcitabine combination treatment may be a potentially useful therapeutic regimen for NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese non-small cell lung cancer (NSCLC) patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To explore the clinical efficacy of gemcitabine concomitant with nedaplatin and drug resistance in the treatment of non-small cell lung cancer (NSCLC) and associated molecular predicators. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " In this study, we investigated whether COL4A3 mRNA expression levels were associated with clinical outcomes after treatment with a combination of gemcitabine (Gem)/cis-diamminedichloroplatinum(II) (CDDP) regimen for patients with advanced stage non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "NSCLC, mesothelioma and prostate cancer cell lines were treated with decitabine and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This trial tested custirsen (OGX-011), an inhibitor of CLU protein production, combined with gemcitabine/platinum in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on these results, treatment with gemcitabine should be considered a standard treatment option for second-line NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced non small-cell lung cancer (NSCLC), selected on the basis of a comprehensive geriatric assessment (CGA). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggested that metuzumab could significantly enhance chemosensitivity of human NSCLC cells to gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Metuzumab/gemcitabine combination treatment may be a potentially useful therapeutic regimen for NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively evaluated all patients with NSCLC treated with first-line gemcitabine-based chemotherapy in two Italian hospitals. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Thrombocytosis is neither a prognostic nor a predictive factor for PFS or OS in patients with advanced NSCLC treated with first-line gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment of advanced non-small cell lung cancer (NSCLC) have shown inconsistent findings. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In the present study, we have developed gemcitabine (GEM)-loaded AS1411 aptamer surface-decorated polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersome (Apt-GEM-NP) to target nucleolin-overexpressing non-small cell lung cancer (NSCLC; A549). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine the association between single nucleotide polymorphisms (SNPs) of the RRM1 promoter (-37C>A, -524C>T) and the effectiveness of first-line chemotherapy based on platinum compounds and gemcitabine in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on these results, treatment with gemcitabine should be considered a standard treatment option for second-line NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " To enhance the anticancer efficacy of gemcitabine in the treatment of non-small cell lung cancer (NSCLC), the potential synergistic effect of piceatannol on gemcitabine cytotoxicity was investigated in the human NSCLC A459 cell line. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The findings from this study show that piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak, thereby providing the rational basis for a novel combination strategy for the treatment of NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Treatment of NSCLC cells with the 4EASO resulted in decreased cap-dependent complex formation, decreased cell proliferation and increased sensitivity to gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Through a meta-analysis of observational studies, we evaluated whether RRM1 expression levels are associated with the clinical outcome of gemcitabine-containing treatment regimens in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The meta-analysis reported here indicates that RRM1 expression is associated with the response rate and overall survival rate of advanced NSCLC patients treated with gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "NSCLC patients with the WEE1 rs3910384 G/G homozygote genotype showed 13.5 months extended OS, 3.2 months extended PFS, and a 274% relative increase in their 3-year survival rate (from 7.4% to 27.7%) compared to the A/A+A/G genotype after treatment with platinum-gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In conclusion, the WEE1 rs3910384 G/G homozygote genotype can be used as a selective biomarker for NSCLC patients to indicate treatment with platinum and gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese non-small cell lung cancer (NSCLC) patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Here, we studied the genetic variations underlying NSCLC pathogenesis based on their association to patient outcome after gemcitabine therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: ERCC1 negativity with platinum therapy, gemcitabine therapy, good PS, and female gender all correlated with improved overall survival in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: NAMI-A administered in combination with gemcitabine is only moderately tolerated and less active in NSCLC patients after first line treatment than gemcitabine alone. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " AIM: To identify the single-nucleotide polymorphism (SNP) of hENT1 G-706C that is associated with response to gemcitabine-containing chemotherapy, and to determine the prognosis in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To explore the clinical efficacy of gemcitabine concomitant with nedaplatin and drug resistance in the treatment of non-small cell lung cancer (NSCLC) and associated molecular predicators. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MV combined with gemcitabine could be explored further as chemovirotherapy for NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study examined the prognostic factors associated with survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum regimens as first-line therapy in real-world clinical settings in China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Data was analyzed from a multinational, prospective, non-interventional, observational study of individuals receiving gemcitabine-platinum regimens as first-line therapy for NSCLC, focusing on 300 patients from mainland China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gender, T staging, M staging, liver metastases, superior vena cava obstruction, and serum albumin are prognostic factors affecting overall survival in mainland Chinese patients receiving first-line gemcitabine-platinum regimens for advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the present study was to investigate the effects of a gemcitabine plus platinum (GP) regimen combined with dendritic cell-cytokine induced killer (DC-CIK) immunotherapy on the recurrence and survival rate in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This pilot study evaluated the sensitivity of gemcitabine in micrometastasis and CTCs from NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Additionally, the survival rate in the gemcitabine group (24 months) was better than in non-gemcitabine group (21 months), suggesting a therapeutic benefit for NSCLC patient survival with the common therapy plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the impact of the cytidine deaminase (CDA) A79C polymorphism on both the response to gemcitabine in non-small cell lung cancer (NSCLC) patients and the risk of hematologic toxicities in patients bearing any kind of cancer taking gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Eligible studies included clinical trials that contained the keywords \"gemcitabine\" or \"cytidine deaminase\" and information about response rate of NSCLC patients or hematologic toxicities in patients with any kind of cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The A79C CDA polymorphism did not show a significant impact on the response rate to gemcitabine in NSCLC patients, while the wild type CDA genotype was indeed correlated to a lower rate of incidence of severe anemia in patients taking gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Genes involved in the drug metabolism or elimination (SLC29A3) may be new prognostic biomarkers for patients with advanced NSCLC who receive gemcitabine as the first-line chemotherapy and may unveil an unexplored molecular pathway correlated with the drug response and further may be predictive biomarkers for these patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "NSCLC H292 cells were cultured in the presence or absence of gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Exploratory subgroup analysis revealed the highest RR of hemorrhage in non-small-cell lung cancer (NSCLC) patients (RR: 3.234; 95%CI, 1.678-6.233; p<0.001), phase II trials (RR 7.053, 95%CI: 1.591-31.27; p = 0.01), trials reported during 2006-2012 (RR: 3.750; 95%CI: 1.735-8.108, p<0.001) and gemcitabine used as single agent (RR 7.48; 95%CI: 0.78-71.92, p = 0.081). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Gemcitabine is one of the most widely used drugs for the treatment of advanced Non-small cell lung cancer (NSCLC), but modest objective response rate of patients to gemcitabine makes it necessary to identify novel biomarkers for patients who can benefit from gemcitabine-based therapy and to improve the effect of clinical therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this work, 3 NSCLC cell lines displaying different sensitivities to gemcitabine were applied for mRNA and microRNA (miR) expression chips to figure out the biomarkers for gemcitabine sensitivity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The most intriguing is the activation of Wnt/\u03b2-catenin signaling in gemcitabine resistant NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results might provide potential biomarkers for gemcitabine sensitivity prediction and putative targets to overcome gemcitabine resistance in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We investigated whether ERCC1 (19007C>T) and RRM1 (-37C>A) polymorphisms impact response to chemotherapy and survival in 62 patients with NSCLC treated with platinum and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "By encapsulating a chemodrug, gemcitabine monophosphate (GMP), and siRNA specific to the undruggable cMyc oncogene (cMyc siRNA) into a single nano-sized vesicle and systemically administering them to nude mice, we achieved potent anti-tumor activity in both subcutaneous and orthotopic models of NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This may suggest that first-line therapies, including the use of gemcitabine and oxalipaltin, may be appropriate for the treatment of non-small cell lung carcinoma (NSCLC) with LM involvement. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We also investigated the efficacy of concurrent and sequential administration of sorafenib and gemcitabine in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-sensitive and EGFR-TKI-resistant NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The PC-9 (EGFR-TKI-sensitive, EGFR-mutated) and A549 (EGFR-TKI-resistant, K-Ras-mutated) NSCLC cell lines were treated with sorafenib and gemcitabine, alone, in combination or with different schedules. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We found that sorafenib exhibited dose-dependent growth inhibition in the EGFR-TKI-sensitive and EGFR-TKI-resistant NSCLC cell lines, and the sequence gemcitabine\u2192sorafenib exhibited the strongest synergism. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The results suggest that sorafenib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR and K-Ras mutations and that the sequential administration of gemcitabine followed by sorafenib is superior to sorafenib followed by gemcitabine and concurrent administration. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The NSCLC cell lines A549 (mutant KRAS), H1666 (mutant BRAF) and H1975 (mutant EGFR-T790M) were treated with sorafenib and gemcitabine alone and in combination. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In conclusion, we found that sorafenib exhibits antiproliferative effects in EGFR-TKI-resistant NSCLC cell lines and when combined with gemcitabine demonstrates synergistic activity in A549 and H1666 cells but antagonistic activity in H1975 cells. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IV NSCLC receiving at least two cycles of first-line doublet chemotherapy (gemcitabine plus platinum) were reviewed retrospectively. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Timing of CIN is predictive of prognosis in patients with metastatic NSCLC receiving gemcitabine/platinum doublet chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " In this study, we investigated whether COL4A3 mRNA expression levels were associated with clinical outcomes after treatment with a combination of gemcitabine (Gem)/cis-diamminedichloroplatinum(II) (CDDP) regimen for patients with advanced stage non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare the response, survival, hematological and non-hematological toxicities of gemcitabine administrated at fixed-dose rate infusion (10 mg/m(2)/min, FDR) and standard 30 min infusion in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This meta-analysis found that FDR infusion of gemcitabine had equal ORR and 1-year SR with standard infusion in patients with advanced NSCLC, while FDR infusion was associated with more grade 3/4 hematological and non-hematological toxicities. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "NSCLC, mesothelioma and prostate cancer cell lines were treated with decitabine and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Ectopic expression of DSP in the NSCLC cell line H157 significantly inhibited cell proliferation, anchorage-independent growth, migration and invasion and also increased the sensitivity of NSCLC cells to apoptosis induced by an anticancer drug, gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "AIM: To determine whether low dose gemcitabine increased event-free survival in patients with T1-2 N0-1 M0 NSCLC deemed unfit for surgery. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with T1-2 N0-1 M0 NSCLC deemed unfit for surgery were randomised to 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks to known sites of cancer with (Arm B) or without (Arm A) 100mg/m(2) weekly gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: No evidence of an improvement in event-free survival was seen with the addition of weekly gemcitabine at this dose for patients with early stage NSCLC unfit for surgery, although the power of the study was low. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We evaluated whether single nucleotide polymorphisms of DN- repair genes excision repair cross-complementing group 1 (ERCC1), ERCC2, x-ray repair cross-complementing group 1 (XRCC1), XRCC3, and RRM1 associate with treatment outcome in NSCLC patients receiving gemcitabine plus platinum as their first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Genotyping for eight polymorphisms in five DNA-repair genes was performed with the GenomeLab nucleotide polymorphismstream Genotyping System in 62 advanced NSCLC patients in a training set and 45 patients in a validation set treated with gemcitabine/platinum. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In the validation set, only XRCC1 399 CONCLUSIONS: Genetic polymorphism of XRCC1 Arg399Gln may be a candidate for contributing interindividual difference in the OS of gemcitabine/platinum-treated advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced non small-cell lung cancer (NSCLC), selected on the basis of a comprehensive geriatric assessment (CGA). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate whether the T393C polymorphism of the GNAS1 gene could be used as a chemotherapy sensitivity and prognosis predictive marker of advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum (GP). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) treated by gemcitabine/platinum chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This trial tested custirsen (OGX-011), an inhibitor of CLU protein production, combined with gemcitabine/platinum in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Gemcitabine is one of the most widely used drugs for the treatment of NSCLC, and several phase II trials specifically designed for elderly patients with advanced NSCLC have confirmed the role of gemcitabine in this setting. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, we performed a phase II study using the combination of gemcitabine and UFT as first-line therapy in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of gemcitabine and UFT was effective in disease control and well tolerated first-line regimen in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the pharmacogenomic effects of the entire gemcitabine metabolic pathway, we genotyped single nucleotide polymorphisms (SNPs) within the 17 pathway genes using DNA samples from patients with NSCLC treated with gemcitabine to determine the effect of genetic variants within gemcitabine pathway genes on overall survival (OS) of patients with NSCLC after treatment of gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Functional studies demonstrated that downregulation of SLC29A1, NT5C2, and RRM1 in NSCLC cell lines altered cell susceptibility to gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: These studies help in identifying biomarkers to predict gemcitabine response in NSCLC, a step toward the individualized chemotherapy of lung cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This meta-analysis is performed to systematically evaluate whether RRM1 expression is associated with the clinical outcome of gemcitabine-containing regimen in advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A systemic review of the studies on the association between RRM1 expression in advanced NSCLC and clinical outcome of gemcitabine-containing regimen was performed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Low/negative RRM1 expression in advanced NSCLC was associated with higher response rate to gemcitabine-containing regimen and better prognosis. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Large phase III randomized trials are required to identify whether RRM1 detection is clinically valuable for predicting the prognosis and sensitivity to gemcitabine-containing regimen in advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggested that metuzumab could significantly enhance chemosensitivity of human NSCLC cells to gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Metuzumab/gemcitabine combination treatment may be a potentially useful therapeutic regimen for NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based doublets (PBDs) remain the cornerstone of treatment in non-small-cell lung cancer (NSCLC) and may include gemcitabine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "gemcitabine"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "bavituximab"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "bavituximab"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "bavituximab"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Further analysis and validation of Cav-1 and SPARC expression in tumor and stromal compartments as prognostic and/or predictive biomarkers of NSCLC or nab-paclitaxel treatment is warranted. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of this clinical study was to evaluate the efficacy and safety of nab-paclitaxel to treat patients with advanced non-small cell lung cancer (NSCLC) who failed first-line chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Given the tolerability on grade 3 or 4 adverse events, nab-paclitaxel may be considered an alternative second-line treatment option for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the [UNICAMP], Brazil. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95\u00a0% CI 1.03-90.41], p\u2009=\u20090.047). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "AIM: To evaluate the safety and efficacy of a metronomic schedule of paclitaxel administered weekly in relapsed refractory NSCLC or upfront in patients not eligible for platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with recurrent and treatment-na\u00efve platinum-ineligible advanced NSCLC were treated with weekly paclitaxel at 80 mg/m 2 with palliative intent. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly low-dose continuous metronomic-type scheduling of paclitaxel is safe and effective for relapsed refractory NSCLC and in the first line in platinum-ineligible patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Further analysis and validation of Cav-1 and SPARC expression in tumor and stromal compartments as prognostic and/or predictive biomarkers of NSCLC or nab-paclitaxel treatment is warranted. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "An increase of CEC and CEP was observed in patients with NSCLC treated with paclitaxel and bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or subtherapeutic exposure. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: PK-guided dosing of paclitaxel does not improve severe neutropenia, but reduces paclitaxel-associated neuropathy and thereby improves the benefit-risk profile in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced non-small-cell lung cancer (NSCLC) and diabetes. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Further analysis and validation of Cav-1 and SPARC expression in tumor and stromal compartments as prognostic and/or predictive biomarkers of NSCLC or nab-paclitaxel treatment is warranted. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC) study. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human non-small-cell lung cancer (NSCLC) cells to carbon-ion beam irradiation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study was to evaluate the efficacy and safety of intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy as induction therapy in clinical stage III unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The clinical experience with nab-paclitaxel to date and the role of this newly approved therapy in the management of NSCLC will be summarized in this article. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Patients with unresectable stage III NSCLC were treated with paclitaxel 15 mg/m(2) IV, followed by TTR 6 h later on Monday/Wednesday/Friday, and TTR only on Tuesday/Thursday mornings (total 55 Gy). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Low-dose paclitaxel with concurrent TTR is an effective chemoradiotherapy regimen in unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced non-small-cell lung cancer (NSCLC) based on preplanned stratification factors specified in the phase III trial protocol. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Carboplatin-paclitaxel chemotherapy combination is the standard first-line treatment of advanced ovarian cancer and is the most commonly used treatment combination shown to be effective in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This randomized phase II study evaluated ixabepilone-based chemotherapy in stage IIIb/IV NSCLC, compared with paclitaxel-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "\u03b23T-positive patients had worse PFS relative to \u03b23T-negative patients, regardless of treatment; hence, \u03b23T expression seems to be a negative prognostic factor, but not a predictive factor, in advanced NSCLC treated with either ixabepilone or paclitaxel platinum-based doublets. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 \u03bcM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or subtherapeutic exposure. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: PK-guided dosing of paclitaxel does not improve severe neutropenia, but reduces paclitaxel-associated neuropathy and thereby improves the benefit-risk profile in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage non-small cell lung cancer (NSCLC) after 1st line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with non-small cell lung cancer (NSCLC), then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in non-small-cell lung cancer (NSCLC) patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We performed an open-label, multicenter, single-arm phase II study (UMIN ID 000010532) to prospectively evaluate the efficacy and safety of nab-paclitaxel for previously treated patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with advanced NSCLC who experienced failure of prior platinum-doublet chemotherapy received weekly nab-paclitaxel (100mg/m(2)) on days 1, 8, and 15 of a 21-day cycle until disease progression or the development of unacceptable toxicity. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Weekly nab-paclitaxel was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Currently, nab-paclitaxel is approved for the treatment of metastatic breast cancer, locally advanced/metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Clinical studies suggest that nab-paclitaxel may be particularly effective in cancers with squamous histology, including NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "An increase of CEC and CEP was observed in patients with NSCLC treated with paclitaxel and bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of the current study was to identify whether the 2(nd) TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study was to evaluate the efficacy and safety of intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy as induction therapy in clinical stage III unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "AREAS COVERED: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Patients with unresectable stage III NSCLC were treated with paclitaxel 15 mg/m(2) IV, followed by TTR 6 h later on Monday/Wednesday/Friday, and TTR only on Tuesday/Thursday mornings (total 55 Gy). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Low-dose paclitaxel with concurrent TTR is an effective chemoradiotherapy regimen in unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here, we report results of a randomized phase 3 study comparing two CCRT regimens in improving chest tumor control by low-dose paclitaxel chemoradiation for LA-NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pulsed low-dose paclitaxel CCRT resulted in significantly better RFS and tumor response rate, and less hematologic toxicities than weekly CCRT for LA-NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "There is as yet no predictive marker for cytotoxic agents against non-small-cell lung cancer (NSCLC), and hence we believed that SPARC expression might be associated with tumor response to nab-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Stromal SPARC was detected by immunohistochemical staining in \u223c70% of NSCLC cases, and good tumor response to nab-paclitaxel was correlated with high stromal SPARC reactivity. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here, we explored the molecular basis resulting in Survivin overexpression in NSCLC and investigated the antitumor activity of the class I HDAC inhibitor entinostat in combination with paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our data showed that entinostat significantly enhanced paclitaxel-mediated anti-proliferative/anti-survival effects on NSCLC cells in vitro and in vivo. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our findings also support that the combinatorial treatments of entinostat and paclitaxel will likely exhibit survival benefit in the NSCLC patients with overexpression of DNMT1 and/or Survivin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Mouse xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of LCL161 alone or in combination with paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "LCL161, an IAP inhibitor, cooperated with paclitaxel to reduce cell viability and induce apoptosis in NSCLC cells. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Thus, LCL161 could be a useful agent for the treatment of NSCLC in combination with paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We performed an open-label, multicenter, single-arm phase II study (UMIN ID 000010532) to prospectively evaluate the efficacy and safety of nab-paclitaxel for previously treated patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with advanced NSCLC who experienced failure of prior platinum-doublet chemotherapy received weekly nab-paclitaxel (100mg/m(2)) on days 1, 8, and 15 of a 21-day cycle until disease progression or the development of unacceptable toxicity. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Weekly nab-paclitaxel was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the safety and short-term efficacy of sigle drug albumin-bound paclitaxel (ABP) in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or subtherapeutic exposure. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: PK-guided dosing of paclitaxel does not improve severe neutropenia, but reduces paclitaxel-associated neuropathy and thereby improves the benefit-risk profile in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here, we aimed to examine M30 and M65 values for predicting the therapeutic outcome of paclitaxel treatment of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The serum levels of M30 and M65 before and after paclitaxel treatment in advance-stage NSCLC patients were analyzed, and compared to those in healthy controls. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Two days after paclitaxel treatment, the serum levels of both M30 and M65 significantly increased in NSCLC patients (p\u00a0<\u00a00.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that the serum M30/M65 ratio may be a prognostic factor for the outcome of paclitaxel treatment in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced non-small-cell lung cancer (NSCLC) and diabetes. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage non-small cell lung cancer (NSCLC) after 1st line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We compared survival of mice bearing established MDA-MB-231 breast cancer or PC-14 non-small cell lung cancer (NSCLC) brain metastases that were treated with vehicle, macitentan, paclitaxel, or macitentan plus paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A randomized phase II trial was carried out to compare the efficacy/safety of three doses of linifanib with that of CBDCD + paclitaxel (PTX), as the largest and first placebo-controlled trial of linifanib for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Currently, nab-paclitaxel is approved for the treatment of metastatic breast cancer, locally advanced/metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Clinical studies suggest that nab-paclitaxel may be particularly effective in cancers with squamous histology, including NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "However, some NSCLCs are not sensitive to paclitaxel treatment with undetermined underlying molecular mechanisms. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we found that paclitaxel dose-dependently activated Beclin-1 in 2 NSCLC cell lines, A549 and Calu-3. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Inhibition of autophagy significantly increased the paclitaxel-induced NSCLC cell death in a cell counting kit-8 (CCK-8) assay. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Moreover, microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Together, these data suggest that paclitaxel may decrease miR-216b levels in NSCLC cells, which subsequently upregulates Beclin-1 to increase NSCLC cell autophagy to antagonize paclitaxel-induced cell death. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Strategies that increase miR-216b levels or inhibit cell autophagy may improve the outcome of paclitaxel treatment in NSCLC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Chemotherapy paclitaxel yields significant reductions in tumor burden in the majority of advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here we demonstrated that the histone deacetylase (HDAC) was activated in paclitaxel-resistant NSCLC cells, and its activation promoted proliferation and tumorigenesis of paclitaxel-resistant NSCLC cells in vitro and in vivo. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Furthermore, we observed that overexpression of HDAC1 was associated with the downregulation of p21, a known HDAC target, in advanced NSCLC patients with paclitaxel treatment, and predicted chemotherapy resistance and bad outcome. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In summary, our data demonstrate a role of HDAC in paclitaxel-resistant NSCLC and provide a promising therapeutic strategy to overcome paclitaxel-acquired resistance. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Weekly paclitaxel combined with a platinum-based agent has been advocated as an alternative regimen for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Limited studies exist on the tolerability of weekly paclitaxel in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To address this issue, we assessed the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of weekly paclitaxel in Japanese patients with advanced NSCLC in a dose-escalation Phase I trial and examined the feasibility of dexamethasone taper in these patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "IMPLICATIONS: Weekly paclitaxel at 100 mg/m(2) given as a 1-hour infusion for 6 weeks followed by a 2-week treatment interval was well tolerated by Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The role of single-agent nab-paclitaxel in relapsed or platinum-refractory advanced non-small cell lung cancer (NSCLC) has not been well reported in Western populations. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We analyzed the records of stage IV NSCLC patients with relapsed or platinum-refractory disease treated with single-agent nab-paclitaxel at Weill Cornell Medical College between October 2008 and December 2013. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Thirty-one stage IV NSCLC patients received a median of 4 cycles (range 1-40) of nab-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Notably, silencing SET enhanced the pro-apoptotic effects of paclitaxel, while ectopic expression of SET diminished the sensitivity of NSCLC cells to paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Since the SET protein was shown to affect chemosensitivity, we next examined whether combining a novel SET antagonist, EMQA, sensitized NSCLC cells to paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with non-small cell lung cancer (NSCLC), then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In addition, RYBP expression was induced by paclitaxel, the first-line chemotherapeutic agent for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of our study was to evaluate the efficacy and safety of nab-paclitaxel in the treatment of advanced non-small-cell lung cancer [NSCLC]. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We assessed 101 Chinese patients who were diagnosed with Stage IIIB or IV NSCLC from August 2009 to November 2014.The patients were injected with nab-paclitaxel [260 mg/m(2) , day1] with or without platinum. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The nab-paclitaxel chemotherapy could achieve significant tumour responses and encourage survival in advanced NSCLC patients with tolerable toxicities. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD), the recommended dose (RD) and the safety profile of amrubicin (AMR) plus paclitaxel (PTX) combination regimen for patients with previously treated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Tumor-associated stromal caveolin-1 (Cav-1) expression was correlated with improved response rate and survival in NSCLC patients who received nab-paclitaxel in this phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin and nab-paclitaxel every 21 days demonstrated promising efficacy with tolerable toxicity in NSCLC patients ineligible for bevacizumab therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Further analysis and validation of Cav-1 and SPARC expression in tumor and stromal compartments as prognostic and/or predictive biomarkers of NSCLC or nab-paclitaxel treatment is warranted. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this work, sequential exposure of two anticancer agents, paclitaxel (Tx) followed by topotecan (TPT), was shown to have a synergistic effect on non-small cell lung cancer (NSCLC) cell line, NCI-H460. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of this clinical study was to evaluate the efficacy and safety of nab-paclitaxel to treat patients with advanced non-small cell lung cancer (NSCLC) who failed first-line chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Given the tolerability on grade 3 or 4 adverse events, nab-paclitaxel may be considered an alternative second-line treatment option for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC) study. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The findings demonstrated that paclitaxel effect may be interfered with stathmin; overexpression of stathmin is a predictive marker for a worse prognosis in patients with NSCLC who were treated by both platinum and paclitaxel chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here, we generated isogenic LKB1-wild type and mutant non-small cell lung cancer (NSCLC) cell lines to evaluate the role of LKB1 in paclitaxel resistance. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: SRB, flow cytometry and immunoblotting were used to assess cell proliferation and apoptosis in NSCLC cell lines after paclitaxel treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "These data suggest that LKB1 does not promote paclitaxel-induced apoptosis in most NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In contrast, in some NSCLC, the presence of LKB1 may facilitate increases in either MDR1 or class III beta-tubulin expression which can lead to paclitaxel resistance. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here, we report the outcomes of concurrent paclitaxel-based chemo-radiotherapy (CRT) for NSCLC patients with microscopically positive bronchial margins or peribronchial infiltration. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For NSCLC patients with post-surgical microscopic residual tumor at the bronchial stump, concurrent paclitaxel-based chemo-radiotherapy achieved promising outcomes with accepted treatment-related toxicity. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human non-small-cell lung cancer (NSCLC) cells to carbon-ion beam irradiation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Taxols, such as paclitaxel, independently potentiate tumor destruction via apoptosis and are used as first line therapy in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Human NSCLC cell lines (A-549 and H-322m) were incubated in the presence of PAC-1 and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: PAC-1 significantly enhances the antitumor activity of paclitaxel against NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study was to evaluate the efficacy and safety of intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy as induction therapy in clinical stage III unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Further, mitochondrial membrane potential was monitored in non-small-cell lung cancer cells (NSCLC) when treated with paclitaxel, \u03b1-pinene and \u03b2-pinene alone and in combination. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u5316\u7597\u8010\u836f\u5bfc\u81f4\u80bf\u7624\u5f88\u5feb\u590d\u53d1\u548c/\u6216\u8f6c\u79fb\uff0c\u662f\u76ee\u524d\u80ba\u764c\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00\u3002\u03b2-tubulin\u662f\u6297\u5fae\u7ba1\u836f\u7269\u7684\u4e3b\u8981\u7ec6\u80de\u9776\u70b9\u3002\u5df2\u6709\u7684\u7814\u7a76\u8bc1\u660e\uff1a\u03b2III-tubulin\u9ad8\u8868\u8fbe\u4e0e\u975e \u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u8010\u836f\u6709\u5173\u3002\u5229\u7528RNA\u5e72\u6270\u6280\u672f\u6c89\u9ed8\u8010\u7d2b\u6749\u9187A549\u7ec6\u80de\uff08A549/Taxol\uff09\u4e2d\u03b2III-tubulin\u57fa\u56e0\u8868\u8fbe\uff0c\u63a2\u8ba8\u9776\u57fa\u56e0\u4e0b\u8c03\u540e\u5bf9\u5316\u7597\u836f\u7269\u7d2b\u6749\u9187\u7684\u654f\u611f \u6027\u7684\u53d8\u5316\u4ee5\u53ca\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u60c5\u51b5\u3002\u65b9\u6cd5 \u6784\u5efa\u9776\u5411\u03b2III-tubulin\u7684siRNA\uff0c\u4ee5\u8102\u8d28\u4f53\u4e3a\u8f7d\u4f53\u4ecb\u5bfc\u03b2III-tubulin siRNA\u8f6c\u67d3A549/Taxol\u7ec6\u80de\uff0c\u5229\u7528qRT-PCR\u68c0\u6d4b\u7ec6\u80de\u5185\u03b2III-tubulin mRNA\u7684\u53d8\u5316\u60c5\u51b5\uff0c\u5e76\u7b5b\u9009\u51fa\u6700\u4f73\u5e72\u6270\u5e8f\u5217\uff1bWestern blot\u6cd5\u68c0\u6d4bA549/Taxol\u7ec6\u80de\u5185\u03b2III-tubulin\u86cb\u767d\u8868\u8fbe\u7684\u53d8\u5316\uff1bMTT\u6cd5\u68c0\u6d4b\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u5bf9\u7d2b\u6749\u9187\u654f\u611f\u6027\u7684\u53d8\u5316\uff1b\u6d41\u5f0f\u7ec6\u80de\u4eea\u68c0\u6d4b\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u7684\u53d8 \u5316\u3002\u7ed3\u679c \u5b9e\u65f6\u8367\u5149qRT-PCR\u6cd5\u663e\u793a\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u9776\u57fa\u56e0\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u964d\u4f4e\uff0c\u5176\u4e2d\u03b2III-tubulin siRNA-1\u5e8f\u5217\u6291\u5236\u7387\u6700\u9ad8\u4e3a\uff0887.73\u00b14.87\uff09%\uff08P<0.01\uff09\uff1bWestern blot\u663e\u793a\u8f6c\u67d3\u540e\u9776\u86cb\u767d\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u964d\u4f4e\uff1bMTT\u6cd5\u8868\u660e\u7d2b\u6749\u9187\u5904\u7406\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u7684\u7ec6\u80de\u6291\u5236\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff0851.77\u00b14.60\uff09%\uff08P<0.01\uff09\uff1b\u7ec6\u80de\u51cb\u4ea1\u663e \u793a\u03b2III-tubulin siRNA+Taxol\u7ec4\u7ec6\u80de\u65e9\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff08P<0.01\uff09\uff0c\u4e24\u8005\u7684\u5dee\u5f02\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff1b\u7ec6\u80de\u5468\u671f\u68c0\u6d4b\u7ed3\u679c\u663e\u793a\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684G2/M\u671f\u7ec6\u80de\u767e\u5206\u7387\u9ad8\u4e8e\u5bf9\u7167\u7ec4\uff0c \u4e14\u8f6c\u67d3\u540e\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684\u7ec6\u80de\u665a\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u589e\u52a0\u3002\u7ed3\u8bba \u03b2III-tubulin\u8868\u8fbe\u4e0b\u8c03\u660e\u663e\u63d0\u9ad8A549/Taxol\u7ec6\u80de\u682a\u5bf9Taxol\u7684\u654f\u611f\u6027\u3002 DOI: 10.3779/j.issn.1009-3419.2014.08.01 PMID: 25130963 [PubMed - indexed for MEDLINE]  INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " A nanoparticle (NP) formulation with 2'-(2-bromohexadecanoyl)-paclitaxel (Br-16-PX) conjugate was developed in these studies for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the predictive value of APE1, BRCA1, ERCC1 and TUBB3 in advanced NSCLC patients who received platinum-paclitaxel treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and thirty-six advanced NSCLC patients, who were treated with first-line platinum-paclitaxel chemotherapy, were enrolled in this study. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The data indicate that APE1, ERCC1 and TUBB3 could be a useful biomarker to predict clinical outcome in patients with advanced NSCLC receiving first-line platinum-paclitaxel chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A 69-year-old female with postoperatively recurrent NSCLC was treated weekly with nanoparticle-albumin-bound paclitaxel (nab-paclitaxel) monotherapy every 4 weeks as a tenth line chemotherapy, and stable disease was achieved by seven cycles of this regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To our knowledge this is the first report of the efficacy of nab-paclitaxel monotherapy in a heavily treated NSCLC patient. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This procedure significantly improves the treatment of metastatic breast cancer compared to conventional paclitaxel-based therapies, including other type of cancers such as metastatic pancreatic cancer, stage IIIB-IV non-small cell lung cancer (NSCLC) and metastatic melanoma. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here we report that intrinsic resistance to paclitaxel in NSCLC occurs at a cell-autonomous level because of the uncoupling of mitotic defects from apoptosis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This strategy revealed that prolonging mitotic arrest with a small molecule inhibitor of the APC/cyclosome could sensitize otherwise paclitaxel-resistant NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the [UNICAMP], Brazil. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95\u00a0% CI 1.03-90.41], p\u2009=\u20090.047). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Its in vitro antiproliferative activity was then evaluated in human non-small cell lung cancer A549 (NSCLC), stomach adenocarcinoma BGC-823, hepatocellular carcinoma HepG2 and gastric carcinoma HGC-27 cell lines using conventional cancer drugs (paclitaxel, doxorubicin and mitomycin C) as positive controls. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Metronomic paclitaxel synergized with adoptive CIK cell immunotherapy to inhibit the growth of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "AREAS COVERED: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The clinical experience with nab-paclitaxel to date and the role of this newly approved therapy in the management of NSCLC will be summarized in this article. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "An increase of CEC and CEP was observed in patients with NSCLC treated with paclitaxel and bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Patients with unresectable stage III NSCLC were treated with paclitaxel 15 mg/m(2) IV, followed by TTR 6 h later on Monday/Wednesday/Friday, and TTR only on Tuesday/Thursday mornings (total 55 Gy). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Low-dose paclitaxel with concurrent TTR is an effective chemoradiotherapy regimen in unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To ascertain whether ICAM-3 also promotes anticancer drug resistance, mock control (H1299/pcDNA3) or ICAM-3-expressing stable transfectants (H1299/ICAM-3) of the non-small cell lung cancer (NSCLC) cell line, NCI-H1299, were generated and treated with the microtubule-damaging agents, paclitaxel (TXL) and vincristine (VCS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "To date, paclitaxel albumin-bound nanoparticles (Abraxane\u00ae) have been approved by the FDA for the treatment of metastatic breast cancer and non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in non-small-cell lung cancer (NSCLC) patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The effect of sodium-R-alpha lipoate on camptothecin- and paclitaxel-induced cytotoxicity was evaluated on A549 NSCLC and BEAS-2B \"normal\" lung epithelial cells. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Given controversy remains on monotherapy and combinatory chemotherapy in elderly patients (> or = 70 years) with advanced non-small cell lung cancer (NSCLC), we conducted this study to compare the safety and efficacy of liposome paclitaxel and platinum-containing doublets. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Platinum-containing doublet chemotherapy achieved a higher response rate, longer time-to-progression and overall survival compared with liposome paclitaxel monotherapy in the treatment of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "AIM: To evaluate the safety and efficacy of a metronomic schedule of paclitaxel administered weekly in relapsed refractory NSCLC or upfront in patients not eligible for platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with recurrent and treatment-na\u00efve platinum-ineligible advanced NSCLC were treated with weekly paclitaxel at 80 mg/m 2 with palliative intent. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly low-dose continuous metronomic-type scheduling of paclitaxel is safe and effective for relapsed refractory NSCLC and in the first line in platinum-ineligible patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we evaluated the dynamics and feasibility of imaging non-small cell lung cancer (NSCLC) apoptosis induced by paclitaxel treatment using a (99)Tc(m)-labeled Annexin V recombinant with ten consecutive histidines (His10-Annexin V) in a mouse model. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The human H460 NSCLC tumor cell line (H460) tumor-bearing mice were treated with intravenous paclitaxel 24, 48 and 72 hours later. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced non-small-cell lung cancer (NSCLC) based on preplanned stratification factors specified in the phase III trial protocol. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Carboplatin-paclitaxel chemotherapy combination is the standard first-line treatment of advanced ovarian cancer and is the most commonly used treatment combination shown to be effective in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and safety of albumin-bound paclitaxel (ABP) monotherapy in treating recurrent advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This randomized phase II study evaluated ixabepilone-based chemotherapy in stage IIIb/IV NSCLC, compared with paclitaxel-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "\u03b23T-positive patients had worse PFS relative to \u03b23T-negative patients, regardless of treatment; hence, \u03b23T expression seems to be a negative prognostic factor, but not a predictive factor, in advanced NSCLC treated with either ixabepilone or paclitaxel platinum-based doublets. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In combination with paclitaxel, anti-PLK-1 siRNA chemosensitized non-small cell lung cancer (NSCLC) and prostate carcinoma cell lines, leading up to a 2-fold increase in the drug cytotoxic effect. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Nanoparticle albumin-bound (nab)-paclitaxel has been recently approved for the use in breast and NSCLC with very promising results in pancreatic adenocarcinoma. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 \u03bcM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In our experience, combination of bevacizumab and weekly paclitaxel exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond for non-squamous NSCLC patients, supporting further evaluation in larger prospective studies. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The usefulness of paclitaxel plus S1 (PTX+S1) was evaluated in 46 pretreated NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "On the other hand, paclitaxel (Taxol) is a new antineoplastic drug that has shown promise in the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This phase I study investigated the tolerability, safety and pharmacokinetics (PK) of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Matuzumab combined with paclitaxel was generally well tolerated in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "RESULTS: We demonstrated that radiation and paclitaxel alone inhibited tumor growth, but a combined therapy of radiation and paclitaxel was more effective in inhibiting NSCLC tumor growth. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our study suggested that a PTEN-PI3K-Akt-Bax signaling cascade is involved in the therapeutic effect of combined radiation/paclitaxel treatment in NSCLC without p53 expression. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated the cytotoxicities of paclitaxel and sorafenib alone and in combination in NSCLC cell lines with KRAS or BRAF mutations and investigated the mechanism of the interaction between the drugs. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We found synergistic antitumor efficacy with paclitaxel followed by sorafenib in in vitro and in vivo models of NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In the present study, paclitaxel and parthenolide were loaded into mixed micelles and tested against taxol sensitive (A549) and resistant (A549-T24) NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The aim of the current study was to identify whether the 2(nd) TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The clinical efficacy of paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients with advanced NSCLC is more better than that of the single-agent paclitaxel liposome. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: It has been proposed that the level of class III \u03b2-tubulin gene expression can be used to predict clinical sensitivity to paclitaxel/vinorebine-based chemotherapy in non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We conducted a meta-analysis of all relevant published data to provide a combined statistical assessment of the proposed association of expression variations of class III \u03b2-tubulin with objective response and median survival in patients with NSCLC treated with paclitaxel/vinorebine-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We conducted the meta-analysis using data from ten studies, each of which evaluated the correlation between class III \u03b2-tubulin expression levels and objective response in patients treated with paclitaxel/vinorebine-based chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This result supports the usefulness of class III \u03b2-tubulin mRNA level as a biomarker for sensitivity to paclitaxel/vinorebine-based chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The published data on the curative effects of comparing the once weekly paclitaxel-based chemotherapies (W-paclitaxel) with the standard every 3 weeks paclitaxel-based chemotherapies (S-paclitaxel) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) were still controversial. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Medical databases and conference proceedings were searched for randomized controlled trials which compared W-paclitaxel with S-paclitaxel in patients with first-line treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In the five NSCLC (non small cell lung cancer) trials, the summary effect revealed a better response rate with weekly paclitaxel (odds ratio: 1.24, p=0.042). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "A randomized phase II trial was carried out to compare the efficacy/safety of three doses of linifanib with that of CBDCD + paclitaxel (PTX), as the largest and first placebo-controlled trial of linifanib for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " The aim of this clinical study was to evaluate the efficacy and safety of nab-paclitaxel to treat patients with advanced non-small cell lung cancer (NSCLC) who failed first-line chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Given the tolerability on grade 3 or 4 adverse events, nab-paclitaxel may be considered an alternative second-line treatment option for NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Vinorelbine and paclitaxel are effective as single agents in advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: It has been proposed that the level of class III \u03b2-tubulin gene expression can be used to predict clinical sensitivity to paclitaxel/vinorebine-based chemotherapy in non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "We conducted a meta-analysis of all relevant published data to provide a combined statistical assessment of the proposed association of expression variations of class III \u03b2-tubulin with objective response and median survival in patients with NSCLC treated with paclitaxel/vinorebine-based chemotherapy. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "METHODS: We conducted the meta-analysis using data from ten studies, each of which evaluated the correlation between class III \u03b2-tubulin expression levels and objective response in patients treated with paclitaxel/vinorebine-based chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": "This result supports the usefulness of class III \u03b2-tubulin mRNA level as a biomarker for sensitivity to paclitaxel/vinorebine-based chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "paclitaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the first-line treatment of non-small cell lung cancer (NSCLC); it is therefore important to discover biomarkers that can be used to predict the efficacy and toxicity of this treatment. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the standard treatment for NSCLC patients with EGFR wild-type, and as alternative to failure to EGFR inhibitors. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Platinum-based chemotherapy is the first-line treatment for non-small-cell lung cancer (NSCLC), however, the therapeutic efficiency varies remarkably among individuals. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but the chemotherapy often results in the development of chemoresistance. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Platinum-based chemotherapy and 3rd generation drugs is still the main treatment option for advanced non-small cell lung cancer (NSCLC) patients without activating EGFR mutations or ALK rearrangements. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy has been shown to improve the survival of advanced non-small cell lung cancer (NSCLC) patients; the platinum-induced toxicity severely impedes the success of chemotherapy. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Platinum-based chemotherapy remains as the standard of treatment for most of advanced non-small cell lung cancer (NSCLC) patients, and although therapeutic improvements have been achieved in the last years, the benefits are quite modest. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is a standard strategy for non-small cell lung cancer (NSCLC), while chemoresistance remains a major therapeutic challenge in current clinical practice. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy improves survival among patients with non-small cell lung cancer (NSCLC), but the efficiency is limited due to resistance. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " To investigate whether theNAD(P)H: quinone oxidoreductase 1 (NQO1) gene polymorphisms determine the Platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) in a Chinese cohort. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Platinum-based chemotherapy regimens are the standard treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the standard treatment for patients with advanced non-small cell lung cancer (NSCLC), but the evidence of its efficacy among ECOG performance status (PS)2 patients is weak because these patients are usually excluded from clinical trials; concern exists about tolerability and feasibility of standard chemotherapy in these patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is a primary treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Platinum-based chemotherapy was given to each patient with NSCLC, and the therapeutic effect was evaluated. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " PURPOSE: Platinum-based chemotherapy is the most common treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-operative NSCLC patients without EGFR gene mutation. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " AIM: To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is a standard strategy for non-small cell lung cancer (NSCLC), while chemoresistance remains a major therapeutic challenge in current clinical practice. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy improves survival among patients with non-small cell lung cancer (NSCLC), but the efficiency is limited due to resistance. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": "Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the standard treatment for patients with advanced non-small cell lung cancer (NSCLC), but the evidence of its efficacy among ECOG performance status (PS)2 patients is weak because these patients are usually excluded from clinical trials; concern exists about tolerability and feasibility of standard chemotherapy in these patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Platinum-based chemotherapy is standard for untreated, advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy with third generation drugs (such as gemcitabine) is an efficacious regimen of first-line treatment of patients with advanced, unresectable non-small cell lung cancer (NSCLC), without activating EGFR mutations. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " Platinum-based chemotherapy is the standard treatment for patients with advanced non-small cell lung cancer (NSCLC), but the evidence of its efficacy among ECOG performance status (PS)2 patients is weak because these patients are usually excluded from clinical trials; concern exists about tolerability and feasibility of standard chemotherapy in these patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Platinum-based chemotherapy is standard for untreated, advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Platinum-based chemotherapy and 3rd generation drugs is still the main treatment option for advanced non-small cell lung cancer (NSCLC) patients without activating EGFR mutations or ALK rearrangements. ", "disease": "NSCLC", "drug": "Platinum-based chemotherapy"}, {"polarity": 0, "orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The aim of this study was to determine the response of advanced-stage non-small cell lung cancer (NSCLC) patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The results indicate that patients with advanced-stage NSCLC with EGFR mutations have a\u00a0better response to chemotherapy followed by gefitinib than chemotherapy alone and a\u00a0better response to chemotherapy than wild-type patients.KEYWORDS: chemotherapy, gefitinib, NSCLC, tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, first-line gefitinib should not be recommended for advanced non-small cell lung cancer (NSCLC) patients only based on clinical factors, due to a very small sample-size in our study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic non-small-cell lung cancer (NSCLC) after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We retrospectively reviewed 81 advanced NSCLC patients with disease progression following tumor response and durable (\u2265 6 months) disease stabilization with first-line or second-line gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer (NSCLC); however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) non-small cell lung cancer (NSCLC) after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " A phase II clinical trial was performed to evaluate the efficacy and safety of gefitinib on pretreated Chinese female non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVES: The combination use of gefitinib and epidermal growth factor receptor (EGFR) testing is a standard first-line therapy for patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, first-line gefitinib should not be recommended for advanced non-small cell lung cancer (NSCLC) patients only based on clinical factors, due to a very small sample-size in our study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The Iressa Alliance program provided standardized EGFR mutation testing and appropriate access to gefitinib to all patients in British Columbia with advanced, non squamous non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These LCSS outcomes provide further evidence that patients with wild-type EGFR might not benefit from first-line treatment of advanced NSCLC with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Patients, who were \u2265 18 years, chemona\u00efve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer (NSCLC); however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, whether Ori can be used in gefitinib-resistant non-small cell lung cancer (NSCLC) cells remains unclear. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Results demonstrated that this compound dose-dependently inhibited the proliferation, invasion, and migration of the gefitinib-resistant NSCLC cells in\u00a0vitro. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In addition, Ori upregulated protein phosphatase 2A (PP2A) activity of gefitinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These findings indicated that Ori can inhibit the proliferation, invasion, and migration of gefitinib-resistant NSCLC cells by suppressing EGFR/ERK/MMP-12 and CIP2A/PP2A/Akt signaling pathways. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Thus, Ori may be a novel effective candidate to treat gefitinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: Docetaxel and gefitinib play key roles in the treatment of non-small-cell lung cancer (NSCLC), and their combination could be of interest. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant non-small cell lung cancer (NSCLC) patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/non-small cell lung cancer/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: The emergence of EGFR-inhibitors such as gefitinib, erlotinib and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Importantly, we show here that the Src family inhibitor, dasatinib, dramatically inhibits cell adhesion-related response and greatly enhances the cell-killing effects of EGFR TKI (gefitinib for the PC9 cells; afatinib for the H1975 cells) in NSCLC cells, which would otherwise escape the TKI-induced apoptosis. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Hence, despite being the earliest EGFR TKI developed, gefitinib continues to be one of the first-line treatments for advanced EGFR-mutated NSCLC, especially when skin and gastrointestinal toxicity is a concern. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Seven NSCLC patients harboring activating EGFR mutations who had developed LM during or after therapy with gefitinib, an EGFR TKI, were retrospectively analyzed. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Results from another large-scale randomized trial (ARCHER 1050) comparing dacomitinib to gefitinib as first-line treatment of advanced treatment-na\u00efve EGFR-mutant NSCLC patients will soon be available and will serve as the lynchpin trial for the potential approval of dacomitinib in NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence of acquired drug resistance. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The anticancer effect of USP8 inhibitor was determined by testing anchorage-dependent or independent growth of gefitinib-sensitive or resistant NSCLCs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "RESULTS: Inhibition of USP8 induced overall degradation of oncogenic receptor tyrosine kinases including EGFR and Met, leading to a suppression of anchorage-dependent or independent cell growth of gefitinib-sensitive or resistant NSCLCs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Inhibition of USP8 could be an effective strategy for overcoming gefitinib resistance in NSCLCs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Eight patients diagnosed with non-small cell lung cancer (NSCLC) (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations within the kinase domain of EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Erlotinib and gefitinib are among the most widely researched, used and available molecularly targeted therapies for treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Here we show miR-200c overexpression was correlated with the epithelial phenotype and sensitivity to gefitinib in EGFR wild-type NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Twenty-five NSCLC patients with epidermal growth factor receptor (EGFR) mutation were initially treated with gefitinib (250 mg/day). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This study reports an EGFR mutation in NSCLC treated with gefitinib and is notable due to the patient's marked improvement following a shorter than average duration of treatment with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In 2004, activating mutations in the EGFR gene were discovered to be a predictive biomarker for EGFR-TKI treatment, and gefitinib, which is not effective for patients with EGFR wild-type NSCLC, has since been used only in patients with EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u5206\u5b50\u9776\u5411\u6cbb\u7597\u662f\u80ba\u764c\u4e2a\u4f53\u5316\u6cbb\u7597\u7684\u65b9\u5411\uff0c\u76ee\u524d\u5df2\u6709\u5b66\u8005\u5efa\u7acb\u9776\u5411\u6cbb\u7597\u9884\u6d4b\u6a21\u578b\uff0c\u4e3a\u4e34\u5e8a\u4e2a\u4f53\u5316\u6cbb\u7597\u63d0\u4f9b\u66f4\u591a\u7684\u6307\u5bfc\u3002\u672c\u7814\u7a76\u63a2\u8ba8\u8840\u6e05\u80ba\u8868\u9762\u6d3b\u6027\u7269\u8d28\u76f8\u5173\u86cb\u767d\uff08pulmonary surfactant-associated protein D, SP-D\uff09\u3001\u8f6c\u5316\u751f\u957f\u56e0\u5b50-\u03b1\uff08transforming growthfactor \u03b1, TGF-\u03b1\uff09\u3001\u57fa\u8d28\u91d1\u5c5e\u86cb\u767d-9\uff08matrix metalloproteinase 9, MMP-9\uff09\u3001\u7ec4\u7ec7\u591a\u80bd\u7279\u5f02\u6027\u6297\u539f\uff08tissue polypeptide specific antigen, TPS\uff09\u3001\u80ba\u817a\u764c\u76f8\u5173\u6297\u539f\uff08Krebs von den Lungen-6, KL-6\uff09\u4e0e\u665a\u671f\u590d\u6cbb\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u6cbb\u7597\u7597\u6548\u53ca\u751f\u5b58\u7684\u5173\u7cfb\uff0c\u5e76\u6784\u5efa\u751f\u5b58\u9884\u6d4b\u6a21\u578b\u3002\u65b9\u6cd5 \u91c7\u7528\u9176\u8054\u514d\u75ab\u5438\u9644\u6cd5\uff08enzyme-linked immuno sorbent assay, ELISA\uff09\u68c0\u6d4b114\u4f8b\u665a\u671f\u590d\u6cbbNSCLC\u60a3\u8005\u6cbb\u7597\u524d\u5916\u5468\u8840\u6e05\u4e2dSP-D\u3001TGF-\u03b1\u3001MMP-9\u3001TPS\u3001KL-6\u542b\u91cf\uff0c\u7ed3\u5408\u4e34\u5e8a\u56e0\u7d20\u5206\u6790\u4e0e\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u7597\u6548\u7684\u5173\u7cfb\uff0c\u91c7 \u7528Kaplan-Meier\u751f\u5b58\u66f2\u7ebf\u3001Cox\u591a\u56e0\u7d20\u751f\u5b58\u5206\u6790\u6a21\u578b\u8fdb\u884c\u5355\u56e0\u7d20\u548c\u591a\u56e0\u7d20\u5206\u6790\uff0c\u5e76\u6784\u5efa\u751f\u5b58\u9884\u6d4b\u6a21\u578b\u3002\u7ed3\u679c 114\u4f8b\u60a3\u8005\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u603b\u6709\u6548\u7387\u4e3a22.8%\uff0c\u7a33\u5b9a\u7387\u4e3a72.8%\uff0c\u4e2d\u4f4d\u65e0\u75be\u75c5\u8fdb\u5c55\u65f6\u95f4\uff08progression-free survival, PFS\uff09\u4e3a5.13\u4e2a\u6708\uff0c1\u5e74\u751f\u5b58\u7387\u4e3a69.3%\u3002SP-D>110 ng/mL\u7ec4\u7684\u6709\u6548\u7387\u53ca\u7a33\u5b9a\u7387\u5747\u9ad8\u4e8e\u2264110 ng/mL\u7ec4\uff08P=0.011, P=0.017\uff09\uff0cMMP-9\u2264535 ng/mL\u7684\u7a33\u5b9a\u7387\u9ad8\u4e8e>535 ng/mL\u7ec4\uff08P=0.009\uff09\u3002TPS <80 U/L\u7ec4\u7684\u7a33\u5b9a\u7387\u8981\u9ad8\u4e8e\u226580 U/L\u7ec4\uff08P=0.002\uff09\u3002SP-D>110 ng/mL\u7ec4\u7684mPFS\u957f\u4e8e\u2264110 ng/mL\u7ec4\uff085.95\u4e2a\u6708 vs 3.25\u4e2a\u6708\uff0cP=0.009\uff09\uff0cMMP-9\u2264535 ng/mL\u7684mPFS\u8981\u957f\u4e8e>535 ng/mL\u7ec4\uff085.83\u4e2a\u6708 vs 3.47\u4e2a\u6708\uff0cP=0.046\uff09\uff0cKL-6\u4e2d<500 U/mL\u7ec4\u8981\u4f18\u4e8e\u2265500 U/mL\u7ec4\uff086.03\u4e2a\u6708 vs 3.40\u4e2a\u6708\uff0cP=0.040\uff09\uff0cTPS<80 U/L\u7ec4\u7684mPFS\u8981\u957f\u4e8e\u226580 U/L\u7ec4\uff086.15\u4e2a\u6708 vs 2.42\u4e2a\u6708\uff0cP=0.014\uff09\u3002\u591a\u56e0\u7d20\u5206\u6790\u663e\u793a\u5438\u70df\u53f2\u3001EGFR\u57fa\u56e0\u91ce\u751f\u578b\u3001\u672b\u6b21\u5316\u7597\u7597\u6548\u8fdb\u5c55\u3001\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u671f\u95f4\u65e0\u76ae\u75b9\u3001LDH\u5347\u9ad8\u548cTPS\u226580 U/L\u662fPFS\u4e0d\u4f73\u7684\u72ec\u7acb\u5f71\u54cd\u56e0\u7d20\u3002\u901a\u8fc7\u5efa\u7acb\u9884\u540e\u9884\u6d4b\u6a21\u578b\uff0c\u6839\u636e\u60a3\u8005\u7684\u9884\u540e\u6307\u6570\u53ef\u5206\u62104\u7ec4\uff1a\u4f4e\u5371\u7ec4\u3001\u4e2d\u4f4e\u5371\u7ec4\u3001\u4e2d\u5371\u7ec4\u548c\u9ad8\u5371\u7ec4\uff0c\u4e2d\u4f4dPFS\u5206\u522b\u662f9.12\u4e2a\u6708\u30016.88\u4e2a\u6708 \u30013.52\u4e2a\u6708\u548c0.93\u4e2a\u6708\uff0c\u7ec4\u95f4\u5dee\u5f02\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff08P<0.001\uff09\u3002\u7ed3\u8bba \u8840\u6e05\u80bf\u7624\u6807\u5fd7\u7269TPS\u6c34\u5e73\u8054\u5408\u60a3\u8005\u4e34\u5e8a\u7279\u5f81\u5efa\u7acb\u9884\u6d4b\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u590d\u6cbbNSCLC\u751f\u5b58\u6a21\u578b\uff0c\u5728\u4e34\u5e8a\u4e0a\u6709\u4e00\u5b9a\u7684\u6307\u5bfc\u610f\u4e49\u3002 DOI: 10.3779/j.issn.1009-3419.2014.05.05 PMID: 24854556 [PubMed - indexed for MEDLINE]  BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Between January 2008 and September 2009, we enrolled 50 patients with advanced NSCLC who had received one or more chemotherapy regimens, including gefitinib monotherapy to which they had partial responses (PR) or stable disease (SD). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Although non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We demonstrated that addition of simvastatin to gefitinib enhanced caspase-dependent apoptosis in T790M mutant NSCLC cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "To determine the role of survivin in simvastatin-induced apoptosis of gefitinib-resistant NSCLC, we showed that the proportion of apoptotic cells following treatment with survivin siRNA and the gefitinib-simvastatin combination was greater than the theoretical additive effects, whereas survivin up-regulation could confer protection against gefitinib and simvastatin-induced apoptosis. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In our previous study, we found that combined treatment with fulvestrant and gefitinib decreases the proliferation of H1975 NSCLC cells, compared to treatment with either fulvestrant or gefitinib alone; however, the molecular mechanism for the improved effects of the combination treatment are still unknown. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell lung cancer (NSCLC) because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Our purpose was to test ubiquitin-specific peptidase 8 (USP8) as a potential therapeutic target for gefitinib-resistant and -sensitive non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "EXPERIMENTAL DESIGN: Testing the effect of knockdown of USP8 and use of a synthetic USP8 inhibitor to selectively kill gefitinib-resistant (or -sensitive) NSCLCs with little effect on normal cells in cell culture and a xenograft mouse model. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "RESULTS: Knockdown of ubiquitin-specific peptidase 8 (USP8) selectively kills gefitinib-resistant NSCLCs while having little toxicity toward normal cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression while having no effect on normal cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Polymorphisms of the CYP2D6 gene were analyzed in 55 patients with NSCLC who experienced grade \u2265 2 transaminase elevation from gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations develop acquired resistance. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In this study, we synthesized a dozen of novel gefitinib analogues and evaluated their effects on L858R/T790M-EGFR harboring NSCLC cells, and reported that one of these gefitinib mimetics, N-(2-bromo-5-(trifluoromethyl) phenyl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine (hereafter, V1801), triggered apoptosis of the NSCLC cells and overcame gefitinib-resistance in mice inoculated with NCI-H1975 cells. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of non-small cell lung cancer (NSCLC), and to date a large amount of clinical data are available. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib have shown efficacy in patients with NSCLC and brain metastases. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We found that a high efficacy of antitumor activity was shown with GDC-0941 treatment in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Additionally, the blockade of PI3K, mTOR and Erk with GDC-0941 and MEK inhibitors shows promise for treating gefitinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " OBJECTIVES: The combination use of gefitinib and epidermal growth factor receptor (EGFR) testing is a standard first-line therapy for patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: NSCLC patients with a smoking history or the EGFR L858R mutation may demonstrate a poorer response to gefitinib treatment. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "However, first-line gefitinib should not be recommended for advanced non-small cell lung cancer (NSCLC) patients only based on clinical factors, due to a very small sample-size in our study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The Iressa Alliance program provided standardized EGFR mutation testing and appropriate access to gefitinib to all patients in British Columbia with advanced, non squamous non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: QoL was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first-line therapy for advanced EGFR-mutated NSCLC in spite of no survival advantage. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: P+G improved PFS compared with gefitinib alone in East Asian patients with advanced NS NSCLC and activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "These LCSS outcomes provide further evidence that patients with wild-type EGFR might not benefit from first-line treatment of advanced NSCLC with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Patients, who were \u2265 18 years, chemona\u00efve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We retrospectively reviewed 81 advanced NSCLC patients with disease progression following tumor response and durable (\u2265 6 months) disease stabilization with first-line or second-line gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: In the Dutch health care setting, the previously established progression free survival benefit of first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life benefits of gefitinib over doublet chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This is the first randomized clinical trial that showed a significant and clinical meaningful OS benefit in EGFR mutation-positive NSCLC patients following maintenance therapy with gefitinib as compared to placebo. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced non-small-cell lung cancer without disease progression after first-line chemotherapy, were published previously. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Maintenance gefitinib significantly prolonged progression-free survival (PFS) compared with placebo in patients from eastern Asian with locally advanced/metastatic non-small-cell lung cancer (NSCLC) after four chemotherapeutic cycles (21 days per cycle) of first-line platinum-based combination chemotherapy without disease progression. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "In addition, several large phase III clinical trials (e.g., INFORM trial) provided evidence that maintenance therapy with gefitinib also significantly improved PFS in NSCLC patients, with greatest PFS benefit in patients harboring EGF-R mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy were randomly assigned (1:1) to receive gefitinib 250 mg per day or placebo for 2 years. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: A phase II trial was conducted in patients with stage III/IV NSCLC, to assess the efficacy, safety and impact on quality of life (QoL) and disease-related symptoms of gefitinib rechallenge. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Therefore, we here aimed to investigate the efficacy of platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS/PATIENTS: We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations was effective and showed equivalent outcomes to first-line platinum combination chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " PURPOSE: Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The aim of this trial was to evaluate the efficacy and toxicity of gefitinib in NSCLC patients with WT EGFR who failed previous chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: Small proportion of NSCLC patients with the WT EGFR benefits with gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The Iressa Alliance program provided standardized EGFR mutation testing and appropriate access to gefitinib to all patients in British Columbia with advanced, non squamous non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) non-small cell lung cancer (NSCLC) after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in non-small cell lung cancer (NSCLC) cell lines with the rationale of potentially translating these findings into the clinical setting. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. ", "disease": "NSCLC", "drug": "gefitinib"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancers (NSCLC) are commonly treated with a platinum-based chemotherapy such as cisplatin (CDDP) in combination with ionizing radiation (IR). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We identified and interrogated the unique time and agent-dependent activation of the DDR in NSCLC cells treated with cisplatin-IR combination therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results indicate that BAG1 is important in cisplatin-induced cell death in lung adenocarcinoma, suggesting that endoplasmic reticulum stress may promote the sensitivity of NSCLC patients to chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin-based chemotherapy, respectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In\u00a0vitro treatment studies with cisplatin or vismodegib (Shh pathway inhibitor), or both, were performed on NSCLC cell lines (H322 and A549) and primary cultures from patients with sarcomatoid carcinoma (n\u00a0=\u00a04). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, abnormal expressions of miR-17 and miR-92 families are observed in cisplatin-resistant cells, suggesting that miR-17 and miR-92 families are involved in the regulation of cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to investigate the regulatory functions of miR-17 and miR-92 families on the formation of cisplatin resistance and the predictive functions of them as biomarkers of platinum-based chemotherapy resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PAPSS1 knockdown in combination with low-dose (IC10) cisplatin reduces clonogenicity of NSCLC cells by 98.7% (p < 0.001), increases DNA damage, and induces G1/S phase cell cycle arrest and apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study compared the survival benefits of NDP and cisplatin (DDP) in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our present study was aimed to determine whether inhibition of the NF-\u03baB/miR-21/PTEN pathway could increase the sensitivity of NSCLC to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Modulation of the NF-\u03baB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "IGF2R silencing significantly enhanced the chemo-resistance of NSCLC cell lines to cisplatin treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our results indicate that advanced NSCLC patients with positive expression of EZH2 exhibited resistance to cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "EZH2 may be a predictive and prognostic factor for cisplatin-based therapy response and disease survival in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study is to assess whether ERCC1 expression level is linked to cisplatin sensitivity and clinical outcomes in resected NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we aimed to identify the expression of Aurora-A and its correlation with cisplatin resistance and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We used immunohistochemical analysis to determine the expression of Aurora-A protein in 102 NSCLC patients treated by surgery and adjuvant cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The potential role of Aurora-A in the regulation of cisplatin resistance in NSCLC cells was examined by transfections using expression vector and small interfering RNA or using small-molecule inhibitors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The current findings suggest that high Aurora-A expression is correlated with cisplatin-based chemotherapeutic resistance and predicts poor patient survival in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we studied Pt-(GpG) DNA adducts in circulating tumour cells (CTC) treated with cisplatin in medium upfront to systemic therapy from patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Among them, high levels of expression of ERCC1, both at protein and mRNA levels, have been associated with resistance to cisplatin in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "No prospective randomized trial has tested the addition of cisplatin to single-agent chemotherapy in patients with advanced NSCLC and PS2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Silencing XPA gene can partly reverse the cisplatin resistance in human cisplatin-resistant NSCLC cell line A549/DDP. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: eIF3\u03b1 Arg803Lys C > T polymorphism was associated with cisplatin-induced toxicity in NSCLC patients (P = 0.02, OR = 0.54, 95% CI 0.32, 93). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a series of in vitro and cell culture assays in a NSCLC model, we investigated both the downstream and direct treatment and damage effects of cisplatin on NHEJ catalyzed repair of a DNA DSB. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ATP7A expression was evaluated by immunohistochemistry in tumor tissues of unresectable NSCLC patients who received cisplatin-basing chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4\u00a0cycles is recommended. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with non-small cell lung cancer (NSCLC), immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmall cell lung cancer, carried out by the ELCWP aim to answer the following questions: 1) What benefits can we expect from chemotherapy and which are the treatment goals? 2) Do we have to integrate a palliative approach into the cancer treatment? 3) What are the chemotherapeutic agents for which efficacy has been established? 4) Can carboplatin replace cisplatin? 5) What are the most active cisplatin-based combination chemotherapy? 6) What should be the dose of cisplatin? 7) Can non-platinum regimens replace platinum-based for first-line treatment? 8) What is the role of targeted therapies? 9) When can we or should we customize chemotherapy? 10) What is the optimal number of cycles of induction therapy to administer? Should be done consolidation or maintenance treatment? 11) Is it an indication for sequential chemotherapy? 12) What is the efficacy of salvage chemotherapy and which drugs can be given in this indication? 13) Which treatment for oligometastatic diseases? 14) What are the places of chemotherapy and radiotherapy in the treatment of patients with brain metastases? 15) Which drugs can be used specifically in cases of bone metastases? 16) Which treatment for patient unfit to receive conventional treatment because of its general status, age or comorbid conditions?  Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCLC) per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The weekly fractionated administration of cisplatin for patients with NSCLC has been shown to be active. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed plus cisplatin was approved for first-line treatment of non-small-cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: PCRT using cisplatin plus S-1 with concurrent radiation therapy is useful for inducing downstaging in patients with locally advanced stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We investigated the association between clinical outcome and XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms in advanced NSCLC patients treated with cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, there was no association between Arg399Gln and Arg280His polymorphisms and response to cisplatin-based chemotherapy and overall survival in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We herein report that sulforaphane (SFN), a potent anti-cancer and well-tolerated dietary compound, inhibits cancer stem-like cell (CSC) properties and enhances therapeutic efficacy of cisplatin in human non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Experiments with nude mice carrying xenograft tumors showed that SFN sensitized NSCLC cells to cisplatin's efficacy, which is accompanied by inhibition of cisplatin-induced c-MYC accumulation in tumor tissues. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our results provided strong evidence and mechanisms to support consideration of SFN or synthetic derivatives as a therapeutic agent in combination with cisplatin for the treatment of patients with NSCLC and, potentially, other types of c-MYC-addicted tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, whether co-inhibition of REV3 and ATR can further increase sensitivity of non-small cell lung cancer (NSCLC) cells to cisplatin is not clear. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we show that REV3 knockdown combined with ATR inhibition further enhance cytotoxicity of cisplatin in NSCLC cells, including cisplatin-sensitive and -resistant cell lines, compared to individual knockdown of REV3 or ATR, which are accompanied by markedly caspase-dependent apoptosis response, pronounced DNA damage accumulation and severe impediment of interstrand crosslink (ICL) and double strand break (DSB) repair. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that REV3 knockdown synergize strongly with ATR inhibition to significantly increase sensitivity of cisplatin in NSCLC cells by inhibiting ICL and DSB repair. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thus simultaneously targeting REV3 and ATR may represent one approach to overcome cisplatin resistance and improve chemotherapeutic efficacy in NSCLC treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, we found that miRNA-488 was associated with cisplatin resistance in three NSCLC cells (A549, H1299 and SK-MES-1). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, miRNA-488 also participates in eIF3a mediated cisplatin resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study, non-small cell lung cancer (NSCLC) cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Combination of cisplatin and belinostat was investigated in two pairs of parental and cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our present study revealed that VPA at 1 mM, which had no effect on cell proliferation, can significantly increase the sensitivity of non-small cell lung cancer (NSCLC) cells to cisplatin (DDP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study, we investigated the role of astragaloside IV in the chemoresistance to cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We established astragaloside IV-suppressed NSCLC cell lines including A549, HCC827, and NCI-H1299 and evaluated their sensitivity to cisplatin in vitro. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, combined treatment with astragaloside IV significantly increased chemosensitivity to cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, ectopic expression of B7-H3 diminished the sensitization role of astragaloside IV in cellular responses to cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we therefore investigated whether CXCR4 plays a role in the cisplatin associated resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Finally, we found CXCR4 was significantly highly expressed in cisplatin-resistant NSCLC patients and the A549/DDP cell line. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Immunohistochemistry also verified that CYP1B1 was upregulated in NSCLC tissues of cisplatin-resistant patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, our results indicate that overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thus, it can be used as a potential therapeutic target in NSCLC chemoresistance patients and be used as a clinical predictor of cisplatin response. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our purpose is to investigate the association of miR-185-5p expression with the sensitivity of non-small cell lung cancer (NSCLC) to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results of the present study demonstrated that inhibition of miR-185-5p was involved in chemo-resistance of NSCLC cells to cisplatin via down-regulating ABCC1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Clinically, combined therapy of cisplatin (CDDP) and metformin is an effective treatment for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Cisplatin is commonly used in non-small-cell lung cancer (NSCLC) chemotherapy; however, chemoresistance to cisplatin remains a great clinical challenge. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we aimed to investigate the potential role of OCT4 in NSCLC with chemoresistance to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Knockdown of OCT4 in NSCLC cells could decrease cell proliferation, and potentiate apoptosis induced by cisplatin, suggesting OCT4 may contribute to cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings indicate that targeting OCT4 could improve cisplatin effect in NSCLC, confirming their role in modulating cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we found that miR-101 expression was downregulated in cisplatin-resistant non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Restoration of miR-101 expression inhibited EMT and increased the sensitivity of cisplatin-resistant NSCLC cells to cisplatin in vitro by targeting ROCK2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In summary, our results provide novel mechanistic insights into the role of miR-101/ROCK2 signaling in the cisplatin resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Platinum agents, including cisplatin, are the first line treatment in lung cancer, including non-small cell lung cancer (NSCLC), which is the predominant form of lung cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We enrolled 87 NSCLC patients who had received cisplatin-based chemotherapy to confirm the association between PAK1 expression and response to chemotherapy and outcomes. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, PAK1 confers cisplatin resistance in NSCLC via \u03b2-catenin-mediated stemness. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, we suggest that clinical use of a combination of the MEK/ERK inhibitor AZD6244 and cisplatin might improve sensitivity to cisplatin-based chemotherapy and outcomes in NSCLC patients who harbor high-PAK1-expressing tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Together, our results suggest that the combination of low dose cisplatin and scriptaid is cytotoxic to NSCLC lines, can overcome hypoxia induced resistance and mutant p53- induced instability often associated with this cancer, and has the potential to be an effective therapeutic modality. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A combination of cisplatin and salinomycin resulted in synergistic enhancement of cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-AKT, and TS expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the cisplatin-induced cytotoxicity in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We recruited 284 NSCLC patients at advanced stage from Department of Radiotherapy in Peace Hospital Attached to Changzhi Medical College between May 2009 and May 2011, who had received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed/cisplatin is the preferred chemotherapy in nonsquamous NSCLC, but the efficacy of this treatment for nonsquamous NSCLC with BM is uncertain. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Calotropin (M11), an active compound isolated from Asclepias curasavica L., was found to exert strong inhibitory and pro-apoptotic activity specifically against cisplatin-induced resistant non-small cell lung cancer (NSCLC) cells (A549/CDDP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Results of this study supported the potential application of M11 on the non-small lung cancer (NSCLC) with cisplatin resistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we aimed to assess the contribution of the Fanconi anemia (FA), homologous recombination (HR) and nucleotide excision repair (NER) pathways to cisplatin resistance in non-small cell lung cancer (NSCLC)-derived cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: We found that acquired cisplatin-resistant NSCLC-derived A549/DR cells exhibited markedly enhanced FA and HR repair pathway capacities compared to its parental A549 cells and another independent NSCLC-derived cell line, Calu-1, which possesses a moderate innate resistance to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Although we found that expression knockdown of the NER-associated genes XPA and ERCC1 sensitized the three NSCLC-derived cell lines to cisplatin, the sensitization effect was more significant in Calu-1 cells than in A549 and A549/DR cells, implying that the innate cisplatin resistance in Calu-1 cells may result from an increased NER activity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our results indicate that the functional status of DNA repair pathways determine the sensitivity of NSCLC cells to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Direct targeting of the pathway that is involved in cisplatin resistance may be an effective strategy to surmount cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, cisplatin-induced apoptosis of EZH2-knocking down NSCLC cells was elevated as a consequence of increased PUMA expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, Rad51c knockdown increased the killing effect of ionizing radiation (IR) and enhanced cisplatin-induced apoptotic cells in NSCLC cells by disrupting the repair of cisplatin- and IR-induced DNA damage. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, ectopic expression of Rad51c dramatically enhanced NSCLC cell resistance to cisplatin and radiotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Using DNA microarrays, we performed a genome-wide analysis of cisplatin-resistant NSCLC cells to identify the involvement of the EHD1 gene in this resistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to investigate the role of miR-141 in cisplatin resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PG also significantly enhanced the sensitivity of NSCLC cells to cisplatin-induced apoptosis, and this effect was attenuated by overexpression of HO-1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therapeutic approaches targeting COL11A1 may facilitate the optimization of cisplatin treatment of NSCLC by overcoming chemoresistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We investi-gated the possible roles of GSTP1 Ile105Val and XRCC1 Arg194Trp, and Arg399Gln gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma (NSCLC) patients with cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: From January 2007 to March 2010, 58 patients with NSCLC were included who were received 18F-fluorodeoxyglucose (18F-FDG) PET/CT before and following 40 Gy radiotherapy with the concurrent cisplatin-based chemotherapy (CCRT). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, the regulation of FN1 on cisplatin resistance in non-small cell lung cancer (NSCLC) has not been investigated. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study aims to illustrate the effect of FN1 on cisplatin resistance in NSCLC and explore potential mechanisms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Taken together, our findings first suggest that FN1 plays a role in the development of cisplatin resistance in NSCLC, possibly by modulation of \u03b2-catenin signaling through interaction with integrin-\u03b21 in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage non-small cell lung cancer (NSCLC) after 1st line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study is to investigate the value of Pan-Bcl-2 inhibitor as sensitizer for the chemotherapy of cisplatin-resistant non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We found the obatoclax but not the ABT-737 significantly decreased the IC50 (half maximal inhibitory concentration) of cisplatin in cisplatin-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, inhibition of MCL-1 recovered the function of NOXA and BAK in cisplatin-resistant NSCLC cells, leading to the promotion of mitochondrial apoptosis induced by cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Interestingly, our date indicated the obatoclax also reversed the cross-resistance in cisplatin-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Non-small cell lung cancer (NSCLC) cell lines A549 and H2228 were exposed to cisplatin in a variety of cell density conditions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: CDR to cisplatin was induced in NSCLC cells, whereas CDR to crizotinib, an inhibitor of activin receptor-like kinase, was not observed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: CDR to cisplatin can occur in NSCLC cells, and the TGF-\u03b2 pathway is associated with the regulation of CDR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We here hypothesized that miR-184 could be down-regulated by E6 oncoprotein to confer cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, a decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected NSCLC patients via increasing Bcl-2 expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to find and investigate the function of miRNAs in cisplatin (DDP)-resistant non-small cell lung cancer (NSCLC) A549 cell. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several landmark study elucidated that adjuvant cisplatin-based chemotherapy for stage II-IIIA non-small cell lung cancer (NSCLC)patients after appropriate surgical resection can significantly improve 5-year survival rate. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "According to these evidence, cisplatin-based adjuvant chemotherapy for stage II-III A NSCLC and UFT for stage I NSCLC patients with a tumor lager than 2 cm are used standard postoperative adjuvant chemotherapy in Japan. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we characterize the role of curcumin in the cytotoxicity, p38 MAPK activation, and XRCC1 expression affected by cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We show that curcumin enhanced the cytotoxicity induced by cisplatin in two NSCLC cells, A549 and H1703. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of p38 MAPK resulted in enhancing the cytotoxicity and cell growth inhibition induced by cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Curcumin inhibited the expression of XRCC1 in cisplatin-exposed NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These findings suggested that the downregulation of XRCC1 expression by curcumin can enhance the chemosensitivity of cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we demonstrated that DNA-damage inducible proapoptotic BH3 (Bcl-2 homology region 3)-only Bcl-2 family members, Noxa, Puma, Bim and Bid, are not involved in cisplatin-induced apoptosis in human NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "From this result, we tested the effect of ABT-263 (Navitoclax), the specific inhibitor of Bcl-2 and Bcl-XL, but not Mcl-1, and found that ABT-263 synergistically enhanced cisplatin-induced apoptosis in NSCLC cells in the presence or absence of p53. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These results indicate a novel regulatory system in cisplatin-induced NSCLC cell apoptosis, and a candidate efficient combination chemotherapy method against lung cancers. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancers (NSCLC) are commonly treated with a platinum-based chemotherapy such as cisplatin (CDDP) in combination with ionizing radiation (IR). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We identified and interrogated the unique time and agent-dependent activation of the DDR in NSCLC cells treated with cisplatin-IR combination therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Currently, chemotherapy with platinum-based drugs including cisplatin is the most effective therapy for the treatment of non-small cell lung carcinoma (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, we determined that SKA1 contributed to cisplatin resistance in NSCLC cells by protecting these cells from cisplatin-induced cell apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study was done to explore the function of periostin in the development of cisplatin (CDDP) resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, expression of MICA/B was assessed in NSCLC cell lines treated with cisplatin in order to evaluate the regulatory mechanisms of MICA/B expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Although miRNA-196a has been implicated in the progression of human lung cancer, its role in enhancing the sensitivity of non\u2011small cell lung cancer (NSCLC) cells to cisplatin has not yet been confirmed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the effects of miRNA\u2011196a on the sensitivity of NSCLC cells to cisplatin in vitro and in vivo. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, the downregulation of miRNA-196a sensitized the SPC\u2011A\u20111 and A549 NSCLC cells to cisplatin in vitro and in vivo, by inducing apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The findings of this study demonstrate that the administration of cisplatin in combination with miRNA-196a-targeted therapy may be a potential therapeutic strategy for the treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: The effects of pirfenidone alone and in combination with cisplatin on human patient-derived CAF cell lines and non-small cell lung cancer (NSCLC) cell lines were examined. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the combination of cisplatin and pirfenidone in NSCLC cells (A549 and H157 cells) leads to increased apoptosis and synergistic cell death. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our studies reveal for the first time that the combination of cisplatin and pirfenidone is active in preclinical models of NSCLC and therefore may be a new therapeutic approach in this disease. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, miR-194 was downregulated in in cisplatin-resisted human NSCLC cell line-A549/DDP and overexpression of miR-194 increases cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These findings suggested that miR-194 inhibits proliferation and metastasis and reverses cisplatin-resistance of NSCLC cells and may be useful as a new potential therapeutic target for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: It is important to know the tumor resistance against cisplatin before the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results indicate that BAG1 is important in cisplatin-induced cell death in lung adenocarcinoma, suggesting that endoplasmic reticulum stress may promote the sensitivity of NSCLC patients to chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A concerning clinical challenge with cisplatin-based NSCLC chemotherapy is the intrinsic and acquired chemoresistance to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To the best of our knowledge the present study explored the role of miRNA/SAMD9 signaling in regulating cisplatin chemoresistance in NSCLC for the first time. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "miR-96 and SAMD9 were overexpressed and knocked down in the human NSCLC H358 and H23 cell lines and the half maximal inhibitory concentration (IC50) of cisplatin and cell apoptosis rate under cisplatin treatment were used as measures of cisplatin chemoresistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present results identified that overexpression of miR-96 in NSCLC cells markedly decreased SAMD9 expression and cisplatin-induced apoptosis, and increased the cisplatin IC50, which could be eliminated by overexpression of SAMD9. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "By contrast, knocking down miR-96 in NSCLC cells using antagomir-96 significantly increased SAMD9 expression and the cisplatin-induced apoptosis and decreased cisplatin IC50, which could be completely reversed by a knockdown of SAMD9. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the current study demonstrates that miR-96 targets and downregulates SAMD9 in NSCLC, which decreases cisplatin-induced apoptosis and induces cisplatin chemoresistance in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between October 2009 and October 2011, a total of 308 patients of NSCLC on stage IIIA, IIIB or IV, treated with cisplatin-based chemotherapy were included. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin-based chemotherapy, respectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we examined the effects of suberoylanilide hydroxamic acid (SAHA) and cisplatin on DNA damage repairs, and determined the combination effects of SAHA and cisplatin on human non-small cell lung cancer (NSCLC) cells in response to treatment of ionizing radiation (IR), and on tumor growth of lung cancer H460 xenografts receiving radiotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our results showed that SAHA and cisplatin compromise distinct DNA damage repair pathways, and treatment with SAHA enhanced synergistic radiosensitization effects of cisplatin in established NSCLC cell lines in a p53-independent manner, and decreased the DNA damage repair capability in cisplatin-treated primary NSCLC tumor tissues in response to IR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We conducted a study to investigate the association between the clinical outcome and GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We further found that TFAM downregulation in NSCLC cells led to increased apoptotic cell death and enhanced the sensitivity of NSCLC cells to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In\u00a0vitro treatment studies with cisplatin or vismodegib (Shh pathway inhibitor), or both, were performed on NSCLC cell lines (H322 and A549) and primary cultures from patients with sarcomatoid carcinoma (n\u00a0=\u00a04). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "YAP1 ablation significantly improved sensitivities not only to cisplatin but also to ionizing radiation, both of which are DNA-damaging interventions, in non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Besides, evaluations revealed that phloretin enhanced the anticancer effects of cisplatin on inhibition of proliferation and induction of apoptosis in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the present study demonstrated that phloretin possessed anticancer effects and enhanced the anticancer effects of cisplatin on NSCLC cell lines by suppressing proliferation, inducing apoptosis and inhibiting invasion and migration of the cells through regulating apoptotic pathways and MMPs. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thus, it was hypothesized that ATO may also be active against cisplatin-resistant non-small cell lung cancer (NSCLC) PC-9/CDDP and PC-14/CDDP cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study also evaluated the effects of ATO on the cisplatin-sensitive NSCLC PC-9 and PC-14 cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Although it is likely that cisplatin resistance in PC-9 cells does not depend on the GS-X pump systems, ATO was effective against cisplatin-resistant NSCLC PC-9/CDDP and PC-14/CDDP cells in combination chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We sought to explore the potential synergistic antitumor activity and underlying mechanisms of the pro-apoptotic agent PAC-1 plus cisplatinum (Cis) in non-small cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: PAC-1 showed anti-tumor activity in NSCLCs\u2005in vitro and a synergistic effect with cisplatin in EGFR(wt)KRAS(wt) H1299 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study, we showed that curcumin enhanced the sensitivity of the double-positive (CD166+/EpCAM+) CSC subpopulation in non-small cell lung cancer (NSCLC) cell lines (A549 and H2170) to cisplatin-induced apoptosis and inhibition of metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our results revealed that initial exposure of NSCLC cell lines to curcumin (10-40 \u00b5M) markedly reduced the percentage of viability to an average of ~51 and ~54% compared to treatment with low dose cisplatin (3 \u00b5M) with only 94 and 86% in both the A549 and H2170 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, sensitisation of NSCLC cell lines to curcumin through combined treatment enhanced the single effect induced by low dose cisplatin on the apoptosis of the double-positive CSC subpopulation by 18 and 20% in the A549 and H2170 cells, respectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, we provided novel evidence of the previously unknown therapeutic effects of curcumin, either alone or in combination with cisplatin on the inhibition of the CD166+/EpCAM+ subpopulation of NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This finding demonstrated the potential therapeutic approach of using curcumin that may enhance the effects of cisplatin by targeting the CSC subpopulation in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, our findings testified that CD166(+) cells which were derived from fresh primary NSCLC samples displayed stem cell-like features and were resistant to chemotherapy drug cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thus, this study widens the window for identification and targeting of a cisplatin-resistant population and contributes to the development of potential therapeutics to improve the current treatment modalities in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We made use of three different sets of cell lines, A549 and H2030 non-small-cell lung cancer (NSCLC) and A2780 ovarian cancer cells and their cisplatin-resistant variants. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, abnormal expressions of miR-17 and miR-92 families are observed in cisplatin-resistant cells, suggesting that miR-17 and miR-92 families are involved in the regulation of cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to investigate the regulatory functions of miR-17 and miR-92 families on the formation of cisplatin resistance and the predictive functions of them as biomarkers of platinum-based chemotherapy resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, we suggest that cytoplasmic p27 (N-/C+) via ERK-activated Bcl-2 expression may predict an unfavorable response to cisplatin-based chemotherapy and poor outcomes in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with non-small cell lung cancer (NSCLC), then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIMS: To study the effectiveness of human recombinant endostatin injection (Endostar\u00ae) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Nitric oxide (NO) and cisplatin releasing wrinkle-structured amine-modified mesoporous silica (AMS) nanoparticles have been developed for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results show that for NSCLC cell lines (i.e., H596 and A549), the toxicity of NO- and cisplatin-loaded silica nanoparticles (NO-Si-DETA-cisplatin-AMS) is significantly higher than that of silica nanoparticles loaded with only cisplatin (Si-DETA-cisplatin-AMS). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We aimed to explore the possible mechanism of microRNA-196a (miR-196a) inhibition and reversion of drug resistance to cisplatin (DDP) of the A549/DDP non-small-cell lung cancer (NSCLC) cell line. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed global gene expression profiles of NSCLC clones surviving a pulse treatment with cisplatin and mapped deregulated signaling networks in silico by Ingenuity Pathway Analysis (IPA). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The pooled cisplatin-surviving NSCLC clones from each of the biological replicates demonstrated heterogeneous gene expression patterns both in terms of the number and the identity of the altered genes. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Knockdown of DKK1 by siRNA sensitized for cisplatin in two different NSCLC cell lines and in ovarian A2780 cells, but not in the A2780 cis subline made resistant to cisplatin by chronic exposure, suggesting a role of DKK1 in intrinsic but not acquired platinum refractoriness. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We investigated the association between the polymorphisms GSTP1 rs1695 and XRCC1 rs1799782 and rs25487 and the clinical outcome of patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results of our study suggest that the GSTP1 rs1695 and XRCC1 rs25487 polymorphisms might affect the clinical outcome of patients with advanced NSCLC receiving cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The potential implication of IL-6 signaling in the cisplatin resistance of NSCLC was explored by testing whether NSCLC cells with different levels of intracellular IL-6 show different responses to the cytotoxic treatment of cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "When the cisplatin cytotoxicity of the IL-6 knocked down human NSCLC cells (A549IL-6si and H157IL-6si) were compared with their corresponding scramble control cells (A549sc and H157sc), higher cisplatin cytotoxicity was found in IL-6 si cells than sc cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These results provide potential for combining cisplatin and inhibitors of IL-6 signaling or its downstream signaling pathway as a future therapeutic approach in preventing development of cisplatin resistant NSCLC tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our present study demonstrated for the first time that downregulation of miR-218 may contribute to the chemoresistance of NSCLC cells to cisplatin, which leads to upregulation of RUNX2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, high ABCG4 expression was associated with a poor prognosis in patients with NSCLC treated with cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study we first found that HVJ-E exhibited cytotoxic effects in the non-small cell lung cancer cell (NSCLC) line A549 and cisplatin-resistant A549\u00a0cells (A549/DDP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4\u00a0cycles is recommended. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PAPSS1 knockdown in combination with low-dose (IC10) cisplatin reduces clonogenicity of NSCLC cells by 98.7% (p < 0.001), increases DNA damage, and induces G1/S phase cell cycle arrest and apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Previously known effects of miR-138 upregulation on NSCLC, proliferation, cell cycle division, and cisplatin sensitivity were examined in H460 and SPC-A1 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The effects of forced overexpression of CCND3 on miR-138-induced NSCLC regulations were further examined by proliferation, cell cycle, cisplatin sensitivity, and migration assays, respectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Our previous study demonstrated that promoter methylation of human mutL homolog 1 (hMLH1) is involved in determining sensitivity to cisplatin in NSCLC A549/DDP cell line, The present study was designed to determine whether DNA methylation of hMLH1 affects the prognosis of non-small cell lung cancer patients who received cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Methylation status of hMLH1 was examined by nested methylation-specific PCR (nested MSP) in 84 archived NSCLC surgically resected tissue specimens from patients receiving cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Multivariate logistic regression analysis showed that hMLH1 methylation may function as a significant independent prognostic factor for tumor recurrence in NSCLC patients treated with adjuvant cisplatin (HR 3.114, 95% CI 1.032-9.399; P=0.044). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To conclude, the cisplatin-based adjuvant chemotherapy is more beneficial for NSCLC patients without hMLH1 methylation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Due to its critical role in translesion DNA synthesis, whether REV3L modulates cisplatin response in NSCLC cells remains unknown. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study compared the survival benefits of NDP and cisplatin (DDP) in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We investigated the association between the clinical outcome and GSTP1 and XRCC1 gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "GSTP1 A313G and XRCC1 Arg399Gln gene polymorphisms might influence the response to cisplatin-based chemotherapy and affect the clinical outcome of advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We intended to evaluate the superiority of cisplatin-based chronotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and investigate the relationship between the circadian rhythm and the variability of pharmacokinetics for cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our recent study has demonstrated that AT-101 enhanced the antitumor effect of cisplatin (CDDP) in a murine model of NSCLC via inhibition of the interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Finally, when PTEN was up-regulated in NSCLC cells, it reversed the effects of miR-2b over-expression on NSCLC migration and cisplatin chemosensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of NSCLC patients receiving cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese non-small cell lung cancer (NSCLC) patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Vinorelbine plus cisplatin is a commonly used doublet for the treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Acquired resistance to cisplatin treatment is a caveat when treating patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would reduce their expression and reverse cisplatin-resistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Cell surface expression of Gb3, MDR1 and MRP1 and intracellular expression of MDR1 and MRP1 was analyzed by flow cytometry and confocal microscopy on P31 MPM and H1299 NSCLC cells and subline cells with acquired cisplatin resistance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistance of NSCLC and MPM cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Whether nedaplatin and cisplatin are equally effective for advanced non-small cell lung cancer (NSCLC) remains uncertain. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We conducted a literature search to identify trials that had investigated the substitution of nedaplatin for cisplatin in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed in combination with cisplatin is approved in the first line setting and as monotherapy in the switch or continuous maintenance of Non Squamous A-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to investigate the predictive value of Nin one binding (NOB1) expression for response to cisplatin-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Logistic regression analysis showed TMN stage, histopathological grade and NOB1 expression were independent prognosis factors for early response to cisplatin-based chemotherapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with non-small cell lung cancer (NSCLC), immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results showed that in patients with an EGFR mutation, adjuvant EGFR-tyrosine kinase inhibitor monotherapy after complete resection significantly prolongs disease-free survival compared with adjuvant chemotherapy and/or radiotherapy.BACKGROUND: Adjuvant cisplatin-based chemotherapy improves non-small-cell lung cancer (NSCLC) 5-year survival rates after resection. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In vivo data further revealed that cisplatin induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638 expression patterns after chemotherapy significantly correlated with lymph node metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our study found that panobinostat, an HDAC inhibitor, increased the cisplatin sensitivity of several NSCLC cell lines with low ERCC1 expression but not those with high ERCC1 expression or gain-of-function (GOF) p53 mutation despite of ERCC1 expression level. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ERCC1 knockdown increased the cisplatin sensitivity of NSCLC cell lines with high ERCC1 expression without GOF p53 mutations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, in low ERCC1 expression NSCLC cell lines, knockdown of GOF mutant p53 enhanced cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this study demonstrated that ERCC1 expression combined with p53 mutation status may determine the efficacy of cisplatin and HDACi combined therapy and guide the development of future NSCLC therapies. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Downregulation of TSN by RNAi in NSCLC cells led to strong potentiation of cell death in response to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Downregulation of S100A11 by RNAi resulted in enhanced sensitivity of NSCLC cells to cisplatin, oxaliplatin and 5-fluouracil. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The data showed a down-regulated of miR-148b expression and evaluated methyltransferases (DNMTs) expression in cisplatin-resisted human non-small cell lung cancer (NSCLC) cell line-A549/DDP and SPC-A1/DDP compared with their parental A549 and SPC-A1 cell line. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant cisplatin-based chemotherapy (ACT) after resection of stages II-IIIA non-small cell lung cancer (NSCLC) modestly increased survival in several clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Adjuvant cisplatin-based chemotherapy significantly improves outcomes of completely resected early-stage non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our present study was aimed to determine whether inhibition of the NF-\u03baB/miR-21/PTEN pathway could increase the sensitivity of NSCLC to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Modulation of the NF-\u03baB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this context, cofilin-1 (a cytosolic protein involved with actin dynamics) has been widely studied as a biomarker of an aggressive phenotype in tumors, and overexpression of cofilin-1 is associated with cisplatin resistance and poor prognosis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to highlight new perspectives of how these interactions might affect cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study was carried out to determine the cytotoxic effects of matrine on cisplatin-resistant non-small cell lung cancer (NSCLC) cells and the associated molecular mechanisms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Parental and cisplatin-resistant A549 and H460 NSCLC cells were treated with 1 or 2 g/l of matrine for 48 h, and cell viability and apoptosis were assessed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Compared to the parental cells, cisplatin-resistant NSCLC cells showed increased \u03b2-catenin transcriptional activity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Matrine caused apoptotic death in the cisplatin-resistant NSCLC cells, coupled with loss of \u0394\u03a8m and activation of caspase-9 and -3. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Matrine-induced apoptosis of the cisplatin-resistant NSCLC cells was significantly reversed by overexpression of survivin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, matrine exposure induces mitochondrial apoptosis in cisplatin-resistant NSCLC cells, which is largely mediated through inactivation of \u03b2-catenin/survivin signaling. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Further investigation of the therapeutic benefit of matrine in overcoming cisplatin resistance in NSCLC is warranted. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present findings suggest that Med19 facilitates tumorigenic properties of NSCLC cells and knockdown of Med19 may be a rational therapeutic tool for lung cancer cisplatin sensitization. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results of this study suggest that split-dose cisplatin may offer fewer grade III-IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapyin patients with histologically diagnosed early stage NSCLC.(2)To investigate whether or not predefined patient subgroups benefit more or less from cisplatin-based chemotherapy in terms of survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Cell cycle inhibition, currently being tested in clinical trials, might be antagonistic to cisplatin and other cytotoxic drugs.BACKGROUND: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "An inhibitor of CDK4/6 (PD0332991) protected parental NSCLC cells from cisplatin cytotoxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Inhibition of CDK6 antagonizes cisplatin-induced NSCLC cell cytotoxicity, suggesting that agents that inhibit CDK6 should be avoided during cisplatin therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The standard of care for advanced non-small cell lung cancer (NSCLC) consists in cisplatin-combination chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our hypothesis is that EGCG could resensitize non-small-cell lung cancer (NSCLC) cells to cisplatin (DDP) through candidate genes demethylation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Even though cisplatin treatment after surgical resection of the primary tumor has been established as a standard chemotherapy for residual disease including metastatic spread, NSCLC often acquires a resistance against chemotherapy, and metastatic disease is often observed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We used two NSCLC cell lines (H460 and A549) and the cisplatin-resistant variants (H460/Pt and A549/Pt), to mimic a frequent clinical condition. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Strikingly, RPN2 silencing repressed tumorigenicity and sensitized the tumors to cisplatin treatment, which led to the longer survival of NSCLC-bearing mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR) over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In summary, we demonstrated that S-1 and cisplatin with concurrent thoracic radiation was more effective than cisplatin plus radiotherapy in NSCLC patients with acceptable toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To assess the role of FoxM1 in chemoresistance, we investigated FoxM1 protein expression and the correlation between FoxM1 expression, sensitivity to cisplatin-based therapy, and the survival of non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our results revealed that the positive expression rate of FoxM1 in NSCLC was associated with chemosensitivity to cisplatin and a\u00a0poor prognosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although cisplatin-based chemotherapy combined with thoracic irradiation (TRT) is a standard treatment for unresectable, locally advanced non-small cell lung cancer (NSCLC), this treatment outcome has remained unsatisfactory. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II trial, 48 patients with stage III NSCLC received cisplatin (40mg/m(2) on days 1, 8, 29 and 36) and S-1 (80mg/m(2) on days 1-14 and 29-42) and TRT (60Gy). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In particular, cisplatin has been used to treat late stage non-small cell lung cancer (NSCLC) as the standard of care. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Considerable efforts have been invested to identify biomarkers that can be used to predict cisplatin sensitivity in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Response of NSCLC cells to cisplatin was detected utilizing MTT assays, and the intracellular drug concentrations were determined by the high performance liquid chromatography (HPLC) analysis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study, the results demonstrated that ERCC1 had no effect on cell proliferation, cell cycle and the ability of invasion, but showed significant impact on cisplatin response of the NSCLC H1299 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, siRNA-induced suppression of ERCC1 evidently enhanced sensitivity to cisplatin of NSCLC A549 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "IGF2R silencing significantly enhanced the chemo-resistance of NSCLC cell lines to cisplatin treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, the effects of miR-107 and the mechanism through which miR-107 affects the cisplatin chemoresistance in NSCLC have not been reported. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the present study provides the first evidence that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in NSCLC cell lines, suggesting that miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel potential maker for NSCLC therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: We found low concentrations of GC7 have little effect on NSCLC viability, but could enhance cisplatin cytotoxicity in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our data indicated GC7 enhances cisplatin cytotoxicity and prevents the EMT in NSCLC cells by inhibiting eIF5A-2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against non-small cell lung cancer (NSCLC) cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Although cisplatin (DDP) has been reported to be a promising antitumor therapy for non-small cell lung cancer (NSCLC), the effectiveness of the treatment remains limited due to an inherent tumor resistance to DDP. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of the present study was to investigate whether ATF2 may have a role in acquired resistance to cisplatin in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u8840\u7ba1\u5185\u76ae\u6291\u7d20\u53ef\u4ee5\u6291\u5236\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u7684\u751f\u6210\uff0c\u4f46\u5bf9\u80bf\u7624\u5fae\u6dcb\u5df4\u7ba1\u7684\u5f62\u6210\u4e0e\u53d1\u5c55\u662f\u5426\u5b58\u5728\u6291\u5236\u6548\u5e94\u5f15\u8d77\u6211\u4eec\u5173\u6ce8\u3002\u672c\u7814\u7a76\u65e8\u5728\u63a2\u8ba8\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\uff08recombinant human endostatin injection\uff09\u5bf9\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7\u4e2d\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff08vascular endothelial growth factor, VEGF\uff09-C\u3001VEGF-D\u548cVEGF\u53d7\u4f53\uff08VEGFR\uff09-3\u8868\u8fbe\u53ca\u5bf9\u5916\u5468\u8840\u5faa\u73af\u80bf\u7624\u7ec6\u80de\u6570\u76ee\u7684\u5f71\u54cd\u3002\u65b9\u6cd5 \u8377\u7624\u88f8\u9f20\u968f\u673a\u5206\u4e3a\u7a7a\u767d\u5bf9\u7167\u7ec4\u3001\u987a\u94c2\u7ec4\u3001\u4e0d\u540c\u6d53\u5ea6\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u7ec4\u53ca\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20+\u987a\u94c2\u7ec4\uff0c\u8fde\u7eed\u7ed9\u836f2\u5468\u30021\u5468\u540e\u68c0\u6d4b\u80bf\u7624\u7ec4\u7ec7\u4e2dVEGF-C\u3001VEGF-D\u3001VEG FR-3\u7684\u8868\u8fbe\u6c34\u5e73\u548c\u5fae\u6dcb\u5df4\u7ba1\u5bc6\u5ea6\u3002\u514d\u75ab\u8367\u5149\u67d3\u8272\u8bca\u65ad\u548c\u8ba1\u6570\u5faa\u73af\u80bf\u7624\u7ec6\u80de\u3002\u7ed3\u679c \u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u7ec4\u4e0e\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u8054\u5408\u987a\u94c2\u7ec4\u7684\u8868\u8fbe\u9633\u6027\u7387\u3001\u5fae\u6dcb\u5df4\u7ba1\u5bc6\u5ea6\u5747\u660e\u663e\u4f4e\u4e8e\u7a7a\u767d\u5bf9\u7167\u7ec4\u4e0e\u987a\u94c2\u7ec4\uff08P<0.05\uff09\uff1b\u8f83\u9ad8\u6d53\u5ea6\u7684\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u8054\u5408\u987a\u94c2\u7ec4\u4e0e \u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u7ec4\u8868\u8fbe\u9633\u6027\u7387\u548c\u5fae\u6dcb\u5df4\u7ba1\u5bc6\u5ea6\u4f4e\u4e8e\u76f8\u5e94\u8f83\u4f4e\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u6d53\u5ea6\u7684\u7ec4\u522b\uff08P<0.05\uff09\u3002\u5404\u7ec4\u5fae\u6dcb\u5df4\u7ba1\u5bc6\u5ea6\u4e0eVEGF-C\u3001VEGF-D\u3001VEGFR-3 \u8868\u8fbe\u9633\u6027\u7387\u5b58\u5728\u6b63\u76f8\u5173\u3002\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u8054\u5408\u987a\u94c2\u5404\u7ec4\u7684\u5faa\u73af\u80bf\u7624\u7ec6\u80de\u6570\u76ee\u660e\u663e\u4f4e\u4e8e\u5355\u72ec\u4f7f\u7528\u987a\u94c2\u6216\u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\uff08P<0.05\uff09\u3002\u7ed3\u8bba \u91cd\u7ec4\u4eba\u8840\u7ba1\u5185\u76ae\u6291\u7d20\u53ef\u4ee5\u6291\u5236\u80bf\u7624\u65b0\u751f\u6dcb\u5df4\u7ba1\u751f\u6210\uff0c\u51cf\u5c11\u5faa\u73af\u80bf\u7624\u7ec6\u80de\uff0c\u4f5c\u7528\u5927\u5c0f\u4e0e\u6d53\u5ea6\u6709\u5173\u3002\u4e0e\u987a\u94c2\u8054\u5408\u4f7f\u7528\u80fd\u591f\u66f4\u6709\u6548\u7684\u51cf\u5c11\u5faa\u73af\u80bf\u7624\u7ec6\u80de\u3002 DOI: 10.3779/j.issn.1009-3419.2014.10.03 PMID: 25342038 [PubMed - indexed for MEDLINE]  MicroRNAs (miRNAs) have been discovered to have pivotal roles in regulating the drug resistance of various types of human cancer, including cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we demonstrate that hyaluronan (HA)-conjugated cisplatin has highly selective and sensitive anticancer effects in NSCLC cells that overexpress the trans-membrane receptor, CD44, as HA is a specific ligand for CD44. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Based on our experimental results, we strongly believe that HA-cisplatin conjugate is a potential anticancer chemo-agent, which target CD44 overexpression in NSCLC, with minimal side effects and high therapeutic properties. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our results indicate that advanced NSCLC patients with positive expression of EZH2 exhibited resistance to cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "EZH2 may be a predictive and prognostic factor for cisplatin-based therapy response and disease survival in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we hypothesized that the dual inhibitor of phosphatidylinositol-3 kinase/mammalian target of rapamycin, NVP-BEZ-235, could potentially enhance radiosensitization in cisplatin-resistance (CDDP-R) non-small cell lung cancer (NSCLC) cells by disabling autophagy as a mechanism of self-preservation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Combinational treatment with zerumbone and cisplatin significantly accelerated apoptosis and promoted p53 expression and ROS production in NSCLC cells, compared with each alone. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These findings demonstrate that zerumbone induces mitochondrial apoptosis and enhances the susceptibility to cisplatin in NSCLC cells, which are, at least partially, mediated through activation of p53 signaling and promotion of ROS generation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study is to assess whether ERCC1 expression level is linked to cisplatin sensitivity and clinical outcomes in resected NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study was aimed to elucidate the roles of inhibition of related JAK/STAT pathways in regulating cytotoxicity induced by cisplatin in non-small-cell lung cancer (NSCLC) cell. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We also investigated the effect of combination treatment inhibited tumor xenograft growth in two human NSCLC xenograft models bearing the cisplatin resistant (H1299) and sensitive (A549) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study indicates that further study is warranted to determine the effectiveness of combination treatment with cisplatin and Jak2/stat3 pathway inhibitor for platinum-resistant NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The expression changes of lung CSCs cell marker in A549-Luc-C8 human non-small-cell lung cancer (NSCLC) cell line with or without cisplatin treatment were detected by flow cytometry. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmall cell lung cancer, carried out by the ELCWP aim to answer the following questions: 1) What benefits can we expect from chemotherapy and which are the treatment goals? 2) Do we have to integrate a palliative approach into the cancer treatment? 3) What are the chemotherapeutic agents for which efficacy has been established? 4) Can carboplatin replace cisplatin? 5) What are the most active cisplatin-based combination chemotherapy? 6) What should be the dose of cisplatin? 7) Can non-platinum regimens replace platinum-based for first-line treatment? 8) What is the role of targeted therapies? 9) When can we or should we customize chemotherapy? 10) What is the optimal number of cycles of induction therapy to administer? Should be done consolidation or maintenance treatment? 11) Is it an indication for sequential chemotherapy? 12) What is the efficacy of salvage chemotherapy and which drugs can be given in this indication? 13) Which treatment for oligometastatic diseases? 14) What are the places of chemotherapy and radiotherapy in the treatment of patients with brain metastases? 15) Which drugs can be used specifically in cases of bone metastases? 16) Which treatment for patient unfit to receive conventional treatment because of its general status, age or comorbid conditions?  The present updated guidelines on the management of resectable non-small cell lung cancer (NSCLC) formulated by the ELCWP are designed to answer the following questions: 1) Is conventional surgery the best treatment for potentially resectable cancer? 2) What is the definition of a complete resection? 3) Should we make a systematic lymphadenectomy in case of surgery for a N0 or N1 tumor? 4) What is the role of radiation therapy after complete resection? 5) In case of clinical stage I or II, should administer adjuvant or neoadjuvant chemotherapy? 6) In case of pathological stage I or II, should administer adjuvant chemotherapy? 7) In case of complete resection for stage IIIA N2 disease, should be offered adjuvant therapy and if so which one: chemotherapy, radiotherapy, chemoradiotherapy? 8) In case of clinical stage IIIA or B, what are the indications for surgery after induction therapy? 9) In case of clinical stage IIIA or B, if surgical indication is retained, should we do an induction treatment, and if so, which one? 10) In case of incomplete resection after primary surgery, what should be the postoperative therapy? 11) In case of (neo)adjuvant chemotherapy, which association should be offered and what dosage of cisplatin to be prescribed? 12) Can stereotactic radiotherapy replace surgery in operable patients? 13) What is proposed for the patient unfit for conventional surgery treatment? 14) Have targeted therapies a place in the treatment ?  BACKGROUND:: Pemetrexed is the preferred treatment of nonsquamous non-small cell lung cancer (ns-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we aimed to identify the expression of Aurora-A and its correlation with cisplatin resistance and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We used immunohistochemical analysis to determine the expression of Aurora-A protein in 102 NSCLC patients treated by surgery and adjuvant cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The potential role of Aurora-A in the regulation of cisplatin resistance in NSCLC cells was examined by transfections using expression vector and small interfering RNA or using small-molecule inhibitors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The current findings suggest that high Aurora-A expression is correlated with cisplatin-based chemotherapeutic resistance and predicts poor patient survival in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, targeted inhibition of three strategic points of the PI3K-NF\u03baB axis was performed with the aim of exploiting vulnerabilities in cisplatin-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results of the present study demonstrated that overexpression of miR-182 may involve in chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Fragile histidine triad (FHIT) loss by the two-hit mechanism of loss of heterozygosity and promoter hypermethylation commonly occurrs in non-small cell lung cancer (NSCLC) and may confer cisplatin resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, the underlying mechanisms of FHIT loss in cisplatin resistance and the response to cisplatin-based chemotherapy in NSCLC patients have not yet been reported. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Among NSCLC patients, low FHIT, high p-AKT, high Slug and low PUMA were correlated with shorter overall survival, relapse-free survival and poorer response to cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Pemetrexed, a folate antimetabolite, combined with cisplatin is used as a first-line therapy for malignant pleural mesothelioma (MPM) and locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our data also show that overexpression of miR216a suppresses NSCLC cell growth and metastasis, and enhances cisplatin-induced cell growth inhibition and apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In contrast, inhibition of miR216a stimulates NSCLC cell growth and metastasis, and suppresses cisplatin-induced cell growth inhibition and apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the A549 non-small cell lung cancer (NSCLC) cell line, ME2 depletion inhibits cell proliferation and induces cell death and differentiation, accompanied by increased reactive oxygen species (ROS) and NADP(+)/NADPH ratio, a drop in ATP, and increased sensitivity to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Three of six trials involving 300 or more patients with early-stage NSCLC demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve 5-year survival in carefully selected patients with resected NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "AIM: The aim of the work was to compare values of Glasgow Prognostic Score (GPS) before application of the chemotherapy medication with response to chemotherapy and toxic side effects associated with chemotherapy in patients treated with cisplatin-etopozid (PE) and cisplatin-gemcitabin (PG) in stages IIIb and IV of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Twenty one NSCLC patients receiving cisplatin- based first-line treatment were analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Recent studies have shown that plasma miR-21 is a biomarker of chemotherapeutic response in lung cancer, but the influence of miR-21 on the sensitivity of non-small-cell lung cancer (NSCLC) to cisplatin (DDP) has not been confirmed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The data demonstrated that CIP2A silencing led to decreased proliferation, impaired clonogenicity and enhanced chemosensitivity and apoptosis to cisplatin in human NSCLC cells, as well as reduced Akt phosphorylation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, overexpression of CIP2A diminished NSCLC cell chemosensitivity to cisplatin by inducing activation of Akt pathway, suggesting critical roles of CIP2A in NSCLC cell chemoresistance to cisplatin and rasing the possibility of CIP2A inhibition as a promising approach for lung cancer therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Naturally occurring phenethyl isothiocyanate (PEITC) was previously shown to sensitize human non-small cell lung cancer (NSCLC) cells to the platinum anticancer drug cisplatin (CDDP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Over-expressed eukaryotic initiation factor 3a (eIF3a) in non-small cell lung cancer (NSCLC) contributed to cisplatin sensitivity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, interaction research between biomarkers and chemotherapy status disclosed cisplatin-based regimen trend to prolong DSS of stage II NSCLC patients with high eIF3a-C (P=0.036)and low p27-N (P=0.031). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our study of azithromycin+paclitaxe l+cisplatin on stage III-IV NSCLC patients achieved favorable results in terms of side effects and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, oral administration of luteolin, either alone or combined with intraperitoneal injection of the cytotoxic drug cisplatin, greatly inhibited the growth of xenograft tumors from non-small-cell lung cancer (NSCLC) cell line A549 cells grown subcutaneously in athymic nude mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study investigated efficacy of computed tomography-guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Consequently, our study suggests that miRNA 17 family (including miR-17, 20a, 20b) can act as TGF\u03b2R2 suppressor for reversing cisplatin-resistant and suppressing metastasis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to assess the predictive value of survival in patients with advanced non-small cell lung cancer (NSCLC) treated with cisplatin-based first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to identify candidate DNA methylation drivers of cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the effects of chemically modified anti-STAT3 small interfering (si)RNAs on cell viability, proliferation and apoptosis of parental and cisplatin resistant non-small cell lung cancer (NSCLC) cells were investigated with the aim to provide a new therapeutic strategy for overcoming cisplatin resistance in lung cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: The parental NSCLC cell line Calu1 and its cisplatin- resistant subline CR-Calu1 were used to study the effects of STAT3 suppression with chemically modified anti-STAT3 siRNAs. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: NSCLC cells could be sensitized to cisplatin by targeting STAT3 with chemically modified siRNAs together, a fact which was accompanied with increased apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, Disulfiram/copper significantly increased the sensitivity of cisplatin in NSCLC cells tested by MTT assay. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Surgery remains the corner stone of treatment in early-stage NSCLC when feasible, and the addition of adjuvant cisplatin-based chemotherapy has improved these results in resected NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Adjuvant cisplatin-based chemotherapy is the standard of care for completely resected high-risk stage IB and stage II NSCLC based on a ~5% improvement in 5-year overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Adjuvant cisplatin-based chemotherapy only marginally improves survival in patients with completely resected non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " It is reported that MicroRNA-503 (miR-503) regulates cell apoptosis, and thus modulates the resistance of non-small cell lung cancer cells (NSCLC) to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Re-challenge with platinum combination chemotherapy was effective and safe; therefore, this therapy should be considered as a treatment option for relapsed patients after postoperative cisplatin-based adjuvant chemotherapy for resected NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Depletion of Mcl-1 via siRNA or pharmacologic inhibition of Mcl-1, using EU-5148, sensitized TWEAK-treated NSCLC cells to cisplatin- or radiation-mediated inhibition of cell survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To test the hypothesis that daily intravenous pre-hydration decreases renal toxicity and improves chemotherapy adherence in patients receiving daily cisplatin to concurrent radiotherapy for locally advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced NSCLC were treated between 2008 and August 2012 with daily 6 mg/m(2) cisplatin as a bolus injection in 10 ml; of saline and 66 Gy/24 fr radiotherapy in 32 days. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Daily pre-hydration was associated with a reduced rate of both renal and acute esophageal toxicity and an increased chemotherapy adherence in patients receiving daily dose of cisplatin and concurrent radiotherapy for locally advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Cancer cells that develop resistance to cisplatin (DDP) are a major clinical obstacle to the successful treatment of cancer, including non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we sought to investigate the effects of arctigenin on cisplatin-treated non-small-cell lung cancer (NSCLC) H460 cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We used cell viability assays, Western blotting, and immunofluorescence combined with siRNA interference or plasmid transfection to investigate the underlying mechanism of cisplatin resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: Three large randomized clinical trials and two meta-analyses have demonstrated a survival benefit for adjuvant cisplatin-based chemotherapy compared with surgery alone in patients with early-stage NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Since response to platinum-based therapy in non-small-cell lung cancer (NSCLC) is poor, the present study was designed to rationally identify novel drug combinations in cell models including the A549 cell line and the cisplatin-resistant subline A549/Pt, characterized by reduced sensitivity to cisplatin-induced apoptosis and by upregulation of efflux transporters of the ATP binding cassette (ABC) superfamily. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Cisplatin-based therapy is a pivotal type of chemotherapy for non-small cell lung cancer (NSCLC) and chemoresistance to cisplatin represents one of the most significant barriers to improving long-term clinical outcomes. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The present study aimed at examining metallothionein (MT) expression in six NSCLC cell lines as well as examining effects of exposure to cisplatin on MT expression in the most cisplatin-resistant (97/97) and the cisplatin-sensitive (DV90) cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The most cisplatin-resistant NSCLC cell line [97/97; (IC50)=4.659 \u03bcM] exposed to the highest concentration of cisplatin (10 \u03bcM) exhibited decreased nuclear MT expression (MTn=6) compared to cells cultured in medium with a lower concentration of cisplatin (0, 1 and 5 \u03bcM) (MTn=12). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The most cisplatin-sensitive NSCLC cell line (DV90; IC50=0.184 \u03bcM) was characterized by a significant decrease of both nuclear and cytoplasmic MT expression with increasing cisplatin concentrations (5 vs. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study suggests that cisplatin resistance in NSCLC is metallothionein-independent. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, HDAC inhibitors synergized with TRAIL and cisplatin in NSCLC cells in a FLIP- and caspase-8-dependent manner. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study aims to investigate whether GA would be synergistic with cisplatin (CDDP) against the NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In vitro, HGF reduced expression of apoptosis-inducing factor (AIF) and cisplatin sensitivity in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In an autochthonous model of non-small-cell lung cancer (NSCLC), we demonstrate that MK2 is responsible for resistance of p53-deficient tumors to cisplatin, indicating synthetic lethality between p53 and MK2 can successfully be exploited for enhanced sensitization of tumors to DNA-damaging chemotherapeutics in vivo. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Not all NSCLC patients are likely to benefit from EGFR-TKIs and, therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant EMT cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, the possible role of miR-31 in cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC) remains unclear. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These data indicate that the miR-92b play an oncogene roles by regulates cell growth, cisplatin chemosensitivity phenotype, and could serve as a novel potential maker for NSCLC therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy and safety of oral S-1 in combination with cisplatin and thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of oral S-1 plus cisplatin with concurrent radiotherapy is a promising treatment with a high efficacy and lower toxicity in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, we suggest that Src or ERK inhibitor might be helpful to improve the sensitivity for cisplatin-based chemotherapy in NSCLC patients with PXN-positive tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in non-small-cell lung cancer (NSCLC) patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The drug sensitivity assay indicated that miR-495 enhanced the cell response to cisplatin (CDDP) in NSCLC cells, while inhibition of miR-495 led to the opposite effects. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In vitro evidences suggest that cofilin-1 is a biological predictor of cisplatin resistance, supporting new treatment initiatives based on cofilin-1 levels to guide chemotherapeutic interventions in NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our aim was to test the hypothesis that cisplatin resistance is associated with alteration of SOX1 expression in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We also found that SOX1 silencing enhanced the cisplatin-mediated autophagy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study shows that inactivation of SOX1 by promoter hypermethylation, at least in part, is responsible for cisplatin resistance in human NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The findings were included into randomized controlled trials (RCTs) of elemene injection combined with cisplatin chemotherapeuties in treating small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "2 software, in order to assess the efficacy and safety of elemene injection combined with cisplatin chemotherapeutics in treating NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we studied Pt-(GpG) DNA adducts in circulating tumour cells (CTC) treated with cisplatin in medium upfront to systemic therapy from patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This view has gained recent support with the finding that USP1 inhibition may contribute to revert cisplatin resistance in an in vitro model of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Finally, we discuss the emerging potential of USP1 as a target, integrating published data with our novel findings on the effects of the USP1 inhibitor pimozide in combination with cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Adjuvant chemotherapy using a cisplatin-based regimen is currently recommended for patients with stage II and III non-small cell lung cancer (NSCLC) after complete tumor resection and may be considered for patients with stage IB NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In human NSCLC-cell-A549-xenograft models, Mst1 gene or cisplatin alone suppressed the growth of tumors and increased the cytoplasm-positive expression levels of YAP and Phospho-YAP (Ser127) proteins; however, their combination had the strongest anticancer effects. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCLC) per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous non-small cell lung cancer (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We correlated clinical and dosimetric parameters with acute toxicity grade \u2265 3 in patients with locally advanced NSCLC treated with IMRT and concurrent low-dose cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent low-dose cisplatin using IMRT is effective in a large cohort of consecutive patients with NSCLC and life threatening toxicity is rare (1%). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to determine whether subtoxic-dose cisplatin and TRAIL could synergistically enhance apoptosis on NSCLC cells and investigate its underlying mechanisms.MATERIALS AND METHODS: NCI-H460 and A549 cells were treated with TRAIL alone, cisplatin alone or combination treatment in this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Subtoxic-dose cisplatin could enhance both TRAIL- sensitive and TRAIL- resistant NSCLC cells to TRAIL-mediated apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We conducted a systematic review and a study-level meta-analysis of published randomized controlled trials (RCTs) in order to determine the overall risk of non-lung cancer-related mortality associated with adjuvant cisplatin-based chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Eligible publications included prospective RCTs in which cisplatin-based adjuvant chemotherapy plus local therapy was compared with local therapy alone in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this meta-analysis of RCTs in NSCLC, cisplatin-based adjuvant chemotherapy was associated with a 30\u00a0% increase in non-lung cancer-related mortality compared with local therapy alone. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, it was found that ERCC1 protein expression might play an important role in the prognosis of p-stage III/N2 NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of this study was to explore the correlation between mRNA expression of \u03b2-tubulin-III and stathmin in patients with stage II non-small cell lung cancer (NSCLC) and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Among them, high levels of expression of ERCC1, both at protein and mRNA levels, have been associated with resistance to cisplatin in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Its role in STIM1 cisplatin-induced apoptosis of non-small cell lung cancer was the focus of study with focus on SOCE inhibitors 2-APB- and SKF96365-cisplatin-induced apoptosis in the non-small cell lung cancer (NSCLC) cell lines A549 and H460. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, acquired cisplatin resistance is ubiquitous in patients with NSCLC, but the molecular mechanism of such resistance remains ambiguous. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, activation of the Wnt/\u03b2-catenin signaling pathway and upregulated survivin expression due to cytoplasmic GSK-3\u03b2 inhibition might lead to cisplatin resistance in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: 153 patients with locally advanced NSCLC treated with 66 Gy/2.75 Gy/24 fractions of radiotherapy and concurrent daily low dose cisplatin were selected. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For NSCLC patients treated with concurrent chemotherapy and IMRT A higher number of cisplatin administrations, non-Caucasian background and higher V50oes were associated with grade 3 AET. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "No prospective randomized trial has tested the addition of cisplatin to single-agent chemotherapy in patients with advanced NSCLC and PS2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The cytotoxicities of the complexes to human non-small-cell lung cancer (NSCLC) cell lines sensitive and resistant to cisplatin were assayed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Complex 1 was more cytotoxic than cisplatin in both PC-9 and PC-14 NSCLC cell lines, and cross-resistance to 1 in the cisplatin-resistant cells was largely circumvented. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, the regulation of eIF2\u03b1 may improve treatment outcomes of cisplatin-based chemotherapy for patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These observations indicate that CAERS induced apoptosis and sensitized NSCLC to cisplatin via a mitochondria-mediated apoptotic pathway. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The weekly fractionated administration of cisplatin for patients with NSCLC has been shown to be active. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The FAST was a factorial trial in first-line treatment of advanced non-small-cell lung cancer (NSCLC), addressing the role of replacing cisplatin with a non-platinum agent. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Both estrogen and progesterone pre-treatment led to chemoresistance of A549 NSCLC cells in vitro by attenuating cisplatin-induced apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective standard treatment of non-small cell lung carcinoma (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Chemosensitivity of cisplatin in NSCLC cell lines was correlated with the accumulation of cisplatin DNA adducts (P=0.0004). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We assessed clonogenic survival of 16 NSCLC cell lines in response to cisplatin, mitomycin C (MMC), and the PARP inhibitor olaparib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thirteen tumor explants from patients with NSCLC were subjected to cisplatin ex vivo. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we investigated whether \u03b2-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "\u03b2-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, \u03b2-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G(2)/M. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we addressed if such a phenotype may contribute to radio- and cisplatin resistance in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: An isogenic model of cisplatin resistance was generated in a panel of NSCLC cell lines (A549, SKMES-1, MOR, H460). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results identified cisplatin resistant subpopulations of NSCLC cells with a putative stem-like signature, providing a further understanding of the cellular events associated with the cisplatin resistance phenotype in lung cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed plus cisplatin was approved for first-line treatment of non-small-cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with non-small cell lung cancer (NSCLC), investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We have investigated the effect of ADAM8 on the cisplatin resistance in non-small-cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Thus, ADAM8 is implicated in cisplatin resistance of NSCLC cells through activation of the STAT3 signalling pathway, and thus represents a potential therapeutic target in this malignancy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: Compared to NLT-MSC, NSCLC-MSC showed accelerated growth kinetics and reduced sensitivity to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 non-small-cell lung cancer (NSCLC) treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The effect of small interfering RNA-induced BIRC6 knockdown on the growth of human NSCLC cell cultures and apoptosis (in combination with cisplatin) was investigated. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Small interfering RNA-induced BIRC6 down-regulation inhibited growth of the NSCLC cells and sensitized the cells to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We examined in different human NSCLC cell lines and detected cellular senescence after cisplatin (DDP) treatment in the presence or absence of DEX. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Failure to efficiently induce apoptosis contributes to cisplatin resistance in non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In H460 NSCLC cells, caspase-8 cleavage was shown to be induced by cisplatin and is dependent on death receptor 4, death receptor 5, Fas-associated protein with death domain, acid sphingomyelinase and ceramide synthesis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To investigate the effect of olaparib and cisplatin on PTEN-deficient lung tumors, two EGFR-mutant (deletion in exon19) non-small cell lung cancer (NSCLC) cell lines, PC-9 (PTEN wild-type) and H1650 (PTEN loss), were used. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Liposomal cisplatin is an agent with negligible toxicity and reasonably high effectiveness even when administered to pretreated patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: PCRT using cisplatin plus S-1 with concurrent radiation therapy is useful for inducing downstaging in patients with locally advanced stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m(2) of D and 60 mg/m(2) of cisplatin (P), as a treatment for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Silencing XPA gene can partly reverse the cisplatin resistance in human cisplatin-resistant NSCLC cell line A549/DDP. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Sera were collected from 37 NSCLC patients before they were treated with concurrent cisplatin-based CRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this retrospective single-center study was to evaluate prognostic factors for overall survival (OS) in elderly (\u226565 years) patients with advanced NSCLC who received first-line cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively reviewed 110 elderly patients with locally advanced or metastatic NSCLC who had been administered cisplatin-based first-line chemotherapy between December 2004 and November 2011. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Following the results of the 1995 meta-analysis on the role of chemotherapy (CT) in non-small-cell lung cancer (NSCLC), many randomized, controlled trials were launched to evaluate the effect of adjuvant cisplatin-based CT after the complete resection of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we showed that depletion of HDAC6 in two NSCLC cell lines, H292 and A549, sensitized cells to cisplatin, one of the first-line chemotherapeutic agents used to treat NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, we showed that HDAC6 protein levels were positively correlated with cisplatin IC(50) in 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Patients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: eIF3\u03b1 Arg803Lys C > T polymorphism was associated with cisplatin-induced toxicity in NSCLC patients (P = 0.02, OR = 0.54, 95% CI 0.32, 93). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Treatment with a combination of delta-tocotrienol and cisplatin resulted in a dose-dependent, significant inhibition of cell growth, migration, invasiveness, and induction of apoptosis in NSCLC cells, as compared to the single agents. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These results suggest that down-regulation of Notch-1, via inhibition of NF-\u03baB signaling pathways by delta-tocotrienol and cisplatin, in combination, could provide a potential novel approach for tumor arrest in NSCLC, while lowering the effective dose of cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The data suggest that the PKG-I\u03b1 kinase activity is necessary for maintaining higher levels of CREB phosphorylation at ser133 and protein expression of c-IAP1, livin, survivin, and Mcl-1, preventing spontaneous apoptosis and promoting colony formation in NSCLC cells, which may limit the effectiveness of chemotherapeutic agents like cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The intrinsic characteristics of NSCLC (which near-to-always is chemoresistant and associated with poor prognosis) and/or the type of therapy that is employed to treat this malignancy (which near-to-always is based on cisplatin) may explain why two genes that affect the immune response to dying cells fail to influence the clinical progression of NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Induction cisplatin-based CT improves survival in resectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the current study, we investigated the underlying mechanism initiated by silencing of Twist1 that sensitizes NSCLC cells to cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Between 2003 and 2010, 87 patients with stage III NSCLC underwent cisplatin-based CCRT and all subsequent follow-up at the VU University Medical Center. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Randomised trials of cisplatin-based adjuvant chemotherapy for resected NSCLC were identified. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a series of in vitro and cell culture assays in a NSCLC model, we investigated both the downstream and direct treatment and damage effects of cisplatin on NHEJ catalyzed repair of a DNA DSB. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULT: CTR1 rs10981694 A>C polymorphism is associated with cisplatin induced severe toxicity in NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: NSCLC patients carrying C allele of CTR1 rs10981694 presented more sensitivity to ototoxicity after cisplatin treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Three of 6 trials with 300 or more patients with early-stage NSCLC have demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve 5-year survival in carefully selected patients with resected NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Taken together, our results suggest that the down-modulation of TP protein induced by 17-AAG represents a key factor in enhancing the cytotoxic effects of cisplatin in NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for non-small-cell lung cancer(NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For this purpose, A549 and Calu1 NSCLC (non-small-cell lung cancer) cell lines were treated with cisplatin to obtain resistant sub-lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ATP7A expression was evaluated by immunohistochemistry in tumor tissues of unresectable NSCLC patients who received cisplatin-basing chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The transcriptional level of IGFBP7 was decreased in cisplatin-resistant human cancer cell lines and NSCLC xenografts. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The expression of MKP3 increased in a cisplatin-resistant NSCLC cell line and lung xenografts. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We conducted a dose escalation study of amrubicin and cisplatin in previously untreated patients with stage IIIB or IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This amrubicin and cisplatin regimen may be feasible and promising against advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Most non-small-cell lung cancer (NSCLC) patients receive cisplatin-based chemotherapy though clinical response is restricted to a subset of patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although the survival benefit of cisplatin-based adjuvant chemotherapy has been proven for patients with non small cell lung cancer (NSCLC), the resistance to cisplatin and its dose-dependent side effects remain a challenge. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Improvement in survival and reduction of side effects require a biomarker capable of defining the response to cisplatin treatments in patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we investigated whether the quantified mRNA expression of FATS can predict cisplatin sensitivity in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For those NSCLC patients receiving cisplatin-based chemotherapy, the overall survival was significantly longer in FATS-high subgroup than that in FATS-low subgroup (P=0.038). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Multivariate analysis revealed the independent value of FATS mRNA in predicting the overall survival for NSCLC patients receiving cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, enhanced expression of FATS significantly sensitized NSCLC cells to cisplatin-induced apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C\u00a0\u2192\u00a0T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n\u00a0=\u00a0142) to cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, two stably transfected cell lines (A549/shSTAT3 and SPC-A1/shSTAT3) were successfully established, and RNAi-mediated STAT3 inhibition could significantly increase the sensitivity of NSCLC cells to cisplatin by enhancing caspase-3-dependent apoptosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: It is important to know the tumor resistance against cisplatin before the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our recent study has demonstrated that AT-101 enhanced the antitumor effect of cisplatin (CDDP) in a murine model of NSCLC via inhibition of the interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Strikingly, RPN2 silencing repressed tumorigenicity and sensitized the tumors to cisplatin treatment, which led to the longer survival of NSCLC-bearing mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 non-small-cell lung cancer (NSCLC) treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m(2) of D and 60 mg/m(2) of cisplatin (P), as a treatment for NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "YAP1 ablation significantly improved sensitivities not only to cisplatin but also to ionizing radiation, both of which are DNA-damaging interventions, in non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Adjuvant cisplatin-based chemotherapy is the standard of care for completely resected high-risk stage IB and stage II NSCLC based on a ~5% improvement in 5-year overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Not all NSCLC patients are likely to benefit from EGFR-TKIs and, therefore, cisplatin was used to further demonstrate a role of inhibition of Hh signaling in sensitization of resistant EMT cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the present study, non-small cell lung cancer (NSCLC) cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4\u00a0cycles is recommended. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCLC) per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we showed that depletion of HDAC6 in two NSCLC cell lines, H292 and A549, sensitized cells to cisplatin, one of the first-line chemotherapeutic agents used to treat NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, we showed that HDAC6 protein levels were positively correlated with cisplatin IC(50) in 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In summary, our findings suggest that HDAC6 is positively associated with cisplatin resistance in NSCLC and reveal HDAC6 as a potential novel therapeutic target for platinum refractory NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The efficacy of cisplatin in combination with Abraxane is better than that with gemcitabine in the treatment of NSCLC, and the treatment has less risk of hematologic toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "On the basis of the SQUIRE results, necitumumab was approved in combination with cisplatin and gemcitabine as a first-line treatment for advanced squamous NSCLC, both in the US and Europe, where its availability is limited to patients with EGFR-expressing tumors. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m(2) i.v., days 1 and 8) and cisplatin (75 mg/m(2) i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In line with SQUIRE ITT, addition of necitumumab to gemcitabine-cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Necitumumab is approved as a part of combination therapy (with gemcitabine and cisplatin) in the USA for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), and regulatory submissions have been made in the EU for this same indication. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This article summarizes the milestones in the development of necitumumab leading to this first approval for the first-line treatment of metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 60 patients with advanced NSCLC were divided into two groups using a random number table, i.e., the gemcitabine plus cisplatin (GP) chemotherapy alone group (26 patients) and the FRG + GP chemotherapy group (34 patients), for 60-day treatment. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine-125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese non-small cell lung cancer (NSCLC) patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "combination of gemcitabine/cisplatin (GC) as neoadjuvant treatment in stage IIIA-N2 NSCLC with sensitizing EGFR mutation in exon 19 or 21. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study was performed to evaluate the therapeutic effect of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among the two cisplatin-based doublets of induction chemotherapy for inoperable NSCLC, both schedules of gemcitabine have a comparable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC\u2009+\u2009N) versus gemcitabine plus cisplatin (GC) for the first-line treatment of patients with stage IV squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We used polymerase chain reaction-restriction fragment length polymorphism to evaluate genetic polymorphisms of XPD (Asp312Asn and Lys751Gln) and CDA (Lys27Gln and Ala70Thr) in 93 NSCLC patients treated with a cisplatin-gemcitabine regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "H1975 NSCLC cells were treated with curcumin (0-50 \u03bcM) alone, or combined with gemcitabine or cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous NSCLC: a phase I/II trial of nintedanib added to first-line gemcitabine/cisplatin and a phase II trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed FGFR kinase amplification or mutation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In advanced NSCLC, cisplatin-based CT is not superior to a platinum-free regimen (ifosfamide-gemcitabine) with a favourable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Among them, high levels of expression of ERCC1, both at protein and mRNA levels, have been associated with resistance to cisplatin in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, low levels of expression of RRM1, a target for gemcitabine, have been associated with improved OS in advanced NSCLC patients treated with cisplatin and gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "No prospective randomized trial has tested the addition of cisplatin to single-agent chemotherapy in patients with advanced NSCLC and PS2. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin-gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To prospectively evaluate the efficacy and toxicity of irinotecan plus cisplatin (IP regimen) compared with gemcitabine plus cisplatin (GP regimen) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Induction cisplatin-based CT improves survival in resectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m(2) of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The present study was performed to investigate the anti-tumor efficacy of metuzumab combined with gemcitabine and cisplatin (GP), paclitaxel and cisplatin (TP) or navelbine and cisplatin (NP) regimens in multiple NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage non-small cell lung cancer (NSCLC) after 1st line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PD-L1 rs2297136T\u2009>\u2009C and rs4143815C\u2009>\u2009G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " We evaluated the effects of cisplatin and paclitaxel on taste acuity and their associations with nutritional and health-related quality of life (HRQL) in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sensitivity to taste increased with paclitaxel and cisplatin CT, making foods more unpleasant, and it was associated with neuropathy, worse HRQL, and reduced nutrient intake in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites with the clinical outcomes of first line paclitaxel-cisplatin chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "These findings suggest that the four SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the clinical outcomes of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We firstly investigated the expression of Pokemon in patients with non-small cell lung cancer (NSCLC), then characterized the role of Pokemon in evaluating the response to combined cisplatin and paclitaxel chemotherapy and prognosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this study, 61 patients with previously untreated locally advanced or metastatic NSCLC were treated with a combination chemotherapy comprising cisplatin and paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The serum level of Pokemon correlated with efficacy of cisplatin and paclitaxel combination chemotherapy and survival time, which indicated that Pokemon may be a potentially useful biomarker for predicting treatment effectiveness of first-line chemotherapy and prognosis in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4\u00a0cycles is recommended. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our study of azithromycin+paclitaxe l+cisplatin on stage III-IV NSCLC patients achieved favorable results in terms of side effects and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of this study was to assess systemic immunological responses in non-small-cell lung cancer (NSCLC) patients with stage III/IV disease during treatment with paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways and determine the relationship between polymorphisms and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, these findings suggest that the six SNPs identified, particularly their combined genotypes, could be used as biomarkers predicting chemotherapy response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Mediastinoscopically proven IIIA(N2)/selected IIIB NSCLC received three cycles cisplatin (50 mg/m(2) day 1+8) and paclitaxel (175 mg/m(2)d1) qd 22. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: PPM in combination with cisplatin was well tolerated, and its response rate was noninferior to that of paclitaxel plus cisplatin in patients with advanced NSCLC and who were chemonaive. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We evaluated the effectiveness of PCRT for inducing downstaging using mainly three chemoradiotherapy regimens; cisplatin plus Tegafur-Gimeracil-Oteracil Potassium (S-1), cisplatin plus Tegafur-Uracil (UFT), or 1,1'cyclobutanedicarboxylate (Carboplatin, CBDCA) plus paclitaxel, with concurrent radiation therapy in 19 patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: PCRT using cisplatin plus S-1 with concurrent radiation therapy is useful for inducing downstaging in patients with locally advanced stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or paclitaxel and after irradiation of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed/cisplatin is the preferred chemotherapy in nonsquamous NSCLC, but the efficacy of this treatment for nonsquamous NSCLC with BM is uncertain. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed in combination with cisplatin is approved in the first line setting and as monotherapy in the switch or continuous maintenance of Non Squamous A-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Pemetrexed, a folate antimetabolite, combined with cisplatin is used as a first-line therapy for malignant pleural mesothelioma (MPM) and locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer (NSCLC) patients, but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCLC) per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous non-small cell lung cancer (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed plus cisplatin was approved for first-line treatment of non-small-cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this study. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with non-small cell lung cancer (NSCLC), investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: These results offer a preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for patients with NSCLC, and provide potential molecular biomarkers for tailoring therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of cisplatin and gemcitabine, with and without necitumumab, revealed an improvement in overall survival with the addition of necitumumab in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This study investigated efficacy of computed tomography-guided percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-pretreated stage IV NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed and cisplatin are recommended in front-line chemotherapy of non-squamous non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: It is important to know the tumor resistance against cisplatin before the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The results indicate that BAG1 is important in cisplatin-induced cell death in lung adenocarcinoma, suggesting that endoplasmic reticulum stress may promote the sensitivity of NSCLC patients to chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This post-hoc analysis illustrated real-life differences in patients with NSCLC prescribed platinum-based first-line treatment, and suggested that baseline patient and disease characteristics were associated with physician's choice of platinum agent, with cisplatin being more frequently prescribed to younger and fitter patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Vinorelbine plus cisplatin is a commonly used doublet for the treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results of this study suggest that split-dose cisplatin may offer fewer grade III-IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against non-small cell lung cancer (NSCLC) cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "130 patients with inoperable stage III NSCLC and PS 0-1 were randomised to receive cisplatinum and vinorelbine with either sequential or concurrent chemo-radiation using 55Gy in 20 fractions over four weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Re-challenge with platinum combination chemotherapy was effective and safe; therefore, this therapy should be considered as a treatment option for relapsed patients after postoperative cisplatin-based adjuvant chemotherapy for resected NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCLC) per American Society of Clinical Oncology and European Society for Medical Oncology clinical practice guidelines. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "Following the results of the 1995 meta-analysis on the role of chemotherapy (CT) in non-small-cell lung cancer (NSCLC), many randomized, controlled trials were launched to evaluate the effect of adjuvant cisplatin-based CT after the complete resection of NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " Induction cisplatin-based CT improves survival in resectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for non-small-cell lung cancer(NSCLC). ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "disease": "NSCLC", "drug": "cisplatin"}, {"polarity": 0, "orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "haemorrhage"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Two randomized phase III trials of carboplatin-based chemotherapy in advanced NSCLC were used for learning and validating the predictive value of ERCC1 in situ protein levels, as measured by accurate quantitative analysis (AQUA). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine and carboplatin combination chemotherapy is an effective and manageable treatment option in elderly advanced NSCLC patients with good performance status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line therapy for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Ixabepilone can be safely combined with carboplatin in newly diagnosed patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This multicenter study evaluated the feasibility of novel adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent, long-term maintenance with S-1 in patients with completely resected stage II-IIIA non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We concluded that adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 is feasible and tolerable in patients with completely resected NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In preclinical models of NSCLC with gain of NRF2 function, ML385 in combination with carboplatin showed significant antitumor activity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " CONTEXT: Paclitaxel (PTX) and carboplatin (CBP) are widely used for the combined chemotherapy of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53(-/-) (also known as KRAS p53) and Kras;Stk11(-/-) (also known as KRAS Lkb1) mouse models of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We compared the combination of chemotherapy drug carboplatin and the radish-derived isothiocyanate compound sulforaphene, which synergistically induces higher apoptosis and growth inhibition in A549, to the drug alone in human NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To summarize, this is the first report that sulforaphene-carboplatin combination treatment synergistically promotes enhanced apoptosis and antiproliferative effect over single drug treatment against A549, human NSCLC cells through caspase activation, MMP disruption, and cell cycle arrest. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the cytotoxic effects of ampelopsin sodium (Amp-Na) and carboplatin (CBP) used alone or in combination on human non-small cell lung cancer (NSCLC) cells SPC-A1 in vitro and its related mechanism. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Chemo-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) who received carboplatin-based chemotherapy were treated with doublet antiemetic therapy with dexamethasone and a 5-HT3 receptor antagonist during the first cycle of chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Subsequent addition of aprepitant significantly improved the overall complete response rate in NSCLC patients receiving a second cycle of carboplatin-based chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced non-small-cell lung cancer (NSCLC) and diabetes. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This is the first prospective study to evaluate the safety and efficacy of S-1 plus carboplatin treatment for NSCLC patients with ILD. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to EGFR-wild-type cases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The participants were patients with chemo-na\u00efve advanced NSCLC treated with PMT plus carboplatin (CBDCA) in prospective clinical phase II study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Here, using Epo-Cy5.5 as theranostic near-infrared fluorescent probe we analyzed the effects of rhuEpo as co-medication to carboplatin in non-small-cell-lung-cancer (NSCLC)-xenografts with different tumor cell EpoR-expression (H838 ~8-fold higher than A549). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Nude mice bearing subcutaneous A549 and H838 NSCLC-xenografts received either only carboplatin or carboplatin and co-medication of rhuEpo in two different doses. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MSA-eCrCl was used to simulate carboplatin dosing in a retrospective series of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In calculating carboplatin doses for 89 NSCLC patients with MSA and CG-eCrCl, median error of CG-determined carboplatin dose was 5.5\u00a0% (range -19.0 to 44.2\u00a0%), assuming that MSA was better at estimating CrCl. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with non-small cell lung cancer (NSCLC), immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC) study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Food and Drug Administration in October 2012 for use along with carboplatin in advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Although carboplatin is one of the standard chemotherapeutic agents for non-small cell lung cancer (NSCLC), it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Based on this mechanism, curcumin has potential as a chemosensitizer for carboplatin in the treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human non-small-cell lung cancer (NSCLC) cells to carbon-ion beam irradiation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous non-small cell lung cancer (non-sq NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmall cell lung cancer, carried out by the ELCWP aim to answer the following questions: 1) What benefits can we expect from chemotherapy and which are the treatment goals? 2) Do we have to integrate a palliative approach into the cancer treatment? 3) What are the chemotherapeutic agents for which efficacy has been established? 4) Can carboplatin replace cisplatin? 5) What are the most active cisplatin-based combination chemotherapy? 6) What should be the dose of cisplatin? 7) Can non-platinum regimens replace platinum-based for first-line treatment? 8) What is the role of targeted therapies? 9) When can we or should we customize chemotherapy? 10) What is the optimal number of cycles of induction therapy to administer? Should be done consolidation or maintenance treatment? 11) Is it an indication for sequential chemotherapy? 12) What is the efficacy of salvage chemotherapy and which drugs can be given in this indication? 13) Which treatment for oligometastatic diseases? 14) What are the places of chemotherapy and radiotherapy in the treatment of patients with brain metastases? 15) Which drugs can be used specifically in cases of bone metastases? 16) Which treatment for patient unfit to receive conventional treatment because of its general status, age or comorbid conditions?  Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Gemcitabine combined with carboplatin (GC) is a widely used regimen for advanced non-small cell lung cancer (NSCLC), but clinical outcome is still hampered by its toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The Japan Clinical Oncology Group 0301 trial (JCOG0301) was the first study to demonstrate that thoracic radiation therapy (TRT) with daily low-dose carboplatin may improve the outcome of elderly patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of triple antiemetic therapy with aprepitant, a 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, and dexamethasone in patients with advanced non-small-cell lung cancer (NSCLC) who received carboplatin-based first-line chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed plus carboplatin is routinely used for the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "(18)F-ICMT-11 uptake was compared to molecular biochemical measures of cell death in PC9 and A549 NSCLC cells following treatment with carboplatin in vitro and in vivo. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Two randomized phase III trials of carboplatin-based chemotherapy in advanced NSCLC were used for learning and validating the predictive value of ERCC1 in situ protein levels, as measured by accurate quantitative analysis (AQUA). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine and carboplatin combination chemotherapy is an effective and manageable treatment option in elderly advanced NSCLC patients with good performance status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We evaluated the impact of a carboplatin-based doublet in two groups of elderly patients with advanced non-small cell lung cancers (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of all consecutive elderly patients (\u226770 year old) with advanced NSCLC who received a carboplatin-based doublet as front-line therapy at our medical oncology unit was performed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This evaluation shows the safety and efficacy of a carboplatin-based doublet given as first-line chemotherapy in elderly advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "AUTHORS' CONCLUSIONS: The initial treatment of people with advanced NSCLC is palliative, and carboplatin can be a treatment option. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced non-small-cell lung cancer (NSCLC) based on preplanned stratification factors specified in the phase III trial protocol. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected non-small cell lung cancer (NSCLC) of pathological stage IB-IIIB. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A 74-year-old male developed relapsed NSCLC two years after a lobectomy and adjuvant chemotherapy including carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Irinotecan and carboplatin are effective against NSCLC and demonstrated synergism with non-cross-resistance in preclinical studies. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We conducted a phase II study of weekly combination of carboplatin and irinotecan as first-line chemotherapy for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The weekly combination of carboplatin and irinotecan showed favorable activity and manageable toxicity profiles in chemo-na\u00efve patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These results establish the efficacy and safety of carboplatin-S-1 in patients with advanced NSCLC regardless of tumor histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This randomised phase II study of iscador combined with carboplatin-containing regimens was conducted in chemotherapy-na\u00efve advanced non-small-cell lung cancer (NSCLC) patients to assess its influence on chemotherapy-related side-effects and QoL. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combining ABT-751 with carboplatin suppressed growth of lung cancer cell lines and had modest clinical antitumor activity in advanced NSCLC previously treated predominantly with carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line therapy for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Ixabepilone can be safely combined with carboplatin in newly diagnosed patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We propose to define the recommended dose (RD) of VFL in combination with carboplatin in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Twenty-one chemonaive patients with advanced NSCLC were treated with a first-line chemotherapy of VFL and carboplatin both given on day 1 every 3 weeks with 3 dose levels. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of VFL (320 mg/m(2)) and carboplatin AUC 5 given once every 3 weeks is established as the RD of the combination, which was shown to be active in these chemonaive NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy of nimotuzumab combined with palitaxel liposome and carboplatin (LP) regimen for treatment of advanced non-small cell lung cancer (NSCLC), and to observe the changes of tumor markers and toxicities in the treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS Forty-one patients with advanced NSCLC were randomly divided into 2 groups: 21 patients in the observation group were treated with nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2 and carboplatin (AUC = 6). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess whether radiotherapy plus carboplatin results in longer survival than radiotherapy alone in elderly patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients older than 70 years with unresectable stage III NSCLC were randomly assigned to chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m(2) per day, 5 days a week for 20 days]) or radiotherapy alone, using a minimisation method with biased-coin assignment balancing on Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), stage (IIIA vs IIIB), and institution. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The platinum compounds currently used in NSCLC are cisplatin and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To investigate whether the abnormal expression of CNTN-1 is associated with characteristics of patients with non-small cell lung cancer (NSCLC), immunohistochemistry was used to detect CNTN-1 expression in 143 tissue samples from NSCLC patients and the results showed that the degree of CNTN-1 expression positively correlated with lymphatic invasion in patients with lung adenocarcinoma who received adjuvant cisplatin- or carboplatin-based treatment after surgery. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmall cell lung cancer, carried out by the ELCWP aim to answer the following questions: 1) What benefits can we expect from chemotherapy and which are the treatment goals? 2) Do we have to integrate a palliative approach into the cancer treatment? 3) What are the chemotherapeutic agents for which efficacy has been established? 4) Can carboplatin replace cisplatin? 5) What are the most active cisplatin-based combination chemotherapy? 6) What should be the dose of cisplatin? 7) Can non-platinum regimens replace platinum-based for first-line treatment? 8) What is the role of targeted therapies? 9) When can we or should we customize chemotherapy? 10) What is the optimal number of cycles of induction therapy to administer? Should be done consolidation or maintenance treatment? 11) Is it an indication for sequential chemotherapy? 12) What is the efficacy of salvage chemotherapy and which drugs can be given in this indication? 13) Which treatment for oligometastatic diseases? 14) What are the places of chemotherapy and radiotherapy in the treatment of patients with brain metastases? 15) Which drugs can be used specifically in cases of bone metastases? 16) Which treatment for patient unfit to receive conventional treatment because of its general status, age or comorbid conditions?  The present updated guidelines on the management of resectable non-small cell lung cancer (NSCLC) formulated by the ELCWP are designed to answer the following questions: 1) Is conventional surgery the best treatment for potentially resectable cancer? 2) What is the definition of a complete resection? 3) Should we make a systematic lymphadenectomy in case of surgery for a N0 or N1 tumor? 4) What is the role of radiation therapy after complete resection? 5) In case of clinical stage I or II, should administer adjuvant or neoadjuvant chemotherapy? 6) In case of pathological stage I or II, should administer adjuvant chemotherapy? 7) In case of complete resection for stage IIIA N2 disease, should be offered adjuvant therapy and if so which one: chemotherapy, radiotherapy, chemoradiotherapy? 8) In case of clinical stage IIIA or B, what are the indications for surgery after induction therapy? 9) In case of clinical stage IIIA or B, if surgical indication is retained, should we do an induction treatment, and if so, which one? 10) In case of incomplete resection after primary surgery, what should be the postoperative therapy? 11) In case of (neo)adjuvant chemotherapy, which association should be offered and what dosage of cisplatin to be prescribed? 12) Can stereotactic radiotherapy replace surgery in operable patients? 13) What is proposed for the patient unfit for conventional surgery treatment? 14) Have targeted therapies a place in the treatment ?  BACKGROUND:: Pemetrexed is the preferred treatment of nonsquamous non-small cell lung cancer (ns-NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "AUTHORS' CONCLUSIONS: The initial treatment of people with advanced NSCLC is palliative, and carboplatin can be a treatment option. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A 74-year-old male developed relapsed NSCLC two years after a lobectomy and adjuvant chemotherapy including carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Irinotecan and carboplatin are effective against NSCLC and demonstrated synergism with non-cross-resistance in preclinical studies. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We conducted a phase II study of weekly combination of carboplatin and irinotecan as first-line chemotherapy for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The weekly combination of carboplatin and irinotecan showed favorable activity and manageable toxicity profiles in chemo-na\u00efve patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The present study was a phase I/II study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities of the biweekly carboplatin/gemcitabine combination and evaluate its safety and efficacy in patients aged\u00a0\u2265 70 years with advanced squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients aged\u00a0\u2265 70 years with advanced or metastatic squamous NSCLC received escalated doses of carboplatin (area under the curve [AUC] 2-2.5 intravenously) and gemcitabine (800-1100 mg/m(2) intravenously) every 2 weeks (phase I). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The biweekly regimen of gemcitabine and carboplatin showed satisfactory efficacy and a favorable toxicity profile in elderly patients with advanced or metastatic squamous cell NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Gemcitabine combined with carboplatin (GC) is a widely used regimen for advanced non-small cell lung cancer (NSCLC), but clinical outcome is still hampered by its toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty patients with stage IIIB or IV NSCLC were randomized to receive either a biweekly regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 14) and carboplatin (area under the concentration-time curve, AUC = 3 on days 1 and 14)] every 28 days or a standard regimen of GC [gemcitabine (1,000 mg/m(2) on days 1 and 8) and carboplatin (AUC = 5 on day 1)] every 21 days. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Two randomized phase III trials of carboplatin-based chemotherapy in advanced NSCLC were used for learning and validating the predictive value of ERCC1 in situ protein levels, as measured by accurate quantitative analysis (AQUA). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the efficacy and safety of gemcitabine and carboplatin as first-line treatment in elderly patients with advanced NSCLC and to evaluate the prognostic factors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine and carboplatin combination chemotherapy is an effective and manageable treatment option in elderly advanced NSCLC patients with good performance status. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We evaluated the impact of a carboplatin-based doublet in two groups of elderly patients with advanced non-small cell lung cancers (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of all consecutive elderly patients (\u226770 year old) with advanced NSCLC who received a carboplatin-based doublet as front-line therapy at our medical oncology unit was performed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This evaluation shows the safety and efficacy of a carboplatin-based doublet given as first-line chemotherapy in elderly advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Tissue samples were collected from NSCLC mice treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This study sought to investigate the efficacy and tolerability of the regimen of low-dose gemcitabine combined with carboplatin in chemo-na\u00efve patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "AUTHORS' CONCLUSIONS: The initial treatment of people with advanced NSCLC is palliative, and carboplatin can be a treatment option. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This randomised phase II study of iscador combined with carboplatin-containing regimens was conducted in chemotherapy-na\u00efve advanced non-small-cell lung cancer (NSCLC) patients to assess its influence on chemotherapy-related side-effects and QoL. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We wanted to evaluate the efficacy and safety of biweekly gemcitabine and low-dose carboplatin combination therapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase-II trial, chemotherapy-naive elderly patients (aged \u226576 years) with NSCLC were randomly treated with biweekly combination therapy with gemcitabine and carboplatin (1000 mg/m(2) gemcitabine and carboplatin at an area under the curve (AUC) of 3 on days 1 and 15, every 4 weeks) or gemcitabine monotherapy (1000 mg/m(2) on days 1, 8 and 15, every 4 weeks). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Biweekly gemcitabine and low-dose carboplatin combination chemotherapy showed acceptable efficacy, toxicity, and tolerability in those aged \u226576 years with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A combination phase I/II study was conducted in chemo-naive elderly patients with NSCLC to establish the toxicity and maximum tolerated dose (MTD) and to investigate the antitumor activity of carboplatin (CBDCA) plus gemcitabine (GEM). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The results showed the concentrations of paclitaxel and carboplatin in sputum of patients treated with ambroxol hydrochloride were significantly higher than those of the control group, suggesting that ambroxol hydrochloride significantly increased the local concentrations of chemotherapeutic agents in lung tissues of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " CONTEXT: Paclitaxel (PTX) and carboplatin (CBP) are widely used for the combined chemotherapy of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This phase I study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase (HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with newly diagnosed, advanced NSCLC were randomly assigned to receive up to 6 cycles of 3-weekly carboplatin AUC 6 or cisplatin 80 mg/m(2) either with standard paclitaxel at 200 mg/m(2) (arm A) or PK-guided dosing of paclitaxel (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m(2), d1), and gemcitabine (1,000 mg/m(2) d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this clinical trial was to explore the efficacy and tolerability of first-line chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a novel agent that uses a drug delivery system, plus carboplatin, in elderly Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus carboplatin, without dose reduction, is indicated to be toxic and intolerable as first-line chemotherapy in elderly Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We previously reported that carboplatin-paclitaxel plus bevacizumab was effective for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and MPE, although we did not evaluate the relationship between treatment outcomes and plasma or pleural effusion levels of VEGF. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced non-small-cell lung cancer (NSCLC) and diabetes. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Several phase III clinical trials had authenticated that the addition of bevacizumab to paclitaxel plus carboplatin or gemcitabine plus cisplatin showed encouraging efficacy as first-line therapy for advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed that the SLCO1B3 c.699 G>A polymorphism may predict anemia and ABCB1, HIF1A polymorphism are highly predictive for worse survival in advanced NSCLC with first-line paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and toxicity of a chemotherapeutic regimen using weekly carboplatin in combination with weekly paclitaxel as first-line therapy for advanced/metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: All patients with stage IIIB/IV NSCLC treated with weekly carboplatin AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly paclitaxel 75 mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Weekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results suggest that gemcitabine or combination of gemcitabine+carboplatin could serve as an excellent therapy against CYP3A4 in NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We hypothesized that nab-paclitaxel and carboplatin would be superior to alternative doublets in advanced NSCLC patients ineligible for bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4\u2009\u00b1\u20090.9\u00a0MBq (mean\u2009\u00b1\u2009SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC) study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present meta-analysis aims to investigate prognostic factors affecting overall survival (OS), progression-free survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin and paclitaxel-based first-line chemotherapies for advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We performed a literature search in PubMed for randomized phase II and III clinical trials in patients with NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy published from January 2000 to December 2013 to investigate prognostic factors affecting OS, PFS or TTP, and ORR by linear regression analysis and logistic regression analysis. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " LESSONS LEARNED: The concomitant use of weekly nab-paclitaxel and carboplatin with concurrent radiotherapy was demonstrated to be a safe therapeutic approach in this phase I trial of 10 evaluable patients with stage III NSCLC.Despite the lack of systemic glucocorticoids, there were no reported infusion reactions or cases of peripheral neuropathy in this trial, both of which are known to occur with the use of paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Food and Drug Administration in October 2012 for use along with carboplatin in advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study was undertaken to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly nab-paclitaxel given in combination with carboplatin and concurrent radiotherapy in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m(2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The most common regimen at all stages was carboplatin and paclitaxel.BACKGROUND: Platin-based adjuvant chemotherapy has extended survival in clinical trials in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The BRAIN study demonstrates encouraging efficacy and acceptable safety of bevacizumab with first-line paclitaxel and carboplatin in patients with NSCLC and asymptomatic, untreated brain metastases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated dynamic CT-based vascular parameters and plasma cytokines after bevacizumab alone and after bevacizumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore potential biomarkers of treatment response and resistance to this regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study investigated the ability of carboplatin and paclitaxel to sensitize human non-small-cell lung cancer (NSCLC) cells to carbon-ion beam irradiation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "NSCLC H460 cells treated with carboplatin or paclitaxel were irradiated with X-rays or carbon-ion beams, and radiosensitivity was evaluated by clonogenic survival assay. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61\u00a0%). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We have conducted a phase 2 study to evaluate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab in patients with non-squamous non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR) mutation positive and for whom EGFR-tyrosine kinase inhibitor (TKI) 1st-line has failed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study aimed to compare overall survival for Medicare patients diagnosed with NSCLC and treated with either first-line bevacizumab-carboplatin-paclitaxel (BCP) or carboplatin-paclitaxel (CP). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Recently, a subset analysis of a completed phase III trial demonstrated that use of nab-paclitaxel with carboplatin led to improved responses in patients with squamous NSCLC compared with solvent-based paclitaxel with carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In this review, the current experience and evolving role of nab-paclitaxel with carboplatin in the treatment of squamous NSCLC is discussed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: Optimal chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD) is established for paclitaxel and carboplatin, but is otherwise controversial. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed the outcomes of 21 patients with advanced nonsquamous NSCLC with ILD who received paclitaxel and carboplatin without (paclitaxel-carboplatin group; n\u00a0=\u00a011) or with bevacizumab (paclitaxel-carboplatin-bevacizumab group; n\u00a0=\u00a010) between April 2008 and October 2013. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to paclitaxel and carboplatin may provide an effective and safe treatment option for patients with advanced nonsquamous NSCLC with ILD. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bavituximab in combination with paclitaxel-carboplatin as first-line therapy demonstrated a tolerable safety profile and potential efficacy in this single-arm phase II trial in patients with advanced local or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel 125 mg/m2 on day 1 and day 8, cisplatin 75 mg/m2 on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotherapy for stage III/IV squamous NSCLC, and its adverse effects are tolerable. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel-carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the historic rate for bevacizumab combined with paclitaxel-carboplatin in this patient population. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this phase II, single-arm, open-label, multicenter study, 40 patients with advanced NSCLC received ramucirumab (10 mg/kg intravenous [IV]) followed by paclitaxel (200 mg/m IV) and carboplatin area under the curve = 6 on day 1 every 21 days as first-line therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u5316\u7597\u8010\u836f\u5bfc\u81f4\u80bf\u7624\u5f88\u5feb\u590d\u53d1\u548c/\u6216\u8f6c\u79fb\uff0c\u662f\u76ee\u524d\u80ba\u764c\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00\u3002\u03b2-tubulin\u662f\u6297\u5fae\u7ba1\u836f\u7269\u7684\u4e3b\u8981\u7ec6\u80de\u9776\u70b9\u3002\u5df2\u6709\u7684\u7814\u7a76\u8bc1\u660e\uff1a\u03b2III-tubulin\u9ad8\u8868\u8fbe\u4e0e\u975e \u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u8010\u836f\u6709\u5173\u3002\u5229\u7528RNA\u5e72\u6270\u6280\u672f\u6c89\u9ed8\u8010\u7d2b\u6749\u9187A549\u7ec6\u80de\uff08A549/Taxol\uff09\u4e2d\u03b2III-tubulin\u57fa\u56e0\u8868\u8fbe\uff0c\u63a2\u8ba8\u9776\u57fa\u56e0\u4e0b\u8c03\u540e\u5bf9\u5316\u7597\u836f\u7269\u7d2b\u6749\u9187\u7684\u654f\u611f \u6027\u7684\u53d8\u5316\u4ee5\u53ca\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u60c5\u51b5\u3002\u65b9\u6cd5 \u6784\u5efa\u9776\u5411\u03b2III-tubulin\u7684siRNA\uff0c\u4ee5\u8102\u8d28\u4f53\u4e3a\u8f7d\u4f53\u4ecb\u5bfc\u03b2III-tubulin siRNA\u8f6c\u67d3A549/Taxol\u7ec6\u80de\uff0c\u5229\u7528qRT-PCR\u68c0\u6d4b\u7ec6\u80de\u5185\u03b2III-tubulin mRNA\u7684\u53d8\u5316\u60c5\u51b5\uff0c\u5e76\u7b5b\u9009\u51fa\u6700\u4f73\u5e72\u6270\u5e8f\u5217\uff1bWestern blot\u6cd5\u68c0\u6d4bA549/Taxol\u7ec6\u80de\u5185\u03b2III-tubulin\u86cb\u767d\u8868\u8fbe\u7684\u53d8\u5316\uff1bMTT\u6cd5\u68c0\u6d4b\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u5bf9\u7d2b\u6749\u9187\u654f\u611f\u6027\u7684\u53d8\u5316\uff1b\u6d41\u5f0f\u7ec6\u80de\u4eea\u68c0\u6d4b\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u7684\u53d8 \u5316\u3002\u7ed3\u679c \u5b9e\u65f6\u8367\u5149qRT-PCR\u6cd5\u663e\u793a\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u9776\u57fa\u56e0\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u964d\u4f4e\uff0c\u5176\u4e2d\u03b2III-tubulin siRNA-1\u5e8f\u5217\u6291\u5236\u7387\u6700\u9ad8\u4e3a\uff0887.73\u00b14.87\uff09%\uff08P<0.01\uff09\uff1bWestern blot\u663e\u793a\u8f6c\u67d3\u540e\u9776\u86cb\u767d\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u964d\u4f4e\uff1bMTT\u6cd5\u8868\u660e\u7d2b\u6749\u9187\u5904\u7406\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u7684\u7ec6\u80de\u6291\u5236\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff0851.77\u00b14.60\uff09%\uff08P<0.01\uff09\uff1b\u7ec6\u80de\u51cb\u4ea1\u663e \u793a\u03b2III-tubulin siRNA+Taxol\u7ec4\u7ec6\u80de\u65e9\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff08P<0.01\uff09\uff0c\u4e24\u8005\u7684\u5dee\u5f02\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff1b\u7ec6\u80de\u5468\u671f\u68c0\u6d4b\u7ed3\u679c\u663e\u793a\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684G2/M\u671f\u7ec6\u80de\u767e\u5206\u7387\u9ad8\u4e8e\u5bf9\u7167\u7ec4\uff0c \u4e14\u8f6c\u67d3\u540e\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684\u7ec6\u80de\u665a\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u589e\u52a0\u3002\u7ed3\u8bba \u03b2III-tubulin\u8868\u8fbe\u4e0b\u8c03\u660e\u663e\u63d0\u9ad8A549/Taxol\u7ec6\u80de\u682a\u5bf9Taxol\u7684\u654f\u611f\u6027\u3002 DOI: 10.3779/j.issn.1009-3419.2014.08.01 PMID: 25130963 [PubMed - indexed for MEDLINE]  INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (area under the concentration-time curve, 6 mg \u00b7 min/mL) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The Japan Clinical Oncology Group 0301 trial (JCOG0301) was the first study to demonstrate that thoracic radiation therapy (TRT) with daily low-dose carboplatin may improve the outcome of elderly patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We retrospectively assessed the efficacy and toxicity of weekly paclitaxel in combination with carboplatin and concurrent TRT in patients aged \u226575 years with previously untreated locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The 130 nm albumin-bound form of paclitaxel, nab-paclitaxel (Abraxane(\u00ae)), was recently approved by the US FDA for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a Phase III registrational trial, nab-paclitaxel plus carboplatin demonstrated a significantly improved overall response rate, the primary endpoint, and a trend toward improved survival compared with solvent-based paclitaxel plus carboplatin in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: The aim of this retrospective study was to evaluate bevacizumab combined with weekly paclitaxel with and without carboplatin in pre-treated patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between November 2009 and October 2011, 43 pre-treated patients with non-squamous NSCLC received bevacizumab (15 mg/kg, day 1) plus weekly paclitaxel (60-80 mg/m(2), days 1, 8, 15) with carboplatin (area under the curve=4-5, day 1) (n=36), or bevacizumab plus weekly paclitaxel (n=7) alone every four weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Even for heavily pre-treated patients, bevacizumab plus weekly paclitaxel with or without carboplatin was effective and tolerable in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The purpose of the proposed study is to evaluate the effectiveness and safety of low-dose paclitaxel with timed thoracic radiotherapy (TTR) for local control by inducing maximum radiosensitization through G2-M phase cell cycle arrest, followed by full dose adjuvant chemotherapy with gemcitabine and carboplatin for eradication of possible micrometastasis in unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemo-naive Chinese patients with locally advanced, metastatic or recurrent NSCLC were randomized to receive Bev 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To assess the efficacy and safety of carboplatin-based chemotherapy when compared with cisplatin-based chemotherapy, both in combination with a third-generation drug, in people with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "To compare quality of life in people with advanced NSCLC receiving chemotherapy with cisplatin and carboplatin combined with a third-generation drug. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "SELECTION CRITERIA: Randomised clinical trials comparing regimens with carboplatin or cisplatin combined with a third-generation drug in people with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "AUTHORS' CONCLUSIONS: The initial treatment of people with advanced NSCLC is palliative, and carboplatin can be a treatment option. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of bevacizumab (Bev) with carboplatin-paclitaxel (CP) for NSCLC with MPE. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus C in patients with advanced non-small-cell lung cancer (NSCLC) based on preplanned stratification factors specified in the phase III trial protocol. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The study was prospectively performed from February 2009 to July 2011 and involved 103 patients with stages Ic-IV ovarian (n = 51) and advanced NSCLC (n = 52) who were administered a maximum of 6 cycles of carboplatin-paclitaxel as a first-line treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin\u2009\u00b1\u2009bevacizumab for advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The combination of carboplatin and paclitaxel is one of the most commonly used regimens for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed the weekly [paclitaxel, 70 mg/m(2)/week on days 1, 8 and 15, and carboplatin, area under the curve (AUC)=6, every 4 weeks] and standard tri-weekly (paclitaxel, 200 mg/m(2), and carboplatin, AUC=6, on day 1 every 3 weeks] schedules in patients with previously untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: A patient with advanced NSCLC received four cycles of carboplatin AUC 6, paclitaxel 200\u2009mg/m(2), and bevacizumab 15\u2009mg/kg, and was continued on every-3-week maintenance bevacizumab 15\u2009mg/kg. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These results establish the efficacy and safety of carboplatin-S-1 in patients with advanced NSCLC regardless of tumor histology. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of the present study was to evaluate whether expression of resistance genes (MDR1, MRP3 and LRP) can predict clinical outcome in NSCLC patients treated with paclitaxel and carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with CP chemotherapy alone in patients with previously untreated advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with NSCLC stage IIIB or IV received as first-line treatment four cycles of carboplatin (AUC 5) (day 1) plus gemcitabine 1000\u00a0mg/m(2) (days 1 and 8) every 3\u00a0weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential chemotherapy with carboplatin-gemcitabine and weekly paclitaxel is active and feasible in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Between January 2007 and January 2012, 141 patients with advanced NSCLC were treated with curative intent according to the CRT protocol (50-70 Gy at 2 Gy/day with paclitaxel 135-175 mg/m(2) and carboplatin 100 mg/m(2) on days 1, 22, and 43). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P\u00a0=\u00a00.05). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase Ib study evaluated volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III locally advanced NSCLC received paclitaxel, 50\u2009mg/m(2)/week, with carboplatin area under the curve (AUC)\u2009=\u20092, weekly for 7\u2009weeks, and concurrent radiotherapy, 64.8\u2009Gy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus carboplatin in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 1,052 untreated patients with stage IIIB to IV NSCLC were randomly assigned 1:1 to receive 100 mg/m(2) nab-paclitaxel weekly and carboplatin at area under the concentration-time curve (AUC) 6 once every 3 weeks (nab-PC) or 200 mg/m(2) sb-paclitaxel plus carboplatin AUC 6 once every 3 weeks (sb-PC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS AND MATERIALS: Nine of 44 patients with stage III NSCLC in a prospective phase II trial of concurrent paclitaxel/carboplatin with proton radiation [74 Gy(RBE) in 37 fractions] had modifications to their original treatment plans after re-evaluation revealed changes that would compromise coverage of the target volume or violate dose constraints; plans for the other 35 patients were not changed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " CONTEXT: A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "RESULTS: The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC(50) of 2.5 \u03bcmol/l in a variety of NSCLC cells. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In particular, ipilimumab showed promising results in a first-line NSCLC phase II study combining carboplatin/paclitaxel chemotherapy with concurrent or phased ipilimumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Nineteen patients with regionally advanced NSCLC were treated with concurrent chemotherapy (carboplatin and paclitaxel [n = 18]) and proton therapy from August 2008 to April 2010 either with (n = 7) or without (n = 12) induction chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg\u00b7min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-na\u00efve, advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-na\u00efve Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to EGFR-wild-type cases. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The participants were patients with chemo-na\u00efve advanced NSCLC treated with PMT plus carboplatin (CBDCA) in prospective clinical phase II study. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous non-small cell lung cancer (non-sq NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of triple antiemetic therapy with aprepitant, a 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, and dexamethasone in patients with advanced non-small-cell lung cancer (NSCLC) who received carboplatin-based first-line chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed plus carboplatin is routinely used for the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TS immunohistochem\u00edstry was performed on biopsies and available resection specimens from 65 NSCLC patients stage T1-3N0-2 treated with preoperative carboplatin and paclitaxel [neoadjuvant chemotherapy (NAC)-group] and from 53 NSCLC patients stage T1-4N0-1 treated with surgery without preceding chemotherapy [operation (OP)-group] that served as controls. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Pemetrexed plus carboplatin (PC) had better chemotherapy compliance and efficiency in advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This randomised phase II study of iscador combined with carboplatin-containing regimens was conducted in chemotherapy-na\u00efve advanced non-small-cell lung cancer (NSCLC) patients to assess its influence on chemotherapy-related side-effects and QoL. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients age \u2265 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for \u2264 six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/mL\u2022min/paclitaxel, 200 mg/m) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-na\u00efve patients with metastatic/unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Tigatuzumab was well tolerated but did not improve efficacy of carboplatin/paclitaxel in systemic therapy-na\u00efve, unselected advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study evaluated the efficacy, safety, and pharmacokinetics of conatumumab combined with paclitaxel-carboplatin (PC) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Images were acquired in 22 consecutive patients with advanced non-small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml \u00b7 min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients (N = 204) with chemotherapy-naive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1:1 to receive paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) with either placebo (control) or ipilimumab in one of the following two regimens: concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimumab plus paclitaxel and carboplatin).Treatment was administered intravenously every 3 weeks for \u2264 18 weeks (induction). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipilimumab in NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "S-1 and cisplatin is an active first-line chemotherapy regimen for advanced NSCLC and S-1 and carboplatin is noninferior to a carboplatin and paclitaexel regimen. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: TUBB3 expression was investigated by immunohistochemistry performed on diagnostic biopsies and on available subsequent resection specimens in 65 NSCLC patients stage T1-3N0-2 who received neoadjuvant carboplatin and paclitaxel (NAC-group). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Although paclitaxel plus carboplatin (PC) failed to demonstrate efficacy in patients with stage IB NSCLC, an exploratory analysis suggested that patients with large tumors can benefit from adjuvant PC therapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We evaluated the impact of a carboplatin-based doublet in two groups of elderly patients with advanced non-small cell lung cancers (NSCLC). ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of all consecutive elderly patients (\u226770 year old) with advanced NSCLC who received a carboplatin-based doublet as front-line therapy at our medical oncology unit was performed. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This evaluation shows the safety and efficacy of a carboplatin-based doublet given as first-line chemotherapy in elderly advanced NSCLC patients. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "But as the first-line treatment of advanced NSCLC, carboplatin doublets is superior to cisplatin doublets in terms of PFS. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "carboplatin"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Thus, maintenance treatment with erlotinib in patients with advanced/metastatic NSCLC without EGFR-activating mutations is considered unfavorable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Active smokers with non-small-cell lung cancer (NSCLC) have increased erlotinib metabolism versus non-smoking patients, which reduces exposure. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The CurrentS study (NCT01183858) assessed efficacy and safety of 300mg erlotinib (E300) as second-line therapy in current smokers with locally advanced or metastatic NSCLC versus the standard 150mg dose (E150). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Herein, we report two occurrences of erlotinib-associated gastrointestinal perforation (GIP) in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two patients aged 60 and 79 years received erlotinib as third- and second-line NSCLC treatment, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in non-small cell lung cancer (NSCLC) with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "JUNIPER is a randomized study of abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC) versus erlotinib (150 mg orally every 24 hours) with BSC in patients with stage IV non-small-cell lung cancer (NSCLC) whose tumors have detectable Kirsten rat sarcoma (KRAS) mutations and whose disease has progressed after platinum-based chemotherapy and 1 other previous therapy, or who are not eligible for further chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We concluded that the erlotinib plus chemotherapy for advanced NSCLC could increase PFS and objective response rate, but not benefit OS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients in our single arm phase II study had stage IV NSCLC with no more than six sites of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and concurrent erlotinib until disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of SBRT with erlotinib for unselected patients with stage IV NSCLC as a second- or subsequent line therapy resulted in dramatic changes in patterns of failure, was well tolerated, and resulted in high PFS and OS, substantially greater than historical values for patients who only received systemic agents. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with stage IIIB/IV NSCLC previously treated with platinum-based chemotherapy were randomized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "SATURN (Sequential Tarceva in Unresectable NSCLC) was a randomised, double-blind, placebo-controlled, multicentre study investigating the impact of erlotinib maintenance therapy on HRQoL in patients with locally advanced or recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies evaluating bevacizumab and erlotinib as MTx in 1632 patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore we have evaluated the inter-reader reproducibility of response classification by DCE-MRI in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab and erlotinib enrolled in a multicenter trial.MATERIALS AND METHODS: Twenty-one patients were scanned before and 3 weeks after start of treatment with DCE-MRI in a multicenter trial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our study was aimed to determine whether there were conditions under which the addition of bevacizumab would enhance the antitumor activity of erlotinib against NSCLC tumors in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In primarily erlotinib-resistant NSCLC cells, the levels of VEGF protein were highest in H157 cell followed in order by H460 and A549 cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage 3/4 NSCLC and progressive disease (PD) following chemotherapy received IMO-2055 0.08, 0.16, 0.32, or 0.48 mg/kg once weekly plus erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: IMO-2055 demonstrated good tolerability and possible antitumor activity in combination with erlotinib and bevacizumab in heavily pretreated patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We identified the expression of EGFR exon 18 as a new predictive marker for patients with untreated metastatic NSCLC treated with bevacizumab and erlotinib in the first line setting. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Survival in an unselected population of patients with NSNSCLC treated with bevacizumab and erlotinib approximated that expected with conventional chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A phase II study combining erlotinib and bevacizumab for treatment of recurrent NSCLC showed encouraging efficacy and acceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This single-arm phase II study evaluated erlotinib and bevacizumab as first-line therapy for newly diagnosed nonsquamous advanced NSCLC patients with Eastern Cooperative Oncology Group PS \u2265 2 or age 70 or older. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib and bevacizumab had insufficient activity in the absence of known activating epidermal growth factor receptor gene mutations to warrant study in newly diagnosed elderly or poor PS patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human non-small cell lung cancer (NSCLC), breast cancer and colorectal cancer were evaluated in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with refractory NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Variables with the greatest influence in the model were erlotinib-associated progression-free survival (EGFRm AC), toxicity (EGFRm AC), cost of SBRT (NSCLC SCC), and patient utilities (all histologies). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In light of the potential role for serum proteomics in predicting the benefit of erlotinib beyond that of epidermal growth factor receptor gene (EGFR) mutational status, we conducted a trial in which the Veristrat proteomics assay was used for data enrichment when selecting a cohort of patients with NSCLC and PS2 to receive erlotinib with and without chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In a proteomics-enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlotinib alone and surpassed the protocol-specified benchmark of PFS of at least 3 months required for further study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients \u226518 years old with histologically/cytologically confirmed stage IIIB/IV EGFR mutation-positive NSCLC and Eastern Cooperative Oncology Group performance status 0-2 were randomized 1:1 to receive erlotinib (oral; 150 mg once daily until progression/unacceptable toxicity) or GP [G 1250 mg/m(2) i.v. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: These analyses demonstrate that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The first phase II study of biomarker-guided neoadjuvant therapy for stage IIIA-N2 NSCLC patients stratified by EGFR mutation status, sponsored by CSLC0702, showed erlotinib tended to improve response rate, but failed to show benefits of disease-free survival (DFS) or OS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but preliminary studies suggest that sequential administration might be effective. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR) are responsive to erlotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we investigated the effect of curcumin on the tumor growth of erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Furthermore, curcumin significantly increased the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, enhanced erlotinib-induced apoptosis, downregulated the expressions of EGFR, p-EGFR, and survivin, and inhibited the NF-\u03baB activation in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the combined treatment of curcumin and erlotinib significantly inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that curcumin is a potential adjuvant for NSCLC patients during erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we investigated the role of Hh signaling in erlotinib resistance of TGF-\u03b21-induced NSCLC cells that are reminiscent of EMT cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but preliminary studies suggest that sequential administration might be effective. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The cost comparison findings for Italy show that erlotinib is still the less costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Treatment options for patients whose tumors have failed to respond to two or more conventional chemotherapy regimens are limited, with erlotinib, which targets the epidermal growth factor receptor, and crizotinib, which targets EML4/ALK, the only agents currently approved in the United States as third-line therapy for patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive factors on the outcome of therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring epidermal growth factor receptor (EGFR) mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, our study suggests that maintenance therapy with low-dose erlotinib might be useful and tolerable in selected NSCLC patients harboring EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring activating mutations of EGFR, most subsequently develop acquired resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Four NSCLC cell lines (HCC827, PC9, H1666, and H358) were treated with either single-agent INC-280 or in combination with erlotinib with or without HGF. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although the MET inhibitor INC-280 alone had no discernible effect on cell growth, it was able to restore sensitivity to erlotinib and promote apoptosis in NSCLC models rendered erlotinib resistant by HGF. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These data provide a preclinical rationale for an ongoing phase 1 clinical trial of erlotinib plus INC-280 in EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "erlotinib in the second- and third-line non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant non-small cell lung cancer (NSCLC) patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Thus, maintenance treatment with erlotinib in patients with advanced/metastatic NSCLC without EGFR-activating mutations is considered unfavorable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This alteration is associated with a poor clinical response to erlotinib and represents an independent prognostic factor for patients who had NSCLC with an EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A multicenter, open-label, single-arm phase II clinical trial was performed to test the efficacy of erlotinib in the first-line treatment of NSCLC patients harboring high EGFR gene copy number defined as \u22654 copies in \u226540% of cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant non-small-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Addition of the thioredoxin reductase 1 inhibitor (TXNRD1) auranofin (AF) to NSCLC cells treated with combination of TUSC2 forced expression with erlotinib increased tumor cell apoptosis and inhibited colony formation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In NSCLC tumor xenografts, tumor growth was markedly inhibited and animal survival was prolonged over controls by AF-TUSC2-erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Tyrosine kinase inhibitors, such as erlotinib, display reliable responses and survival benefits for the treatment of human non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To identify secreted proteins that are differentially regulated in erlotinib-sensitive (PC-9) and -resistant (PC-9ER) NSCLC cell lines, SILAC experiments were performed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Fourteen proteins were found to be differently regulated among erlotinib-sensitive and -resistant NSCLC cell lines, with five proteins (tissue-type plasminogen activator, epidermal growth factor receptor, urokinase-type plasminogen activator, platelet-derived growth factor D, and myeloid-derived growth factor) showing the most prominent regulation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Tissue-type plasminogen activator (t-PA) was up to 10-times upregulated in erlotinib-resistant NSCLC cells compared with erlotinib-sensitive cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "T-PA is an established tumor marker for various cancer types and seems to be a promising prognostic marker to differentiate erlotinib-sensitive from erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Fourteen proteins were identified as potential t-PA interaction partners, deserving a closer inspection to unravel the mechanisms underlying erlotinib resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Background Older non-small cell lung cancer (NSCLC) patients under erlotinib are reported to experience more acute toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of the present study was to test whether early changes of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in animal models bearing erlotinib-resistant NSCLC may have different imaging patterns of response to erlotinib depending on the molecular mechanisms underlying resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the approved dose of either agent. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Based on these findings, the patient was treated with erlotinib combined with cabozantinib, a type II MET inhibitor, and exhibited a response.SIGNIFICANCE: With several structurally distinct MET inhibitors undergoing development for treatment of NSCLC, it is critical to identify mechanism-based therapies for drug resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To (a) describe utilization patterns and costs associated with biopsy procedures and biomarker testing in patients with NSCLC who received erlotinib or crizotinib between 2009 and 2012 and (b) investigate the timing of these procedures relative to the erlotinib or crizotinib index date. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Because there is no specific ICD-9-CM diagnostic code for NSCLC, patients with metastatic lung cancer who received erlotinib or crizotinib were considered to have metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/non-small cell lung cancer/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The emergence of EGFR-inhibitors such as gefitinib, erlotinib and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The mechanism of erlotinib resistance in NSCLC is largely unknown. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Consistently, miR-17-5p was down-regulated in the tumor tissues and the plasma of erlotinib-resistant NSCLC patients in comparison to those who are sensitive to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that miR-17-5p down-regulation contributes to erlotinib resistance of NSCLC by modulating its target genes such as EZH1 and plasma miR-17-5p might be a potential biomarker of erlotinib response in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To explore this, we have utilized an EGFR-null CHO overexpression system as well as NSCLC cell lines expressing various EGFR mutants and determined the effects of erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present study compares the concentration of sPD-1 in the serum of advanced NSCLC patients with Epidermal Growth Factor Receptor (EGFR) mutation prior to erlotinib treatment and at the time of progression and correlates these results to patient outcome. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Blood samples from 38 patients with EGFR-mutated advanced NSCLC treated with erlotinib were analyzed for sPD-1 by sandwich ELISA. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Controversy exists about the integration of erlotinib in patients with EGFR wildtype, advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The present study suggests erlotinib to have similar clinical efficacy compared to chemotherapy in patients with pretreated advanced NSCLC and no known molecular targetable alterations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Active smokers with non-small-cell lung cancer (NSCLC) have increased erlotinib metabolism versus non-smoking patients, which reduces exposure. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The CurrentS study (NCT01183858) assessed efficacy and safety of 300mg erlotinib (E300) as second-line therapy in current smokers with locally advanced or metastatic NSCLC versus the standard 150mg dose (E150). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Herein, we report two occurrences of erlotinib-associated gastrointestinal perforation (GIP) in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two patients aged 60 and 79 years received erlotinib as third- and second-line NSCLC treatment, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose celecoxib-erlotinib combination in NSCLC in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (excluding sensitizing EGFR mutations and ALK gene fusions) refractory to more than one prior therapy were randomly assigned, stratified by KRAS status, to four arms: (1) erlotinib, (2) erlotinib plus MK-2206, (3) MK-2206 plus AZD6244, or (4) sorafenib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of an erlotinib-based targeted dual agent with erlotinib alone in previously treated patients with advanced non-small lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The role of erlotinib-based combinations in previously treated patients with NSCLC seemed insignificant. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies evaluating bevacizumab and erlotinib as MTx in 1632 patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here we show that YAP promotes resistance to erlotinib in human non-small cell lung cancer (NSCLC) cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that YAP promotes erlotinib resistance in the erlotinib-sensitive NSCLC cell line HCC827. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Inhibition of YAP by siRNA increases sensitivity of erlotinib-resistant NSCLC cell line H1975 to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Tyrosine kinase inhibitors (TKIs), such as erlotinib, approved by the FDA as first/second line therapy for NSCLC patients have limited clinical efficacy due to acquired resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Data on erlotinib use in squamous NSCLC are limited. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This observational study aimed at evaluating the efficacy and safety of second-line erlotinib in patients with stage IIIB/IV squamous NSCLC in a real-life setting. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results of this real-life cohort study like those of previous phase III/IV subgroups study analyses indicate that erlotinib is a valuable option for second-line treatment of stage IIIB/IV squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To determine the extent to which PLK1 inhibition overcomes EGFR TKI resistance we measured the effects of the PLK1 inhibitor volasertib alone and in combination with the EGFR inhibitor erlotinib in vitro and in vivo in EGFR mutant NSCLC cell lines with acquired resistance to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In all NSCLC cell lines with T790M mutations, volasertib markedly reduced erlotinib resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "All erlotinib-resistant NSCLC cell lines with T790M mutations had higher sensitivity to erlotinib plus volasertib than to erlotinib alone, and the combination treatment caused G2/M arrest and apoptosis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study is a retrospective review of patients with non-squamous, non-small-cell lung cancer (NS-NSCLC) and wild-type EGFR who were treated with erlotinib alone as second- or later-line chemotherapy at the Tokyo Metropolitan Cancer and Infectious Diseases Center of Komagome Hospital (Tokyo, Japan) between December, 2008 and December, 2013. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, the expression of TTF-1 may serve as a useful tool for predicting the efficacy of erlotinib in patients with NS-NSCLC expressing wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in non-small cell lung cancer (NSCLC) with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Less than a quarter of NSCLC patients diagnosed in 2010 received EGFR testing and less than half of the patients with EGFR-mutant stage IV tumors received erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This prospective trial evaluated CTCs and cfDNA in EGFR-mutant NSCLC patients treated with erlotinib until progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: EGFR-mutant NSCLC patients were enrolled in a phase II trial of erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Recently, AMPK activation was proposed to sensitize NSCLC cells against erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although the percentage of patients requiring dose reduction seemed relatively higher than that in previous studies, erlotinib is a potentially useful therapeutic option for unselected elderly patients with previously treated advanced or recurrent NSCLC, as has been also shown for younger patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The primary objective of this study is to determine if metabolic progression observed between the 7th and 14th day after initiation of treatment with erlotinib by 3'-Deoxy-3'-[18F]-Fluorothymidine PET in patients with EGFR naive NSCLC is predictive for morphological progression after 6 to 8 weeks of treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, a previous study shows that a combination of EGFR TKI erlotinib (ER) with VEGFR TKI sunitinib (SU) did not improve the overall survival in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the present study, to characterize the biological behavior of miR\u2011223 in NSCLC, we established an miR\u2011223 overexpression model in erlotinib-resistant PC\u20119\u00a0(PC\u20119/ER) cells by infection with lentivirus to induce the overexpression of miR\u2011223. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present study reports a case of a 62-year-old, non-smoking female patient with advanced NSCLC, presenting with concurrent EGFR 19+21 sensitizing mutations, who had a poor response to the first-line EGFR-TKI erlotinib and succumbed 5 months subsequent to diagnosis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Response monitoring using fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: GSE38310, the gene expression profiles of NSCLC cell lines treated with dimethylsulfoxide or erlotinib, including HCC827, ER3, and T15-2, were downloaded from Gene Expression Omnibus database and preprocessed by normalization. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "STAT3, SOX9, STAT5B, EGR1, and STAT6 might affect the resistance of NSCLC to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OS adjusted for mean Charlson Comorbidity Index (CCI) was not different between erlotinib- and chemotherapy-treated groups in patients with non-squamous NSCLC (adjusted HR=0.91, 95% CI= 0.37-2.23; p=0.84), but was inferior in patients with squamous NSCLC treated with erlotinib (adjusted HR=10.6, 95% CI=1.28-87.8; p=0.029). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Variables with the greatest influence in the model were erlotinib-associated progression-free survival (EGFRm AC), toxicity (EGFRm AC), cost of SBRT (NSCLC SCC), and patient utilities (all histologies). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Although many studies have confirmed the synergic effects of combining chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and efficacy of erlotinib in combination with RT in locally advanced non-small-cell lung cancer (NSCLC) are limited. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine the feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to the standard three-dimensional conformal thoracic RT in patients with unresectable or locally advanced NSCLC who are not candidates for receiving standard CT. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib with RT produced, in our study, a scarce clinical benefit in the treatment of unresectable or locally advanced NSCLC, limited to complete responses and longer CSS rate compared with RT alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We examined pre-operative erlotinib in early stage NSCLC to assess response and correlation with potential biomarkers. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Clinical stage IA-IIB NSCLC patients received erlotinib 150 mg daily for 4 weeks followed by resection. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: High MTV and TLG are independently correlated with shorter PFS and OS in advanced EGFR wild-type NSCLC patients treated with second or third-line erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Preclinical and retrospective data for erlotinib provide evidence of CNS penetration, and objective responses in the setting of BM from EGFR mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Phase I and II data have demonstrated the feasibility of concomitant delivery of erlotinib and WBRT in the treatment of BM from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "As such, EGFR TKI-resistant NSCLC cells (A549, H1299, H1975) were treated with the EGFR TKI erlotinib and FAK inhibitors (PF-573,228 or PF-562,271) both as single agents and in combination. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Treatment of EGFR TKI-resistant NSCLC cells with FAK inhibitor alone effectively inhibited cell viability in all cell lines tested; however, its use in combination with the EGFR TKI erlotinib was more effective at reducing cell viability than either treatment alone when tested in both 2- and 3-dimensional assays in vitro, with enhanced benefit seen in A549 cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the randomized phase III LUX-Lung 8 trial afatinib showed a statistical significant efficacy advantage compared to erlotinib as second-line treatment of advanced/metastatic squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of our retrospective study was to evaluate the association of baseline serum albumin with outcomes in a\u00a0large cohort of patients with advanced-stage NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Clinical data of 457 patients with locally-advanced (III B) or metastatic stage (IV) NSCLC treated with erlotinib were analysed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, the results of present retrospective study indicate that pretreatment hypoalbuminemia is associated with poor outcome of NSCLC patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "NSC305787 showed synergism with erlotinib in wild-type EGFR-expressing NSCLC cells, whereas no synergy was observed in EGFR-null cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These findings suggest that ezrin-EGFR interaction augments oncogenic functions of EGFR and that targeting ezrin may provide a potential novel approach to overcome erlotinib resistance in NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We therefore conducted a cost-effectiveness analysis of first-line treatment with erlotinib versus standard chemotherapy in European\u00a0patients with advanced-stage EGFR-mutated NSCLC who were enrolled in the European Erlotinib versus Chemotherapy trial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: This economic analysis shows that first-line treatment with erlotinib, versus standard chemotherapy, is a dominant strategy for EGFR-mutated advanced-stage NSCLC in three European countries. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore we have evaluated the inter-reader reproducibility of response classification by DCE-MRI in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab and erlotinib enrolled in a multicenter trial.MATERIALS AND METHODS: Twenty-one patients were scanned before and 3 weeks after start of treatment with DCE-MRI in a multicenter trial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sorafenib combined with erlotinib is well-tolerated with manageable toxicity and appears to be effective against advanced NSCLC with one or two prior line of systemic treatment (NCT00801385). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using [(11)C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, the aims of this study were to evaluate tumor [(11)C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [(11)C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Quantitative assessment of (11)C-erlotinib uptake may be useful in selecting non-small cell lung cancer (NSCLC) patients for erlotinib therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The purpose of this study was to find the optimal pharmacokinetic model for quantification of uptake and to evaluate various simplified methods for routine analysis of (11)C-erlotinib uptake in NSCLC patients.METHODS: Dynamic (15)O-H2O and (11)C-erlotinib scans were obtained in 17 NSCLC patients, 8 with and 9 without an activating epidermal growth factor receptor mutation (exon 19 deletion or exon 21-point mutation). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The optimal model for quantitative assessment of (11)C-erlotinib uptake in NSCLC was the 2T4k-WB model. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u8111\u662f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u5e38\u89c1\u7684\u8f6c\u79fb\u90e8\u4f4d\u3002\u6709\u7814\u7a76\u663e\u793a\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKI\uff09\u53ef\u900f\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u53d1\u6325\u6297\u80bf\u7624\u4f5c\u7528\u3002\u672c\u4f8b\u62a5\u9053\u91c7\u7528\u7a81\u53d8\u6269\u589e\u963b\u6ede\u7cfb\u7edf\uff08amplification refractory mutation system, ARMS\uff09\u68c0\u6d4b\u8111\u810a\u6db2EGFR\u7a81\u53d8\u6307\u5bfc\u4e34\u5e8a\u6cbb\u7597\u7684\u53ef\u884c\u6027\uff0c\u5e76\u5206\u6790TKI\u6cbb\u7597\u80ba\u764c\u8111\u8f6c\u79fb\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8170\u7a7f\u53d6\u5f97\u8111\u810a\u6db2\u6807\u672c\uff0c\u68c0\u6d4b\u9885\u5185\u538b\u529b\uff0c\u68c0\u9a8c\u5e38\u89c4\u3001\u751f\u5316\u53ca\u80bf\u7624\u6807\u5fd7\u7269\uff0c\u67e5\u627e\u8131\u843d\u7ec6\u80de\uff0c\u91c7\u7528ARMS\u6cd5\u68c0\u6d4bEGFR\u57fa\u56e0\u7a81\u53d8\uff0c\u5f97\u5230\u9633\u6027\u7ed3\u679c\u540e\u7ed9\u4e88\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\uff08erlotinib \uff0ctarceva\uff0c\u7279\u7f57\u51ef\uff09\u6cbb\u7597\uff0c150 mg\uff0c\u6bcf\u59291\u6b21\u3002\u6309\u7167\u5b9e\u4f53\u7624\u7597\u6548\u8bc4\u4ef7\u6807\u51c61.1\u7248\uff08Response Evaluation Criteriation in Solid Tumours, RECIST v1.1\uff09\u8bc4\u4ef7\u5ba2\u89c2\u7597\u6548\uff0c\u6309\u7167\u4e0d\u826f\u53cd\u5e94\u901a\u7528\u672f\u8bed\u6807\u51c64.0\u7248\uff08Common Terminology Criteria for Adverse Events v4.0, CTC AE v4.0\uff09\u8bc4\u4f30\u7528\u836f\u671f\u95f4\u53d1\u751f\u7684\u4e0d\u826f\u4e8b\u4ef6\u3002\u7ed3\u679c \u8be5\u60a3\u8005\u591a\u7ebf\u6cbb\u7597\u540e\uff0c\u9885\u5185\u75c5\u7076\u63a7\u5236\u6b20\u4f73\uff0c\u8111\u810a\u6db2\u4e2d\u53d1\u73b0\u5f02\u578b\u7ec6\u80de\uff0cEGFR\u57fa\u56e019\u5916\u663e\u5b50\u7f3a\u5931\u7a81\u53d8\uff0c\u670d\u7528\u5384\u6d1b\u66ff\u5c3c4\u5468\u540e\uff0c\u9885\u5185\u5ba2\u89c2\u7597\u6548\u4e3a\u90e8\u5206\u7f13\u89e3\uff08partial response, PR\uff09\uff0c\u9885\u5916\u5ba2\u89c2\u7597\u6548\u4e3a\u75be\u75c5\u7a33\u5b9a\uff08stable disease, SD\uff09\uff0c\u9885\u5185\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff0910.5\u4e2a\u6708\uff0c\u603b\u751f\u5b58\u671f\uff08overall survival, OS\uff0911\u4e2a\u6708\u3002\u4e3b\u8981\u4e0d\u826f\u53cd\u5e94\u4e3a\u76ae\u75b9\uff081\u7ea7\uff09\u3002\u7ed3\u8bba \u8111\u810a\u6db2\u68c0\u6d4bEGFR\u7a81\u53d8\u53ef\u4e3a\u5236\u5b9a\u6cbb\u7597\u7b56\u7565\u63d0\u4f9b\u7406\u8bba\u652f\u6301\uff0c\u6839\u636e\u4e0d\u540c\u7684\u7a81\u53d8\u72b6\u6001\u7ed9\u4e88\u5c0f\u5206\u5b50\u9776\u5411\u836f\u7269\u8054\u5408\u5316\u7597\uff0c\u53ef\u5206\u522b\u63a7\u5236\u9885\u5185\u53ca\u9885\u5916\u75c5\u7076\u3002. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In sqNSCLC patients who respond to induction chemotherapy, maintenance therapy with erlotinib delays disease progression and may improve the survival of patients with stable disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensitizing EGFR mutations.We conducted a meta-analysis to compare the efficacy of erlotinib and chemotherapy for advanced NSCLC, and evaluated the efficacy of them to provide references for further clinical practice and research.PubMed, EMBASE, CBM, CNKI, WanFang database, The Cochrane library, and Web of Science, as well as abstracts presented at ASCO conferences and ClinicalTrials.gov were searched to identify relevant studies. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In light of the potential role for serum proteomics in predicting the benefit of erlotinib beyond that of epidermal growth factor receptor gene (EGFR) mutational status, we conducted a trial in which the Veristrat proteomics assay was used for data enrichment when selecting a cohort of patients with NSCLC and PS2 to receive erlotinib with and without chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In a proteomics-enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlotinib alone and surpassed the protocol-specified benchmark of PFS of at least 3 months required for further study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent different agents commonly used for the second-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS AND RELEVANCE: ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation-positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This phase Ib trial used a 3\u00a0+\u00a03 escalation design with a combination of erlotinib (100\u00a0mg daily) with increasing doses of capecitabine (500, 750 and 1000\u00a0mg/m(2) BD, 14/21\u00a0days), in first- and second-line aNSCLC of adenocarcinoma histology. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Capecitabine did not improve the efficacy of erlotinib in aNSCLC unselected for EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In a retrospective study, 34 erlotinib-treated aNSCLC patients were genotyped by DMET Plus chip: 23 patients experienced SR (cases), while 11 patients did not (controls). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although exploratory, this study indicates rs8176345 in CYP27B1 gene as significantly correlated with erlotinib-induced SR in aNSCLC patients probably through a mechanism mediated by vitamin D3 and inflammation at skin level. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has been approved based on the clinical benefit in non-small cell lung cancer (NSCLC) patients over the past decade. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we propose a novel strategy to overcome acquired erlotinib resistance in NSCLC by inhibiting glutaminase activity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Compound 968, an inhibitor of the glutaminase C (GAC), when combined with erlotinib potently inhibited the cell proliferation of erlotinib-resistant NSCLC cells HCC827ER and NCI-H1975. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Taken together, our study provides a valuable approach to overcome acquired erlotinib resistance by blocking glutamine metabolism and suggests that combination of EGFR-TKI and GAC inhibitor maybe a potential treatment strategy for acquired erlotinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients receiving erlotinib in the second- or third-line setting for advanced NSCLC were randomly assigned to prophylactic minocycline (100 mg twice per day for 4 weeks), reactive treatment (after rash developed, per grade of rash), or no treatment unless severe (grade 3). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Prophylactic minocycline and reactive treatment are both acceptable options for the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present trial was designed to examine the efficacy and toxicity of combined erlotinib and palliative chest thoracic RT in non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with newly diagnosed stage III-IV (American Joint Committee on Cancer, version 6) or recurrent NSCLC received 3 weeks of erlotinib at a dose of 150 mg daily, starting 1 week before palliative thoracic RT to 30 Gy in 10 fractions within 2 weeks. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The present single-arm, phase II trial did not demonstrate additional symptomatic benefit from concurrent erlotinib therapy with standard palliative thoracic RT for patients with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the development of CSLPHNPs composed of the lipid monolayer shell and the biodegradable polymeric core for the delivery of erlotinib, an anticancer drug, clinically used to treat non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, CSLPHNPs could be a potential delivery system for erlotinib in the therapy of NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this surveillance study of Japanese non-small-cell lung cancer (NSCLC) patients treated with erlotinib, rash management using topical steroids was analyzed in routine clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: From December 2007 to October 2009, all recurrent/advanced NSCLC patients in Japan treated with erlotinib were enrolled into this study (POst-Launch All-patient Registration Surveillance in TARceva). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Applying a focused shRNA screening approach to identify genes whose knockdown can prevent and/or overcome acquired resistance to erlotinib in several EGFR-mutant non-small cell lung cancer (NSCLC) cell lines, we identified casein kinase 1 \u03b1 (CSNK1A1, CK1\u03b1). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Preclinical studies demonstrated anti-tumor efficacy of the combination of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in non-small cell lung cancer (NSCLC) models that were insensitive to erlotinib monotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Romidepsin 8 mg/m(2) plus erlotinib appears well tolerated, has evidence of disease control, and exhibits effects on relevant molecular targets in an unselected advanced NSCLC population. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, the safety of erlotinib plus chemotherapy (CT) or erlotinib alone for advanced NSCLC remains controversial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present meta-analysis suggested that erlotinib could decrease the incidence of neutropenia and leukopenia in patients with advanced NSCLC undergoing erlotinib regardless of whether combined with CT or not. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "JUNIPER is a randomized study of abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC) versus erlotinib (150 mg orally every 24 hours) with BSC in patients with stage IV non-small-cell lung cancer (NSCLC) whose tumors have detectable Kirsten rat sarcoma (KRAS) mutations and whose disease has progressed after platinum-based chemotherapy and 1 other previous therapy, or who are not eligible for further chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib can overcome heregulin-mediated resistance to erlotinib in EGFR mutant NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Following resection and completion of standard adjuvant therapy, patients with EGFR-mutant NSCLC will be randomized to erlotinib versus placebo (1:1), those with ALK-rearranged NSCLC will be randomized to crizotinib versus placebo (1:1), while those not enrolled onto the adjuvant trials will continue to be followed on the screening trial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The 181946C>T polymorphisms in the EGFR gene seems to be a potential predictor of higher DCR, longer PFS and OS in advanced NSCLC patients treated with erlotinib, especially in EGFR mutation-positive patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This hypothesis-generating retrospective analysis examined data from two studies of erlotinib in NSCLC, Marker Identification Trial (MERIT; n = 102) and Sequential Tarceva in Unresectable NSCLC (SATURN; n = 262), to determine whether PTPRF expression was prognostic and/or predictive of patient outcomes. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is frequently associated with adverse events (AE). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We used the framework to investigate the safety of high-dose erlotinib pulses proposed to limit acquired resistance while treating NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Continuous-time Markov models were developed using rash and diarrhea AE data from 39 NSCLC patients treated with erlotinib (150\u00a0mg/day). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of anti-EGFR treatment and concurrent therapy for smoking cessation seems to be more effective than erlotinib alone in improving lung function and clinical response in advanced NSCLC patients with EGFR-mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This model was parameterized using a novel experimental dataset derived from the HCC827 erlotinib-sensitive and -resistant NSCLC cell lines. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " IMPORTANCE: The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) in tumor tissue. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients had advanced NSCLC, oncogenic EGFR mutations in the tumor, and no prior chemotherapy for metastatic disease and were treated with erlotinib or chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, combination of ZSTK474 and an EGFR inhibitor (erlotinib) in NSCLC resistant to each single agent reduced cellular proliferation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with chemotherapy pretreated NSCLC harbouring EGFR mutations received erlotinib at 50 mg/d until disease progression or unacceptable toxicities. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T) or erlotinib plus placebo (E + P) until disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Whether a combination of chemotherapy and erlotinib is beneficial for advanced non-small cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study aimed to summarize the currently available evidence and compare the efficacy and safety of chemotherapy plus erlotinib versus chemotherapy alone for treating advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combination of chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, especially for patients who never smoked and patients with EGFR mutation-positive disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: HERALD (NCT02134015) was a double-blind, phase 2 study in patients with non-small cell lung cancer (NSCLC) randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Preclinical modeling in non-small cell lung cancer (NSCLC) showed that stimulation with hepatocyte growth factor (HGF), the ligand for MET, could reverse the cytostatic and cytotoxic effects of the EGFR inhibitor erlotinib in erlotinib-sensitive cell lines. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a phase II trial of erlotinib plus MK-2206, a highly selective inhibitor of AKT, in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination MK-2206 and erlotinib met its primary endpoint in erlotinib-pretreated patients with EGFR wild-type NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients \u226518 years old with histologically/cytologically confirmed stage IIIB/IV EGFR mutation-positive NSCLC and Eastern Cooperative Oncology Group performance status 0-2 were randomized 1:1 to receive erlotinib (oral; 150 mg once daily until progression/unacceptable toxicity) or GP [G 1250 mg/m(2) i.v. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: These analyses demonstrate that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with advanced-stage NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed clinical data of 595 patients with advanced-stage NSCLC (IIIB or IV) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, the results of the conducted retrospective study suggest that high baseline level of CRP was independently associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell lines resistant to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and analyzed their sensitivity to erlotinib in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These results suggest that TUSC2 restoration in wild type EGFR NSCLC may overcome erlotinib resistance, and identify FGFR2 and mTOR as critical regulators of this activity in varying cellular contexts. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The erlotinib sensitivity of cells isolated from 41 untreated NSCLC patients was determined and compared with the presence of the more frequent EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The possible correlation between erlotinib sensitivity and the expression of these genes was further analyzed using the data for the NSCLC, breast cancer and colon cancer cell lines of the NCI60 collection. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to determine the benefit of survival and toxicity of Conformal Radiotherapy (CRT) combined with erlotinib-based multimodality therapy in newly diagnosed metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Newly diagnosed metastatic NSCLC patients were treated with CRT and erlotinib, with or without chemotherapy matched protocol. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this study, patients with newly diagnosed metastatic NSCLC had survival benefits when erlotinib was used combined with CRT. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A previous phase III trial suggested that patients with EGFR wild-type (EGFR-wt) NSCLC or elderly patients with disease progression after cytotoxic chemotherapy might benefit from erlotinib monotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, few studies have prospectively evaluated the efficacy and safety of second- or third-line erlotinib monotherapy for elderly patients with EGFR-wt advanced or recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Pretreated patients aged \u226570 years with EGFR-wt stage IIIB/IV NSCLC or those with postoperative recurrence were enrolled and received oral erlotinib at a dose of 150 mg/day until disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In pretreated elderly patients with advanced or recurrent EGFR-wt NSCLC, daily oral erlotinib was well tolerated; however, administration of the drug should not be considered as a second line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The patients included those diagnosed with NSCLC or PC who were treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, the benefit of ARBs on OS disappeared in the multivariate analysis.The use of ARBs during erlotinib treatment may prolong OS of patients with metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we find that mTOR-AKT-FOXO1 signaling cascade is deregulated in TKI-resistant NSCLC cells and that FOXO1 was highly phosphorylated and lowly acetylated upon erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Combination of mTOR or PI3K inhibitor and erlotinib overcomes TKI resistance to inhibit cell growth and induce apoptosis in TKI-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV (AJCC 6th edition) NSCLC who progressed after at least 1 line of therapy or refused standard chemotherapy were randomized to receive erlotinib and celecoxib versus erlotinib and placebo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We initially observed PIK3C\u03b2(D1067V) by exome sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patient with acquired erlotinib resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2015.04.10 PMID: 25936890 [PubMed - indexed for MEDLINE]  PURPOSE: We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively evaluated the efficacy and safety of high-dose erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients with refractory LM after failure of standard-dose EGFR-TKIs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: Between January 2007 and April 2013, we identified 35 patients with EGFR-mutant NSCLC, complicated with LM, and 12 underwent high-dose erlotinib, while the other 23 received only standard-dose EGFR-TKIs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The aim of this study has been to investigate the potential of serum biomarkers used in clinical practice (CEA, CYFRA 21-1, SCC) together with the serum epidermal growth factor receptor (EGFR) and its associated ligands (EGF, TGF-\u03b1, HB-EGF) as outcome predictors of non-small cell lung cancer (NSCLC) patients treated with the TKI erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results suggest that the pre-treatment CEA and sEGFR serum levels may provide a comparable source of information to that supplied by the EGFR gene mutational status with respect to the prognosis of erlotinib treated NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine if first-order and high-order textural features on fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non-small cell lung cancer (NSCLC) (a) at baseline, (b) at 6 weeks, or (c) the percentage change between baseline and 6 weeks can predict response or survival in patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The study included 47 patients with NSCLC who underwent (18)F-FDG PET/computed tomography (CT) at baseline (n = 47) and 6 weeks (n = 40) after commencing treatment with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here we found that resveratrol (RV) enhanced the anti-tumor effects of epidermal growth factor receptor (EGFR) inhibitor erlotinib in NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggested that RV synergistically enhanced the anti-tumor effects of erlotinib in NSCLC cells were involved in decrease of survivin expression and induction of PUMA expression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we investigated the effect of TG101348 (a JAK2 inhibitor) on the tumor growth of erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "TG101348 significantly enhanced the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, stimulated erlotinib-induced apoptosis and downregulated the expressions of EGFR, p-EGFR, p-STAT3, Bcl-xL and survivin in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the combined treatment of TG101348 and erlotinib induced apoptosis, inhibited the activation of p-EGFR and p-STAT3, and inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that TG101348 is a potential adjuvant for NSCLC patients during erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence of acquired drug resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The first phase II study of biomarker-guided neoadjuvant therapy for stage IIIA-N2 NSCLC patients stratified by EGFR mutation status, sponsored by CSLC0702, showed erlotinib tended to improve response rate, but failed to show benefits of disease-free survival (DFS) or OS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ROR1 expression has a differential effect on outcome to erlotinib and chemotherapy in EGFR-mutant NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The role of chemotherapy and erlotinib in EGFR-mutant NSCLC patients with high ROR1 expression warrants further investigation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive non-small-cell lung cancer (NSCLC) in pre-specified subgroup analyses of a randomized phase II study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In a small correlative pilot human study, patients with EGFR-mutant metastatic NSCLC underwent FMISO-PET scans before and 10 to 12 days after erlotinib initiation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These results suggest that low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-MYC/HIF-1\u03b1/VEGF pathway in NSCLC with EGFR exon 19 deletions. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The role of Hsp27 in both erlotinib and cytotoxic treatment resistance was evaluated in HCC-827 and A549 NSCLC cells using the Hsp27 antisense drug OGX-427. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Hsp27 is induced by erlotinib and protects NSCLC cells from treatment-induced apoptosis, whereas OGX-427 sensitizes NSCLC cells to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To address a potential role of protein kinase C (PKC) isozymes in the resistance to TKIs, we used the isogenic NSCLC H1650 cell line and its erlotinib-resistant derivative H1650-M3, a cell line that displays a mesenchymal-like morphology driven by transforming growth factor-\u03b2 signaling. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Targeted therapeutics, including the epidermal growth factor receptor (EGFR) inhibitor erlotinib, have recently emerged as clinical alternatives for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Together, our findings indicate that NSCLC cells can be effectively sensitized to erlotinib by supplementation with tumor suppressor miRNAs, and suggest that the use of combinations of miRNAs as adjuvant therapeutics for the treatment of lung cancer is a viable clinical strategy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the case of an NSCLC patient with unknown EGFR mutation status who developed resistance to erlotinib and was treated with afatinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Eight patients diagnosed with non-small cell lung cancer (NSCLC) (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFR mutation frequency was 22.1% in NSCLC, and erlotinib achieved a response rate of 60% (95% CI, 32.3% to 83.7%). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " We performed a systematic review and meta-analysis to assess the potential of erlotinib plus platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Search of PubMed, EMBASE, Web of Science, CBM, CNKI, China Wan Fang databases and the Cochrane library was performed for studies regarding erlotinib plus platinum-based chemotherapy for advanced NSCLC published between 1 January 2000 and 28 August 2014. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We concluded that the erlotinib plus chemotherapy for advanced NSCLC could increase PFS and objective response rate, but not benefit OS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations within the kinase domain of EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We considered a case series of 34 EGFR wt NSCLC patients responsive to erlotinib after at least one line of therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METODS: We analyzed data of 544 patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONSLUSION: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "P7170 at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our results provide evidence of antitumor activity of P7170 in the erlotinib -sensitive and -insensitive models of NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC).The phase I trial determined the recommended dose and safety of erlotinib plus dalotuzumab at 5\u00a0mg/kg or 10\u00a0mg/kg weekly in 20 patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of dalotuzumab to erlotinib did not improve efficacy outcome in patients with refractory advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: This study aimed to elucidate the pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer (NSCLC) and to investigate the relationship between erlotinib exposure and the occurrence of interstitial lung disease (ILD)-like events. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Factors predicting the efficacy of erlotinib treatment in patients with EGFR mutation-negative non-small-cell lung cancer (NSCLC) have not been well studied. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This retrospective study investigates whether patient characteristics, such as site of metastasis, can predict the efficacy of erlotinib treatment in NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In total, 53 EGFR mutation-negative NSCLC patients treated with erlotinib were enrolled, and the associations between clinicopathological characteristics and patient survival were analyzed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Among the NSCLC patients treated with erlotinib, 27 patients with pulmonary metastasis exhibited significantly longer progression-free survival (PFS) and overall survival (OS) times than those without pulmonary metastasis (median PFS time, 2.9 versus 1.2 months; P=0.0010 and median OS time, 12.4 versus 4.1 months; P=0.0007). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The presence of pulmonary metastasis may be a predictive factor in patients with EGFR mutation-negative NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients in our single arm phase II study had stage IV NSCLC with no more than six sites of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and concurrent erlotinib until disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of SBRT with erlotinib for unselected patients with stage IV NSCLC as a second- or subsequent line therapy resulted in dramatic changes in patterns of failure, was well tolerated, and resulted in high PFS and OS, substantially greater than historical values for patients who only received systemic agents. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our study was aimed to determine whether there were conditions under which the addition of bevacizumab would enhance the antitumor activity of erlotinib against NSCLC tumors in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In primarily erlotinib-resistant NSCLC cells, the levels of VEGF protein were highest in H157 cell followed in order by H460 and A549 cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "An analysis of the phase IV POLARSTAR surveillance study examined the safety and efficacy of erlotinib in elderly Japanese patients with previously treated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: From December 2007 to October 2009, all erlotinib-treated patients with unresectable, recurrent/advanced NSCLC in Japan were enrolled. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "TKIs are used first line in EGFR mutation-positive NSCLC; erlotinib is the only TKI approved for subsequent lines of treatment in EGFR wild-type NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small-cell lung cancer (NSCLC), the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a phase II study of erlotinib for previously treated patients with EGFR WT NSCLC screened by the peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method, which is known to be highly sensitive. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study did not meet the primary endpoint, although erlotinib was found to be moderately effective in pretreated patients with EGFR WT NSCLC, even when the EGFR mutational status was confirmed by the highly sensitive PNA-LNA clamp PCR method. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, some studies have reported survival benefits in NSCLC patients with wild-type EGFR upon erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Records of advanced NSCLC patients who received erlotinib from 2007 to 2012 at a large, centralized, cancer institution were retrospectively reviewed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our objectives were to develop models describing non-small-cell lung cancer (NSCLC) dynamics during first-line treatment with erlotinib, and survival of the cohort. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Data from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Models describing tumor dynamics and survival of advanced NSCLC patients first-treated with erlotinib were developed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for antitumor activity in a panel of non-small cell lung cancer (NSCLC) cell lines and found to selectively inhibit growth of NSCLC cells carrying mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutant and erlotinib-resistant H1975 cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that ibrutinib could be a candidate drug for treatment of EGFR-mutant NSCLC, including erlotinib-resistant tumors. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In addition, erlotinib therapy would be preferable in NSCLC patients with BM and EGFR mutation, especially those with exon 19 deletion. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib and dasatinib is safe and feasible in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Blood samples were collected from 37 patients enrolled in the TRIGGER study, a prospective phase II multi-center trial of erlotinib treatment in advanced NSCLC patients with activating EGFR mutations in tumor tissue. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Successful treatment of systemic metastasis from NSCLC using erlotinib has been documented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We document a case and study the effect of oral erlotinib on choroidal metastasis from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results suggest that erlotinib represents a valid treatment option for patients with KRAS WT lung adenocarcinoma and, moreover, that KRAS mutation analysis could help to identify clinically relevant subgroups of NSCLC patients that may benefit from EGFR-TKI therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non-small cell lung cancer (NSCLC) during treatment with erlotinib and its relation to disease progression was investigated. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Blood samples from 23 patients with adenocarcinoma of NSCLC that carried tyrosine kinase inhibitor-sensitizing EGFR mutations were taken immediately before treatment with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but preliminary studies suggest that sequential administration might be effective. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nude mice bearing NSCLCs with and without MET amplification were subjected to [(18)F]FLT PET/CT before and after treatment with crizotinib or erlotinib (50 mg/kg and 100 mg/kg p.o. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo (n = 40) or erlotinib (100mg, n = 40) given concurrently with WBRT (20 Gy in 5 fractions). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our study showed no advantage in nPFS or OS for concurrent erlotinib and WBRT followed by maintenance erlotinib in patients with predominantly EGFR wild-type NSCLC and multiple brain metastases compared to placebo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with histologically or cytologically proven NSCLC (n = 84) treated with erlotinib in second-line (n = 34), third-line (n = 36), and more-line therapy (n = 14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This preclinical study shows that quinacrine overcomes erlotinib resistance by inhibiting FACT and cell-cycle progression, and supports a clinical trial testing erlotinib alone versus this combination in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Somatic mutations in the epidermal growth factor receptor (EGFR) are predictors of efficacy for treatment with the EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study evaluates the association between the CA repeat polymorphism and outcome in NSCLC patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Number of CA repeats in the EGFR gene was evaluated with PCR-fragment length analysis by capillary electrophoresis in 432 advanced NSCLC patients treated with erlotinib irrespective of EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our study demonstrate that in EGFR mutation positive NSCLC patients treated with erlotinib a low number of CA repeats in intron 1 of the EGFR gene is a predictor for both longer progression free survival and overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine if erlotinib can also inhibit the growth of NSCLC cells by inactivating the CIP2A-dependent signaling pathway. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Four NSCLC cell lines (H358 H441 H460 and A549) were treated with erlotinib to determine their sensitivity to erlotinib-induced cell death and apoptosis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The CIP2A-dependent pathway mediates the tumoricidal effects of erlotinib on NSCLC cells without EGFR mutations in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Capillary electrophoresis time-of-flight mass spectrometry analysis was performed to identify the metabolic signatures associated with erlotinib resistance in erlotinib-resistant PC-9ER NSCLC cells established from the EGFR-mutant NSCLC cell line PC-9. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI-sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Twenty-three patients with stage IIIB/IV NSCLC with a total of 53 measurable lung lesions, treated in a phase II trial of erlotinib, were studied with institutional review board approval. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u5206\u5b50\u9776\u5411\u6cbb\u7597\u662f\u80ba\u764c\u4e2a\u4f53\u5316\u6cbb\u7597\u7684\u65b9\u5411\uff0c\u76ee\u524d\u5df2\u6709\u5b66\u8005\u5efa\u7acb\u9776\u5411\u6cbb\u7597\u9884\u6d4b\u6a21\u578b\uff0c\u4e3a\u4e34\u5e8a\u4e2a\u4f53\u5316\u6cbb\u7597\u63d0\u4f9b\u66f4\u591a\u7684\u6307\u5bfc\u3002\u672c\u7814\u7a76\u63a2\u8ba8\u8840\u6e05\u80ba\u8868\u9762\u6d3b\u6027\u7269\u8d28\u76f8\u5173\u86cb\u767d\uff08pulmonary surfactant-associated protein D, SP-D\uff09\u3001\u8f6c\u5316\u751f\u957f\u56e0\u5b50-\u03b1\uff08transforming growthfactor \u03b1, TGF-\u03b1\uff09\u3001\u57fa\u8d28\u91d1\u5c5e\u86cb\u767d-9\uff08matrix metalloproteinase 9, MMP-9\uff09\u3001\u7ec4\u7ec7\u591a\u80bd\u7279\u5f02\u6027\u6297\u539f\uff08tissue polypeptide specific antigen, TPS\uff09\u3001\u80ba\u817a\u764c\u76f8\u5173\u6297\u539f\uff08Krebs von den Lungen-6, KL-6\uff09\u4e0e\u665a\u671f\u590d\u6cbb\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u6cbb\u7597\u7597\u6548\u53ca\u751f\u5b58\u7684\u5173\u7cfb\uff0c\u5e76\u6784\u5efa\u751f\u5b58\u9884\u6d4b\u6a21\u578b\u3002\u65b9\u6cd5 \u91c7\u7528\u9176\u8054\u514d\u75ab\u5438\u9644\u6cd5\uff08enzyme-linked immuno sorbent assay, ELISA\uff09\u68c0\u6d4b114\u4f8b\u665a\u671f\u590d\u6cbbNSCLC\u60a3\u8005\u6cbb\u7597\u524d\u5916\u5468\u8840\u6e05\u4e2dSP-D\u3001TGF-\u03b1\u3001MMP-9\u3001TPS\u3001KL-6\u542b\u91cf\uff0c\u7ed3\u5408\u4e34\u5e8a\u56e0\u7d20\u5206\u6790\u4e0e\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u7597\u6548\u7684\u5173\u7cfb\uff0c\u91c7 \u7528Kaplan-Meier\u751f\u5b58\u66f2\u7ebf\u3001Cox\u591a\u56e0\u7d20\u751f\u5b58\u5206\u6790\u6a21\u578b\u8fdb\u884c\u5355\u56e0\u7d20\u548c\u591a\u56e0\u7d20\u5206\u6790\uff0c\u5e76\u6784\u5efa\u751f\u5b58\u9884\u6d4b\u6a21\u578b\u3002\u7ed3\u679c 114\u4f8b\u60a3\u8005\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u603b\u6709\u6548\u7387\u4e3a22.8%\uff0c\u7a33\u5b9a\u7387\u4e3a72.8%\uff0c\u4e2d\u4f4d\u65e0\u75be\u75c5\u8fdb\u5c55\u65f6\u95f4\uff08progression-free survival, PFS\uff09\u4e3a5.13\u4e2a\u6708\uff0c1\u5e74\u751f\u5b58\u7387\u4e3a69.3%\u3002SP-D>110 ng/mL\u7ec4\u7684\u6709\u6548\u7387\u53ca\u7a33\u5b9a\u7387\u5747\u9ad8\u4e8e\u2264110 ng/mL\u7ec4\uff08P=0.011, P=0.017\uff09\uff0cMMP-9\u2264535 ng/mL\u7684\u7a33\u5b9a\u7387\u9ad8\u4e8e>535 ng/mL\u7ec4\uff08P=0.009\uff09\u3002TPS <80 U/L\u7ec4\u7684\u7a33\u5b9a\u7387\u8981\u9ad8\u4e8e\u226580 U/L\u7ec4\uff08P=0.002\uff09\u3002SP-D>110 ng/mL\u7ec4\u7684mPFS\u957f\u4e8e\u2264110 ng/mL\u7ec4\uff085.95\u4e2a\u6708 vs 3.25\u4e2a\u6708\uff0cP=0.009\uff09\uff0cMMP-9\u2264535 ng/mL\u7684mPFS\u8981\u957f\u4e8e>535 ng/mL\u7ec4\uff085.83\u4e2a\u6708 vs 3.47\u4e2a\u6708\uff0cP=0.046\uff09\uff0cKL-6\u4e2d<500 U/mL\u7ec4\u8981\u4f18\u4e8e\u2265500 U/mL\u7ec4\uff086.03\u4e2a\u6708 vs 3.40\u4e2a\u6708\uff0cP=0.040\uff09\uff0cTPS<80 U/L\u7ec4\u7684mPFS\u8981\u957f\u4e8e\u226580 U/L\u7ec4\uff086.15\u4e2a\u6708 vs 2.42\u4e2a\u6708\uff0cP=0.014\uff09\u3002\u591a\u56e0\u7d20\u5206\u6790\u663e\u793a\u5438\u70df\u53f2\u3001EGFR\u57fa\u56e0\u91ce\u751f\u578b\u3001\u672b\u6b21\u5316\u7597\u7597\u6548\u8fdb\u5c55\u3001\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u671f\u95f4\u65e0\u76ae\u75b9\u3001LDH\u5347\u9ad8\u548cTPS\u226580 U/L\u662fPFS\u4e0d\u4f73\u7684\u72ec\u7acb\u5f71\u54cd\u56e0\u7d20\u3002\u901a\u8fc7\u5efa\u7acb\u9884\u540e\u9884\u6d4b\u6a21\u578b\uff0c\u6839\u636e\u60a3\u8005\u7684\u9884\u540e\u6307\u6570\u53ef\u5206\u62104\u7ec4\uff1a\u4f4e\u5371\u7ec4\u3001\u4e2d\u4f4e\u5371\u7ec4\u3001\u4e2d\u5371\u7ec4\u548c\u9ad8\u5371\u7ec4\uff0c\u4e2d\u4f4dPFS\u5206\u522b\u662f9.12\u4e2a\u6708\u30016.88\u4e2a\u6708 \u30013.52\u4e2a\u6708\u548c0.93\u4e2a\u6708\uff0c\u7ec4\u95f4\u5dee\u5f02\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff08P<0.001\uff09\u3002\u7ed3\u8bba \u8840\u6e05\u80bf\u7624\u6807\u5fd7\u7269TPS\u6c34\u5e73\u8054\u5408\u60a3\u8005\u4e34\u5e8a\u7279\u5f81\u5efa\u7acb\u9884\u6d4b\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u590d\u6cbbNSCLC\u751f\u5b58\u6a21\u578b\uff0c\u5728\u4e34\u5e8a\u4e0a\u6709\u4e00\u5b9a\u7684\u6307\u5bfc\u610f\u4e49\u3002 DOI: 10.3779/j.issn.1009-3419.2014.05.05 PMID: 24854556 [PubMed - indexed for MEDLINE]  BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To prospectively evaluate diagnostic computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for identification of histopathologic response to neoadjuvant erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with resectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We investigated whether E7820 in combination with erlotinib, an EGFR-TKI, could overcome EGFR-TKI-resistance in the NSCLC cell lines A549 (KRAS; G12S), H1975 (EGFR; L858R/T790M), and H1650 (PTEN; loss, EGFR; exon 19 deletion), which are resistant to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The combination of E7820 with erlotinib is an alternative strategy to overcome erlotinib resistance in NSCLC by enhancement of the anti-angiogenic activity of E7820. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this phase II randomized study, 55 African Americans with NSCLC received 150\u2009mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to the maximum-allowable dose, 200\u2009mg/day, to achieve rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage 3/4 NSCLC and progressive disease (PD) following chemotherapy received IMO-2055 0.08, 0.16, 0.32, or 0.48 mg/kg once weekly plus erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: IMO-2055 demonstrated good tolerability and possible antitumor activity in combination with erlotinib and bevacizumab in heavily pretreated patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent non-small cell lung cancer(NSCLC)patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with stage IIIB/IV NSCLC previously treated with platinum-based chemotherapy were randomized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: A recent phase III trial showed that patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first-line treatment with erlotinib compared to chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Coverage for targeted first-line erlotinib therapy in NSCLC likely results in a small budget impact for US health plans. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Gefitinib and erlotinib are used to treat advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this retrospective subgroup analysis of data from a population-based observational study was to assess the efficacy and safety of erlotinib in an elderly (\u226575 years, n=74) and a younger group of patients (<75 years, n=233) who received treatment for NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (\u226575 years) and younger (<75 years) groups of patients were similar in our population-based observational study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "By screening 40 non-small cell lung cancer cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We prospectively studied the activity of vorinostat plus erlotinib in EGFR-mutated NSCLC patients with progression to tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with advanced NSCLC harboring EGFR mutations and progressive disease after a minimum of 12 weeks on erlotinib were included. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Although non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this review, we summarize current data of clinical trials with erlotinib and discuss its role in the targeted treatment of NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Tyrosine kinase inhibitors directed against epidermal growth factor receptor (EGFR-TKI), such as erlotinib, are effective in a limited fraction of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we investigated the relationship of miR-34a and erlotinib and determined the therapeutic activity of the combination in NSCLC cells with primary and acquired erlotinib resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The data suggest that a majority of NSCLC and other cancers previously not suited for erlotinib may prove sensitive to the drug when used in combination with a miR-34a-based therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR) are responsive to erlotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we investigated the effect of curcumin on the tumor growth of erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Furthermore, curcumin significantly increased the cytotoxicity of erlotinib to erlotinib-resistant NSCLC cells, enhanced erlotinib-induced apoptosis, downregulated the expressions of EGFR, p-EGFR, and survivin, and inhibited the NF-\u03baB activation in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The combination of curcumin and erlotinib exhibited the same effects on apoptosis as the combination of curcumin and cisplatin in erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the combined treatment of curcumin and erlotinib significantly inhibited tumor growth of erlotinib-resistant NSCLC cells in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our results indicate that curcumin is a potential adjuvant for NSCLC patients during erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with advanced NSCLC, progression on 1 or 2 regimens of chemotherapy and erlotinib, KRAS wild-type or known EGFR-sensitizing mutant tumor, and Eastern Cooperative Oncology Group performance status of 0 to 2 received 45 mg of dacomitinib once daily continuously in 21-day cycles. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "KEY RESULTS: Luteolin exerted significant anti-tumourigenic effects on the EGF receptor L858R/T790M mutation and erlotinib-resistant NSCLC both at the cellular and animal levels. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION AND IMPLICATIONS: Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We performed a single-arm study of pertuzumab, a monoclonal antibody that inhibits HER2 dimerization, and erlotinib in relapsed non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently 3 targeted therapies (erlotinib, afatinib, and crizotinib) are approved by the FDA to treat patients with specific genetic abnormalities in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Compared to a single agent alone, tamoxifen combined with erlotinib resulted in cytotoxicity and cell growth inhibition synergistically in NSCLC cells, accompanied with reduced activation of phospho-AKT and phospho-ERK1/2, and reduced TP protein levels. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These findings may have implications for the rational design of future drug regimens incorporating tamoxifen and erlotinib for the treatment of NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we investigated [(11)C]-erlotinib positron emission tomography (PET) imaging as a tool to identify activating mutations of EGFR in both glioma and NSCLC xenografts. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: An association between skin toxicity and outcome has been reported for NSCLC patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The purposes of this study were to characterize erlotinib pharmacokinetic and to correlate drug serum and urine levels to toxicity and outcomes in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IV NSCLC consecutively treated with erlotinib in second- or third-line were enrolled. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase 2, randomized, multicenter, open-label study compared dinaciclib with erlotinib in patients with previously treated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This manuscript describes a dramatic and durable response to high-dose icotinib in a NSCLC patient who did not respond to a previous standard dose of erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this multicenter, open-label, phase II study, patients with advanced NSCLC that progressed after one to two previous chemotherapy regimens were randomized 1:1 to erlotinib 150 mg/day\u00b1everolimus 5 mg/day. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This single arm, phase II study aims to evaluate the role of epidermal growth factor receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent chemoradiotherapy (cCRT) in unresectable locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Conversely, knockdown of K-RAS in K-RASmut NSCLC cells and in HNSCC cells presenting overexpression of K-RASwt resulted in sensitization to the anti-clonogenic activity of erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study we aimed to elucidate remaining unknown mechanisms using erlotinib-resistant NSCLC cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the predictive value of PET response after 2 days of erlotinib in unselected pretreated patients with stage IV NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: FDG-PET assessment after 2 days of erlotinib could be useful to identify early resistant patients and to predict survival in unselected NSCLC pretreated population. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell lung cancer (NSCLC) because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Medical records from 104 patients with NSCLC treated with erlotinib were retrospectively reviewed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3\u00a0weeks and erlotinib daily on a continuous basis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we investigated the role of Hh signaling in erlotinib resistance of TGF-\u03b21-induced NSCLC cells that are reminiscent of EMT cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: siRNA-mediated inhibition as well as pharmacological inhibition of Hh signaling abrogated resistance of NSCLC cells to erlotinib and cisplatin. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we established novel erlotinib resistant NSCLC cells and examined their resistant mechanisms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Objective: This study investigates the effect of exemestane, an aromatase inhibitor, and erlotinib, an EGFR inhibitor, on human NSCLC cell lines; H23, H358 and A549. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous clinical study in non-small cell lung cancer (NSCLC) patients in Western countries suggested the potential for combination of a first-in-class non-ATP-competitive c-Met inhibitor tivantinib with an epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Japanese patients with advanced/metastatic NSCLC received tivantinib in combination with erlotinib to evaluate safety and pharmacokinetics. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: A total of 162 patients with advanced NSCLC who received erlotinib as either second or third line therapy were enrolled in this study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND AND PURPOSE: The purpose of the current study was to assess a novel anti-cancer drug, MPT0B014, which is not a substrate for the P-glycoprotein (P-gp) transporter, alone and in combination with erlotinib, against human non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Publisher: \u76ee\u524d\uff0c\u80ba\u764c\u662f\u5168\u4e16\u754c\u8303\u56f4\u5185\u53d1\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u6700\u9ad8\u7684\u6076\u6027\u80bf\u7624\uff0c\u5176\u4e2d\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u5360\u5168\u90e8\u80ba\u764c\u768480%\u5de6\u53f3\uff0c\u800cNSCLC\u60a3\u8005\u4e2d\u6709\u5f88\u5927\u4e00\u90e8\u5206\u5728\u786e\u8bca\u65f6\u5df2\u7ecf\u5904\u4e8e\u665a\u671f\u3002\u56e0\u6b64\uff0c\u5bf9\u4e8e\u665a\u671fNSCLC\u7684\u6cbb\u7597\u4e5f\u8d8a\u6765\u8d8a\u53d7\u5230\u4eba\u4eec\u7684\u91cd\u89c6\u3002\u867d\u7136\u665a\u671fNSCLC\u7684 \u6807\u51c6\u6cbb\u7597\u4e3a\u542b\u94c2\u53cc\u836f\u8054\u5408\u5316\u7597\uff0c\u4f46\u662f\u5316\u7597\u836f\u7269\u5bf9\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u7684\u751f\u5b58\u671f\u65b9\u9762\u4f5c\u7528\u5341\u5206\u6709\u9650\uff0c\u56e0\u6b64\u5bfb\u6c42\u65b0\u7684\u6cbb\u7597\u65b9\u5f0f\u8feb\u5728\u7709\u776b\u3002\u968f\u7740\u5bf9\u80ba\u764c\u53d1\u75c5\u673a\u5236\u53ca\u5176\u751f\u7269\u5b66\u884c\u4e3a\u7684\u6df1\u5165\u7814\u7a76 \uff0c\u5206\u5b50\u9776\u5411\u6cbb\u7597\u5df2\u6210\u4e3a\u6cbb\u7597\u665a\u671fNSCLC\u6700\u5177\u524d\u666f\u7684\u7814\u7a76\u9886\u57df\u3002\u5176\u4e2d\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53-\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs\uff09\u5728\u665a\u671fNSCLC\u6cbb\u7597\u65b9\u9762\u53d6\u5f97\u4e86\u7a81\u7834\u6027\u8fdb\u5c55\uff0c\u5176\u4ee3\u8868\u836f\u7269\u4e3a\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\uff0c\u8fd9\u4e24\u79cdEGFR-TKIs\u5df2\u5728\u5168\u4e16\u754c\u8303\u56f4\u5185\u5f97\u5230\u8ba4\u53ef\u5e76\u88ab\u5e7f\u6cdb\u7528\u4e8e\u665a\u671fNS CLC\u7684\u6cbb\u7597\uff0c\u5c24\u5176\u662f\u5bf9\u4e8eEGFR\u654f\u611f\u7a81\u53d8\u8005\u3002\u7136\u800c\uff0c\u7ecf\u8fc7\u4e00\u6bb5\u65f6\u95f4\uff08\u4e2d\u4f4d\u65f6\u95f4\u4e3a6\u4e2a\u6708-12\u4e2a\u6708\uff09\u7684\u6cbb\u7597\u540e\uff0c\u5927\u90e8\u5206\u60a3\u8005\u4f1a\u5bf9EGFR-TKIs\u4ea7\u751f\u8010\u836f\uff0c\u5176\u8010\u836f\u673a\u5236\u4e3b\u8981\u5305\u62ec \u539f\u53d1\u6027\u548c\u83b7\u5f97\u6027\u8010\u836f\u3002\u7531\u4e8eEGFR-TKIs\u5728\u6539\u5584\u665a\u671fNSCLC\u60a3\u8005\u603b\u751f\u5b58\u671f\u548c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u65b9\u9762\u7684\u7a81\u51fa\u4f5c\u7528\uff0c\u5bf9\u4e8eEGFR-TKIs\u8010\u836f\u673a\u5236\u7684\u63a2\u7d22\u5df2\u6210\u4e3a\u56fd\u5185\u5916\u7814\u7a76\u7684\u70ed\u70b9 \u3002\u8be5\u6587\u7ae0\u5c31EGFR-TKI\u8010\u836f\u673a\u5236\u7684\u7814\u7a76\u8fdb\u5c55\u8fdb\u884c\u4e86\u7efc\u8ff0\u3002 DOI: 10.3779/j.issn.1009-3419.2013.10.07 PMID: 24113007 [PubMed - indexed for MEDLINE]  PURPOSE: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The enrichment of cancer stem cell (CSC)-like cellular states has not previously been considered to be a causative mechanism in the generalized progression of EGFR-mutant non-small cell lung carcinomas (NSCLC) after an initial response to the EGFR tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To explore this possibility, we utilized a pre-clinical model of acquired erlotinib resistance established by growing NSCLC cells containing a TKI-sensitizing EGFR exon 19 deletion (\u0394E746-A750) in the continuous presence of high doses of erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This report is the first to show that: (1) loss of responsiveness to erlotinib in EGFR-mutant NSCLC can be explained in terms of erlotinib-refractory ALDH(bright) cells, which have been shown to exhibit stem cell-like properties; and (2) erlotinib-refractory ALDH(bright) cells are sensitive to the natural agent silibinin. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We identified the expression of EGFR exon 18 as a new predictive marker for patients with untreated metastatic NSCLC treated with bevacizumab and erlotinib in the first line setting. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of ge\ufb01tinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We also revealed a MEK2 signal that may be associated with NSCLC cell sensitivity to the EGF receptor inhibitor erlotinib, and distinguished erlotinib-sensitive cells from intrinsic as well as acquired resistant cells to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "With 8 \u03bcg of tumor aspirates, we precisely quantified the response of 18 signaling molecules to erlotinib and MEK1 inhibitor treatments in an NSCLC patient. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the current study we investigated a novel mechanism of NSCLC resistance to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: The mechanisms of acquired erlotinib resistance were evaluated by microarray analysis in thirteen NSCLC cell lines and in vivo in mice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Correlations between plasma neutrophil gelatinase associated lipocalin (NGAL) levels, erlotinib response and the EGFR mutational status were assessed in advanced stage NSCLC patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Evaluation of the plasma NGAL levels in NSCLC patients that received erlotinib revealed that patients with lower baseline NGAL demonstrated a better erlotinib response. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The fact that advanced NSCLC patients with wild type (wt) EGFR can benefit from erlotinib therapy makes it critical to find out biomarkers for effective selection of patients and improving the therapy effects. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In present study, 3 NSCLC cell lines (U1752, Calu-6 and NCI-H292) with wt EGFR and different sensitivities to erlotinib were used for microarray analysis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Collectively, activation of RAF1-MEK1-ERK/AKT axis may determine the resistance of NSCLC cell lines bearing wt EGFR to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib is associated with survival benefits in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase II, single-arm study examined the efficacy and safety of first-line erlotinib in Japanese patients with EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: NSCLC cells that are wild type for EGFR were assayed for sensitivity to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The results of these studies support further clinical development of translation inhibitors for treatment of NSCLC in combination with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The NSCLC cell lines and xenograft models were treated with CH5164840 and erlotinib to examine their mechanisms of action and cell growth inhibition. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Taken together, these data indicate that CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Recently, efficacy erlotinib plus concurrent WBRT for patients with brain metastases from NSCLC was reported. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective analysis of 109 patients with advanced NSCLC who had previously failed at least one line of chemotherapy and received subsequent treatment with erlotinib (150 mg/day orally) was performed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The Cox model indicated that an Eastern Cooperative Oncology Group performance status (ECOG PS) \u2265 2 (HR 3.82; p<0.001), presence of intra-abdominal metastasis (HR 3.42; p=0.002), 2 or more prior chemotherapy regimens (HR 2.29; p=0.021), and weight loss >5% (HR 2.05; p=0.034) were independent adverse prognostic factors for OS in NSCLC patients treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This study suggests that NSCLC patients should be enrolled in erlotinib treatment after a first round of unsuccessful chemotherapy to improve treatment success, during which they should be monitored for intra-abdominal metastasis and weight loss. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The effectiveness of erlotinib in second- or third-line treatment of NSCLC patients without EGFR activating mutation gene remains debatable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The present study was conducted in a group of 71 patients with inoperable, locally advanced or metastatic NSCLC treated with erlotinib as the second- or third-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Different erlotinib-failure modes have been reported in NSCLC, and strategies to prolong erlotinib efficacy are perhaps adaptable to them. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the feasibility and efficacy of continued erlotinib maintenance and local salvage radiation to overcome erlotinib resistances in selected NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Thirty of 52 consecutive erlotinib-treated advanced NSCLC from the NYU Langone Medical Center and the Arnau de Vilanova Hospital of Lleida responded initially to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Continued erlotinib maintenance and local salvage radiation is feasible and could contribute to a better outcome in selected NSCLC patients with solitary-progression to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non-small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The epidermal growth factor receptor (EGFR) inhibitor erlotinib is much less effective in non-small-cell lung cancer (NSCLC) tumors with wild-type EGFR, than in tumors with activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We used wild-type EGFR erlotinib-sensitive and erlotinib-resistant NSCLC cell lines to determine whether inhibiting autophagy by a therapeutic agent potentiated the antitumor activity of erlotinib in vitro and in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The ability of CQ to potentiate the antitumor activity of erlotinib was also seen in mice bearing NSCLC tumor xenografts. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The ability to adapt to anti-EGFR therapy by triggering autophagy may be a key determinant for resistance to erlotinib in wild-type EGFR NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Inhibition of autophagy by CQ represents a novel strategy to broaden the spectrum of erlotinib efficacy in wild-type EGFR NSCLC tumors. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We retrospectively analyzed all consecutive patients with advanced NSCLC who developed acneiform skin rash during erlotinib treatment at our Clinical Oncology Unit from June 2006 to May 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Among 25 patients affected by advanced NSCLC treated with erlotinib during the reference period, 19 patients (76.0 %) developed acneiform skin rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, we can affirm that age is an insufficient predictor of acneiform skin rash during erlotinib treatment in advanced NSCLC and does not seem to statistically influence the appearance, duration and grade of skin rash. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The primary objective of this study was to clarify the population pharmacokinetics/pharmacodynamics of erlotinib in Japanese patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ABCG2 can influence the apparent clearance of erlotinib and OSI-420, and their CSF permeabilities in patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study aims to evaluate the efficacy and safety of erlotinib versus doublets (erlotinib plus another targeted agent) in advanced NSCLC and, if adequate data are available, to investigate whether or not predefined patient groups benefit more or less from doublet-targeted therapy based on erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomized controlled clinical trials were conducted in which any erlotinib was compared with doublets based on erlotinib in patients with NSCLC who had failed to respond to any previous chemotherapy regimen. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A systematic review and meta-analysis based on aggregate data extracted from trial publications were carried out to assess the effectiveness of doublets (erlotinib plus another targeted drug) in NSCLC treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The results of this systematic review suggest that patients with advanced NSCLC might benefit from doublet-targeted therapy based on erlotinib compared to erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In phase IIa, erlotinib-na\u00efve (cohort A) or erlotinib-resistant (cohort B) patients with advanced non-small-cell lung cancer (NSCLC) received BMS-690514 once-daily at the MTD. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: This phase I-IIa study suggests that BMS-690514 has manageable safety profile and antitumour activity in patients with NSCLC at 200mg/d, including those with EGFR mutations conferring resistance to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We sought to identify proteomic biomarkers associated with ILD development in erlotinib-treated Japanese patients with non-small-cell lung cancer (NSCLC) to build predictive models. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The participants were patients with NSCLC enrolled in a phase IV study of erlotinib in whom ILD developed within 120 days after erlotinib administration. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Some patients with advanced NSCLC show prolonged disease stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We retrospectively analyzed all NSCLC patients treated with erlotinib at our institutions since 2004who progressed after at least stable disease on erlotinib for at least 6 months. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "SATURN (Sequential Tarceva in Unresectable NSCLC) was a randomised, double-blind, placebo-controlled, multicentre study investigating the impact of erlotinib maintenance therapy on HRQoL in patients with locally advanced or recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We deduce that erlotinib is effective against NSCLC and is tolerated in clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CASE DESCRIPTION: A 68-year-old man with NSCLC, who had been undergoing treatment with erlotinib (150 mg daily) for the previous two weeks, presented with dyspnoea. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Because temozolomide (TMZ) and erlotinib (ETN) cross the blood-brain barrier and have documented activity in NSCLC, a phase 3 study was designed to test whether these drugs would improve the OS associated with WBRT + SRS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The aim of this study is to estimate the costs for the foreseeable management of skin toxicity (papulo-pustular reactions) in patients treated with erlotinib for non-small cell lung cancer (NSCLC) in order to value the direct medical economical impact. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed all consecutive patients with NSCLC treated with erlotinib at Clinical Oncology Unit of University Hospital of Ferrara, Italy from June 2007 to May 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation therapy (WBRT) in an attempt to extend survival time for patients with BM from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " In the EU, the approved use of erlotinib (Tarceva(\u00ae)), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations develop acquired resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced non-small-cell lung cancer (A-NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured by positron emission tomography (PET) in patients with metastatic non-small cell lung cancer (NSCLC) prior to systemic therapy with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "FLT and FDG maximum standardized uptake (SUVmax) values per patient were analyzed in 40 chemotherapy naive patients with advanced NSCLC (stage IV) before treatment with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Survival in an unselected population of patients with NSNSCLC treated with bevacizumab and erlotinib approximated that expected with conventional chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the curative and adverse side effects of erlotinib in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Seven-two elderly patients with pathologically confirmed NSCLC in advanced stage (III or IV) received treatment with oral erlotinib at the daily dose of 150 mg, and the treatment was discontinued until intolerance of the side effects or the occurrence of disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This presented study is focused on comparison of erlotinib and chemotherapy efficacy in the second line treatment of the advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study investigated retrospectively the benefits of local ablative therapy (LAT) to central nervous system (CNS) and/or limited systemic disease progression and continuation of crizotinib or erlotinib in patients with metastatic ALK gene rearrangement (ALK+) or EGFR-mutant (EGFR-MT) NSCLC, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic ALK+ NSCLC treated with crizotinib (n = 38) and EGFR-MT NSCLC treated with erlotinib (n = 27) were identified at a single institution. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: This phase II, open-label study evaluated the efficacy and safety of erlotinib as second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases (BM). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Single-agent erlotinib was active and well tolerated in NSCLC patients with BM. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A phase II study combining erlotinib and bevacizumab for treatment of recurrent NSCLC showed encouraging efficacy and acceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This single-arm phase II study evaluated erlotinib and bevacizumab as first-line therapy for newly diagnosed nonsquamous advanced NSCLC patients with Eastern Cooperative Oncology Group PS \u2265 2 or age 70 or older. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of erlotinib and bevacizumab had insufficient activity in the absence of known activating epidermal growth factor receptor gene mutations to warrant study in newly diagnosed elderly or poor PS patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: VeriStrat has shown its potential for stratification of unselected, advanced stage NSCLC patients treated in first line with a combination of erlotinib and sorafenib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Two hundred and fifty-five chemorefractory NSCLC patients received tumor molecular analysis, and were randomized to erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MK-0646 treatment caused increased erlotinib sensitivity in NSCLC cells poorly responsive to it. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: FDG-PET and FLT-PET were performed in 30 patients with untreated Stage IV NSCLC before start of therapy, 1 (early) and 6 (late) weeks after erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC, percentage changes of TLG and TLP and absolute residual TLG and TLP levels under erlotinib treatment emerged as strong predictive factors for PFS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We subsequently examined the effect of combining 1,25(OH)2D3 with erlotinib, which is used clinically in the treatment of EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of non-small cell lung cancer (NSCLC), and to date a large amount of clinical data are available. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we evaluated mechanisms underlying sorafenib-erlotinib interaction in seven NSCLC cell lines selected for their heterogeneous pattern of EGFR and Raf-kinase-inhibitor protein (RKIP) expression, and EGFR/K-Ras mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "No direct drug interaction was detected by LC-MS/MS measurement, while lysates from A549 and H1975 cells exposed to erlotinib+sorafenib showed a significant inhibition in the phosphorylation of 16 overlapping peptides, including sites from RAF, VEGFR2, PDGFR, CDK2 and SRC, suggesting new markers to identify NSCLC patients who are likely to respond to this treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, several mechanisms, including apoptosis-induction, modulation of expression/phosphorylation of RKIP and crucial kinases contribute to erlotinib-sorafenib synergistic interaction and should be evaluated in future trials for the rational development of this combination in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human non-small cell lung cancer (NSCLC), breast cancer and colorectal cancer were evaluated in vivo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The cost comparison findings for Italy show that erlotinib is still the less costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The epidermal growth factor receptor inhibitor erlotinib is an approved treatment for chemotherapy-refractory advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a phase I study to determine feasible dosages of combination therapy with erlotinib and everolimus for previously treated metastatic or unresectable NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " AIMS: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been demonstrated in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Tarceva lung cancer survival treatment (TRUST) is an open-label, single-arm, phase IV global trial which investigated erlotinib in advanced NSCLC patients who had failed prior therapy or were unsuitable for chemo/radiotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Outcomes for Australian patients confirmed the efficacy and tolerability of erlotinib for the treatment of advanced NSCLC in routine clinical practice. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer (NSCLC), especially for those with EGFR-activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this study was to assess the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared to the reverse strategy, in fit elderly patients with advanced NSCLC participating in a prospective randomized phase 2 trial (GFPC0504). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In terms of cost effectiveness, in fit elderly patients with NSCLC, erlotinib followed by chemotherapy compares well with the reverse strategy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Regardless of epidermal growth factor receptor (EGFR) mutation status, erlotinib improves survival for patients with advanced non-small cell lung cancer (NSCLC) after one or more chemotherapy regimens. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase II study was designed to evaluate the efficacy and safety of erlotinib and enzastaurin in NSCLC, a combination with promise to overcome EGFR resistance based on preclinical models. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Eligible patients with advanced NSCLC (IIIB or IV) who had failed one or two prior systemic treatment regimen(s) were enrolled and received erlotinib 150 mg/day and enzastaurin 500 mg/day (after a 1125-mg loading dose on day 1, cycle 1), both orally in 28-day cycles. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this prospective study was to investigate the safety of preoperative erlotinib treatment and the (in vivo) response in patients with early-stage resectable non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Treatment options for patients whose tumors have failed to respond to two or more conventional chemotherapy regimens are limited, with erlotinib, which targets the epidermal growth factor receptor, and crizotinib, which targets EML4/ALK, the only agents currently approved in the United States as third-line therapy for patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The objective of this study was to assess the cost-effectiveness of erlotinib followed by chemotherapy after progression, compared with the reverse strategy, in frail elderly patients with advanced NSCLC participating in a prospective randomized phase II trial (GFPC 0505). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: No difference in cost-effectiveness was found between an erlotinib-first strategy and a chemotherapy-first strategy in frail elderly patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in Japanese patients with non-small-cell lung cancer (NSCLC) receiving erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: All patients with recurrent/advanced NSCLC receiving erlotinib in Japan were enrolled (December 2007-October 2009). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These interim data support the clinical benefits of erlotinib in Japanese NSCLC patients with no new safety signals. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The risk/benefit balance for erlotinib in recurrent/advanced NSCLC remains favorable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "At equivalent doses, erlotinib achieved lower kinase-site occupancy in glioma-derived EGFRvIII compared with NSCLC-derived EGFR mutants. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EGFRvIII released erlotinib rapidly compared with wild-type EGFR, whereas NSCLC-derived mutants released erlotinib slowly.SIGNIFICANCE: These data suggest that kinase-site occupancy is a biomarker for efficacy of EGFR inhibitors, that rapid binding and release of erlotinib in glioma-derived EGFRvIII opposes the blockade of downstream signaling, and that slower cycling of erlotinib within the active site of NSCLC-derived mutants underlies their improved clinical response. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with refractory NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This randomized phase 2b trial was designed to further evaluate pralatrexate activity in NSCLC by estimating overall survival (OS) relative to erlotinib in patients with relapsed/refractory disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pralatrexate demonstrated a trend toward improved survival relative to erlotinib in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the predictive value of early and late residual (18)F-fluorodeoxyglucose (FDG) and (18)F-fluorothymidine (FLT) uptake using different SUV measurements in PET in patients with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively reviewed data from 30 patients with untreated stage IV NSCLC who had undergone a combined FDG PET and FLT PET scan at 1 week (early) and 6 weeks (late) after the start of erlotinib treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Early and late residual FDG uptake, measured using different quantitative SUV parameters, are predictive factors for short-term outcome in patients with advanced NSCLC treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The global phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN) study evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression after first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with advanced NSCLC with no evidence of progression after four cycles of chemotherapy were randomized to receive erlotinib 150 mg/day or placebo, until progressive disease or limiting toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: An erlotinib resistant subline (H1650-ER1) was generated upon continuous exposure of NSCLC cell line NCI-H1650 to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " This study assesses the predictive value of (18)F-FDG PET for overall survival in lung cancer patients treated with a targeted drug.METHODS: (18)F-FDG PET was performed in 125 second- or third-line non-small cell lung cancer (NSCLC) patients with a baseline Eastern Cooperative Oncology Group performance status less than 3 before treatment with erlotinib (150 mg daily) and 2 wk into treatment. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: (18)F-FDG PET in second- or third-line NSCLC patients at 2 wk after starting treatment with erlotinib carries information about overall survival. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced non small-cell lung cancer (NSCLC), selected on the basis of a comprehensive geriatric assessment (CGA). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study evaluates erlotinib in the treatment for brain metastases from NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to estimate the incremental cost-effectiveness of erlotinib 150 mg/day versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive factors on the outcome of therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Tyrosine kinase inhibition (TKI) such as erlotinib is a well established treatment option in the palliative care of patients with non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, show favorable response to EGFR mutant lung cancer in some populations of NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Resistant NSCLC cells bearing a T790M mutation (H1975) showed mean increases in (18)F-FLT uptake of 27% and 33% with high and low doses of erlotinib, respectively. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in (18)F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: PET/CT with (18)F-FLT may contribute to the selection of patients who may benefit from treatment with reversible and irreversible EGFR TKIs and may provide clues about which patients with NSCLC may be candidates for combination treatment with erlotinib and Bcl-x(L) inhibitors. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " AIM: This study aimed to analyze whether or not the efficacy and safety of erlotinib are influenced by differences among treatment lines and initiation timing in advanced non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This phase I/II study evaluated the safety and antitumor effect of the combination of erlotinib with cixutumumab, a recombinant fully humanized anti-insulin-like growth factor-1 receptor IgG1 monoclonal antibody, in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with advanced NSCLC were treated in an initial safety-lead and drop-down cohorts using erlotinib 150 mg/d with cixutumumab 6 or 5 mg/kg on days 1, 8, 15, and 22 in 28-day cycles (cohorts 1 and 2). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combinations of cixutumumab at 6 mg/kg every 7 days and 15 mg/kg every 21 days and full-dose erlotinib are not tolerable in unselected patients with NSCLC, as measured by DLT. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Taken together, we suggest that elevated eIF4E in NSCLC cells is associated with proliferation, invasion and acquired erlotinib resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "A cost-effectiveness analysis was conducted to compare costs and effectiveness in patients who received third-line erlotinib to those in a historical patient cohort that would have been eligible had erlotinib been available.METHODS: In a population of patients who have been treated with drugs for advanced NSCLC, overall survival (OS), progression-to-death survival (PTD) and probability of survival one year after end of second-line (1YS) were determined using a Kaplan-Meier survival analysis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our analysis suggests that erlotinib may be an effective and cost-effective third-line treatment for advanced NSCLC compared to best supportive care. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib have shown efficacy in patients with NSCLC and brain metastases. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for second-line or third-line indication in previously treated advanced Non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated with daily oral erlotinib versus oral vinorelbine. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However use of clinical (smoking status) and pathologic (adenocarcinoma) criteria may identify a subgroup of patients with advanced/metastatic NSCLC who can benefit from front-line treatment with erlotinib when mutation testing is not feasible. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "HM781-36B treatment of EGFR DelE746_A750-harboring erlotinib-sensitive HCC827 and EGFR L858R/T790M-harboring erlotinib-resistant NCI-H1975 NSCLC cells results in the inhibition of EGFR phosphorylation and the subsequent deactivation of downstream signaling proteins. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additionally, HM781-36B shows an excellent efficacy in a variety of EGFR- and HER-2-dependent tumor xenograft models, including erlotinib-sensitive HCC827 NSCLC cells, erlotinib-resistant NCI-H1975 NSCLC cells, HER-2 overexpressing Calu-3 NSCLC cells, NCI-N87 gastric cancer cells, SK-Ov3 ovarian cancer cells and EGFR-overexpressing A431 epidermoid carcinoma cancer cells. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Patients with advanced NSCLC and SD following first-line platinum-based doublet chemotherapy derive a significant OS benefit from maintenance erlotinib therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We retrospectively reviewed the files of all patients with advanced non-small-cell lung cancer (NSCLC) treated with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250\u00a0mg/m2, days 1 and 4), cisplatin (75\u00a0mg/m2, day 2) and erlotinib (150\u00a0mg, days 5 - 15), followed by continuous erlotinib as maintenance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients \u226518 years old with histologically/cytologically confirmed stage IIIB/IV EGFR mutation-positive NSCLC and Eastern Cooperative Oncology Group performance status 0-2 were randomized 1:1 to receive erlotinib (oral; 150 mg once daily until progression/unacceptable toxicity) or GP [G 1250 mg/m(2) i.v. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: These analyses demonstrate that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "FINDINGS: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The first phase II study of biomarker-guided neoadjuvant therapy for stage IIIA-N2 NSCLC patients stratified by EGFR mutation status, sponsored by CSLC0702, showed erlotinib tended to improve response rate, but failed to show benefits of disease-free survival (DFS) or OS. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: The purpose of the present trial was to investigate whether clinical benefit can be obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status (PS) 2. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Therefore, we decided to conduct a study to compare cost-effectiveness between erlotinib monotherapy and carboplatin-gemcitabine (CG) combination therapy in patients with advanced EGFR mutation-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chinese patients \u2265 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Chemotherapy-na\u00efve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150\u00a0mg/day p.o.) plus gemcitabine (1000\u00a0mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlotinib followed by G at progression (arm B) in vulnerable elderly patients with advanced non small-cell lung cancer (NSCLC), selected on the basis of a comprehensive geriatric assessment (CGA). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "erlotinib in the second- and third-line non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive non-small-cell lung cancer (NSCLC) in pre-specified subgroup analyses of a randomized phase II study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Variables with the greatest influence in the model were erlotinib-associated progression-free survival (EGFRm AC), toxicity (EGFRm AC), cost of SBRT (NSCLC SCC), and patient utilities (all histologies). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In light of the potential role for serum proteomics in predicting the benefit of erlotinib beyond that of epidermal growth factor receptor gene (EGFR) mutational status, we conducted a trial in which the Veristrat proteomics assay was used for data enrichment when selecting a cohort of patients with NSCLC and PS2 to receive erlotinib with and without chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with metastatic NSCLC, PS2, acceptable end-organ function, and Veristrat-good status were randomly assigned to receive either 150 mg of erlotinib orally daily (arm 1) or 150 mg of erlotinib orally daily on days 2 through16 plus four cycles of carboplatin (area under the curve\u00a0= 5 on day 1) and paclitaxel (200 mg/m(2) intravenously on day 1) followed by 150 mg of erlotinib orally (arm 2). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In a proteomics-enriched cohort of patients with NSCLC and PS2, pharmacodynamically separated erlotinib plus chemotherapy had better efficacy than did erlotinib alone and surpassed the protocol-specified benchmark of PFS of at least 3 months required for further study. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV nonsquamous NSCLC, Eastern Cooperative Oncology Group performance status 0-1, and untreated, asymptomatic brain metastases received first-line bevacizumab (15 mg/kg) plus carboplatin (area under the curve \u00d76) and paclitaxel (200 mg/m(2)) every 3 weeks (B + CP), or second-line bevacizumab plus erlotinib (150 mg/d; B + E). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The TASK study evaluated the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab as first-line therapy in unselected, advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The TASK study did not show a benefit in terms of PFS for the combination of erlotinib with bevacizumab in unselected first-line advanced non-squamous NSCLC compared with chemotherapy plus bevacizumab. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and \u2264 10 pack years and quit \u2265 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant non-small-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies evaluating bevacizumab and erlotinib as MTx in 1632 patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " WHAT IS KNOWN AND OBJECTIVE: A randomized phase III study was designed to assess the efficacy and safety of second-line platinum-based chemotherapy with or without erlotinib in non-small cell lung cancer (NSCLC) with EGFR-activating mutation after secondary resistance to EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent different agents commonly used for the second-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Stage IIIB/IV NSCLC patients were randomized after four cycles of cisplatin-gemcitabine chemotherapy to either observation or to receive maintenance therapy with gemcitabine or erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For both squamous and non-squamous NSCLC, switch maintenance with erlotinib has been shown to improve both PFS and OS, although the improvement is modest. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "For this reason, switch maintenance with erlotinib can be considered in patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: The cost comparison findings for Italy show that erlotinib is still the less costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III study investigated whether continuation maintenance with gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with observation in patients with advanced non-small-cell lung cancer (NSCLC) whose disease was controlled after cisplatin-gemcitabine induction chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Four hundred sixty-four patients with stage IIIB/IV NSCLC without tumor progression after four cycles of cisplatin-gemcitabine were randomly assigned to observation or to gemcitabine (1,250 mg/m(2) days 1 and 8 of a 3-week cycle) or daily erlotinib (150 mg/day) study arms. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Treatment options for patients whose tumors have failed to respond to two or more conventional chemotherapy regimens are limited, with erlotinib, which targets the epidermal growth factor receptor, and crizotinib, which targets EML4/ALK, the only agents currently approved in the United States as third-line therapy for patients with advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Thus, maintenance treatment with erlotinib in patients with advanced/metastatic NSCLC without EGFR-activating mutations is considered unfavorable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In sqNSCLC patients who respond to induction chemotherapy, maintenance therapy with erlotinib delays disease progression and may improve the survival of patients with stable disease. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Following resection and completion of standard adjuvant therapy, patients with EGFR-mutant NSCLC will be randomized to erlotinib versus placebo (1:1), those with ALK-rearranged NSCLC will be randomized to crizotinib versus placebo (1:1), while those not enrolled onto the adjuvant trials will continue to be followed on the screening trial. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: This hypothesis-generating retrospective analysis examined data from two studies of erlotinib in NSCLC, Marker Identification Trial (MERIT; n = 102) and Sequential Tarceva in Unresectable NSCLC (SATURN; n = 262), to determine whether PTPRF expression was prognostic and/or predictive of patient outcomes. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T) or erlotinib plus placebo (E + P) until disease progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: HERALD (NCT02134015) was a double-blind, phase 2 study in patients with non-small cell lung cancer (NSCLC) randomized to erlotinib with placebo or with high or low doses of patritumab, a monoclonal antibody targeted against human epidermal growth factor receptor 3 (HER3). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV (AJCC 6th edition) NSCLC who progressed after at least 1 line of therapy or refused standard chemotherapy were randomized to receive erlotinib and celecoxib versus erlotinib and placebo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Additional data on the efficacy of first-line therapy with afatinib and the combination of erlotinib and bevacizumab for patients with EGFR mutant NSCLC were presented. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo (n = 40) or erlotinib (100mg, n = 40) given concurrently with WBRT (20 Gy in 5 fractions). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our study showed no advantage in nPFS or OS for concurrent erlotinib and WBRT followed by maintenance erlotinib in patients with predominantly EGFR wild-type NSCLC and multiple brain metastases compared to placebo. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with stage IIIB/IV NSCLC previously treated with platinum-based chemotherapy were randomized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The phase II study was a randomized two-arm trial in which onartuzumab or placebo was administered in combination with erlotinib in 137 patients with second and third line (2/3L) NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "SATURN (Sequential Tarceva in Unresectable NSCLC) was a randomised, double-blind, placebo-controlled, multicentre study investigating the impact of erlotinib maintenance therapy on HRQoL in patients with locally advanced or recurrent NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This study will investigate onartuzumab (MetMAb) in combination with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients with advanced non-small-cell lung cancer (NSCLC) who are Met-positive by immunohistochemistry. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with refractory NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The global phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN) study evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression after first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Patients with advanced NSCLC with no evidence of progression after four cycles of chemotherapy were randomized to receive erlotinib 150 mg/day or placebo, until progressive disease or limiting toxicity. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " We present the rationale and design for MARQUEE, a phase III, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " BACKGROUND: In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Patients with advanced NSCLC and SD following first-line platinum-based doublet chemotherapy derive a significant OS benefit from maintenance erlotinib therapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Thus, maintenance treatment with erlotinib in patients with advanced/metastatic NSCLC without EGFR-activating mutations is considered unfavorable. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer (NSCLC), especially for those with EGFR-activating mutations. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated with daily oral erlotinib versus oral vinorelbine. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 1, "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "disease": "NSCLC", "drug": "erlotinib"}, {"polarity": 0, "orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " BACKGROUND: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": " BACKGROUND: A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer (NSCLC) who were receiving vandetanib. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "A significant increase in risk was observed for all-grade hypertension (RR 5.58; 95% CI 4.16 to 7.48; P\u2009<\u20090.00001) and grade \u22653 hypertension (RR 4.79; 95% CI 2.31 to 9.93; P\u2009<\u20090.0001) in advanced NSCLC patients who were receiving vandetanib compared with the controls. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "CONCLUSIONS: Current evidence showed that significant risks in developing hypertension and QTc prolongation exist in advanced NSCLC patients who were receiving vandetanib. ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 0, "orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "disease": "NSCLC", "drug": "hypertension"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "SNPs were determined by SNaPshot PCR\u00ae in DNA isolated from peripheral blood of 55 NSCLC patients treated with platinum compound and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Selected SNPs of genes encoding DNA repair enzymes and cell division regulation proteins could be useful biomarkers for prediction of platinum and vinorelbine-based chemotherapy toxicity in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The first trial devoted to older patients with advanced non-small cell lung cancer (NSCLC) was a comparison between vinorelbine and best supportive care. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This study aimed to investigate the efficacy of oral vinorelbine as maintenance therapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, the efficacy of orally administrated vinorelbine in adjuvant treatment of NSCLC is unknown. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against non-small cell lung cancer (NSCLC) cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "AREAS COVERED: This paper reviews the role of vinorelbine , both alone and in combination with platinum-derivates, in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: In the first-line treatment of advanced NSCLC, the use of vinorelbine-based regimens may be less efficacious in controlling disease than other combinations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, since their activity is not related to histology, vinorelbine still has potential as a first-line treatment for NSCLC patients in whom histology has failed to distinguish non-squamous from squamous histotypes. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin plus oral vinorelbine, one of the standard treatments for metastatic non-small-cell lung cancer (NSCLC), is associated with a high rate of neutropenia, and a hemogram is performed on day 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for non-small-cell lung cancer(NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]  PURPOSE: Aurora kinases are key regulators of mitotic events. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Thirty patients with Stage IIIB/IV NSCLC were treated with escalating doses of oral vinorelbine starting at 40 mg/m2 on day 1 and 8 in the CSV group (N = 16) and at 100 mg/week in the MSV group (N = 14). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated with daily oral erlotinib versus oral vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "AREAS COVERED: This paper reviews the role of vinorelbine , both alone and in combination with platinum-derivates, in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: In the first-line treatment of advanced NSCLC, the use of vinorelbine-based regimens may be less efficacious in controlling disease than other combinations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, since their activity is not related to histology, vinorelbine still has potential as a first-line treatment for NSCLC patients in whom histology has failed to distinguish non-squamous from squamous histotypes. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The first trial devoted to older patients with advanced non-small cell lung cancer (NSCLC) was a comparison between vinorelbine and best supportive care. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The first trial devoted to older patients with advanced non-small cell lung cancer (NSCLC) was a comparison between vinorelbine and best supportive care. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "vinorelbine in NSCLC elderly patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In our study, the efficacy and safety of combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced NSCLC was evaluated. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "RESULTS: Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with treatment na\u00efve metastatic NSCLC received two cycles comprising 6 weekly doses of vinorelbine and paclitaxel, with restaging scans at week 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We longitudinally compared health-related quality of life (HRQoL) of the two treatment arms.In total, 451 patients aged 70-89\u2005years with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive carboplatin plus paclitaxel or vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "ARCTIC (NCT02352948) is a global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-L1(+) tumors (\u226525% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A) and the combination of durvalumab\u00a0+ tremelimumab or either agent as monotherapy versus SoC in patients with PD-L1(-) tumors (Sub-study B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A comprehensive review of the literature data regarding use of oral vinorelbine concurrently with radiotherapy in NSCLC was done. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: This study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Thirty patients with Stage IIIB/IV NSCLC were treated with escalating doses of oral vinorelbine starting at 40 mg/m2 on day 1 and 8 in the CSV group (N = 16) and at 100 mg/week in the MSV group (N = 14). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "A total of 108 NSCLC patients (stages I-IIIA) were treated with a standard chemotherapy regimen of cisplatin plus vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Concurrent RT with oral vinorelbine and cisplatin demonstrated a favourable safety profile and represents a suitable treatment regimen for inoperable stage\u00a0III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Two consecutive groups of patients with advanced non-squamous NSCLC received carboplatin, vinorelbine and bevacizumab for four cycles. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This South Australian multicentre prospective phase II study evaluated the safety, activity and outcomes of combination oral vinorelbine and cisplatin administered concurrently with radiotherapy for stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Two cycles of chemotherapy with oral vinorelbine and cisplatin administered concurrently with radical radiation had an acceptable toxicity profile and was active in inoperable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were or were not undergoing standard cisplatin/vinorelbine chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "By using controlled method, 60 radical resected NSCLC patients undergoing NP/NC program in 2012 (vinorelbine 25 mg/m2, combined with cisplatin 75 mg/m2 on day 1 and day 8/on day 1 or on day 1, 2, and 3; or carboplatin AUC = 5 on day 1) were assigned to the control group (29 cases) and the test group (31 cases). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: The combination of platinum compounds and vinorelbine is often used as a first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), without activating EGFR mutations and ALK rearrangement. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of the study was to determine the relationship between a single nucleotide polymorphism (SNP) of the promoter of STMN1 gene -2166T>C) and the effectiveness of chemotherapy based on platinum compounds and vinorelbine in patients with NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: The investigated population consisted of 110 locally advanced or metastatic NSCLC patients treated with first-line chemotherapy, based on platinum compounds and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Rare TT genotype of STMN1 gene may be an unfavorable predictive factor of chemotherapy based on platinum compounds and vinorelbine, in patients with NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "SNPs were determined by SNaPshot PCR\u00ae in DNA isolated from peripheral blood of 55 NSCLC patients treated with platinum compound and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Selected SNPs of genes encoding DNA repair enzymes and cell division regulation proteins could be useful biomarkers for prediction of platinum and vinorelbine-based chemotherapy toxicity in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to investigate whether polymorphisms in BAG-1 and XPD have effects on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine combined cisplatin (NP) regimen. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In our study, the efficacy and safety of combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced NSCLC was evaluated. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in non-small cell lung cancer (NSCLC) cell lines with the rationale of potentially translating these findings into the clinical setting. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This study aimed to investigate the efficacy of oral vinorelbine as maintenance therapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II open-label, non-comparative study was designed to evaluate the three-weekly combination of cisplatin 80 mg/m(2) on day 1 in combination with oral vinorelbine on day 1 and 8 in advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Metronomic oral vinorelbine could be a safe option for elderly patients with advanced non small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Metronomic oral vinorelbine is safe in elderly patients with advanced NSCLC with an interesting activity mainly consisting in long-term disease stabilization coupled with an optimal patient compliance (Eudra-CT 2010-018762-23, AIFA OSS on 26 February 2010). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Sorafenib and metronomic oral vinorelbine is active in advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, the efficacy of orally administrated vinorelbine in adjuvant treatment of NSCLC is unknown. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adjuvant chemotherapy with vinorelbine plus cisplatin (VC) improves survival in resected non-small-cell lung cancer (NSCLC), but has negative impact on quality of life (QoL). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the safety and efficacy of metronomic vinorelbine in combination with cisplatin as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 41 patients with inoperable stage IIIb or stage IV NSCLC (14 with adenocarcinomas, 19 with squamous cell carcinoma and eight with other types), PS = 0-2, were treated with cisplatin (80 mg/m(2)) in combination with oral metronomic vinorelbine (60 mg total dose, every other day) in cycles of 21 days. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In this prospective study with advanced NSCLC treated with cisplatin-vinorelbine, we were able to derive with high throughput techniques predictive and prognostic signatures based on transcriptomic analyses. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: A retrospective analysis of all cases of advanced NSCLC treated with either cisplatin-gemcitabine or cisplatin-vinorelbine at the Regional Institute of Oncology Ia\u015fi between January 2012 and December 2013 was performed. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: To enhance the anticancer activity of vinorelbine, cisplatin and ionizing radiation (IR) combination against non-small cell lung cancer (NSCLC) cells by co-administration of sodium valproate (VPA), a histone deacetylase inhibitor, and to elucidate molecular events underpinning treatment efficacy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: The NSCLC A549 cell line was treated with cisplatin (0.2 \u03bcg/ml), vinorelbine (2 nM), VPA (1 mM) and IR (2.5 Gy) alone, or in combination. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "130 patients with inoperable stage III NSCLC and PS 0-1 were randomised to receive cisplatinum and vinorelbine with either sequential or concurrent chemo-radiation using 55Gy in 20 fractions over four weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: Adjuvant vinorelbine and cisplatin chemotherapy is recognized as a standard regimen for patients with completely resected stage II and III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, efficacy of adjuvant chemotherapy in Japanese phase III trials with cisplatin-containing regimen has been controversial, and data are limited on the long-term outcome of adjuvant vinorelbine and cisplatin chemotherapy for NSCLC patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Oral vinorelbine has demonstrated significant activity in different settings for NSCLC, including adjuvant treatment for resected disease, concurrent chemoradiation for locally advanced NSCLC and palliative chemotherapy for recurrent/metastatic NSCLC, as part of combination schedules or as a single-agent treatment. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "AREAS COVERED: The authors explored the available data describing the use of oral vinorelbine in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: This is a phase II trial of locally advanced NSCLC patients treated with cisplatin and vinorelbine plus concurrent nitroglycerin with radiotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well-tolerated and effective in patients with locally advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]  BACKGROUND: Early stage Non-Small Cell Lung Cancer (NSCLC) is potentially curable with surgery. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "vinorelbine in NSCLC elderly patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " AIM: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Adding nitroglycerin to the combination of vinorelbine plus cisplatin has been reported to improve the overall survival (OS) of Asian patients with stage IIIB/IV non-small cell lung cancer (NSCLC) probably due to better drug delivery based on changed vascular tonus. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: 66 chemona\u00efve patients with stage IIIB/IV NSCLC received oral vinorelbine (first cycle 60 mg/m(2), subsequent cycles: 80 mg/m(2) in the absence of any hematological toxicity \u2265 grade 3 in cycle 1) once daily on days 1 and 8 of each cycle and cisplatin (80 mg/m(2) i.v.) on day 1 of each cycle (q3w). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, the lower objective response rate and higher adverse effects of vinorelbine hinder its wide use in treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Therefore, it is of great interest to uncover the biomarkers for sensitivity of NSCLC cells to vinorelbine to allow the identification of patients most likely to benefit from vinorelbine-based chemotherapy and to improve the therapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In present work, four NSCLC cell lines were divided into vinorelbine-sensitive (VS) group and vinorelbine-resistant (VR) group according to their sensitivities to vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The higher expression of RAF1 mRNA and the activation of AKT/ERK proteins in VR NSCLC cell lines may confer resistance to vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To compare the efficacy and toxicity of chemotherapy under the guidance of molecular markers and with vinorelbine in elderly patients with epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: One hundred and forty NSCLC patients with negative EGFR mutation (90 cases) or EGFR mutation (50 cases) underwent gemcitabine or vinorelbine plus cisplatin or carboplatin chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In a prospective study, we assessed the predictive value for response and survival of tumour miRNA in NSCLC patients treated by 1st line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The signature distinguished patients with good (n = 18) and poor (n = 20) prognosis with respective median survival times of 47.3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9).CONCLUSIONS: miRNA signature allows predicting response and is of prognostic value for survival in patients with NSCLC treated with first line cisplatin and vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " The aim of the present study was to determine the frequency and predictive value of the expression of tumor microtubule components in patients with resected non-small cell lung cancer (R-NSCLC) subsequently treated with vinorelbine-based adjuvant chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "These findings suggest that high class III \u03b2-tubulin expression levels in resected tumors are predictive of improved DFS in R-NSCLC patients receiving vinorelbine-based chemotherapy. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Patients with recurrent metastatic breast (BC), prostate (PC) or non-small cell lung cancer (NSCLC) and adequate organ functions were randomly assigned to 30, 40 or 50 mg vinorelbine, taken orally three times a week. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "AREAS COVERED: This paper reviews the role of vinorelbine , both alone and in combination with platinum-derivates, in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: In the first-line treatment of advanced NSCLC, the use of vinorelbine-based regimens may be less efficacious in controlling disease than other combinations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "However, since their activity is not related to histology, vinorelbine still has potential as a first-line treatment for NSCLC patients in whom histology has failed to distinguish non-squamous from squamous histotypes. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This randomized phase II study of concurrent chemoradiotherapy was conducted to compare uracil/tegafur (UFT) and cisplatin with vinorelbine and cisplatin for stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage III NSCLC were randomized to receive UP (400 mg/m(2) UFT on days 1-14 and 29-42 and 80 mg/m(2) cisplatin on days 8 and 36) or NP (20 mg/m(2) vinorelbine on days 1, 8, 29, and 36 and 80 mg/m(2) cisplatin on days 1 and 29). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "This retrospective study analyzed the combined patient-level data from two phase II trials that investigated the efficacy and safety of combination chemotherapy with vinorelbine and mitomycin in patients with locally advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We evaluated a metronomic regimen of oral vinorelbine in pre-treated patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Forty-six pre-treated NSCLC patients received oral vinorelbine at a fixed dose of 50 mg three times a week. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The administration of metronomic oral vinorelbine is feasible and results in acceptable clinical efficacy associated with manageable toxicity in a population consisting mostly of heavily pre-treated NSCLC patients. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin plus oral vinorelbine, one of the standard treatments for metastatic non-small-cell lung cancer (NSCLC), is associated with a high rate of neutropenia, and a hemogram is performed on day 8. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet adjuvant chemotherapy were analyzed for EGFR mutations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the safety and efficacy profiles of the combination chemotherapy of vinorelbine and a platinum agent in patients with advanced NSCLC with ILD. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Nineteen patients with advanced NSCLC with ILD treated with vinorelbine and a platinum agent, either cisplatin or carboplatin, were retrospectively reviewed to examine acute exacerbation of ILD, toxicity, response rate, and survival time. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination chemotherapy with vinorelbine and a platinum agent can be considered as a treatment option for patients with advanced NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In addition, it showed that adjuvant cisplatin-based CT is detrimental in cases of stage Ia resected NSCLC; it also suggested that the combination of vinorelbine and cisplatin was of more benefit than older two and three drug combinations. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The first trial devoted to older patients with advanced non-small cell lung cancer (NSCLC) was a comparison between vinorelbine and best supportive care. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The prognosis signature was found to especially accurate at identifying early stage patients at risk of disease specific death within 24\u2009months of diagnosis when compared to traditional methods of outcome prediction.Separately, NSCLC patients with the 37-gene ACT-response signature (n\u2009=\u200970, 64\u2009%), benefited significantly from cisplatin/vinorelbine (adjusted HR: 0.23, P\u2009=\u20090.0032). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We aimed to determine the respective activity of third-generation (gemcitabine-vinorelbine-cisplatin [GVP]) in comparison with second-generation drugs CT (mitomycine-ifosfamide-cisplatin [MIP]) and their cost-effectiveness as neoadjuvant CT before surgery in NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN) in advanced non-small cell lung cancer (NSCLC) first-line treatment in China. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Multidrug resistance (MDR) is the main cause of chemotherapeutic failure in lung cancer, and vinorelbine (NVB) is one of the most efficient drugs that threaten non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " OBJECTIVE: A previous large, randomized, control trial(JBR.10)revealed that adjuvant chemotherapy with cisplatin(CDDP) and vinorelbine(VNR)was effective for non-small-cell lung cancer(NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "In our analysis, NSCLC patients treated with paclitaxel had more favorable clinical outcomes than those treated with vinorelbine (Chi(2)=3.69, P=0.05). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u226575 years of age and with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSION: Use of 20 mg/m(2) vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chemoradiotherapy with cisplatin and vinorelbine followed by S-1 consolidation demonstrated a reasonable overall survival in patients with stage III NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary objective of this study was to compare the response rates of elderly, chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated with daily oral erlotinib versus oral vinorelbine. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "METHODS: Chemonaive Taiwanese patients aged 70 years or older who had advanced NSCLC were randomized to receive either oral erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m (V) on days 1 and 8 every 3 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the safety and efficacy of concurrent vinorelbine and thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with unresectable Stage III NSCLC, age \u2265 20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20)) \u2264 30% received three to four cycles of cisplatin (80 mg/m(2) Day 1) and vinorelbine (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. ", "disease": "NSCLC", "drug": "vinorelbine"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab maintenance therapy contributed to an OS benefit in this retrospective sample of patients with NSCLC, even after multiple statistical adjustments for selection bias. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with chemotherapy has become the first-line therapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, non-small-cell lung cancer (NSCLC) in 2006. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab used in combination with first-line chemotherapy confers an overall survival (OS) benefit for patients with non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab, monoclonal antibodies targeting VEGF and the VEGFR, respectively, have each led to improvements in overall survival (OS) for NSCLC when added to standard first and second line chemotherapy, respectively. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (BEV), a humanized monoclonal antibody to vascular endothelial cell growth factor (VEGF), in combination with ERL (BEV+ERL) significantly extended progression-free survival in patients with EGFR-mutated NSCLC compared with ERL alone. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, a monoclonal antibody which targets vascular endothelium growth factor (VEGF), has been fully developed in NSCLC, and small-molecule tyrosin kinase inhibitors (TKIs) have been approved as first-line therapy for patients with advanced and metastatic NSCLC harbouring EGFR mutations. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "While Bevacizumab (Avastin) has proven successful in increasing the objective tumor response rate and in prolonging progression and overall survival in patients with NSCLC, the survival benefit is however relatively short and the majority of patients eventually relapse. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bevacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Publisher: \u76ee\u524d\u8868\u76ae\u751f\u957f\u56e0\u5b50\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI\uff09\u5df2\u5e7f\u6cdb\u5e94\u7528\u4e8e\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u60a3\u8005\uff0c\u4f46\u5982\u4f55\u5c06EGFR-TKI\u4e0e\u5316\u7597\u53ca\u5176\u4ed6\u9776\u5411\u836f\u7269\u7ed3\u5408\u4ecd\u5b58\u5728\u8bf8\u591a\u4e89\u8bae\u3002\u672c\u7efc\u8ff0\u9610\u8ff0\u4e86EGFR-TKI\u4e0e\u5316\u7597\u76843\u79cd\u4e0d\u540c\u8054\u5408\u6a21\u5f0f\uff1a\u524d\u540e\u5e8f\u8d2f\u6cbb\u7597\u3001\u540c\u6b65\u8054\u5408\u6cbb\u7597 \u53ca\u95f4\u63d2\u8054\u5408\u6cbb\u7597\uff1b\u5206\u6790EGFR-TKI\u4e0e\u8d1d\u4f10\u73e0\u5355\u6297\u8054\u5408\u6cbb\u7597\u7684\u4f18\u52a3\u6027\uff1b\u521d\u6b65\u63a2\u8ba8\u4e86EGFR\u7a81\u53d8\u60a3\u8005\u7684\u6700\u4f73\u6cbb\u7597\u6a21\u5f0f\u3002 DOI: 10.3779/j.issn.1009-3419.2015.02.11 PMID: 25676406 [PubMed - indexed for MEDLINE]  Bevacizumab is one of the most widely used antiangiogenic drugs in oncology, but the overall beneficial effects of this VEGF-A targeting agent are relatively modest, in part due to the lack of a biomarker to select patients most likely to respond favorably. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab (Bev), a monoclonal antibody against vascular endothelial growth factor, when combined with standard first-line chemotherapy, shows impressive clinical benefit in advanced non-squamous non-small cell lung cancer (ns-NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "RESULTS: Bevacizumab alone did not inhibit NSCLC cell growth in vitro. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab is recommended in first line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patients with NSNSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab was the first US FDA-approved inhibitor of angiogenesis after demonstrating improved progression-free survival and overall survival in combination with chemotherapy in treating NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that provides a survival benefit to patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab improves antitumor efficacy of CIK cells transfer therapy in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, is the only antiangiogenic agent currently recommended by NCCN for the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab has been widely used for the treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OPINION STATEMENT: Bevacizumab is an effective targeted therapy with demonstrated survival benefits for many patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Publisher: \u672c\u6587\u62a5\u90531\u4f8b\u5973\u6027\u80ba\u817a\u764c\u60a3\u8005\uff0c\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08epidermal growth factor receptor, EGFR\uff09\u3001V-Ki-ras2\u9f20Kirsten\u8089\u7624\u75c5\u6bd2\u81f4\u764c\u57fa\u56e0\u540c\u6e90\u7269\uff08V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, KRAS\uff09\u57fa\u56e0\u7a81\u53d8\u53ca\u68d8\u76ae\u52a8\u7269\u5fae\u7ba1\u76f8\u5173\u7c7b\u86cb\u767d4\u4e0e\u95f4\u53d8\u6027\u6dcb\u5df4\u7624\u6fc0\u9176\u878d\u5408\u57fa\u56e0\uff08chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase, EML4-ALK\uff09\u68c0\u6d4b\u7ed3\u679c\u5747\u4e3a\u9634\u6027\uff1b\u4e00\u7ebf\u63a5\u53d7\u8d1d\u4f10\u73e0\u5355\u6297\uff0815 mg/kg\uff09\u8054\u5408\u5e38\u89c4\u5242\u91cf\u7d2b\u6749\u9187\u3001\u5361\u94c2\u65b9\u68486\u5468\u671f\u5316\u7597\u4ee5\u53ca\u540e\u7eed\u8d1d\u4f10\u73e0\u5355\u6297\u7684\u7ef4\u6301\u6cbb\u7597\u3002\u5171\u5e94\u7528\u8d1d\u4f10\u73e0\u5355\u629742\u5468\u671f\uff0c\u5e94\u7528\u603b\u5242\u91cf\u8fbe44,730 mg\uff0c\u60a3\u8005\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff09\u957f\u8fbe39\u4e2a\u6708\uff0c\u60a3\u8005\u7684\u957f\u671f\u751f\u5b58\u83b7\u76ca\u8fdc\u8d85\u51fa\u4e86\u4e0d\u826f\u53cd\u5e94\u6240\u5e26\u6765\u7684\u5371\u5bb3\u3002 DOI: 10.3779/j.issn.1009-3419.2013.06.10 PMID: 23769349 [PubMed - indexed for MEDLINE]  Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients when combined to chemotherapy. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab accompanied by chemotherapy was found to significantly improve patients' response rate, progression free survival (PFS), and overall survival (OS) among chemotherapy-na\u00efve patients compared to other targeted drugs in the treatment of non-small cell lung carcinoma (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab (Avastin(\u00ae)) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Bevacizumab is a recombinant, humanised, monoclonal antibody against the vascular endothelial growth factor receptor (VEGFR), the aim of this meta-analysis is to evaluate the clinical efficacy and safety of bevacizumab combined with chemotherapy for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab is a monoclonal antibody that specifically inhibits vascular endothelial growth factor, and is the first antiangiogenic agent to be approved for first-line treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab maintenance therapy contributed to an OS benefit in this retrospective sample of patients with NSCLC, even after multiple statistical adjustments for selection bias. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, a monoclonal antibody against circulating vascular endothelial growth factor (VEGF), is already approved for the treatment of NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab-based chemotherapy is an efficacious and safe treatment for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab is currently approved when given in combination with first-line platinum-based therapy in selected patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with chemotherapy has become the first-line therapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bevacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab is recommended in first line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bevacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (BEV), a humanized monoclonal antibody to vascular endothelial cell growth factor (VEGF), in combination with ERL (BEV+ERL) significantly extended progression-free survival in patients with EGFR-mutated NSCLC compared with ERL alone. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "RESULTS: Bevacizumab alone did not inhibit NSCLC cell growth in vitro. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSION: Bevacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab is recommended in first line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u5316\u7597\u8010\u836f\u5bfc\u81f4\u80bf\u7624\u5f88\u5feb\u590d\u53d1\u548c/\u6216\u8f6c\u79fb\uff0c\u662f\u76ee\u524d\u80ba\u764c\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00\u3002\u03b2-tubulin\u662f\u6297\u5fae\u7ba1\u836f\u7269\u7684\u4e3b\u8981\u7ec6\u80de\u9776\u70b9\u3002\u5df2\u6709\u7684\u7814\u7a76\u8bc1\u660e\uff1a\u03b2III-tubulin\u9ad8\u8868\u8fbe\u4e0e\u975e \u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u8010\u836f\u6709\u5173\u3002\u5229\u7528RNA\u5e72\u6270\u6280\u672f\u6c89\u9ed8\u8010\u7d2b\u6749\u9187A549\u7ec6\u80de\uff08A549/Taxol\uff09\u4e2d\u03b2III-tubulin\u57fa\u56e0\u8868\u8fbe\uff0c\u63a2\u8ba8\u9776\u57fa\u56e0\u4e0b\u8c03\u540e\u5bf9\u5316\u7597\u836f\u7269\u7d2b\u6749\u9187\u7684\u654f\u611f \u6027\u7684\u53d8\u5316\u4ee5\u53ca\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u60c5\u51b5\u3002\u65b9\u6cd5 \u6784\u5efa\u9776\u5411\u03b2III-tubulin\u7684siRNA\uff0c\u4ee5\u8102\u8d28\u4f53\u4e3a\u8f7d\u4f53\u4ecb\u5bfc\u03b2III-tubulin siRNA\u8f6c\u67d3A549/Taxol\u7ec6\u80de\uff0c\u5229\u7528qRT-PCR\u68c0\u6d4b\u7ec6\u80de\u5185\u03b2III-tubulin mRNA\u7684\u53d8\u5316\u60c5\u51b5\uff0c\u5e76\u7b5b\u9009\u51fa\u6700\u4f73\u5e72\u6270\u5e8f\u5217\uff1bWestern blot\u6cd5\u68c0\u6d4bA549/Taxol\u7ec6\u80de\u5185\u03b2III-tubulin\u86cb\u767d\u8868\u8fbe\u7684\u53d8\u5316\uff1bMTT\u6cd5\u68c0\u6d4b\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u5bf9\u7d2b\u6749\u9187\u654f\u611f\u6027\u7684\u53d8\u5316\uff1b\u6d41\u5f0f\u7ec6\u80de\u4eea\u68c0\u6d4b\u7ec6\u80de\u5468\u671f\u548c\u7ec6\u80de\u51cb\u4ea1\u7684\u53d8 \u5316\u3002\u7ed3\u679c \u5b9e\u65f6\u8367\u5149qRT-PCR\u6cd5\u663e\u793a\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u9776\u57fa\u56e0\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u964d\u4f4e\uff0c\u5176\u4e2d\u03b2III-tubulin siRNA-1\u5e8f\u5217\u6291\u5236\u7387\u6700\u9ad8\u4e3a\uff0887.73\u00b14.87\uff09%\uff08P<0.01\uff09\uff1bWestern blot\u663e\u793a\u8f6c\u67d3\u540e\u9776\u86cb\u767d\u6c34\u5e73\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u964d\u4f4e\uff1bMTT\u6cd5\u8868\u660e\u7d2b\u6749\u9187\u5904\u7406\u8f6c\u67d3\u540e\u7ec6\u80de\u682a\u7684\u7ec6\u80de\u6291\u5236\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff0851.77\u00b14.60\uff09%\uff08P<0.01\uff09\uff1b\u7ec6\u80de\u51cb\u4ea1\u663e \u793a\u03b2III-tubulin siRNA+Taxol\u7ec4\u7ec6\u80de\u65e9\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u660e\u663e\u589e\u52a0\uff08P<0.01\uff09\uff0c\u4e24\u8005\u7684\u5dee\u5f02\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff1b\u7ec6\u80de\u5468\u671f\u68c0\u6d4b\u7ed3\u679c\u663e\u793a\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684G2/M\u671f\u7ec6\u80de\u767e\u5206\u7387\u9ad8\u4e8e\u5bf9\u7167\u7ec4\uff0c \u4e14\u8f6c\u67d3\u540e\u7d2b\u6749\u9187\u5904\u7406\u7ec4\u7684\u7ec6\u80de\u665a\u671f\u51cb\u4ea1\u7387\u8f83\u5bf9\u7167\u7ec4\u589e\u52a0\u3002\u7ed3\u8bba \u03b2III-tubulin\u8868\u8fbe\u4e0b\u8c03\u660e\u663e\u63d0\u9ad8A549/Taxol\u7ec6\u80de\u682a\u5bf9Taxol\u7684\u654f\u611f\u6027\u3002 DOI: 10.3779/j.issn.1009-3419.2014.08.01 PMID: 25130963 [PubMed - indexed for MEDLINE]  INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab is now allowed for non-small cell lung cancer (NSCLC) patients with brain metastases and non-squamous histology. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: Bevacizumab and erlotinib have been shown to improve survival in stage IV non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab, an anti-VEGF antibody, is currently approved for the treatment of advanced NSCLC in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " BACKGROUND: Bevacizumab combined with chemotherapy has become the first-line therapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " Bevacizumab (Bev), a monoclonal antibody against vascular endothelial growth factor, when combined with standard first-line chemotherapy, shows impressive clinical benefit in advanced non-squamous non-small cell lung cancer (ns-NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab, monoclonal antibodies targeting VEGF and the VEGFR, respectively, have each led to improvements in overall survival (OS) for NSCLC when added to standard first and second line chemotherapy, respectively. ", "disease": "NSCLC", "drug": "Bevacizumab"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, pemetrexed is indicated for use in the first-line, maintenance, and second-line settings for the treatment of nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study we compared volasertib, volasertib with pemetrexed, and pemetrexed alone in patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed after first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For treatment in the second-line for advanced or metastatic NSCLC, the combination of volasertib with standard pemetrexed did not increase toxicity significantly but also did not improve efficacy compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among patients with NSCLC who received pemetrexed for an extended time, those with ALK and ROS1 gene rearrangements were proportionally overrepresented compared with that anticipated in a general nonsquamous NSCLC population, and patients with oncogenic driver mutations had improved outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "From January 2007 to December 2010, 25 patients with stage IIIB or IV NSCLC (17 with adenocarcinoma and 8 with squamous cell carcinoma), who had previously failed on platinum-based chemotherapy, received pemetrexed 500 mg/mq every 3 weeks until disease progression or unacceptable toxicities. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This study was designed to evaluate the efficacy of combination treatment of pemetrexed plus oxaliplatin as second-line treatment in advanced/metastatic non-small cell lung cancer (NSCLC) patients who have failed first-line platinum-based chemotherapy, assuming that oxaliplatin can overcome the resistance to a platinum agent and translate into better outcome. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Because histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We investigated whether red blood cell (RBC) total folate, a phenotypic rather than genotypic, marker of cellular folate status was associated with the response to pemetrexed-based chemotherapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We conducted a prospective cohort study of patients with stage IV nonsquamous NSCLC receiving first-line chemotherapy containing pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: A low pretreatment RBC total folate was associated with an inferior response to pemetrexed-based chemotherapy in stage IV nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative US elderly population with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted a feasibility study of pemetrexed plus bevacizumab as a first-line treatment for advanced or recurrent nonsquamous NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among patients with NSCLC who received pemetrexed for an extended time, those with ALK and ROS1 gene rearrangements were proportionally overrepresented compared with that anticipated in a general nonsquamous NSCLC population, and patients with oncogenic driver mutations had improved outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  Although the clinical entity of bronchioloalveolar carcinoma (BAC) has been reclassified into adenocarcinoma in situ, lepidic predominant adenocarcinoma, and mucinous adenocarcinoma, it continues to merit special consideration based on its distinct natural history and response to therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our study aims to investigate whether the addition of Bev to pemetrexed improves progression-free survival (PFS) in advanced ns-NSCLC patients after the failure of at least one prior chemotherapy regimens. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combination of Bev and pemetrexed every 21 days is effective in ns-NSCLC patients who failed of prior therapies with improved PFS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our results may provide more a regimen containing Bev and pemetrexed for Chinese clinical practice in previously treated ns-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "DOI: 10.5114/kitp.2014.43841 PMCID: PMC4283868 PMID: 26336412 [PubMed]  OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative US elderly population with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to EGFR-wild-type cases. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We identified English-language literature (through March\u00a02015) involving completed and ongoing studies through searches of PubMed, meeting abstracts, ClinicalTrials.gov and the European Clinical Trials Register; search terms included 'pemetrexed,' 'NSCLC' and 'PS2'. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This literature search of concurrent pemetrexed and RT treatment of patients with stage III NSCLC included MEDLINE database, meeting abstracts, and the clinical trial registry database. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Of the ongoing trials, there is one phase III and four phase II trials with pemetrexed in locally advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous non-small cell lung cancer (non-sq NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of non-small cell lung cancer (NSCLC), thus making rebiopsy necessary for deciding on pemetrexed second-line treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, pemetrexed use is restricted to non-squamous histology. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MTHFR-C667T polymorphisms appear to predict survival differences in pemetrexed-treated NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Subgroup analyses of randomized studies have consistently shown that pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than squamous cell carcinoma and the combination of pemetrexed and platinum agents is recommended for first-line chemotherapy in advanced non-squamous NSCLC; however, there have been few prospective studies of a selected population. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Although the sample size was small, our results indicate that pemetrexed is a key drug for advanced non-squamous NSCLC, irrespective of the EGFR mutation status (UMIN-CTR number 000002451). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, with the current standard regimen of care for NSCLC including chemotherapy with pemetrexed as a single agent or in combination with platinum-based agents, e.g. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: NSCLC A549 and H460 cells were treated with pemetrexed for 72 h. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, pemetrexed is indicated for use in the first-line, maintenance, and second-line settings for the treatment of nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Histology could represent a positive predictive factor for patients with Non squamous NSCLC (Nsq-NSCLC) respect to pemetrexed treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This literature search of concurrent pemetrexed and RT treatment of patients with stage III NSCLC included MEDLINE database, meeting abstracts, and the clinical trial registry database. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Of the ongoing trials, there is one phase III and four phase II trials with pemetrexed in locally advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Compared with other platinum-based doublet chemotherapy, pemetrexed plus platinum is more effective and tolerable as the first-line treatment for nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, we examined the feasibility of using thoracic radiotherapy combined with concurrent full-dose pemetrexed as the first-line treatment for advanced nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: PARAMOUNT demonstrated a low incidence of low-grade toxicities with long-term pemetrexed exposure without compromising QoL in patients with NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS:: Retrospective analysis of all ns-NSCLC patients undergoing first-line treatment with pemetrexed-containing platinum doublet over 3\u00bd years was carried out. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Among ns-NSCLC patients treated with pemetrexed and with FAS of 400 to 1000 \u03bcg daily, HTox was not associated with either baseline tpHcy levels or with graded baseline FAS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous study showed a survival benefit with maintenance therapy with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Continuation maintenance chemotherapy with pemetrexed is associated with a survival benefit in patients who have completed induction chemotherapy for non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Preclinical experiments analyzed NCI-H2122 and NCI-H441 NSCLC cell lines and in vitro/in vivo models treated with pemetrexed and LY2603618 to provide rationale for evaluating this combination in a clinical setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous non-small cell lung cancer (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the association between thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR) and reduced folate carrier (SLC19A1) gene polymorphisms and the treatment efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The polymorphisms of the 5'-UTR of the TS gene and exon 6 (2522) C/T of the SLC19A1 gene predict the survival of advanced NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with non-small cell lung cancer (NSCLC), investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This phase I report of pemetrexed is dedicated to NSCLC with induction therapy and fixed high-dose RT. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: We completed a trial-based assessment, from the perspective of the Chinese health care system, of the cost-effectiveness of maintenance pemetrexed treatment after a CP strategy for patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "It was based on a clinical trial that compared continuation maintenance pemetrexed therapy plus best supportive care (BSC) versus placebo plus BSC after a CP strategy for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance of pemetrexed after a CP strategy for patients with advanced nonsquamous NSCLC is not cost-effective based on a recent clinical trial. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: To the best of our knowledge, this is the third case of TEN due to pemetrexed in a patient with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "An additional meta-analysis was performed to systematically evaluate pemetrexed/platinum as first-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Meta-analysis supports the use of pemetrexed-platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Expected toxicities from concurrent chemoradiation were not worsened with concurrent TRT at a total dose of 66 Gy combined with pemetrexed in Japanese patients with locally advanced (LA) nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous non-small-cell lung cancer (NSCLC) and PS 0-1. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Of the 42 patients with NSCLC treated with trametinib plus pemetrexed, six (14%) had a PR; the ORR was 17% (four of 23) in patients with KRAS-mutated NSCLC versus 11% (two of 19) in KRAS wild-type NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Docetaxel or pemetrexed is the standard treatment for recurrent advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, the optimal use including treatment schedule of pemetrexed and other drugs in clinical practice remains to be determined, particularly for NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present study investigated a\u00a0potential therapeutic strategy for NSCLC patients with wild-type EGFR who were treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to evaluate the association between polymorphisms of TS and MHFR genes and clinical outcomes in NSCLC patients treated with pemetrexed monotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "DNA was isolated from peripheral blood of 72 non-squamous NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Previously reported superior tumor response of pemetrexed in the second-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) has never been confirmed in real-world studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of pemetrexed in elderly (\u226575) Japanese patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Although this study did not meet our primary endpoint, pemetrexed showed favorable antitumor activity with mild toxicity in elderly patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Because histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant non-small-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, the optimal use including treatment schedule of pemetrexed and other drugs in clinical practice remains to be determined, particularly for NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present study investigated a\u00a0potential therapeutic strategy for NSCLC patients with wild-type EGFR who were treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among patients with advanced NSCLC, pemetrexed-based doublet treatment tended to be associated with improved PFS, ORR, and increased toxicity, but not OS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) to prolong overall survival after first-line therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "An additional meta-analysis was performed to systematically evaluate pemetrexed/platinum as first-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Meta-analysis supports the use of pemetrexed-platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous non-small-cell lung cancer (NSCLC) and PS 0-1. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative US elderly population with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of non-small cell lung cancer (NSCLC), thus making rebiopsy necessary for deciding on pemetrexed second-line treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The phase II portion accrued 37 pts before early closure due to increasing first-line pemetrexed/platinum doublet use in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Hence, an open-label, randomized trial (PEMVITASTART [Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy]; ClinicalTrials.gov identifier, NCT02679443) is being undertaken to evaluate whether any differences exist in pemetrexed-related hematologic toxicity among patients who receive delayed initiation of chemotherapy (after 5-7 days of vitamin B12 and FA supplementation [delayed arm]) compared with those for whom vitamin B12 and FA supplementation is started simultaneously (within 24 hours) of chemotherapy initiation (immediate arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10\u00a0mg/kg), given every 14 days in patients with untreated, advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with dose-dense pemetrexed, gemcitabine, and bevacizumab met the primary endpoint with promising efficacy and a manageable safety profile in patients with untreated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Estimating a 30% reduction in acquisition costs for pemetrexed (Alimta\u00aeEli Lilly Nederland B.V.), due to the forthcoming launch of generic medications, the cis/pem treatment would become the predominant alternative for 1st line treatment of NSCLC patients, by offering the best health results at a lower cost. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Because histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: In this study, we investigated whether single nucleotide polymorphisms (SNPs) in folylpoly-\u03b3-glutamate synthase (FPGS), which catalyzes the polyglutamation of pemetrexed (PEM), is related to FPGS expression and the response to PEM in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta\u00ae) in surgically resected non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant non-small-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m(2) provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it\u00b4s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Of the 42 patients with NSCLC treated with trametinib plus pemetrexed, six (14%) had a PR; the ORR was 17% (four of 23) in patients with KRAS-mutated NSCLC versus 11% (two of 19) in KRAS wild-type NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study sought to evaluate thymidylate synthase (TS) as a predicting biomarker for pemetrexed continuation maintenance treatment in NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our results indicate that in NSCLC patients treated with pemetrexed continuation maintenance therapy, low TS expression is associated with improved PFS and OS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We investigated whether red blood cell (RBC) total folate, a phenotypic rather than genotypic, marker of cellular folate status was associated with the response to pemetrexed-based chemotherapy in advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We conducted a prospective cohort study of patients with stage IV nonsquamous NSCLC receiving first-line chemotherapy containing pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: A low pretreatment RBC total folate was associated with an inferior response to pemetrexed-based chemotherapy in stage IV nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Combination of pemetrexed and astaxanthin resulted in synergistic enhancing cytotoxicity and cell growth inhibition in NSCLC cells, accompanied with reduced activation of phospho-MKK1/2, phopho-ERK1/2, and TS expression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our findings suggested that the down-regulation of MKK1/2-ERK1/2-mediated TS expression by astaxanthin is an important regulator of enhancing the pemetrexed-induced cytotoxicity in NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We investigated pemetrexed-based treatment efficacy in ROS1 translocation NSCLC patients and determined the expression of thymidylate synthetase (TS) to provide a rationale for the efficacy results. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For comparison, we evaluated the TS mRNA status and pemetrexed-based treatment efficacy from 170 NSCLC patients with anaplastic lymphoma kinase (ALK) translocation (n\u00a0=\u00a046), EGFR mutation (n\u00a0=\u00a050), KRAS mutation (n\u00a0=\u00a032), and wild-type of EGFR/ALK/ROS1/KRAS (n\u00a0=\u00a042). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Next, using a mouse model of NSCLC, we validated the kinetics of the pemetrexed-mediated \"flare\" in thymidine salvage pathway activity in vivo using FLT-PET imaging. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In NSCLC cells in vitro, we identified a burst in pemetrexed-mediated thymidine salvage pathway activity, assessed by 3H-thymidine assays, thymidine kinase 1 (TK1) expression, and equilibrative nucleoside transporter 1 (ENT1) mobilization to the cell membrane, that peaked at 2hrs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This 2hr time-point was also optimal for FLT-PET imaging of pemetrexed-mediated TS inhibition in murine xenograft tumors and was demonstrated to be feasible in a NSCLC patient. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: To assess the cost-effectiveness of first-line pemetrexed/platinum and other commonly administered regimens in a representative US elderly population with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, few studies have focused on cisplatin/pemetrexed with bevacizumab as the first-line therapy to treat advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: We speculate that bevacizumab in combination with cisplatin/pemetrexed as the first-line therapy is well tolerated and results in a clinically meaningful treatment benefit, irrespective of the gene drive type in advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, phase III trials of crizotinib have demonstrated superior efficacy compared to platinum-pemetrexed in the first-line setting and standard chemotherapy in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The findings of clinical trials and theoretical studies about the current pemetrexed/cisplatin in the treatment of nonsquamous NSCLC with BM are also summarized to provide a reference for the application of pemetrexed/cisplatin in nonsquamous NSCLC with BM. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Whether or not pemetrexed/cisplatin is definitely effective in nonsquamous NSCLC with BM must be proven by subsequent phase III clinical trials. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with stage IV nonsquamous NSCLC and a performance status of 0 to 1 were randomized (1:1) to receive 20 mg/kg cixutumumab, 500 mg/m(2) pemetrexed, and 75 mg/m(2) cisplatin (cixutumumab [n\u00a0= 87]) or pemetrexed and cisplatin (control [n\u00a0= 85]). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Efficacy was not improved in patients with nonsquamous NSCLC when cixutumumab was added to pemetrexed/cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: We compared the clinical and molecule pathological characteristics of good and poor responders among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed therapy between November 2006 and February 2015. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should be considered when administering pemetrexed therapy for non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of pemetrexed-based first-line chemotherapy in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has been demonstrated in several studies; however, there is a lack of data from Chinese populations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: The clinicopathological characteristics and treatment outcomes of 52 patients with ALK-positive advanced NSCLC who received pemetrexed as first-line chemotherapy at the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences were retrospectively reviewed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase II trial assessed the overall response rate, safety, and pharmacokinetics (PK) of LY2603618 and pemetrexed in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Methods In this open-label, single-arm trial, patients with advanced or metastatic NSCLC progressing after a prior first-line treatment regimen (not containing pemetrexed) and Eastern Cooperative Oncology Group performance status \u22642 received pemetrexed (500\u00a0mg/m(2), day 1) and LY2603618 (150\u00a0mg/m(2), day 2) every 21\u00a0days until disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Conclusions There was no significant clinical activity of LY2603618 and pemetrexed combination therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Docetaxel or pemetrexed is the standard treatment for recurrent advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "During the last decade, pemetrexed, an antifolate agent, gradually became a key component of the treatment for patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, more than 400 trials of pemetrexed for the treatment of nonsquamous NSCLC are ongoing. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thymidylate synthase (TS) expression is recognized as a potential predictor of the response to pemetrexed-based chemotherapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: The records of non-squamous NSCLC patients without driver mutations who received pemetrexed monotherapy as a second or later line of chemotherapy at Kitasato University Hospital between March 2009 and October 2015 were retrospectively reviewed, and the treatment outcomes were evaluated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical data obtained in this study may provide a valuable basis for the use of smoking status as a predictor of pemetrexed monotherapy in wild-type NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted a feasibility study of pemetrexed plus bevacizumab as a first-line treatment for advanced or recurrent nonsquamous NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to EGFR-wild-type cases. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This trial assessed the efficacy and safety of high-dose pemetrexed plus cisplatin in NSCLC with brain metastases after WBRT. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we developed and validated a prediction model for estimating absolute treatment effect of pemetrexed plus carboplatin versus single-agent pemetrexed in the second-line treatment of non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Using data of relapsed patients with advanced non-squamous NSCLC from the NVALT-7 trial, a Weibull model for prediction of gain in median progression-free survival (PFS) by pemetrexed-carboplatin was derived based on patient and tumor characteristics. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "There is important heterogeneity in the effects on PFS of pemetrexed-carboplatin versus pemetrexed in pretreated patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To assess the efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell lung cancer (NSCLC) through a trial-level meta-analysis. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: A total of 2,551 patients with advanced nonsquamous NSCLC from ten trials were included for analysis: 1,565 patients were treated with pemetrexed plus platinum doublet chemotherapy and 986 with platinum plus other first-line chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "When compared to other platinum-based doublet chemotherapies, the use of pemetrexed plus platinum chemotherapy significantly improved OS (hazard ratio [HR] =0.86, 95% CI: 0.77-0.97, P=0.01) but not PFS (HR =0.90, 95% CI: 0.80-1.01, P=0.084) in advanced nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our findings support the use of pemetrexed plus platinum doublet regimen as first-line treatment in advanced nonsquamous NSCLC patients because of its potential survival benefits. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, with the current standard regimen of care for NSCLC including chemotherapy with pemetrexed as a single agent or in combination with platinum-based agents, e.g. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: NSCLC A549 and H460 cells were treated with pemetrexed for 72 h. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In the present single-arm phase II trial, patients with previously untreated, unresectable stage IIIA-IIIB NSCLC (all histologic types) were treated with pemetrexed-cisplatin (500 mg/m(2) intravenously on days 1 and 22, 20 mg/m(2) intravenously on days 1-5 and days 22-26) concurrent with radiotherapy (61-66 Gy in 31-35 fractions), followed by 2 cycles of consolidation pemetrexed-cisplatin (75 mg(2)) therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was undertaken to investigate the efficacy and safety of adding regulatory T cell inhibitor cyclophosphamide to pemetrexed therapy for the second-line treatment of NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present study showed that pemetrexed in combination with low-dose cyclophosphamide may be a better treatment approach than pemetrexed monotherapy when considering second-line treatment for wild-type EGFR NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: We performed a phase I study evaluating the combination of pemetrexed and temsirolimus in advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present review summarizes the main findings on NSCLC pharmacogenetics, critically reappraising the most important studies on polymorphisms correlated with outcome of pemetrexed and EGFR-inhibitors, and provides perspective on clinical application of genomic tests for treatment decision-making. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PROFILE 1014 compared crizotinib to up to six cycles of standard platinum-pemetrexed chemotherapy as the first line treatment of advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Specifically, the benefit of the control arm (platinum-pemetrexed), although inferior to that of crizotinib, was remarkable and expands the dataset on the increased sensitivity of ALK+ NSCLC to pemetrexed; (III) identifying the central nervous system (CNS) as a key battleground for metastatic NSCLC, especially for ALK+ disease. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " A phase I study recommended carboplatin (CBDCA, area under the curve\u00a0=\u00a05) plus pemetrexed (PEM, 500\u00a0mg/m(2)) for elderly patients (\u226575-years old) with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This open-label, phase I, dose-escalation part of a phase I/II study evaluated the safety, pharmacokinetics, and preliminary efficacy of nintedanib, a triple angiokinase inhibitor, combined with pemetrexed in Japanese patients with advanced non-small cell lung cancer (NSCLC) after first-line chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Nintedanib plus pemetrexed had a manageable safety profile and showed promising signs of efficacy in previously treated Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We identified English-language literature (through March\u00a02015) involving completed and ongoing studies through searches of PubMed, meeting abstracts, ClinicalTrials.gov and the European Clinical Trials Register; search terms included 'pemetrexed,' 'NSCLC' and 'PS2'. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In a phase\u00a03 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed\u2011carboplatin versus pemetrexed experienced improved overall survival [hazard ratio\u00a0(HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The purpose of this study was to quantitatively assess the impact of TYMS gene expression in tumor cells as a predictor of the efficacy of pemetrexed therapy in patients with advanced non-small cell lung cancer (NSCLC) treated at our institution. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Sixty-two NSCLC patients were included in this study: 16 patients received platins-pemetrexed as first-line NSCLC, and 46 pemetrexed in monotherapy as second- or subsequent-line treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: TYMS overexpression in tumor cells correlated with a reduced response to pemetrexed-containing chemotherapy and might be used as a predictive biomarker in advanced NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, the optimal use including treatment schedule of pemetrexed and other drugs in clinical practice remains to be determined, particularly for NSCLC with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present study investigated a\u00a0potential therapeutic strategy for NSCLC patients with wild-type EGFR who were treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The cell growth assay confirmed that treatment with pemetrexed followed by erlotinib significantly inhibited proliferation of NSCLC cells regardless of EGFR mutation status. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, use of erlotinib at the time of progression after pemetrexed therapy confers a\u00a0survival benefit in NSCLC patients with wild-type EGFR. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Since the data of pemetrexed in combination with cisplatin were published, several oncologists chose this schedule as first choice in non squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Based on this retrospective analysis, platinum combination with pemetrexed resulted in a better disease control rate and a tendency toward prolongation of progression-free survival in NSCLC patients who progressed after first-line EGFR TKIs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, pemetrexed is indicated for use in the first-line, maintenance, and second-line settings for the treatment of nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we determined whether autophagy could be induced by pemetrexed and simvastatin cotreatment in malignant mesothelioma and NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Malignant mesothelioma MSTO-211H and A549 NSCLC cells were treated with pemetrexed and simvastatin alone and in combination to evaluate their effect on autophagy and apoptosis. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Cotreatment with pemetrexed and simvastatin induced greater caspase-dependent apoptosis and autophagy than either drug alone in malignant mesothelioma and NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our data indicate that pemetrexed and simvastatin cotreatment augmented apoptosis and autophagy in malignant mesothelioma and NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Inhibition of pemetrexed and simvastatin-induced autophagy was shown to enhance apoptosis, suggesting that this could be a novel therapeutic strategy against malignant mesothelioma and NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Erlotinib, bevacizumab, and pemetrexed improved survival of metastatic non-small cell lung cancer (mNSCLC) in clinical trials, but their benefits are restricted to non-squamous histology. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to evaluate the association between polymorphisms of TS and MHFR genes and clinical outcomes in NSCLC patients treated with pemetrexed monotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "DNA was isolated from peripheral blood of 72 non-squamous NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In addition, subgroup analyses indicated that improved OS was only observed in nonsquamous NSCLC patients who received the combination of pemetrexed and erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among patients with advanced NSCLC, pemetrexed-based doublet treatment tended to be associated with improved PFS, ORR, and increased toxicity, but not OS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we showed that chemoresistance to pemetrexed, a multi-target anti-folate (MTA) chemotherapeutic agent for non-small cell lung cancer (NSCLC), is associated with a stem cell-like phenotype characterized by an enriched stem cell gene signature, augmented aldehyde dehydrogenase activity and greater clonogenic potential. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A cost-effectiveness analysis was conducted based on a randomized phase III trial in patients with advanced non-small cell lung cancer (NSCLC) and ECOG performance status of 2 (PS2), comparing doublet regimen pemetrexed plus carboplatin with pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our study suggests superiority of the combined pemetrexed plus carboplatin regimen in terms of efficacy as well as cost-effectiveness in advanced NSCLC patients with a poor performance status of 2. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of the present study was to retrospectively evaluate the feasibility of cisplatin/pemetrexed/bevacizumab (CPB) therapy at a bevacizumab (BEV) dose of 15 mg/kg as a first-line chemotherapeutic strategy for patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, patients positive for the EML4-ALK fusion gene in NSCLC tissues are likely to have a low expression level of TYMS, and may benefit from the first-line chemotherapy drug pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Considering the disease control rate and the tolerance of patients with advanced NSCLC, pemetrexed is strongly recommended to be used in clinical. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2015.06.07 PMID: 26104894 [PubMed - indexed for MEDLINE]  OBJECTIVES: To evaluate the feasibility and adherence to home delivery (HD) of pemetrexed maintenance treatment in patients with advanced non-squamous non-small cell lung cancer (nsqNSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: HD of pemetrexed maintenance treatment in patients with advanced nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study we compared volasertib, volasertib with pemetrexed, and pemetrexed alone in patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed after first-line platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For treatment in the second-line for advanced or metastatic NSCLC, the combination of volasertib with standard pemetrexed did not increase toxicity significantly but also did not improve efficacy compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Histology could represent a positive predictive factor for patients with Non squamous NSCLC (Nsq-NSCLC) respect to pemetrexed treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of this study is to determine the profile of the use of pemetrexed in metastatic or locally advanced NSCLC in Andalusia and its variation over 2 years (2010-2011). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the first term of 2010 or the last term of 2011 were included. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In conclusion, pemetrexed combined with platinum is mainly used as first-line treatment in NSCLC patients with stage IV, adenocarcinoma histologic subtype and good performance status. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "An adequate therapeutic positioning for pemetrexed based on effectiveness and safety analysis should be defined, so that NSCLC patients could be beneficiated with the most cost-effective chemotherapy treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this regard, we have synthesized Pem-PEG-Gem, wherein pemetrexed (Pem) and gemcitabine (Gem) are conjugated to a heterobifunctional polyethylene glycol (PEG) polymer for the effective treatment of Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was the evaluation of the impact of pemetrexed on erythrocyte mean corpuscular volume (MCV) change and its possible correlation with disease control rate (DCR), progression free (PFS) and overall survival (OS) in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: A retrospective collection of clinical and laboratory data (including basal MCV and maximum MCV occurred during therapy) in advanced NSCLC patients treated with pemetrexed at seven Italian centers was performed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Liver toxicity (LT) is a common side effect of pemetrexed (PEM); however, the effect of LT on clinical outcome has not been investigated in patients with non-small-cell lung cancer (NSCLC) treated with PEM. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Plasma samples from 40 patients with stage IV adeno-NSCLC, treated with first-line chemotherapy with carboplatin (AUC5) plus pemetrexed (500 mg/m(2)), were collected prior to chemotherapy and 48 h after treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m/(2)) and pemetrexed (500 mg/m(2)) as a first-line treatment for advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the present study, we investigated the involvement of reactive oxygen species (ROS) and sirtuin 1 (SIRT1) in pemetrexed-induced apoptosis in MSTO-211 malignant mesothelioma cells and A549 NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These results show that pemetrexed induces apoptosis in MSTO-211 mesothelioma cells and A549 NSCLC cells through mitochondrial dysfunction mediated by ROS accumulation and SIRT1 downregulation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report on a dose-escalation study of lapatinib combined with pemetrexed in second-line treatment to evaluate the safety and efficacy in advanced or metastatic non-small-cell lung cancer (NSCLC) and an exploratory study in which circulating cell-free thymidylate synthase ribonucleic acid (cfTSmRNA) was measured in all patients and compared with clinical benefit. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGFR mutations who failed first-line EGFR TKI. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with metastatic NSCLC received pemetrexed (with or without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line platinum-based chemotherapy or as subsequent treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among patients with NSCLC who received pemetrexed for an extended time, those with ALK and ROS1 gene rearrangements were proportionally overrepresented compared with that anticipated in a general nonsquamous NSCLC population, and patients with oncogenic driver mutations had improved outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  The purpose of this study was to explore the predictive factors of the effectiveness and treatment toxicity for pemetrexed as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, a decrease in estimated Ccr was associated with a increased risk of Grade 3/4 neutropenia and anemia.BACKGROUND: The purpose of this study was to explore the predictive factors of the effectiveness and treatment toxicity for pemetrexed as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC treated with pemetrexed as continuation maintenance therapy were enrolled. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This literature search of concurrent pemetrexed and RT treatment of patients with stage III NSCLC included MEDLINE database, meeting abstracts, and the clinical trial registry database. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Of the ongoing trials, there is one phase III and four phase II trials with pemetrexed in locally advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "While results from the ongoing phase III PROCLAIM trial are needed to address definitively the efficacy of pemetrexed-cisplatin plus RT in stage III NSCLC, available results from phase II trials suggest that this regimen has promising activity with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Compared with other platinum-based doublet chemotherapy, pemetrexed plus platinum is more effective and tolerable as the first-line treatment for nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, we examined the feasibility of using thoracic radiotherapy combined with concurrent full-dose pemetrexed as the first-line treatment for advanced nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "From January 2009 to July 2012, 41 patients with stage IIIB or IV nonsquamous NSCLC were treated with full-dose pemetrexed plus cisplatin as the first-line chemotherapy combined with concurrent thoracic radiotherapy, with or without radiotherapy for metastases. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "As the first-line treatment for selected patients with advanced nonsquamous NSCLC, thoracic radiotherapy combined with concurrent full-dose pemetrexed plus cisplatin was safe and highly tolerable. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we investigated whether H9, and/or co-treatment with an anticancer drug, pemetrexed (PEM), inhibited tumor growth in BALB/c nude mice models bearing A549 NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Cisplatin with pemetrexed (CP) and carboplatin with paclitaxel and bevacizumab (CbTB) are standard first-line treatments for patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with untreated stage IIIB/IV NS-NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2), every 3 weeks, for 6 cycles followed by maintenance pemetrexed; or carboplatin area under the curve 6, paclitaxel 200 mg/m(2), and bevacizumab 15 mg/kg, every 3 weeks, for 6 cycles followed by maintenance bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This study was designed to determine the recommended dose of carboplatin and pemetrexed for elderly (\u226570-year-old) chemotherapy-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly chemotherapy-na\u00efve patients with advanced nonsquamous NSCLC, the combination of carboplatin AUC 5 plus pemetrexed 500 mg/m(2) is recommended as a promising regimen; however, a reduction of the pemetrexed dose may be required for patients with renal dysfunction because of the high risk of hematotoxicities. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The study analyzed a cohort of non-squamous NSCLC patients treated in an adjuvant setting by combined cisplatin (75 mg/m(2)) and pemetrexed (500 mg/m(2)), under vitamin B12 and folic acid cover, 4 cycles at 21-day intervals. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our study aims to investigate whether the addition of Bev to pemetrexed improves progression-free survival (PFS) in advanced ns-NSCLC patients after the failure of at least one prior chemotherapy regimens. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combination of Bev and pemetrexed every 21 days is effective in ns-NSCLC patients who failed of prior therapies with improved PFS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our results may provide more a regimen containing Bev and pemetrexed for Chinese clinical practice in previously treated ns-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients \u226518 years of age with stage IV nonsquamous NSCLC (American Joint Committee on Cancer v7.0), and Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 500 mg/m, carboplatin, area under the curve = 6) followed by Pem maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m, carboplatin, area under the curve = 6, and bevacizumab, 15 mg/kg) followed by Bev maintenance in the absence of progressive disease or discontinuation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-na\u00efve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Overall, pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab, was effective and tolerable in the patients with non-squamous NSCLC, and the time to response was relatively short. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression-free survival in individuals with EGFR-mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Since high levels of TS have been linked to clinical resistance to pemetrexed in NSCLC, herein we investigated the molecular and functional effects of combined pemetrexed and ITF2357, a pan-HDACi currently in clinical trials as an anti-cancer agent. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In vivo experiments in NSCLC xenografts confirmed that sequential pemetrexed/ITF2357 is feasible and results in increased inhibition of tumor growth and increased mice survival. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Overall, these data provide a strong rationale for the clinical development of sequential schedules employing pemetrexed followed by HDACi in NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase II study evaluated the response rate (RR) and safety of combination therapy with carboplatin (CBDCA) and pemetrexed (PEM) in Japanese patients with non-squamous non-small cell lung cancer (non-sq NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Rechallenge chemotherapy with pemetrexed was shown to be efficient in malignant pleural mesothelioma; however, its role in non-small-cell lung cancer (NSCLC) has not been investigated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we retrospectively enrolled 31 patients with non-squamous NSCLC who had achieved disease control with initial pemetrexed treatment, followed by rechallenge with pemetrexed-based chemotherapy (PBC) upon disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We report exploratory gene-expression profiling data from a single-arm Phase-II-study in patients with non-squamous (ns)NSCLC treated with pemetrexed and cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Treatment-na\u00efve nsNSCLC patients (IIIB/IV) received 4 cycles of pemetrexed/cisplatin; non-progressing patients continued on pemetrexed-maintenance. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Previously reported superior tumor response of pemetrexed in the second-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) has never been confirmed in real-world studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We found that combining pemetrexed with GMX1777 produced a synergistic therapeutic benefit in A549 and H1299 NSCLC cells in vitro and in a mouse A549 xenograft model of lung cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These findings provide a mechanistic rationale for combining GMX1777 with pemetrexed as an effective new therapeutic strategy to treat nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation of at least one of the drugs used in the induction therapy in the absence of disease progression.Several phase III trials have reported survival benefits with continuation maintenance of pemetrexed and switch maintenance of pemetrexed or erlotinib.Therefore, maintenance therapy has become a part of the standard first-line treatment for advanced NSCLC.However, further research is needed to elucidate the selection criteria of patients who may benefit the most from maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: PARAMOUNT demonstrated a low incidence of low-grade toxicities with long-term pemetrexed exposure without compromising QoL in patients with NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we investigated whether combination treatment with pemetrexed and simvastatin potentiates the apoptotic activity above that is seen with either drug alone in malignant mesothelioma and NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We found that the combination of pemetrexed and simvastatin induced more extensive caspase-dependent apoptosis than either drug alone in malignant mesothelioma cells (MSTO-211) or NSCLC cells (A549). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS:: Retrospective analysis of all ns-NSCLC patients undergoing first-line treatment with pemetrexed-containing platinum doublet over 3\u00bd years was carried out. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Among ns-NSCLC patients treated with pemetrexed and with FAS of 400 to 1000 \u03bcg daily, HTox was not associated with either baseline tpHcy levels or with graded baseline FAS. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m(2)+cisplatin 75mg/m(2) (day 1), or gemcitabine 1250mg/m(2) (days 1 and 8)+cisplatin 75mg/m(2) (day 1). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous non-small-cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Specimens from 160 advanced NSCLC patients receiving pemetrexed-based chemotherapy were assessed for membranous FRA and EGFR protein expression using immunohistochemistry and the Hybrid (H)-score. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our findings suggested different possible strategies of overcoming the resistance of topotecan and pemetrexed in the NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate the feasibility and safety of retreatment the pemetrexed after the failure prior pemetrexed-based chemotherapy in non-small cell lung cancer (NSCLC) from our institute. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Retreatment of pemetrexed seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of initial pemetrexed therapy, especially for the patients with a PFS more than 6 months in the initial pemetrexed treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: A previous study showed a survival benefit with maintenance therapy with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Here, we present our phase II study that assessed the efficacy and safety of cisplatin plus pemetrexed as induction chemotherapy, followed by maintenance therapy with pemetrexed in advanced NSCLC patients in Japan. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Continuation maintenance chemotherapy with pemetrexed is associated with a survival benefit in patients who have completed induction chemotherapy for non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Preclinical experiments analyzed NCI-H2122 and NCI-H441 NSCLC cell lines and in vitro/in vivo models treated with pemetrexed and LY2603618 to provide rationale for evaluating this combination in a clinical setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This is the case report of a patient with NSCLC harboring EML4-ALK rearrangement, who experienced slowly progressive disease within 4 years of maintenance treatment with pemetrexed and later exhibited a marked response to crizotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Forty-six patients with advanced NSCLC were enrolled for a bioequivalence study of two pemetrexed formulations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This study evaluated the efficacy and safety of pemetrexed and carboplatin (CBDCA) or cisplatin (CDDP) followed by maintenance pemetrexed for cases of advanced non-squamous non-small cell lung cancer (NSCLC) that were treated in our hospital. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction is recommended as a first-line treatment for patients who have advanced non-squamous NSCLC and as a maintenance strategy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study showed that stimulation with pemetrexed induced S-phase arrest and cell apoptosis and a parallel increase in sustained Akt phosphorylation and nuclear accumulation in the NSCLC A549 cell line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The safety and effectiveness of pemetrexed(PEM)in patients with non-small cell lung cancer(NSCLC)were reviewed using data from post-marketing surveillance. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The results predict that in nonsquamous NSCLC tumors, reversible S-phase suppression by dexamethasone, possibly combined with a reduction in the drug transporters, attenuates responsiveness to pemetrexed and that GR status is a principal determinant of tumor variability of this response. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: We studied whether thymidylate synthase (TS) genotype has an independent prognostic/predictive impact on a European population of advanced non-small cell lung cancer (NSCLC) patients receiving pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed+erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Proliferation studies demonstrated higher responsiveness to methotrexate, pemetrexed, and other antifolates in KRAS-mutant NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Here, we show that the combination of rapamycin and pemetrexed synergistically inhibits proliferation of NSCLC cells. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In vivo, the combination of rapamycin and pemetrexed inhibited growth of NSCLC xenografts, which correlated with decreased mTOR activity and suppression of pemetrexed-induced TS expression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The ability of rapamycin to enhance the efficacy of pemetrexed and prevent TS expression has implications for the design of Phase I and/or Phase II NSCLC clinical trials with mTOR inhibitors in combination with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combination of pemetrexed and carboplatin has exhibited significant antitumor activity, with mild manageable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), whereas cerebral arterial embolism has not been recognized as a side effect associated with this regimen. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "As a result, pemetrexed monotherapy might be considered as a good option in the treatment of elderly patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This meta-analysis is performed to provide an assessment of whether expression variations of TS are associated with objective response in patients with NSCLC treated with pemetrexed-containing chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A systemic review of the studies on the association between TS expression in NSCLC and objective response of pemetrexed-containing regimen was performed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: -/low expression of TS was associated with higher objective response in NSCLC patients treated with pemetrexed-containing chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "TS may be a suitable marker of sensitivity to pemetrexed-based chemotherapy in patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "AIM OF THE REVIEW: To evaluate the efficacy and safety of pemetrexed in NSCLC, in the different therapy lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In first-line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable choice in patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The current study aimed at investigating whether TS expression changes during non-pemetrexed chemotherapy of non-small cell lung cancer (NSCLC), thus making rebiopsy necessary for deciding on pemetrexed second-line treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To explore the association between different epidermal growth factor receptor (EGFR) mutation status and survival in pemetrexed-based chemotherapy for advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Median progression-free survival (PFS) was determined.For comparison, median PFS was evaluated for EGFR-positive,EGFR-negative versus EGFR mutation unknown NSCLC patients in first-line pemetrexed therapy and pemetrexed maintenance therapy groups. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we evaluated the effects of pemetrexed on NSCLC cell lines (H520 and H1703) and found that treatment with this drug at 20-50 \u00b5M increased the MSH2 mRNA and protein levels in a MKK3/6-p38 MAPK signal activation-dependent manner. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The expression of constitutively active MKK6 (MKK6E) or HA-p38 MAPK vectors significantly rescued the decreased p38 MAPK activity, and restored the MSH2 protein levels and cell survival in NSCLC cells co-treated with pemetrexed and Hsp90 inhibitor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-na\u00efve patients with advanced NSCLC with activating EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC with performance status 0 to 1 progressive after first-line chemotherapy were eligible for randomization to pemetrexed, sunitinib, or the combination. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Furthermore, the superiority of cisplatin/pemetrexed over cisplatin/gemcitabine in non-squamous NSCLC has not been confirmed prospectively. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MILES-3 and MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the first-line therapy of elderly patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These platinum combinations consist of cis- or carboplatin with gemcitabine, while, for non-squamous NSCLC and mesothelioma, of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To determine clinical efficacy, safety and prognostic factors of pemetrexed plus platinum as first- line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Clinical characteristics, short-term efficacy, survival and adverse reactions of 47 advanced non-squamous NSCLC patients who had received pemetrexed plus platinum as first-line treatment in Shanghai Pulmonary Hospital from January 2009 to June 2011 were retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: NSCLC patients with brain metastasis benefited from pemetrexed and/or tyrosine kinase inhibitors along with localized treatments, and the graded prognostic assessment index is a robust model for prognostic evaluation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " AIM: We conducted a phase II study to evaluate the efficacy and safety of pemetrexed continuation-maintenance after carboplatin-based induction for advanced non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Thirty-four patients with advanced or recurrent non-squamous NSCLC received carboplatin (area under the concentration-time curve 6 mg/ml\u00d7min) plus pemetrexed (500 mg/m(2)) on day 1 tri-weekly. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 50 patients with advanced non-squamous NSCLC treated with cisplatin and pemetrexed as first-line chemotherapy were analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate first-line treatment option for elderly patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted phase II study to evaluate the safety and efficacy of pemetrexed in Japanese patients with previously heavily treated, advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB or IV non-squamous NSCLC, performance status (PS) 0-2, previous two to five regimens of chemotherapy were enrolled and received pemetrexed (500 mg/m(2)) on day 1 every 21 days until disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed in previously heavily treated Japanese non-squamous NSCLC patients is feasible and shows encouraging activity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Even if most meta-analyses in NSCLC yielded contradictory results, a number of candidate biomarkers for response/resistance to conventional chemotherapeutic agents such as gemcitabine, platinum-compounds, pemetrexed and taxanes have been proposed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this study, we evaluated the effects of a novel CHK1 inhibitor, MK-8776, in combination with pemetrexed (PMX) on cell proliferation and survival in a panel of p53 mutant non-small cell lung cancer (NSCLC) cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The PARAMOUNT study recently updated for survival analysis, showed that continuous maintenance with pemetrexed (P) lead to a 3 months overall survival (OS) benefit in non-small cell lung cancer (NSCLC) patients not progressing after P-based induction chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Observational and preclinical studies suggested an association between the expression of thymidylate synthase (TS) and clinical effects of pemetrexed-based chemotherapy in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of the study was to further appraise the association between the expression of TS and clinical efficacy pemetrexed-based chemotherapy in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "There was a significant association between TS expression and outcomes of pemetrexed-based chemotherapy for NSCLC (PFS: HR = 0.63 95 % CI 0.52, 0.76; OS: HR = 0.74, 95 % CI: 0.63, 0.88). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This meta-analysis evaluated the predictive value of TS and provided evidence that NSCLC patients with lower TS expression could significantly benefit from pemetrexed-based chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Agents such as carboplatin, taxanes, gemcitabine, irinotecan and pemetrexed proved to be effective in NSCLC with reduced or no nephrotoxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The predictive value of thymidylate synthase (TYMS) to sensitivity to pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is controversial. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted a meta-analysis of all relevant published data to assess the association of TYMS expression with the clinical outcomes of pemetrexed-based regimen in advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The phase II portion accrued 37 pts before early closure due to increasing first-line pemetrexed/platinum doublet use in non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This retrospective observational study evaluated cost effectiveness of first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with pemetrexed/platinum (Pem/Plat) relative to paclitaxel/carboplatin (Pac/Carbo) and paclitaxel/carboplatin/bevacizumab (Pac/Carbo/Bev). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Retrospective analyses suggest enhanced sensitivity to pemetrexed in crizotinib naive ALK+ NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Crizotinib and pemetrexed are active drugs in ALK+ NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to assess the predictive value of RFC expression in patients receiving pemetrexed for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: The study was carried out in a population of 48 patients with advanced NSCLC which have received pemetrexed monotherapy in second and third line. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This prospective observational study evaluated the effect of race on disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in patients with NSCLC treated with second-line pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligibility criteria included stage IIIB or IV NSCLC patients receiving single-agent pemetrexed for second-line therapy in routine clinical practice. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Although pemetrexed/cisplatin (P-C) is a standard treatment for advanced non-squamous non-small cell lung cancer (Nsq-NSCLC), neither its efficacy nor the effects of potential differences between driver mutations, such as the anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) mutations, have been thoroughly examined. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of pemetrexed and cisplatin was effective and safe in Japanese patients with Nsq-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Forty-two inoperable stage IIIB (with pleural effusion) and IV NSCLC patients who had had tumor progression received pemetrexed 500 mg/m(2) iv q3w together with daily TTFields therapy until disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of TTFields and pemetrexed as a second line therapy for NSCLC is safe and potentially more effective than pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This randomised controlled phase 2 study compared pemetrexed and erlotinib in combination with either agent alone in terms of efficacy and safety as second-line treatment in a clinically selected population of never-smokers with non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seventy patients aged 70 years or over with stage IIIb-IV NSCLC were equally and randomly divided into pemetrexed plus cisplatin group (PC) and gemcitabine plus carboplatin group (GC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance with pemetrexed may be a feasible treatment option for patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The correlation between high expression of miR-22 in whole blood and the lack of response in pemetrexed treated NSCLC patients indicates that miR-22 could represent a novel predictive biomarker for pemetrexed-based treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this single-center retrospective study, we analyzed the outcome in 75 Chinese non-squamous NSCLC patients treated with pemetrexed as first-line therapy and assessed its efficacy and tolerability. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Taken together, pemetrexed was safe and effective in Chinese patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to investigate the effect of pemetrexed-induced TS-inhibition on \u00b9\u2078F-FLT uptake 4 hours after pemetrexed administration in metastatic NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Fourteen NSCLC patients underwent dynamic \u00b9\u2078F-FLT positron emission tomography (PET) scans at baseline and 4 hours after the first dose of pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: The main objective of this study was to evaluate the association between polymorphisms of the target genes of pemetrexed and clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The TS genotype was associated with survival and one DHFR polymorphism was associated with fatigue in NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We analyzed adverse events during the first cycle of pemetrexed therapy in 350 patients with advanced non-small-cell lung cancer (NSCLC) who had received pemetrexed monotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Clinical trials and meta-analyses involving pemetrexed in NSCLC were evaluated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: In a search for biomarkers for study of the efficacy of pemetrexed treatment, we examined the thymidylate synthase (TYMS) copy number in NSCLC cell lines and in clinical NSCLC samples treated with pemetrexed, combined with platinum drugs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Moreover, TYMS copy number was significantly lower in clinical NSCLC samples responsive to treatment with pemetrexed combined with platinum drugs (p=0.0067). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the association between thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR) and reduced folate carrier (SLC19A1) gene polymorphisms and the treatment efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The polymorphisms of the 5'-UTR of the TS gene and exon 6 (2522) C/T of the SLC19A1 gene predict the survival of advanced NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ASBI and PS are associated with survival for non-squamous NSCLC patients, suggesting that maintenance pemetrexed is useful for LSB or PS 0 patients following induction. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of pemetrexed in elderly (\u226575) Japanese patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Although this study did not meet our primary endpoint, pemetrexed showed favorable antitumor activity with mild toxicity in elderly patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this cohort of patients treated for stage IV NSCLC, renal function falls below commonly used thresholds for cisplatin and for pemetrexed in fewer than a quarter of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These data will help inform the evaluation of correlative data from a recently completed phase II NSCLC trial and a planned phase IB trial of NVP-AUY922 in combination with pemetrexed in NSCLCs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In this setting, pemetrexed has become one of the most important partners of current chemotherapy regimens for nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Indeed, pemetrexed demonstrated a comparable efficacy to other previously available drugs in NSCLC, with however a better safety profile and an easier schedule of administration. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In addition, pemetrexed demonstrated a greater efficacy in nonsquamous NSCLC that lead to an exploration of the underlying potential biological background. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-na\u00efve patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed/carboplatin followed by pemetrexed was well tolerated and active for front-line treatment of advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This multicenter, single-arm, phase II study included 62 patients (\u226570 years) with chemona\u00efve advanced NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and assigned to receive 6 cycles of 3-weekly pemetrexed 500 mg/m(2) and carboplatin AUC 5. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, pemetrexed use is restricted to non-squamous histology. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The ORR is within the range of data reported for pemetrexed-carboplatin in the general NSCLC population (24-31%). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We present a retrospective single-center series of advanced non-squamous NSCLC patients treated with erlotinib or pemetrexed as second-line therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The combined treatment with pemetrexed-cisplatin and concurrent WBRT are effective in patients with NSCLC with newly diagnosed BM. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study investigated the expressions of TS and its gene SNPs in non-small cell lung cancer (NSCLC), and then its association with sensitivity to pemetrexed treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This study showed that TS protein is highly expressed in NSCLC and that polymorphisms of TS 3'-UTR 1494del 6 bp are associated with sensitivity of lung adenocarcinoma patients to pemetrexed treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Both the pemetrexed plus cisplatin and pemetrexed plus carboplatin arms met their primary endpoints and demonstrated efficacy and tolerability as first-line therapy in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: This is a phase I, escalating-dose trial targeting exclusively patients with non-small cell lung cancer (NSCLC), investigating pemetrexed and fixed-dose cisplatin concurrently administered with high-dose radiotherapy (RT) after induction chemotherapy (CT). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND MATERIALS: Patients with unresected stage III NSCLC, planned V20 \u2264 35%, and FEV \u2265 1.3 L, were treated every 21 days for 2 cycles (pemetrexed 500 mg/m2; cisplatin 75 mg/m2), followed by 2 cycles of concurrent CT-RT: pemetrexed starting dose was 400 mg/m2, escalated up to 800 mg/m2 per 100mg/m2 dose level (DL), cisplatin at 75 mg/m2 and RT at fixed dose of 66 Gy/33 fractions. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: This phase I report of pemetrexed is dedicated to NSCLC with induction therapy and fixed high-dose RT. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: We completed a trial-based assessment, from the perspective of the Chinese health care system, of the cost-effectiveness of maintenance pemetrexed treatment after a CP strategy for patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "It was based on a clinical trial that compared continuation maintenance pemetrexed therapy plus best supportive care (BSC) versus placebo plus BSC after a CP strategy for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance of pemetrexed after a CP strategy for patients with advanced nonsquamous NSCLC is not cost-effective based on a recent clinical trial. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to examine the effect of hydration with magnesium and mannitol without furosemide on the nephrotoxocity accompanying combination chemotherapy using cisplatin and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Fifty patients with NSCLC who received cisplatin plus pemetrexed, using either old hydration protocol including normal saline with mannitol and furosemide, or a new one including normal saline with magnesium and mannitol without furosemide were retrospectively analyzed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Univariate and multivariate analyses were performed to identify the independent factors associated with protection against nephrotoxicity in patients with NSCLC who received cisplatin plus pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The new hydration protocol with supplemented magnesium with mannitol without furosemide was an independent factor for the protection against nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced NSCLC [HR 0.232 (95% CI: 0.055-0.986), P=0.039]. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The purpose of this study was to evaluate the efficacy of pemetrexed monotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) including salvage treatment, and to evaluate whether thymidylate synthase (TS) expression is a predictor for pemetrexed efficacy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Hundred and four previously treated patients with advanced NSCLC who received pemetrexed monotherapy were retrospectively evaluated for clinical efficacy and toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Pemetrexed monotherapy could be considered as an option in the fourth or later lines of treatment of previously treated patients with advanced NSCLC as well as a second- or third-line treatment, and TS expression may be a potentially predictive factor for pemetrexed efficacy in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The both regimens have similar efficacy as the treatment for advanced nonsquamous NSCLC, but pemetrexed plus cisplatin regimen has better safety profile and seems to have longer PFS, which makes it a new option as the first line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Aim of this study was to evaluate the safety and efficacy of a palliative regimen combining pemetrexed and LDR (as a chemopotentiator) on patients affected by recurrent non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Participants (n=50) were patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "TYMS mRNA expression affected the therapeutic efficacy of pemetrexed and could therefore constitute a useful predictive biomarker for NSCLC patients receiving pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: To the best of our knowledge, this is the third case of TEN due to pemetrexed in a patient with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500\u2009mg/m2 every 21\u2009days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4\u2009cycles of induction chemotherapy with pemetrexed (500\u2009mg/m2) and cisplatin (75\u2009mg/m2). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Two notable exceptions are erlotinib and, for non-squamous NSCLC, pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who respond or remain stable after four cycles of platinum-doublet chemotherapy, either continuation of pemetrexed (if included in the induction regimen) or switch to pemetrexed as maintenance has been shown to improve OS compared with observation. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated in second-line with pemetrexed or pemetrexed plus carboplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: MTHFR-C667T polymorphisms appear to predict survival differences in pemetrexed-treated NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "An additional meta-analysis was performed to systematically evaluate pemetrexed/platinum as first-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Meta-analysis supports the use of pemetrexed-platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Subgroup analyses of randomized studies have consistently shown that pemetrexed is exclusively effective in non-small-cell lung cancer (NSCLC) other than squamous cell carcinoma and the combination of pemetrexed and platinum agents is recommended for first-line chemotherapy in advanced non-squamous NSCLC; however, there have been few prospective studies of a selected population. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of carboplatin and pemetrexed in Japanese patients with chemo-naive advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of carboplatin and pemetrexed was safe and effective in advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Although the sample size was small, our results indicate that pemetrexed is a key drug for advanced non-squamous NSCLC, irrespective of the EGFR mutation status (UMIN-CTR number 000002451). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We determined the recommended dose (RD) of thoracic radiotherapy (TRT) with a concurrent chemotherapy combination of pemetrexed and cisplatin in Japanese patients with nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Expected toxicities from concurrent chemoradiation were not worsened with concurrent TRT at a total dose of 66 Gy combined with pemetrexed in Japanese patients with locally advanced (LA) nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with previously untreated advanced non-small cell lung cancer (NSCLC).METHODS: A meta-analysis was performed using trials identified through PubMed, EMBASE, and Cochrane databases. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer (NSCLC), and to explore thymidylate synthetase (TS) expression as the predictive and prognostic factor for this treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The therapeutic effect and tolerance of pemetrexed plus platinum regiment were definite as first-line treatment for chemotherapy-naive advanced NSCLC, and TS expression was an independent prognostic factor. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "From January 2007 to December 2010, 25 patients with stage IIIB or IV NSCLC (17 with adenocarcinoma and 8 with squamous cell carcinoma), who had previously failed on platinum-based chemotherapy, received pemetrexed 500 mg/mq every 3 weeks until disease progression or unacceptable toxicities. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This study evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Clinical data on 37 patients with advanced NSCLC who received pemetrexed as second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from Feb 2005 to Sep 2009 were reviewed and analyzed retrospectively. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We evaluated the antitumor effects of necitumumab, a recombinant human IgG1 antibody targeting EGFR, in combination with cisplatin plus gemcitabine, pemetrexed, or paclitaxel in a panel of 9 subcutaneous tumor models of NSCLC established in nu/nu athymic mice. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We report our experience with an upfront association of carboplatin and pemetrexed (areas under the curve, 5 and 500 mg/m(2), respectively), every 3 weeks, in 30 patients presenting with newly diagnosed brain metastases and NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The upfront association of carboplatin plus pemetrexed allows simultaneous treatment of cerebral and systemic disease in patients with NSCLC with newly diagnosed brain metastases and appears to be particularly interesting in terms of radiologic response and overall survival. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "However, the role of pemetrexed therapy in the third-line and beyond treatment of NSCLC has yet to be generally accepted. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The present retrospective study reports the efficacy and safety of pemetrexed in the third-line and beyond treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A total of 46 patients with advanced non-squamous NSCLC received a combination of pemetrexed plus platinum or a single-agent after multi-line treatment failed to yield positive results. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Administration of pemetrexed after failure of multi-line treatment is clinically beneficial to patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: After four cycles of platinum-based induction therapy, 663 patients with stage IIIB or stage IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (in a 2:1 ratio) from March 15, 2005, to July 20, 2007, using the Pocock and Simon minimisation method to receive pemetrexed (500 mg/m(2) every 21 days; n=441) or placebo (n=222) plus best supportive care until disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In view of the improvements in overall and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous non-small-cell lung cancer (NSCLC) and PS 0-1. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Currently, erlotinib and pemetrexed are registered as maintenance treatment in patients with NSCLC not progressing after four cycles of standard platinum-based doublet chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Against this background, we studied whether inhibition of mTOR could lower expression of TS and thus sensitize NSCLC cells to pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS AND RESULTS: Using squamous cell carcinoma and adenocarcinoma NSCLC cell lines, we observed that constitutive TS expression levels failed to correlate with sensitivity to growth inhibition or apoptosis imposed by pemetrexed in vitro. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Surprisingly, cotreatment with everolimus protected NSCLC cells against pemetrexed-induced apoptosis. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This resulted in increased long-term clonogenic survival of NSCLC cells treated with pemetrexed plus everolimus as compared to pemetrexed alone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This should be considered when combining pemetrexed and mTOR inhibitors in NSCLC treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Using a validated RNA interference approach, dUTPase was effectively silenced in a panel of NSCLC cell lines and response to the fluoropyrimidine fluorodeoxyuridine (FUdR) and the antifolate pemetrexed was analyzed using growth inhibition and clonogenic assays. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RNA interference-mediated silencing of dUTPase significantly sensitized NSCLC cells to growth inhibition induced by FUdR and pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a recent global phase 3 trial, patients with advanced non-small cell lung cancer (NSCLC), who had not progressed after four cycles of platinum-based induction chemotherapy, were randomized to maintenance therapy with pemetrexed or placebo. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The results of this subgroup analysis support pemetrexed as maintenance therapy for East Asian patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) to prolong overall survival after first-line therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We conducted a cost-comparison analysis of erlotinib versus pemetrexed in first-line maintenance treatment of locally advanced or metastatic, non-squamous NSCLC in France, Germany, Italy and Spain, performed from the perspective of national health-care decision-makers or purchasers. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Our objectives were to determine the maximum tolerated dose and recommended dose of pemetrexed in combination with cisplatin, with concurrent late course accelerated hyperfractionated (LCAF) intensity modulated radiotherapy (IMRT) in patients with LANSCLC and to investigate the safety and efficacy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The combination of pemetrexed and cisplatin with concurrent LCAF IMRT optimized based on single photon emission photography lung perfusion imaging is well tolerated in patients with LANSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " This study was designed to evaluate the efficacy of combination treatment of pemetrexed plus oxaliplatin as second-line treatment in advanced/metastatic non-small cell lung cancer (NSCLC) patients who have failed first-line platinum-based chemotherapy, assuming that oxaliplatin can overcome the resistance to a platinum agent and translate into better outcome. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The overall survival benefit was strongest for maintenance therapy with pemetrexed for patients with nonsquamous NSCLC (hazard ratio\u00a0= 0.74, 95% confidence interval: 0.64-0.86) but not significant for patients with squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: For patients with advanced, stable stage IIIB/IV NSCLC whose disease has not progressed after four to six cycles of platinum-based chemotherapy, the\u00a0overall survival benefits were strongest for pemetrexed maintenance therapy followed by epidermal growth factor receptor tyrosine kinase inhibitor maintenance therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The results of a phase III trial of crizotinib compared to platinum-pemetrexed in the first-line setting, and a phase I trial and expansion cohort of ceritinib, provided additional efficacy and toxicity data for patients with anaplastic lymphoma kinase rearranged NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "RESULTS: In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer\") trial, patients with advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival, delaying disease progression, and maintaining quality of life (QoL). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: PARAMOUNT demonstrated a low incidence of low-grade toxicities with long-term pemetrexed exposure without compromising QoL in patients with NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " The PARAMOUNT study recently updated for survival analysis, showed that continuous maintenance with pemetrexed (P) lead to a 3 months overall survival (OS) benefit in non-small cell lung cancer (NSCLC) patients not progressing after P-based induction chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: ASBI and PS are associated with survival for non-squamous NSCLC patients, suggesting that maintenance pemetrexed is useful for LSB or PS 0 patients following induction. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Continuation maintenance treatment with pemetrexed is approved by current clinical guidelines as a category 2A recommendation after induction therapy with cisplatin and pemetrexed chemotherapy (CP strategy) for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "OBJECTIVE: We completed a trial-based assessment, from the perspective of the Chinese health care system, of the cost-effectiveness of maintenance pemetrexed treatment after a CP strategy for patients with advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "It was based on a clinical trial that compared continuation maintenance pemetrexed therapy plus best supportive care (BSC) versus placebo plus BSC after a CP strategy for advanced nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Continuation maintenance of pemetrexed after a CP strategy for patients with advanced nonsquamous NSCLC is not cost-effective based on a recent clinical trial. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The switch maintenance strategy with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor erlotinib (in all the histologies) or with pemetrexed (in non-squamous histologies) have been demonstrated to be two possible effective options versus the classic break from cytotoxic chemotherapy after a fixed course in the treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Continuation maintenance with pemetrexed after cisplatin plus pemetrexed induction for patients selected for a maintenance strategy is recommended as first-line treatment of advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: After four 21-day cycles of pemetrexed-cisplatin (N = 939), patients with advanced nonsquamous NSCLC, whose disease had not progressed and who had a performance status of 0/1, were randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m plus best supportive care or placebo plus best supportive care every 21 days until disease progression or unacceptable toxicity. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This paper aims to systematically review the evidence from all available clinical trials of erlotinib and pemetrexed as maintenance therapy for advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: There is evidence to suggest that maintenance treatment with erlotinib or pemetrexed has clinically relevant and statistically significant advantages over treatment with placebo or observation in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: After four cycles of platinum-based induction therapy, 663 patients with stage IIIB or stage IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (in a 2:1 ratio) from March 15, 2005, to July 20, 2007, using the Pocock and Simon minimisation method to receive pemetrexed (500 mg/m(2) every 21 days; n=441) or placebo (n=222) plus best supportive care until disease progression. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In view of the improvements in overall and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Enzastaurin and cisplatin-pemetrexed is tolerable with preliminary activity in patients with advanced NSCLC, but because of a lack of efficacy improvement in other phase II NSCLC studies, the study was terminated early. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of these analyses was to evaluate the survival and safety of treatment with pemetrexed in elderly patients with nonsquamous non-small-cell lung cancer (NSCLC) and PS 0-1. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: For elderly patients with nonsquamous advanced NSCLC and PS 0-1, pemetrexed therapy, with its favorable toxicity profile, is a viable option, either in combination with cisplatin in the first-line setting or as maintenance therapy after initial chemotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a recent global phase 3 trial, patients with advanced non-small cell lung cancer (NSCLC), who had not progressed after four cycles of platinum-based induction chemotherapy, were randomized to maintenance therapy with pemetrexed or placebo. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: The results of this subgroup analysis support pemetrexed as maintenance therapy for East Asian patients with advanced, nonsquamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to evaluate the association between polymorphisms of TS and MHFR genes and clinical outcomes in NSCLC patients treated with pemetrexed monotherapy. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "DNA was isolated from peripheral blood of 72 non-squamous NSCLC patients treated with pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "New second-line chemotherapy single-regimen nab-paclitaxel showed equivalent efficacy and toxicity profiles as pemetrexed in treating patients with NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGFR mutations who failed first-line EGFR TKI. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " BACKGROUND: Previously reported superior tumor response of pemetrexed in the second-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) has never been confirmed in real-world studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Between April 2009 and June 2011, 39 patients with advanced non-squamous NSCLC who had received second-line chemotherapy following first-line chemotherapy treatment with cisplatin and pemetrexed were analysed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV NSCLC with performance status 0 to 1 progressive after first-line chemotherapy were eligible for randomization to pemetrexed, sunitinib, or the combination. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC, in progression during or after first-line platinum-based chemotherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival outcomes as compared with single-agent pemetrexed. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "The objective of this study was to conduct a cost minimization analysis from the perspective of the national health service (NHS) in each of 12 European countries, based on a randomized phase II study in NS-NSCLC (NAVoTRIAL01), with 100 oral vinorelbine plus cisplatin patients (arm A) and 51 pemetrexed plus cisplatin patients (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Given the reported efficacy with both regimens, this pan-European economic analysis provides compelling evidence supporting oral vinorelbine use over pemetrexed for the treatment of NS-NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: Among Chinese patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC, the higher acquisition costs for nonplatinum cytotoxic drugs associated with pemetrexed-platinum could be partially offset by its significantly lower hospital costs for nonchemotherapy drugs and nondrug care. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: Two adjuvant regimens were evaluated for feasibility in 132 patients with NSCLC: the standard regimen of cisplatin and vinorelbine (CVb) (cisplatin 50 mg/m(2) on day 1 and day 8 and vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 every 4 weeks) and a regimen consisting of cisplatin and pemetrexed (CPx) (cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 every 3 weeks). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "As a result, pemetrexed monotherapy might be considered as a good option in the treatment of elderly patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "METHODS: In a trial on adjuvant chemotherapy (the TREAT trial), 132 patients with R0-resected NSCLC were randomised to 4 cycles of cisplatin-vinorelbine (CVb, n = 65) or cisplatin-pemetrexed (CPx, n = 67). ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "To date, more than 1000 patients with early stage NSCLC have been enrolled in adjuvant therapy studies evaluating various pemetrexed-containing treatment regimens, and additional patients are being enrolled in ongoing studies. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: This was a single-arm phase II study of pemetrexed in elderly (\u226575) Japanese patients with advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Although this study did not meet our primary endpoint, pemetrexed showed favorable antitumor activity with mild toxicity in elderly patients with non-squamous NSCLC. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with completely resected stages IB-pT3N1 NSCLC were randomly assigned to either four cycles cisplatin (C: 50 mg/m(2) day (d)1 + 8) and vinorelbine (V: 25 mg/m(2) d1, 8, 15, 22) q4 weeks or four cycles cisplatin (75 mg/m(2) d1) and pemetrexed (Px: 500 mg/m(2) d1) q3 weeks. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": " INTRODUCTION: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005), while survival with pemetrexed-cisplatin was shorter than with gemcitabine-cisplatin in patients with squamous cell carcinoma. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "CONCLUSION: In the absence of randomized clinical trial data comparing pemetrexed-cisplatin to commonly used doublets in advanced NSCLC other than gemcitabine-cisplatin, this combined analysis of multiple trials provides estimates for such comparisons. ", "disease": "NSCLC", "drug": "pemetrexed"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "In the present study, non-small cell lung cancer (NSCLC) cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Cisplatin and etoposide in these doses with conventionally fractionated TRT is a well-tolerated, effective treatment schedule in the definitive treatment of unresectable or inoperable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "In the present study, non-small cell lung cancer (NSCLC) cell lines (H520 and SK-MES-1) were transfected with ARRB1 plasmids or small interfering ribonucleic acid (siRNA) and received treatment with DNA-damaging agents (cisplatin and etoposide). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle's suppression on migration and invasion of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30\u2009mg/sqm days 1-3q21) and oral etoposide (50\u2009mg, days 1-15q21) (mPE doublet) \u00b1bevacizumab. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "These results suggested that LDH-VP16 diminishes hematotoxicity, targets NSCLC tumor, performs more effectively than VP16, and different signaling pathway is involved compared to VP16.STATEMENT OF SIGNIFICANCE: This paper explored that nano-sized layered double hydroxide (LDH) could be used as a pH sensitive delivery system to overcome hematotoxicity and enhance the bioavailability and anticancer efficacy of etoposide (VP16) against non small cell lung cancer, which was not reported before, as the best of our knowledge. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Cisplatin and etoposide in these doses with conventionally fractionated TRT is a well-tolerated, effective treatment schedule in the definitive treatment of unresectable or inoperable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "However, the role of ERK1/2 and AKT-mediated XRCC1 expression in etoposide treatment alone or combined with resveratrol-induced cytotoxicity in NSCLC cells has not been identified. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Resveratrol inhibited the expression of XRCC1 and enhanced the etoposide-induced cell death and anti-proliferation effect in NSCLC cells. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "These findings suggested that down-regulation of XRCC1 expression by resveratrol can enhance the chemosensitivity of etoposide in NSCLC cells. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Here, we report the case of an NSCLC patient with MC who showed durable response to salvage intrathecal etoposide subsequent to failure of first-line methotrexate. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: To our knowledge, this is the first case report in which intrathecal etoposide was successfully used to treat MC from NSCLC after failure of MTx. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " BACKGROUND: Concurrent chemoradiation with etoposide and cisplatin (EP/XRT) is standard treatment for inoperable stage III locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "In this study, the effects of p38 mitogen-activated protein kinase (MAPK) signal on the ERCC1 expression induced by etoposide in non-small cell lung cancer (NSCLC) cell lines was investigated. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Our results suggest that in human NSCLC cells, ERCC1 is induced by etoposide through the p38 MAPK pathway, and this phenomenon is required for NSCLC survival and resistant DNA damage. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Lung cancer and leukemia cell lines were exposed to low doses of 5-azacytidine with varying doses of cytarabine or etoposide for AML cells (U937 and HL60) as well as cisplatin or gemcitabine for NSCLC cells (A549 and HTB56) for 48 h. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Conclusions and Relevance: Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "OBJECTIVE: Carboplatin plus etoposide chemotherapy, which was formerly used as a low-cost first-line treatment, was used as third-line therapy for advanced NSCLC in order to compare its results with those of best supportive care as a treatment for improved quality of life (QoL) and progression-free survival. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHOD: This prospective study of advanced NSCLC stage IIIB/IV enrolled 47 patients receiving either third-line chemotherapy with carboplatin plus etoposide or best supportive care in the Oncology Unit, Medicine Department, Rajavithi Hospital from 1 January 2005 to 31 December 2012. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "RESULTS: The 47 advanced NSCLC patients were given either carboplatin plus etoposide chemotherapy (27 cases) or best supportive care (20 cases). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Carboplatin plus etoposide as third-line chemotherapy regimen demonstrated higher median progression-free survival in advanced NSCLC patients and did not adversely affect QoL. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60 Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Of 12/97 (12 %) partial responses overall, 11 were seen in the amuvatinib and paclitaxel/carboplatin or carboplatin/etoposide arms and most commonly in the neuroendocrine (NE), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "CONCLUSION: Amuvatinib was well tolerated, modulated RAD51, and showed antitumor activity when combined with paclitaxel/carboplatin and carboplatin/etoposide in NE, NSCLC, and SCLC tumors. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) regimen in patients with unresectable stage III non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "A phase 3 trial of lipegfilgrastim was conducted in patients with advanced non-small cell lung cancer (NSCLC) receiving cisplatin/etoposide (which produces mild-to-moderate myelosuppression). ", "disease": "NSCLC", "drug": "etoposide"}, {"polarity": 1, "orig_sen": "The purpose of the study was to investigate potential factors, including MDR genes polymorphisms, that could be used in qualification for second-line docetaxel therapy in non-small cell lung cancer (NSCLC) patients after failure of platinum based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Expert opinion: Nivolumab is the preferred treatment option for platinum-pretreated advanced NSCLC, having convincingly shown higher efficacy compared with standard docetaxel chemotherapy in phase III trials. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A recent phase III randomized trial named REVEL, demonstrated the efficacy of ramucirumab in combination with docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA approval in this clinical setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3\u00a0mg/kg every 2\u00a0weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Currently, ramucirumab is approved for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) in combination with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the efficacy and safety of the combination of docetaxel (TXT) plus tamoxifen (TAM) in advanced non-small-cell lung cancer (NSCLC) patients who had received platinum-based first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In late December 2014, the US Food and Drug Administration (FDA) obtained the data monitoring committee report of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overall survival benefit for patients treated with nivolumab compared with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBSERVATIONS: In that trial, 272 patients with metastatic SQ NSCLC patients had been randomized to receive nivolumab (n = 135) or docetaxel (n = 137). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV non-small-cell lung cancer (NSCLC) whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The goal of the REVEL study is to demonstrate that ramucirumab in combination with docetaxel improves overall survival of patients with NSCLC with progressive disease after first-line therapy, and to advance our knowledge of the role of angiogenesis blockade in patients with NSCLC by identifying patients who are likely to experience maximum benefit based on extensive clinical biomarker correlative analysis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS/DESIGN: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In particular, we will focus on nintedanib, from the preclinical studies to the latest phase III clinical trial that allowed this new agent to be approved by the European Medicines Agency as a second-line treatment option in association with docetaxel for NSCLC patients with adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In the REVEL trial, ramucirumab, a monoclonal antibody to VEGFR-2, improved overall survival in combination with docetaxel compared to docetaxel alone in the second-line setting of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM: This phase II study was conducted to evaluate the efficacy and safety of docetaxel and bevacizumab combination therapy in patients with previously-treated non-squamous non-small cell lung cancer (Nsq NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Newly diagnosed patients \u226518 years with histologically proven non-squamous NSCLC and Eastern Cooperative Oncology Group performance status (ECOG PS) \u22642 received six 21-day cycles of docetaxel, oxaliplatin, and bevacizumab followed by single-agent bevacizumab for a total of 1 year. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to docetaxel/oxaliplatin is effective with an acceptable safety profile in patients with chemotherapy-na\u00efve advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV non-small-cell lung cancer (NSCLC) whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The goal of the REVEL study is to demonstrate that ramucirumab in combination with docetaxel improves overall survival of patients with NSCLC with progressive disease after first-line therapy, and to advance our knowledge of the role of angiogenesis blockade in patients with NSCLC by identifying patients who are likely to experience maximum benefit based on extensive clinical biomarker correlative analysis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS/DESIGN: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "GHRH antagonists potentiate docetaxel effects on growth of H460 non-small cell lung cancer (NSCLC) and MX-1 breast cancer plus suppressive action of doxorubicin on MX-1 and HCC1806 breast cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first-line treatment for stage IV NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive NSCLC received 60\u2009mg/m(2) docetaxel (day 1) and 70\u2009mg/m(2) oxaliplatin (day 2) every three weeks for up to six cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The results suggest that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC with reasonable toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 non-small-cell lung cancer (NSCLC) treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consolidation docetaxel after EP/XRT does not improve survival in LA-NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The purpose of the study was to investigate potential factors, including MDR genes polymorphisms, that could be used in qualification for second-line docetaxel therapy in non-small cell lung cancer (NSCLC) patients after failure of platinum based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Expert opinion: Nivolumab is the preferred treatment option for platinum-pretreated advanced NSCLC, having convincingly shown higher efficacy compared with standard docetaxel chemotherapy in phase III trials. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aim of this report is to assess the added benefit of nintedanib in combination with docetaxel in comparison with the appropriate comparator therapy (ACT) in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A confirmed partial response (PR) was observed in 10 of the 47 patients with NSCLC who received trametinib plus docetaxel (21%). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A recent phase III randomized trial named REVEL, demonstrated the efficacy of ramucirumab in combination with docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA approval in this clinical setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study explored antitumor activity of high-dose icotinib (an EGFR tyrosine kinase inhibitor) plus sequential docetaxel against wild-type EGFR NSCLC cells-generated nude mouse xenografts. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The study indicate that the high dose of icotinib plus sequential docetaxel (IcoH-DTX) have an additive effect on suppressing the growth of wild-type EGFR NSCLC cell nude mouse xenografts, possibly through microvessel density reduction. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The present study investigated the role of miR-141 regulation of eukaryotic initiation factor-4E (EIF4E) expression in docetaxel chemoresistance of human non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The expression of miR-141 in docetaxel chemoresistant patients with NSCLCs was markedly higher than those of non-docetaxel chemoresistant patients with NSCLCs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The expression of EIF4E in docetaxel chemoresistant patients with NSCLCs was markedly lower than those of non-docetaxel chemoresistant patients with NSCLCs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Thus, the present study is the first to show the induction of miR-141/EIF4E expression in an acquired model of docetaxel chemoresistant patients with NSCLCs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This serves as a mechanism of acquired docetaxel chemoresistant patients with NSCLCs, possibly through direct interactions with VEGF, c-Myc, and Bax, therefore presenting a potential therapeutic target for the treatment of docetaxel chemoresistant patients with NSCLCs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the period when a therapy has gained marketing authorisation and is no longer available to patients through clinical trials, but has not yet been granted approval or reimbursement, compassionate use programmes (CUPs) and named patient programmes (NPPs) can bridge this gap, enabling much-needed therapies to reach patients prior to approval or launch.In this Industry Corner article, we describe the experience with nintedanib in combination with docetaxel, which was first approved in the European Union in 2014 for the treatment of patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "It results non-inferior to docetaxel in a randomized phase III trial including previously treated NSCLC patients; additionally, its safety profile is generally considered manageable. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A population pharmacokinetic-pharmacodynamic (PK-PD) model was introduced to predict the development of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This article has for objective to summarize efficacy and safety data of the use of ramucirumab in combination with docetaxel in second line in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Areas covered: We searched Medline, Embase, Scopus and Cochrane Library for randomized phase III trials that evaluated docetaxel in various clinical settings of NSCLC and for meta-analyses of such trials and we present all relevant data regarding the pharmacology and clinical use of docetaxel in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Expert commentary: Despite its diminishing role, docetaxel in combination with novel targeted agents remains an important option of the therapeutic armamentarium in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We investigated its activity in patients with advanced non-small-cell lung cancer (NSCLC) progressing under or after docetaxel-based regimens. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with locally advanced unresectable or metastatic NSCLC, with an Eastern Cooperative Oncology Group performance status of 0-2, were enrolled; patients had to have received up to two prior chemotherapy regimens for the treatment of advanced disease, including one docetaxel-containing regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Cabazitaxel exhibits activity in NSCLC patients pre-treated with docetaxel-based chemotherapy with a substantial but manageable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim of our study was to explore the relationships between the M2 isoform of pyruvate kinase (PKM2) and the sensitivity of human non-small cell lung cancer (NSCLC) cells to docetaxel in vitro. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Silencing of PKM2 increased docetaxel sensitivity of human NSCLC A549 and H460 cells in a collaborative manner, resulting in strong suppression of cell viability. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "placebo plus docetaxel improved progression free survival (PFS) in NSCLC patients, and improved overall survival in the population of adenocarcinoma patients, particularly in those with progression within 9 months after first line treatment initiation, median 10.9 months ( [95% CI 8.5-12.6] vs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and safety of second-line ramucirumab-docetaxel in Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with NSCLC with progression after platinum-based therapy (28 Japanese sites; 19 December, 2012 to 22 May, 2015) were randomized (computer-generated sequence) to ramucirumab 10mg/kg or placebo, followed by docetaxel 60mg/m(2) (Day 1, 21-day cycle). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line ramucirumab-docetaxel improved PFS similar to that seen in the REVEL trial with a manageable safety profile in Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In two Phase III trials, nivolumab was compared to docetaxel in patients with, respectively, squamous (CheckMate 017) and non-squamous NSCLC (CheckMate 057). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In both trials, nivolumab significantly reduced the risk of death compared to docetaxel (41% and 27% lower risk of death for squamous and non-squamous NSCLC, respectively). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Forkhead box M1 (FoxM1), an oncogenic transcription factor, is believed to be involved in the chemoresistance of various human cancers; whereas the association of FoxM1 with acquired docetaxel-resistance in NSCLC remains unclear. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Our results suggest a critical role of FoxM1 in docetaxel-resistance of the A549 cells and form the basis for the development of combined therapy of docetaxel and FoxM1 depletion in treating NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Selumetinib (AZD6244, ARRY-142886) is a potent and selective inhibitor of MEK1/2 which has demonstrated significant efficacy in combination with docetaxel in patients with KRAS mutant pretreated advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aim of the present study was mainly to assess the advantage of docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against non-small cell lung cancer (NSCLC) compared with the commercial product of docetaxel (Aisu\u00ae) and docetaxel-albumin nanoparticles (DANPs). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Previously treated PS0-1 patients with IIIB/IV EGFR (epidermal growth factor receptor) wild genotype NSCLC were randomly assigned to docetaxel (60\u2009mg/m(2) on Day 1) plus PPV based on preexisting host immunity or docetaxel plus placebo. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PPV did not improve the survival in combination with docetaxel for previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3\u00a0mg/kg every 2\u00a0weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Currently, ramucirumab is approved for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) in combination with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib (Vargatef(\u00ae) ) plus docetaxel is approved in the EU for the treatment of patients with adenocarcinoma non-small cell lung cancer (NSCLC) after first-line chemotherapy, and as monotherapy (Ofev(\u00ae) ) in the United States and EU for the treatment of patients with idiopathic pulmonary fibrosis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this single-center, open-label, dose-escalating phase I trial, patients with epidermal growth factor receptor (EGFR)-expressing stage IV NSCLC were treated with nimotuzumab plus docetaxel according to a dose escalation schedule. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumour cells and tumour-infiltrating immune cells and in the intention-to-treat population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Atezolizumab significantly improved survival compared with docetaxel in patients with previously treated NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The current analysis of data indicates that the benefit from PD-1 inhibitors versus docetaxel in second line treatment of NSCLC is limited to the PD-L1>1% subpopulation. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In a multicenter, open-label, phase III trial, elderly patients \u2265 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS \u2264 1 and age \u2264 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aim of this study was to evaluate the efficacy and safety of the combination of docetaxel (TXT) plus tamoxifen (TAM) in advanced non-small-cell lung cancer (NSCLC) patients who had received platinum-based first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In a recent phase II study, selumetinib (AZD6244, ARRY-142886), an oral, potent and selective, allosteric MEK1/2 inhibitor with a short half-life, combined with docetaxel, improved clinical outcome as second-line treatment for patients with KRASm NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: SELECT-1 (NCT01933932) is a randomized, double-blind, placebo-controlled phase III study assessing the efficacy and safety of selumetinib plus docetaxel in patients with KRASm locally advanced or metastatic NSCLC, eligible for second-line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: If the primary endpoint of PFS is met, selumetinib plus docetaxel would be the first targeted treatment for patients with KRASm advanced NSCLC who are eligible for second-line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in both progression-free survival and overall survival compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Archival tumor samples collected from patients with platinum-refractory NSCLC in the phase III ZODIAC study of vandetanib plus docetaxel or placebo plus docetaxel (N= 294) were screened forKDRamplification by FISH. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with NSCLC whose tumor hadKDRamplification were not associated with clinical benefit for vandetanib in combination with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the pivotal CheckMate 017 trial, intravenous nivolumab 3\u00a0mg/kg every 2\u00a0weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A head-to-head comparison of docetaxel and nivolumab for second-line treatment of squamous cell NSCLC demonstrated superior overall survival and reduced grade 3 or 4 adverse effects in nivolumab-treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In late December 2014, the US Food and Drug Administration (FDA) obtained the data monitoring committee report of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overall survival benefit for patients treated with nivolumab compared with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBSERVATIONS: In that trial, 272 patients with metastatic SQ NSCLC patients had been randomized to receive nivolumab (n = 135) or docetaxel (n = 137). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Several new chemotherapeutic agents have recently shown encouraging activity in NSCLC, especially docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We studied miRNAs in NSCLC cell lines to identify those that can regulate and predict the effectiveness of docetaxel on NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CCK8, Annexin and V-FITC assays were carried out to evaluate the inhibitory effect of docetaxel on NSCLC cell lines A549 and H460, and qRT-PCR was used to detect and compare six miRNAs expression levels in the two cells with docetaxel or not. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MiR-7 overexpression improved anti-proliferative and pro-apoptotic effects of docetaxel on the NSCLC cells and that miR-7 down-regulation decreased those effects. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Among these, nivolumab demonstrated a survival benefit versus docetaxel in refractory squamous NSCLC, reporting 41% reduction in risk of death (median overall survival: 9.2 versus 6.0 months; objective response rate: 20% versus 9%), and better safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% versus 55%). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a dose of 75 mg per square meter of body-surface area every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The present study mainly compared the effect of docetaxel-albumin nanoparticles (DANPs) and docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "DOI: 10.3779/j.issn.1009-3419.2015.06.07 PMID: 26104894 [PubMed - indexed for MEDLINE]  OBJECTIVES: This randomized phase II trial investigated the efficacy and safety of docetaxel plus bevacizumab and S-1 plus bevacizumab in the second-line treatment of non-squamous (non-Sq) non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with non-Sq NSCLC who experienced disease progression after prior platinum-based chemotherapy with or without bevacizumab were randomly assigned to receive docetaxel plus bevacizumab (DB) once every 3 weeks or S-1 orally twice daily on days 1-14 plus bevacizumab (SB) on day 1 every 3 weeks until disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Subgroup analysis showed that OS benefit was presented only in patients treated with docetaxel plus antiangiogenic agents (HR 0.92, 95%CI: 0.86-0.99, p=0.02) and patients with non-squamous NSCLC (HR for OS 0.92, 95%CI: 0.86-0.99, p=0.02). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To further investigate whether rmhTNF with standard chemotherapy provides a survival benefit, 529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or chemotherapy alone (264). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and toxicity of platinum combination chemotherapy versus docetaxel monotherapy in NSCLC patients previously treated with platinum-based CRT. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "From September 2002 to December 2009, at three participating institutions, 24 patients with locally advanced NSCLC, who had previously received platinum-based CRT, were treated with platinum combination re-challenge therapy, whereas 61 received docetaxel monotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In particular, we will focus on nintedanib, from the preclinical studies to the latest phase III clinical trial that allowed this new agent to be approved by the European Medicines Agency as a second-line treatment option in association with docetaxel for NSCLC patients with adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In the REVEL trial, ramucirumab, a monoclonal antibody to VEGFR-2, improved overall survival in combination with docetaxel compared to docetaxel alone in the second-line setting of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the current study, we established a new docetaxel-resistant human non-small lung cancer (NSCLC) cell line A549/Docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In summary, we have established a typical docetaxel-resistant human NSCLC cell line A549/Docetaxel, and it was suggested that the multidrug resistance of A549/Docetaxel was related to EMT. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "GHRH antagonists potentiate docetaxel effects on growth of H460 non-small cell lung cancer (NSCLC) and MX-1 breast cancer plus suppressive action of doxorubicin on MX-1 and HCC1806 breast cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with stage III, stage IV, or recurrent NSCLC age \u2265 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m(2) on day 1, every 3 weeks, or docetaxel 20 mg/m(2) plus cisplatin 25 mg/m(2) on days 1, 8, and 15, every 4 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: This study failed to demonstrate any survival advantage of weekly docetaxel plus cisplatin over docetaxel monotherapy as first-line chemotherapy for advanced NSCLC in elderly patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimycin HCl), a potent and selective inhibitor of HSP90, in combination with the microtubule targeting agent (MTA) docetaxel, in preclinical models of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Our data provide a preclinical rationale for testing the combination of IPI-504 and docetaxel in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Cytochrome P450 1B1 (CYP1B1) is involved in the metabolism of anticancer agents; its overexpression was associated with resistance to docetaxel, a commonly used drug for second-line treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to retrospectively evaluate the correlation of CYP1B1 SNPs with the outcome of NSCLC patients treated with docetaxel in second or third line. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: CYP1B1 4326C>G polymorphism emerged as possible prognostic/predictive marker of activity and efficacy of docetaxel in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To investigate whether blocking survivin expression enhances docetaxel-induced apoptosis in patients with non-small-cell lung cancer (NSCLC), we compared the antitumor activity of the survivin inhibitor LY2181308 plus docetaxel with docetaxel alone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients (N = 162) eligible for second-line NSCLC treatment (stage IIIB/IV) with an Eastern Cooperative Oncology Group performance status of 0 to 1 were randomized 2:1 to receive LY2181308 (750 mg intravenously, weekly) and docetaxel (75 mg/m intravenously, day 1) or docetaxel alone every 21 days. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The objective of this study was to evaluate the efficacy and safety of oxaliplatin combined with docetaxel as a first-line treatment for stage IV NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with chemotherapy-naive NSCLC received 60\u2009mg/m(2) docetaxel (day 1) and 70\u2009mg/m(2) oxaliplatin (day 2) every three weeks for up to six cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The results suggest that the combination of oxaliplatin and docetaxel is effective in patients with NSCLC with reasonable toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The benefit of docetaxel-based therapy in the second-line treatment of advanced non-small cell lung cancer (NSCLC) is still unclear. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The goal of this meta-analysis was to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed to improve with first-line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "IMPLICATIONS: Based on the available evidence, docetaxel-based doublet therapy seems superior to docetaxel monotherapy as a second-line treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM: This phase II study was conducted to evaluate the efficacy and safety of docetaxel and bevacizumab combination therapy in patients with previously-treated non-squamous non-small cell lung cancer (Nsq NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination regimen of docetaxel-plus-bevacizumab is very active in patients with previously-treated Nsq NSCLC and warrants further research. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed was associated with significantly postponed tumor progression and significantly less hematological toxicity than docetaxel in the real-world second-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Paclitaxel and docetaxel are two taxanes approved for the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of our study was to evaluate the response to docetaxel in NSCLC patients with prior PP treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IV NSCLC treated with PP that presented disease progression and received docetaxel as second-line treatment were included. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Previous use of PP does not preclude a favorable response to docetaxel in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Long PFS with PP may help select NSCLC patients who benefit from second-line docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: ZODIAC was a randomized phase III study of second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) that evaluated the addition of vandetanib to docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: After progression following first-line chemotherapy, 1391 patients with locally advanced or metastatic (stage IIIB/IV) NSCLC were randomized 1 : 1 to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days) or placebo plus docetaxel in the ZODIAC study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with untreated advanced NSCLC received oral meloxicam (150 mg daily), carboplatin (area under the curve = 5 mg/ml \u00d7 min on day 1) and docetaxel (60 mg/m(2) on day 1) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical surgery if resectable. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The aim of this study was to confirm the association between the response to docetaxel combined with platinum as first-line chemotherapy and prognosis and subsequent treatment for patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our study demonstrated that the response to docetaxel in combination with platinum as a first-line chemotherapy was an independent prognostic factor for patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The present work evaluated the in vitro effects of chitosan cross-linked \u03b3-poly(glutamic acid) (\u03b3-PGA) nanoparticles (Nps) loaded with docetaxel (DTXL) and decorated with Cetuximab (CET), targeted to EGFR over-expressing non-small-cell-lung-cancer (NSCLC) cells (A549). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This randomized phase 2 study evaluated PX-866 combined with docetaxel in patients with advanced, refractory NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with locally advanced, recurrent, or metastatic NSCLC who had received at least one and no more than two prior systemic treatment regimens were randomized (1:1) to a combination of docetaxel (75 mg/m intravenous every 21 days) with or without PX-866 (8 mg orally daily; arms A and B, respectively). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The addition of PX-866 to docetaxel did not improve PFS, response rate, or OS in patients with advanced, refractory NSCLC without molecular preselection. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aim of this open-label, multicenter, randomized phase II trial was to evaluate the efficacy and safety of zoledronic acid in combination with docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC) and bone metastases. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Zoledronic acid combined with docetaxel was well tolerated but did not meet the primary endpoint of demonstrating a longer progression-free survival in advanced NSCLC patients with bone metastases compared with docetaxel alone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]  PURPOSE: Aurora kinases are key regulators of mitotic events. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The aims of these studies were to establish an orthotopic non-small-cell lung cancer (NSCLC) mouse model and to investigate the therapeutic efficacy of lipid-based nanoparticles (NPs) containing 2'-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) in this new model. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and safety of weekly docetaxel with carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the H1299 human NSCLC bone metastasis model, OPG-Fc plus docetaxel in combination resulted in significantly greater inhibition of skeletal tumor growth compared with either single agent alone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "IPI-504 and ganetespib have activity in NSCLC both as monotherapy and in combination with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC- docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2-every 3 weeks for up to eight cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Combined obatoclax mesylate plus docetaxel is tolerable in patients with NSCLC, but response was minimal and neutropenia was a common adverse event. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To analyze the efficacy and safety of combination of rh-endostatin (Endostar) with docetaxel treatment on patients of non-small cell lung cancer (NSCLC) who presented PD or intolerable toxicity in/after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Endostar may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicities. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: We investigated the efficacy and toxicity of a biweekly schedule of docetaxel and cisplatin in high-risk patients with unresectable (stages IIIB-IV) non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In this study, 48 high-risk patients with previously untreated locally advanced or metastatic NSCLC were treated with combination chemotherapy consisting of docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2); both drugs were given biweekly, on days 1 and 15, every 4 weeks in an outpatient setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: As a front-line chemotherapy for high-risk patients with unresectable NSCLC in an outpatient setting, the biweekly schedule of docetaxel and cisplatin showed feasible efficacy with acceptable hematologic toxicities, comparable to the results of previous studies of triweekly or weekly schedules. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Recently, in a randomised, phase II trial selumetinib plus docetaxel has proven to improve progression free survival compared to docetaxel alone in previously treated patients with advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Newly diagnosed patients \u226518 years with histologically proven non-squamous NSCLC and Eastern Cooperative Oncology Group performance status (ECOG PS) \u22642 received six 21-day cycles of docetaxel, oxaliplatin, and bevacizumab followed by single-agent bevacizumab for a total of 1 year. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The addition of bevacizumab to docetaxel/oxaliplatin is effective with an acceptable safety profile in patients with chemotherapy-na\u00efve advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Results of an observational study on docetaxel-based therapy in non-small cell lung cancer (NSCLC) with focus on symptom control and therapy response, are reported. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: A total of 233 patients with NSCLC treated with docetaxel-containing therapy were analyzed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "With recent development of expanding autologous ex vivo NK cell-enriched lymphocytes (NKL), we designed a trial to augment the anticancer effect by co-administering NKL and docetaxel, one of the second-line agents used for treatment of patients with advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: To our knowledge, this is the first report on the combination of NKL with docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Accordingly, a recent randomized Phase II study evaluating docetaxel plus selumetinib or placebo in KRAS-mutant pretreated advanced NSCLC patients has demonstrated a significant improvement in terms of response rate, progression-free survival and patient-reported outcomes in favor of the combination arm. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non-small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with advanced-stage NSCLC treated with one or two previous systemic therapy regimens were given docetaxel (60 mg/m) and everolimus (5 mg orally once daily on days 1-19) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: To assess the efficacy and potential prognostic factors of patients with stage III N2 non-small-cell lung cancer (NSCLC) treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This phase II single-arm trial of docetaxel and capecitabine in previously untreated non-small cell lung cancer (NSCLC) patients was designed to evaluate response rate of this regimen based on promising efficacy data from phase II testing in pre-treated NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Combination of S-1, an oral fluorouracil derivative, plus docetaxel against non-small cell lung cancer (NSCLC) showed promising efficacy but clinically problematic emesis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A biweekly regimen of docetaxel on day 1 with oral S-1 on days 1-7 was administered to previously treated NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Combination of 1-week administration of S-1 with biweekly docetaxel is safe and active for NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV non-small-cell lung cancer (NSCLC) whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The goal of the REVEL study is to demonstrate that ramucirumab in combination with docetaxel improves overall survival of patients with NSCLC with progressive disease after first-line therapy, and to advance our knowledge of the role of angiogenesis blockade in patients with NSCLC by identifying patients who are likely to experience maximum benefit based on extensive clinical biomarker correlative analysis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS/DESIGN: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and docetaxel are established therapies in second line non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins \u03b1V\u03b23 and \u03b1V\u03b25, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients (n\u2009=\u2009140) with advanced NSCLC who had failed first-line chemotherapy were randomized to cilengitide 240, 400, or 600 mg/m(2) twice weekly, or docetaxel 75 mg/m(2) once every 3 weeks for eight cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We conducted this randomized controlled phase II trial to comparatively evaluate the efficacy and side effects of capecitabine combined with docetaxel in previously treated patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with previously treated NSCLC who failed first-line chemotherapy were randomized into two groups; one received capecitabine combined with docetaxel (XT group) and the other received docetaxel alone (T group). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In conclusion, compared with docetaxel alone, capecitabine combined with docetaxel for patients with previously treated NSCLC achieved a significantly longer TTP and this regimen was well tolerated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Between September 2002 and March 2008, 392 patients with advanced NSCLC were treated with docetaxel and we retrospectively reviewed the radiography. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pre-existing interstitial change on CT was associated with a higher incidence of ILD (25.9%) among NSCLC patients treated with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Compared with the known NSCLC drug docetaxel, BRP800 displayed potent and similar antitumor activity but with less toxicity. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel in second-line treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive factors on the outcome of therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Erlotinib and docetaxel show similar efficacy in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Notably, concurrent exposure to ganetespib and docetaxel improved antitumor activity in 5 of 6 NSCLC xenograft models examined. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consolidation docetaxel after EP/XRT does not improve survival in LA-NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Thirty-one percent of locally advanced patients having NSCLC treated with docetaxel and cisplatin and concurrent thoracic radiation survived beyond five years. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We compared the effects of concurrent and sequential administration of docetaxel and multi-target inhibitor sunitinib malate on tumor cells and xenografts and studied several mechanisms involved in drug interaction to provide experimental data in support of their clinical use in non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eligible patients had castration-resistant prostate cancer (CRPC) or relapsed urothelial or non-small-cell lung cancer (NSCLC) after \u22651 prior chemotherapy regimen not containing docetaxel, performance status of 0-2, and adequate organ function. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: EMPHASIS-lung is a randomized phase III multicenter trial exploring the differential activity of second-line erlotinib versus docetaxel on progression-free survival (PFS) in Veristrat good versus poor patients with squamous cell NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND/AIM: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in non-small-cell lung cancer (NSCLC) patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: To assess the efficacy and tolerability of second-line sequential administration of erlotinib and docetaxel in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: In an open-label phase II trial, patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d (day 2-16)+docetaxel (75 mg/m(2) d1) (arm ED) or docetaxel (75 mg/m(2) d1) alone (arm D) (21-day cycle). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Sequential erlotinib and docetaxel was not more effective than docetaxel alone as second-line treatment for advanced NSCLC with wild-type or unknown EGFR status. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To investigate the efficacy of erlotinib versus docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor receptor (EGFR) -unselected patient population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "EGFR wild-type NSCLC was present in 109 and 90 patients in the erlotinib and docetaxel groups, respectively. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive factors on the outcome of therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Erlotinib and docetaxel show similar efficacy in the treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Consolidation docetaxel after EP/XRT does not improve survival in LA-NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " AIM OF THE STUDY: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: 693 Untreated advanced inoperable NSCLC cases were randomised to either GIP (gemcitabine, ifosfamide, cisplatin), DP (docetaxel, cisplatin) or IG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We are currently performing a prospective, randomized phase III trial comparing non-customized cisplatin/docetaxel with customized therapy in metastatic NSCLC patients (NCT00617656/GECP-BREC) and a parallel phase II study (ChiCTR-TRC-12001860) is being carried out in China (BREC-China) under the auspices of the SLCG. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75\u00a0mg/m(2) cisplatin plus 75\u00a0mg/m(2) docetaxel, both administered on day 1 every 21\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm A), or three cycles of 25\u00a0mg/m(2) cisplatin plus 25\u00a0mg/m(2) docetaxel on days 1, 8 and 15 every 28\u00a0days, followed by three cycles of 1,200\u00a0mg/m(2) gemcitabine on days 1 and 8 every 3\u00a0weeks (arm B). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We investigated its activity in patients with advanced non-small-cell lung cancer (NSCLC) progressing under or after docetaxel-based regimens. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with locally advanced unresectable or metastatic NSCLC, with an Eastern Cooperative Oncology Group performance status of 0-2, were enrolled; patients had to have received up to two prior chemotherapy regimens for the treatment of advanced disease, including one docetaxel-containing regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Cabazitaxel exhibits activity in NSCLC patients pre-treated with docetaxel-based chemotherapy with a substantial but manageable toxicity profile. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Paclitaxel and docetaxel are two taxanes approved for the treatment of non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of our study was to evaluate the response to docetaxel in NSCLC patients with prior PP treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients with stage IV NSCLC treated with PP that presented disease progression and received docetaxel as second-line treatment were included. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Previous use of PP does not preclude a favorable response to docetaxel in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Long PFS with PP may help select NSCLC patients who benefit from second-line docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " The wide use of paclitaxel and docetaxel in NSCLC clinical treatment makes it necessary to find biomarkers for identifying patients who can benefit from paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In present study, NCI-H460, a NSCLC cell line with different sensitivity to paclitaxel and docetaxel, was applied to DNA microarray expression profiling analysis at different time points of lower dose treatment with paclitaxel or docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Carboplatin-paclitaxel was associated with slightly better survival compared with carboplatin-gemcitabine or carboplatin-docetaxel within the Medicare population with advanced NSCLC, and this was most pronounced for patients who had squamous cell histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Here we show that ganetespib potentiates the cytotoxic activity of the taxanes paclitaxel and docetaxel in NSCLC models. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Notably, concurrent exposure to ganetespib and docetaxel improved antitumor activity in 5 of 6 NSCLC xenograft models examined. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A confirmed partial response (PR) was observed in 10 of the 47 patients with NSCLC who received trametinib plus docetaxel (21%). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "RESULTS: The base case assumes 20 NSCLC patients progressing after initial therapy (3 receiving ramucirumab+docetaxel, 2 bevacizumab+erlotinib, 3 docetaxel, 6 erlotinib, and 6 pemetrexed), wholesale acquisition cost (WAC) purchase price, and reimbursement at WAC+4.3%. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with progressive NSCLC following clinical benefit from erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: When planning clinical studies of NSCLC patients recommended to receive docetaxel or pemetrexed as single-agent chemotherapy, the EGFR status and stage before first-line treatment should be considered as stratification factors of randomized clinical studies. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Furthermore, a phase III randomized study demonstrated the superiority of crizotinib to standard chemotherapy (pemetrexed or docetaxel) in the treatment of NSCLC patients harboring the ALK rearrangement who had received one prior platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who did not previously receive an EGF receptor inhibitor. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed was associated with significantly postponed tumor progression and significantly less hematological toxicity than docetaxel in the real-world second-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In view of the similar efficacy of the three agents (docetaxel, pemetrexed and erlotinib) in the second-line treatment of NSCLC in the EGFRwt population, and although there are no prospective studies on predictive variables or new molecular markers available, selection of the treatment will depend on the histological type (pemetrexed); patient preference (oral as opposed to intravenous formulation); the presence of comorbid conditions; quality of life; previous or residual toxicities; the risk of neutropenia; response to and the duration of the first-line chemotherapy; and history of smoking. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m(2) intravenously (IV)) or docetaxel (75 mg/m(2) IV) on day 1 of 21-day cycles. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "OBJECTIVE: This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We evaluated the efficacy and safety of continuation maintenance with pemetrexed and switch maintenance with docetaxel in advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Effectiveness of specific agents was assessed at time periods immediately following the approval of the agent for NSCLC: baseline, 1988-1994; platinum, 1995-1999; docetaxel, 1999-2003; pemetrexed and bevacizumab, 2004-2005. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: This randomized, open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent, second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union: the chemotherapies pemetrexed and docetaxel and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nowadays erlotinib (and docetaxel) are still less expensive than pemetrexed; but docetaxel lost patent protection (basic compound patent) at the end of 2010, so docetaxel drug costs have decreased rapidly and the question remains whether erlotinib is still the least costly therapy alternative in second-line NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIAL AND METHODS: Italy was selected for base case analysis to compare the total therapy costs, estimated by combining country-specific drug costs, administration costs, and adverse event costs of erlotinib and generic docetaxel in second-line NSCLC therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and docetaxel are established therapies in second line non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A recent phase III randomized trial named REVEL, demonstrated the efficacy of ramucirumab in combination with docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA approval in this clinical setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This article has for objective to summarize efficacy and safety data of the use of ramucirumab in combination with docetaxel in second line in NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "placebo plus docetaxel improved progression free survival (PFS) in NSCLC patients, and improved overall survival in the population of adenocarcinoma patients, particularly in those with progression within 9 months after first line treatment initiation, median 10.9 months ( [95% CI 8.5-12.6] vs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and safety of second-line ramucirumab-docetaxel in Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Patients with NSCLC with progression after platinum-based therapy (28 Japanese sites; 19 December, 2012 to 22 May, 2015) were randomized (computer-generated sequence) to ramucirumab 10mg/kg or placebo, followed by docetaxel 60mg/m(2) (Day 1, 21-day cycle). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Second-line ramucirumab-docetaxel improved PFS similar to that seen in the REVEL trial with a manageable safety profile in Japanese patients with NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Previously treated PS0-1 patients with IIIB/IV EGFR (epidermal growth factor receptor) wild genotype NSCLC were randomly assigned to docetaxel (60\u2009mg/m(2) on Day 1) plus PPV based on preexisting host immunity or docetaxel plus placebo. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PPV did not improve the survival in combination with docetaxel for previously treated advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In a recent phase II study, selumetinib (AZD6244, ARRY-142886), an oral, potent and selective, allosteric MEK1/2 inhibitor with a short half-life, combined with docetaxel, improved clinical outcome as second-line treatment for patients with KRASm NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: SELECT-1 (NCT01933932) is a randomized, double-blind, placebo-controlled phase III study assessing the efficacy and safety of selumetinib plus docetaxel in patients with KRASm locally advanced or metastatic NSCLC, eligible for second-line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: If the primary endpoint of PFS is met, selumetinib plus docetaxel would be the first targeted treatment for patients with KRASm advanced NSCLC who are eligible for second-line treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "A report by Edelman recently published in the Journal of Clinical Oncology demonstrated the results of a prospective randomized trial using a combination of chemotherapy (docetaxel or pemetrexed) and either COX-2 inhibitor or a placebo for patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Archival tumor samples collected from patients with platinum-refractory NSCLC in the phase III ZODIAC study of vandetanib plus docetaxel or placebo plus docetaxel (N= 294) were screened forKDRamplification by FISH. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Patients with NSCLC whose tumor hadKDRamplification were not associated with clinical benefit for vandetanib in combination with docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: ZODIAC was a randomized phase III study of second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) that evaluated the addition of vandetanib to docetaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: After progression following first-line chemotherapy, 1391 patients with locally advanced or metastatic (stage IIIB/IV) NSCLC were randomized 1 : 1 to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days) or placebo plus docetaxel in the ZODIAC study. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: To analyze the efficacy and safety of combination of rh-endostatin (Endostar) with docetaxel treatment on patients of non-small cell lung cancer (NSCLC) who presented PD or intolerable toxicity in/after first-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Endostar may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicities. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Accordingly, a recent randomized Phase II study evaluating docetaxel plus selumetinib or placebo in KRAS-mutant pretreated advanced NSCLC patients has demonstrated a significant improvement in terms of response rate, progression-free survival and patient-reported outcomes in favor of the combination arm. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: Eligible patients were older than 18 years of age; had histologically or cytologically confirmed stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performance status of 0-1; had not received previous therapy with either a MEK inhibitor or docetaxel; and had adequate bone marrow, renal, and liver function. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "INTERPRETATION: Selumetinib plus docetaxel has promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "These findings warrant further clinical investigation of selumetinib plus docetaxel in KRAS-mutant NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This international, randomized, placebo-controlled, double-blinded phase III trial examines the efficacy and safety of ramucirumab treatment administered in combination with docetaxel, as compared with docetaxel administered with placebo, in patients with stage IV non-small-cell lung cancer (NSCLC) whose disease progressed during or after first-line platinum-based chemotherapy with or without maintenance treatment. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The goal of the REVEL study is to demonstrate that ramucirumab in combination with docetaxel improves overall survival of patients with NSCLC with progressive disease after first-line therapy, and to advance our knowledge of the role of angiogenesis blockade in patients with NSCLC by identifying patients who are likely to experience maximum benefit based on extensive clinical biomarker correlative analysis. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Forkhead box M1 (FoxM1), an oncogenic transcription factor, is believed to be involved in the chemoresistance of various human cancers; whereas the association of FoxM1 with acquired docetaxel-resistance in NSCLC remains unclear. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Our results suggest a critical role of FoxM1 in docetaxel-resistance of the A549 cells and form the basis for the development of combined therapy of docetaxel and FoxM1 depletion in treating NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the treatment of locally recurrent stage III NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVE: Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study was to retrospectively evaluate the efficacy of erlotinib, pemetrexed, and docetaxel in epidermal growth factor receptor (EGFR) mutation-negative patients with previously treated advanced non-squamous NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: We analyzed the efficacy of these agents in patients with previously treated advanced non-squamous NSCLC who had EGFR wild-type tumors, performance status (PS) of 0, 1, or 2 and received erlotinib, pemetrexed, or docetaxel between December 2007 and September 2011. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND AND OBJECTIVE: This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Subgroup analysis showed that OS benefit was presented only in patients treated with docetaxel plus antiangiogenic agents (HR 0.92, 95%CI: 0.86-0.99, p=0.02) and patients with non-squamous NSCLC (HR for OS 0.92, 95%CI: 0.86-0.99, p=0.02). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "This study aimed to evaluate the efficacy and toxicity of platinum combination chemotherapy versus docetaxel monotherapy in NSCLC patients previously treated with platinum-based CRT. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "From September 2002 to December 2009, at three participating institutions, 24 patients with locally advanced NSCLC, who had previously received platinum-based CRT, were treated with platinum combination re-challenge therapy, whereas 61 received docetaxel monotherapy. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for advNS-NSCLC in four Chinese hospitals from 2007 to 2012. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Pemetrexed singlet cost significantly less for supportive care than pemetrexed or docetaxel-based doublets when treating Chinese patients with AdvNS-NSCLC in the second-line setting. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: A retrospective cohort study was conducted including patients receiving pemetrexed or docetaxel-based chemotherapy in the second-line setting for advNS-NSCLC in four Chinese tertiary care hospitals. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: Pemetrexed was associated with significantly postponed tumor progression and significantly less hematological toxicity than docetaxel in the real-world second-line setting for advNS-NSCLC in Chinese patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: Two standard single-agent chemotherapy treatments (docetaxel and pemetrexed) were combined in this trial and administered as second-line treatment in patients with non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSIONS: We recommend that docetaxel or pemetrexed monotherapies should continue to be considered the standard second-line chemotherapy treatment against NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " OBJECTIVES: To compare the effects of adding targeted agents to standard second-line chemotherapy with a single agent (pemetrexed or docetaxel) in patients with advanced NSCLC, a meta-analysis of all relevant randomized controlled trials was performed and overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were assessed. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " INTRODUCTION: The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Pemetrexed and docetaxel are established therapies in second line non-small cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS AND PATIENTS: We designed and performed a multi-center, randomized, exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks, were randomized to receive either pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone, or docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC (ORR: pemetrexed vs. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "CONCLUSION: Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "docetaxel in second-line treatment of advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In advanced NSCLC, gemcitabine plus cisplatin (GC) and docetaxel plus cisplatin (DC) exhibit comparable efficacy, with possibly superior QoL compared to VC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "PATIENTS AND METHODS: Patients with advanced/metastatic NSCLC, performance status of 0-2 and normal organ function were randomized to receive either 3 cycles every 3 weeks of cisplatin 80 mg/m(2) (day 1), oral vinorelbine 60 mg/m(2) (days 1 and 8) and bevacizumab 15 mg/kg (day 1) every 3 weeks (VCB regimen) followed by 3 cycles of docetaxel (75 mg/m(2), day 1), gemcitabine (1100 mg/m(2), days 1 and 8) and bevacizumab 15 mg/kg (day 1) (DGB regimen) (arm A) or 6 cycles of cisplatin 80 mg/m(2), docetaxel 75 mg/m(2) and bevacizumab 15 mg/kg on day 1 (DCB regimen; arm B) every 3 weeks. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "The aim of this study is to evaluate the efficacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u8054\u5408\u7b2c\u4e09\u4ee3\u836f\u7269\u7684\u53cc\u836f\u5316\u7597\u65b9\u6848\u662f\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u7684\u6807\u51c6\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u3002\u672c\u7814\u7a76\u91c7\u7528meta\u5206\u6790\u7684\u65b9\u6cd5\u8bc4\u4ef7\u591a\u897f\u4ed6\u8d5b\u8054\u5408\u94c2\u7c7b\uff08docetaxel plus platinum, DP\uff09\u65b9\u6848\u5bf9\u6bd4\u957f\u6625\u745e\u6ee8\u8054\u5408\u94c2\u7c7b\uff08vinorelbine plus platinum, VP\uff09\u65b9\u6848\u6cbb\u7597\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u65b9\u6cd5 \u8ba1\u7b97\u673a\u68c0\u7d22Pubmed\u3001EMBASE\u3001Cochrane Library\u3001\u4e2d\u56fd\u671f\u520a\u5168\u6587\u6570\u636e\u5e93\uff08CNKI\uff09\u3001\u4e2d\u56fd\u751f\u7269\u533b\u5b66\u6587\u732e\u6570\u636e\u5e93\uff08CBM\uff09\u3001\u4e2d\u6587\u79d1\u6280\u671f\u520a\u5168\u6587\u6570\u636e\uff08VIP\uff09\u5e93\u53ca\u4e07\u65b9\u6570\u636e\u5e93\u5173\u4e8eDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u6cbb\u7597\u665a\u671fNSC LC\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\uff08randomized controlled trial, RCT\uff09\u3002\u6839\u636eCochrane Handbook 5.1.0\u7684\u8d28\u91cf\u8bc4\u4ef7\u6807\u51c6\uff0c\u7528Stata 12.0\u8f6f\u4ef6\u8fdb\u884c\u7edf\u8ba1\u5b66\u5206\u6790\u3002\u7ed3\u679c \u7814\u7a76\u5171\u7eb3\u51657\u9879RCTs\uff0c\u5305\u62ec\u665a\u671fNSCLC\u60a3\u80052,381\u4f8b\u3002DP\u65b9\u6848\u76842\u5e74\u751f\u5b58\u7387\uff08HR=0.887, 95%CI: 0.810-0.972, P=0.010\uff09\u3001\u6709\u6548\u7387\uff08RR=1.276, 95%CI: 1.107-1.450, P=0.001\uff09\u548c\u8179\u6cfb\u53d1\u751f\u7387\uff08RR=3.134, 95%CI: 1.918-5.121, P<0.001\uff09\u8f83VP\u65b9\u6848\u9ad8\uff1bDP\u65b9\u6848\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff08RR=0.386, 95%CI: 0.311-0.478, P<0.001\uff09\uff1bDP\u65b9\u6848\u4e0eVP\u65b9\u6848\u57281\u5e74\u751f\u5b58\u7387\u3001\u767d\u7ec6\u80de\u51cf\u5c11\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u538c\u98df\u3001\u6076\u5fc3\u3001\u5455\u5410\u65b9\u9762\u7684\u5dee\u5f02\u65e0\u7edf\u8ba1\u5b66\u610f\u4e49\u3002\u7ed3\u8bba DP\u65b9\u6848\u867d\u7136\u589e\u52a0\u4e86\u8179\u6cfb\u53d1\u751f\u7387\uff0c\u4f46\u5374\u51cf\u5c11\u4e86\u8d2b\u8840\u7684\u53d1\u751f\u7387\uff0c\u540c\u65f6\u63d0\u9ad8\u4e862\u5e74\u751f\u5b58\u7387\u548c\u6709\u6548\u7387\u3002\u76f8\u6bd4VP\u65b9\u6848\uff0cDP\u65b9\u6848\u53ef\u80fd\u66f4\u9002\u5408\u4e00\u7ebf\u6cbb\u7597\u665a\u671fNSCLC\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.07 PMID: 24758908 [PubMed - indexed for MEDLINE]  BACKGROUND: Early stage Non-Small Cell Lung Cancer (NSCLC) is potentially curable with surgery. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " Whether cisplatin plus vinorelbine (VC) or cisplatin plus docetaxel (DC) are equally effective in the treatment of advanced non-small-cell lung cancer (NSCLC) remains controversial. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": " BACKGROUND: Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "disease": "NSCLC", "drug": "docetaxel"}, {"polarity": 1, "orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "disease": "NSCLC", "drug": "docetaxel"}]